{"PMC7530875": [["Use of hydroxychloroquine (HCQ) for the treatment of rheumatic disorders in early pregnancy appears to increase the risk of congenital abnormalities, according to findings of a US study published in the American Journal of Obstetrics and Gynecology.", [["hydroxychloroquine", "CHEMICAL", 7, 25], ["HCQ", "CHEMICAL", 27, 30], ["rheumatic disorders", "DISEASE", 53, 72], ["congenital abnormalities", "DISEASE", 124, 148], ["hydroxychloroquine", "CHEMICAL", 7, 25], ["HCQ", "CHEMICAL", 27, 30], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 7, 25], ["HCQ", "SIMPLE_CHEMICAL", 27, 30], ["hydroxychloroquine (HCQ)", "TREATMENT", 7, 31], ["rheumatic disorders", "PROBLEM", 53, 72], ["congenital abnormalities", "PROBLEM", 124, 148], ["a US study", "TEST", 175, 185], ["rheumatic", "OBSERVATION", 53, 62], ["congenital", "OBSERVATION_MODIFIER", 124, 134], ["abnormalities", "OBSERVATION", 135, 148]]]], "709049266c92c8f5ff4ca844d295475989f3ed6d": [["BackgroundPneumonia is the most common cause of fatal nonobstetric infections in pregnant patients [1] .", [["BackgroundPneumonia", "DISEASE", 0, 19], ["nonobstetric infections", "DISEASE", 54, 77], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["fatal nonobstetric infections", "PROBLEM", 48, 77], ["most common", "OBSERVATION_MODIFIER", 27, 38], ["fatal", "OBSERVATION_MODIFIER", 48, 53], ["nonobstetric", "OBSERVATION_MODIFIER", 54, 66], ["infections", "OBSERVATION", 67, 77]]], ["In the United States, pneumonia complicates approximately 1 per 1000 pregnancies [2] .", [["pneumonia", "DISEASE", 22, 31], ["pneumonia", "PROBLEM", 22, 31], ["pneumonia", "OBSERVATION", 22, 31]]], ["In Taiwan, pneumonia complicates 6.7 per 1000 pregnancies [3] .", [["pneumonia", "DISEASE", 11, 20], ["pneumonia", "PROBLEM", 11, 20], ["pneumonia", "OBSERVATION", 11, 20]]], ["In mainland China, this rate may be even higher.", [["this rate", "TEST", 19, 28]]], ["A true estimate of the incidence of severe pneumonia during pregnancy is difficult to obtain because the few published studies in this area are mostly case reports.BackgroundConsidering the potential teratogenicity of radiography and drugs, both patients and their physicians tend to postpone radiation examinations and medical treatment when pneumonia is suspected.", [["pneumonia", "DISEASE", 43, 52], ["pneumonia", "DISEASE", 343, 352], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 246, 254], ["severe pneumonia", "PROBLEM", 36, 52], ["pregnancy", "PROBLEM", 60, 69], ["the few published studies", "TEST", 101, 126], ["radiography", "TEST", 218, 229], ["drugs", "TREATMENT", 234, 239], ["radiation examinations", "TEST", 293, 315], ["medical treatment", "TREATMENT", 320, 337], ["pneumonia", "PROBLEM", 343, 352], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["pneumonia", "OBSERVATION", 43, 52], ["pneumonia", "OBSERVATION", 343, 352]]], ["As a result, delayed diagnoses and referral are common in patients with pneumonia complicating pregnancy [2] .", [["pneumonia", "DISEASE", 72, 81], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["pneumonia complicating pregnancy", "PROBLEM", 72, 104], ["pneumonia", "OBSERVATION", 72, 81]]], ["Several physiological and immunological changes that are experienced during pregnancy, such as altered T lymphocyte immunity, increased oxygen consumption, decreased functional residual capacity, decreased chest compliance, and increased risk of aspiration, may predispose pregnant women to a more severe course of pneumonia, which may result in greater maternal and fetal morbidity and mortality [1, 4] .BackgroundA meta-analysis revealed that influenza infection in pregnant individuals resulted in a higher risk of hospital admission than influenza infection in nonpregnant individuals [5] .", [["T lymphocyte", "ANATOMY", 103, 115], ["chest", "ANATOMY", 206, 211], ["fetal", "ANATOMY", 367, 372], ["oxygen", "CHEMICAL", 136, 142], ["pneumonia", "DISEASE", 315, 324], ["influenza infection", "DISEASE", 445, 464], ["influenza infection", "DISEASE", 542, 561], ["oxygen", "CHEMICAL", 136, 142], ["T lymphocyte", "CELL", 103, 115], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["chest", "ORGANISM_SUBDIVISION", 206, 211], ["women", "ORGANISM", 282, 287], ["fetal", "ANATOMICAL_SYSTEM", 367, 372], ["women", "SPECIES", 282, 287], ["Several physiological and immunological changes", "PROBLEM", 0, 47], ["altered T lymphocyte immunity", "PROBLEM", 95, 124], ["increased oxygen consumption", "PROBLEM", 126, 154], ["decreased functional residual capacity", "PROBLEM", 156, 194], ["decreased chest compliance", "PROBLEM", 196, 222], ["aspiration", "PROBLEM", 246, 256], ["pneumonia", "PROBLEM", 315, 324], ["greater maternal and fetal morbidity", "PROBLEM", 346, 382], ["A meta-analysis", "TEST", 415, 430], ["influenza infection", "PROBLEM", 445, 464], ["pregnant individuals", "PROBLEM", 468, 488], ["influenza infection in nonpregnant individuals", "PROBLEM", 542, 588], ["lymphocyte immunity", "OBSERVATION", 105, 124], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["oxygen consumption", "OBSERVATION", 136, 154], ["residual capacity", "OBSERVATION", 177, 194], ["decreased", "OBSERVATION_MODIFIER", 196, 205], ["chest", "ANATOMY", 206, 211], ["increased", "OBSERVATION_MODIFIER", 228, 237], ["aspiration", "OBSERVATION", 246, 256], ["pneumonia", "OBSERVATION", 315, 324], ["greater", "OBSERVATION_MODIFIER", 346, 353], ["influenza", "OBSERVATION_MODIFIER", 445, 454], ["infection", "OBSERVATION", 455, 464]]], ["Early recognition and prompt treatment of severe pneumonia are essential to improve maternal and perinatal outcomes [6] .", [["pneumonia", "DISEASE", 49, 58], ["Early recognition", "PROBLEM", 0, 17], ["severe pneumonia", "PROBLEM", 42, 58], ["maternal and perinatal outcomes", "PROBLEM", 84, 115], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["pneumonia", "OBSERVATION", 49, 58]]], ["Because of the complexity of such cases and the ethical considerations, no randomized controlled trials have been performed in this area, and few high-quality studies with large samples for the diagnosis and treatment of severe pneumonia during pregnancy have been published.", [["pneumonia", "DISEASE", 228, 237], ["randomized controlled trials", "TREATMENT", 75, 103], ["treatment", "TREATMENT", 208, 217], ["severe pneumonia", "PROBLEM", 221, 237], ["severe", "OBSERVATION_MODIFIER", 221, 227], ["pneumonia", "OBSERVATION", 228, 237]]], ["Herein, we report a series of twelve gravid patients with severe pneumonia who were treated at a single institution.", [["pneumonia", "DISEASE", 65, 74], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["severe pneumonia", "PROBLEM", 58, 74], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["Both the clinical features and the maternal-fetal outcomes were reviewed.MethodsThe retrospective study was conducted at Peking Union Medical College Hospital (PUMCH), which is a tertiary comprehensive hospital and referral center offering medical care for high-risk pregnancies in Beijing, China.", [["fetal", "ANATOMY", 44, 49], ["fetal", "ANATOMICAL_SYSTEM", 44, 49], ["The retrospective study", "TEST", 80, 103]]], ["We searched the medical records of PUMCH to identify patients who were diagnosed with pneumonia complicating pregnancy between January 2010 and June 2017.", [["pneumonia", "DISEASE", 86, 95], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["pneumonia", "PROBLEM", 86, 95], ["pneumonia", "OBSERVATION", 86, 95]]], ["We found 51 such patients.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["The patients' clinical data including symptoms at presentation, laboratory tests, and treatment strategies were reviewed carefully to screen for severe pneumonia.", [["pneumonia", "DISEASE", 152, 161], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["symptoms", "PROBLEM", 38, 46], ["laboratory tests", "TEST", 64, 80], ["treatment strategies", "TREATMENT", 86, 106], ["severe pneumonia", "PROBLEM", 145, 161], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["pneumonia", "OBSERVATION", 152, 161]]], ["Severe pneumonia was defined according to the American Thoracic Society guidelines for the management of adults with community-acquired pneumonia as the presence of either one of two major criteria or two of three minor criteria.", [["pneumonia", "DISEASE", 7, 16], ["pneumonia", "DISEASE", 136, 145], ["Severe pneumonia", "PROBLEM", 0, 16], ["community-acquired pneumonia", "PROBLEM", 117, 145], ["pneumonia", "OBSERVATION", 7, 16], ["Thoracic", "ANATOMY", 55, 63], ["pneumonia", "OBSERVATION", 136, 145]]], ["The major criteria include the need for mechanical ventilation and septic shock.", [["septic shock", "DISEASE", 67, 79], ["mechanical ventilation", "TREATMENT", 40, 62], ["septic shock", "PROBLEM", 67, 79], ["mechanical ventilation", "OBSERVATION", 40, 62], ["septic shock", "OBSERVATION", 67, 79]]], ["The minor criteria include systolic blood pressure \u2264 90 mmHg, multilobar infiltrates, and PaO 2 /FIO 2 ratio < 250 [7] .MethodsAccording to this diagnostic standard, we excluded 39 patients who had mild symptoms or who recovered soon after preliminary treatment.", [["blood", "ANATOMY", 36, 41], ["multilobar infiltrates", "ANATOMY", 62, 84], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["systolic blood pressure", "TEST", 27, 50], ["multilobar infiltrates", "PROBLEM", 62, 84], ["PaO", "TEST", 90, 93], ["FIO 2 ratio", "TEST", 97, 108], ["mild symptoms", "PROBLEM", 198, 211], ["preliminary treatment", "TREATMENT", 240, 261], ["multilobar", "OBSERVATION_MODIFIER", 62, 72], ["infiltrates", "OBSERVATION", 73, 84], ["mild", "OBSERVATION_MODIFIER", 198, 202]]], ["Ultimately, 12 gravid patients who were diagnosed with severe pneumonia were included.", [["pneumonia", "DISEASE", 62, 71], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["severe pneumonia", "PROBLEM", 55, 71], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["pneumonia", "OBSERVATION", 62, 71]]], ["Their detailed data including demographic data, gestational age at diagnosis, symptoms, physical examinations, laboratory tests, chest radiograph findings, treatment strategies, and obstetric and neonatal outcomes were collected from the medical records.", [["chest", "ANATOMY", 129, 134], ["demographic data", "TEST", 30, 46], ["symptoms", "PROBLEM", 78, 86], ["physical examinations", "TEST", 88, 109], ["laboratory tests", "TEST", 111, 127], ["chest radiograph findings", "TEST", 129, 154], ["treatment strategies", "TREATMENT", 156, 176], ["chest", "ANATOMY", 129, 134]]], ["Major medical complications were simultaneously documented.", [["Major medical complications", "PROBLEM", 0, 27]]], ["After the data were collected, they were organized into summary forms to indicate the points in common in patients with severe pneumonia.Maternal characteristics and diagnostic evaluationsA total of 12 pregnant women were diagnosed with severe pneumonia at PUMCH during our study period ( Table 1) .", [["pneumonia", "DISEASE", 127, 136], ["pneumonia", "DISEASE", 244, 253], ["patients", "ORGANISM", 106, 114], ["women", "ORGANISM", 211, 216], ["patients", "SPECIES", 106, 114], ["women", "SPECIES", 211, 216], ["the data", "TEST", 6, 14], ["severe pneumonia", "PROBLEM", 120, 136], ["diagnostic evaluations", "TEST", 166, 188], ["severe pneumonia", "PROBLEM", 237, 253], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["pneumonia", "OBSERVATION", 127, 136], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["pneumonia", "OBSERVATION", 244, 253]]], ["Only patient 12 attended regular antenatal care visits at our hospital.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["The other 11 women were all transferred from other hospitals.", [["women", "ORGANISM", 13, 18], ["women", "SPECIES", 13, 18]]], ["Eight women were in their third trimester (29-38 weeks), and the other 4 patients were in their late second trimester (18-25 weeks) at presentation.", [["women", "ORGANISM", 6, 11], ["patients", "ORGANISM", 73, 81], ["women", "SPECIES", 6, 11], ["patients", "SPECIES", 73, 81]]], ["Anemia was found in six patients (50%) at presentation.", [["Anemia", "DISEASE", 0, 6], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Anemia", "PROBLEM", 0, 6]]], ["The hemoglobin levels of anemic patients ranged from 81 g/L to 93 g/L. Patient 1 was previously diagnosed with membranous nephropathy but was cured 2 years prior to becoming pregnant.", [["anemic", "DISEASE", 25, 31], ["membranous nephropathy", "DISEASE", 111, 133], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 4, 14], ["patients", "ORGANISM", 32, 40], ["hemoglobin", "PROTEIN", 4, 14], ["patients", "SPECIES", 32, 40], ["Patient", "SPECIES", 71, 78], ["The hemoglobin levels", "TEST", 0, 21], ["anemic", "PROBLEM", 25, 31], ["membranous nephropathy", "PROBLEM", 111, 133], ["anemic", "OBSERVATION_MODIFIER", 25, 31], ["membranous", "OBSERVATION_MODIFIER", 111, 121], ["nephropathy", "OBSERVATION", 122, 133]]], ["Patient 3 had a history of tuberculosis.", [["tuberculosis", "DISEASE", 27, 39], ["Patient", "SPECIES", 0, 7], ["tuberculosis", "PROBLEM", 27, 39], ["tuberculosis", "OBSERVATION", 27, 39]]], ["Patient 7 had a history of severe preeclampsia during her last pregnancy.", [["preeclampsia", "DISEASE", 34, 46], ["Patient", "SPECIES", 0, 7], ["severe preeclampsia", "PROBLEM", 27, 46], ["her last pregnancy", "PROBLEM", 54, 72], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["preeclampsia", "OBSERVATION", 34, 46]]], ["Patient 8 had chronic hypertension.", [["hypertension", "DISEASE", 22, 34], ["Patient", "SPECIES", 0, 7], ["chronic hypertension", "PROBLEM", 14, 34], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["hypertension", "OBSERVATION", 22, 34]]], ["The remaining eight patients had unremarkable past medical histories.Maternal characteristics and diagnostic evaluationsAll patients had high fevers (> 38\u00b0C) and dyspnea.", [["fevers", "DISEASE", 142, 148], ["dyspnea", "DISEASE", 162, 169], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 124, 132], ["diagnostic evaluations", "TEST", 98, 120], ["high fevers", "PROBLEM", 137, 148], ["dyspnea", "PROBLEM", 162, 169], ["unremarkable", "OBSERVATION", 33, 45], ["high", "OBSERVATION_MODIFIER", 137, 141], ["fevers", "OBSERVATION", 142, 148], ["dyspnea", "OBSERVATION", 162, 169]]], ["Eight patients (8/12, 67%) reported a productive cough.", [["cough", "DISEASE", 49, 54], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["a productive cough", "PROBLEM", 36, 54], ["productive", "OBSERVATION_MODIFIER", 38, 48], ["cough", "OBSERVATION", 49, 54]]], ["Other symptoms, such as chest pain, malaise, and headache, were also reported.", [["chest", "ANATOMY", 24, 29], ["chest pain", "DISEASE", 24, 34], ["headache", "DISEASE", 49, 57], ["chest", "ORGANISM_SUBDIVISION", 24, 29], ["Other symptoms", "PROBLEM", 0, 14], ["chest pain", "PROBLEM", 24, 34], ["malaise", "PROBLEM", 36, 43], ["headache", "PROBLEM", 49, 57], ["chest", "ANATOMY", 24, 29], ["malaise", "OBSERVATION", 36, 43]]], ["Physical examination revealed decreased or bronchial breath sounds in 10 (83%) patients and rales in 10 (83%) patients.", [["bronchial breath", "ANATOMY", 43, 59], ["decreased or bronchial breath sounds", "DISEASE", 30, 66], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 110, 118], ["Physical examination", "TEST", 0, 20], ["bronchial breath sounds", "TEST", 43, 66], ["rales", "TEST", 92, 97], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["bronchial", "ANATOMY", 43, 52], ["breath sounds", "OBSERVATION", 53, 66]]], ["Dull percussion was found in patient 2.Maternal characteristics and diagnostic evaluationsLeukocytosis (> 10.0 \u00d7 10 9 /L) was observed in 7 patients (58%) at presentation, and leukopenia (< 4.0 \u00d7 10 9 /L) was observed in patient 12.", [["Leukocytosis", "DISEASE", 90, 102], ["leukopenia", "DISEASE", 176, 186], ["patient", "ORGANISM", 29, 36], ["patients", "ORGANISM", 140, 148], ["patient", "ORGANISM", 221, 228], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 140, 148], ["patient", "SPECIES", 221, 228], ["Dull percussion", "TEST", 0, 15], ["diagnostic evaluations", "TEST", 68, 90], ["Leukocytosis", "TEST", 90, 102], ["leukopenia", "PROBLEM", 176, 186], ["percussion", "OBSERVATION", 5, 15], ["leukopenia", "OBSERVATION", 176, 186]]], ["Arterial blood gas analysis showed severe hypoxemia in all patients, with PaO 2 /FiO 2 ratio ranging from 73 to 220.", [["Arterial blood", "ANATOMY", 0, 14], ["hypoxemia", "DISEASE", 42, 51], ["PaO 2 /FiO 2", "CHEMICAL", 74, 86], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Arterial blood gas analysis", "TEST", 0, 27], ["severe hypoxemia", "PROBLEM", 35, 51], ["PaO", "TEST", 74, 77], ["FiO 2 ratio", "TEST", 81, 92], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["hypoxemia", "OBSERVATION", 42, 51]]], ["The two patients with the lowest PaO 2 /FiO 2 ratio both died.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["the lowest PaO", "TREATMENT", 22, 36]]], ["Routine screening tests for the causative pneumonia pathogen, such as sputum culture, blood culture, nasal and throat swabs, and serologic testing, were carried out in 11 patients (except for patient 8).", [["sputum", "ANATOMY", 70, 76], ["blood", "ANATOMY", 86, 91], ["nasal", "ANATOMY", 101, 106], ["throat swabs", "ANATOMY", 111, 123], ["pneumonia", "DISEASE", 42, 51], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["nasal", "ORGANISM_SUBDIVISION", 101, 106], ["patients", "ORGANISM", 171, 179], ["patient", "ORGANISM", 192, 199], ["patients", "SPECIES", 171, 179], ["patient", "SPECIES", 192, 199], ["Routine screening tests", "TEST", 0, 23], ["the causative pneumonia pathogen", "PROBLEM", 28, 60], ["sputum culture", "TEST", 70, 84], ["blood culture", "TEST", 86, 99], ["nasal and throat swabs", "TEST", 101, 123], ["serologic testing", "TEST", 129, 146], ["pneumonia", "OBSERVATION", 42, 51], ["nasal", "ANATOMY", 101, 106], ["throat", "ANATOMY", 111, 117]]], ["Tuberculosis was diagnosed in two patients, and viral pneumonia was diagnosed in three patients; the pathogenic virus was confirmed to be H1N1, H7N9, and respiratory syncytial virus.", [["Tuberculosis", "DISEASE", 0, 12], ["viral pneumonia", "DISEASE", 48, 63], ["respiratory syncytial virus", "DISEASE", 154, 181], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 87, 95], ["respiratory syncytial virus", "ORGANISM", 154, 181], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 87, 95], ["respiratory syncytial virus", "SPECIES", 154, 181], ["H7N9", "SPECIES", 144, 148], ["respiratory syncytial virus", "SPECIES", 154, 181], ["Tuberculosis", "PROBLEM", 0, 12], ["viral pneumonia", "PROBLEM", 48, 63], ["the pathogenic virus", "PROBLEM", 97, 117], ["H1N1", "PROBLEM", 138, 142], ["H7N9", "PROBLEM", 144, 148], ["respiratory syncytial virus", "PROBLEM", 154, 181], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["pneumonia", "OBSERVATION", 54, 63], ["respiratory syncytial virus", "OBSERVATION", 154, 181]]], ["Patient 8 died within 12 h after admission; thus, none of these tests were carried out.", [["Patient", "SPECIES", 0, 7], ["these tests", "TEST", 58, 69]]], ["A chest radiograph revealed pulmonary infiltration or consolidation of the bilateral lungs with or without pleural effusion in all 12 patients.", [["chest", "ANATOMY", 2, 7], ["pulmonary", "ANATOMY", 28, 37], ["lungs", "ANATOMY", 85, 90], ["pleural", "ANATOMY", 107, 114], ["pleural effusion", "DISEASE", 107, 123], ["pulmonary", "ORGAN", 28, 37], ["lungs", "ORGAN", 85, 90], ["pleural", "ORGAN", 107, 114], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["A chest radiograph", "TEST", 0, 18], ["pulmonary infiltration", "PROBLEM", 28, 50], ["consolidation of the bilateral lungs", "PROBLEM", 54, 90], ["pleural effusion", "PROBLEM", 107, 123], ["chest", "ANATOMY", 2, 7], ["pulmonary", "ANATOMY", 28, 37], ["infiltration", "OBSERVATION", 38, 50], ["consolidation", "OBSERVATION", 54, 67], ["bilateral", "ANATOMY_MODIFIER", 75, 84], ["lungs", "ANATOMY", 85, 90], ["without", "UNCERTAINTY", 99, 106], ["pleural", "ANATOMY", 107, 114], ["effusion", "OBSERVATION", 115, 123]]], ["For most patients, the disease progression was quick.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["the disease progression", "PROBLEM", 19, 42], ["disease", "OBSERVATION", 23, 30]]], ["The time interval between the onset of fever and the confirmation of the diagnosis was typically less than 10 days.", [["fever", "DISEASE", 39, 44], ["fever", "PROBLEM", 39, 44], ["fever", "OBSERVATION", 39, 44]]], ["For patients 3 and 5, the interval was longer, at 68 and 23 days, respectively.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Interestingly, the final diagnoses of these two patients were both tuberculosis.TreatmentAll patients were admitted to the intensive care unit (ICU) because of severe hypoxemia ( Table 2 ).", [["tuberculosis", "DISEASE", 67, 79], ["hypoxemia", "DISEASE", 167, 176], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 93, 101], ["tuberculosis", "PROBLEM", 67, 79], ["severe hypoxemia", "PROBLEM", 160, 176], ["tuberculosis", "OBSERVATION", 67, 79], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["hypoxemia", "OBSERVATION", 167, 176]]], ["The length of stay in the ICU ranged from 1 day to 50 days.TreatmentMechanical ventilation was performed in all patients, and the duration of mechanical ventilation ranged from 1 day to 48 days.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Treatment", "TREATMENT", 59, 68], ["Mechanical ventilation", "TREATMENT", 68, 90], ["mechanical ventilation", "TREATMENT", 142, 164], ["length", "OBSERVATION_MODIFIER", 4, 10], ["Mechanical ventilation", "OBSERVATION", 68, 90]]], ["Two patients also received extracorporeal membrane oxygenation (ECMO) therapy for 18 and 12 days.", [["extracorporeal membrane", "ANATOMY", 27, 50], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["extracorporeal membrane oxygenation", "TREATMENT", 27, 62], ["ECMO) therapy", "TREATMENT", 64, 77], ["extracorporeal membrane oxygenation", "OBSERVATION", 27, 62]]], ["All patients were administered broad-spectrum antibiotics, such as beta-lactams, macrolides, or fluoroquinolones.", [["beta-lactams", "CHEMICAL", 67, 79], ["macrolides", "CHEMICAL", 81, 91], ["fluoroquinolones", "CHEMICAL", 96, 112], ["macrolides", "CHEMICAL", 81, 91], ["fluoroquinolones", "CHEMICAL", 96, 112], ["patients", "ORGANISM", 4, 12], ["beta-lactams", "SIMPLE_CHEMICAL", 67, 79], ["macrolides", "SIMPLE_CHEMICAL", 81, 91], ["fluoroquinolones", "SIMPLE_CHEMICAL", 96, 112], ["patients", "SPECIES", 4, 12], ["broad-spectrum antibiotics", "TREATMENT", 31, 57], ["beta-lactams", "TREATMENT", 67, 79], ["macrolides", "TREATMENT", 81, 91], ["fluoroquinolones", "TREATMENT", 96, 112]]], ["Antiviral medications, namely, oseltamivir, ganciclovir or acyclovir, were administered to 7 patients (58%).", [["oseltamivir", "CHEMICAL", 31, 42], ["ganciclovir", "CHEMICAL", 44, 55], ["acyclovir", "CHEMICAL", 59, 68], ["oseltamivir", "CHEMICAL", 31, 42], ["ganciclovir", "CHEMICAL", 44, 55], ["acyclovir", "CHEMICAL", 59, 68], ["oseltamivir", "SIMPLE_CHEMICAL", 31, 42], ["ganciclovir", "SIMPLE_CHEMICAL", 44, 55], ["acyclovir", "SIMPLE_CHEMICAL", 59, 68], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Antiviral medications", "TREATMENT", 0, 21], ["oseltamivir", "TREATMENT", 31, 42], ["ganciclovir", "TREATMENT", 44, 55], ["acyclovir", "TREATMENT", 59, 68]]], ["Standard anti-tuberculosis therapy was initiated in patient 3 and patient 5 as soon as tuberculosis was diagnosed.", [["tuberculosis", "DISEASE", 87, 99], ["patient", "ORGANISM", 52, 59], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 66, 73], ["Standard anti-tuberculosis therapy", "TREATMENT", 0, 34], ["tuberculosis", "PROBLEM", 87, 99], ["anti-tuberculosis therapy", "OBSERVATION", 9, 34], ["tuberculosis", "OBSERVATION", 87, 99]]], ["Intravenous courses of pulsed methylprednisolone were administered to 8 patients (67%).", [["methylprednisolone", "CHEMICAL", 30, 48], ["methylprednisolone", "CHEMICAL", 30, 48], ["methylprednisolone", "SIMPLE_CHEMICAL", 30, 48], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["pulsed methylprednisolone", "TREATMENT", 23, 48]]], ["Four patients also received intravenous immunoglobulin therapy.Complications and outcomesTwo of these patients (patient 8 and patient 11) died of progressive respiratory failure and heart failure ( Table 3) .", [["intravenous", "ANATOMY", 28, 39], ["respiratory", "ANATOMY", 158, 169], ["heart", "ANATOMY", 182, 187], ["respiratory failure", "DISEASE", 158, 177], ["heart failure", "DISEASE", 182, 195], ["patients", "ORGANISM", 5, 13], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 39], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 40, 54], ["patients", "ORGANISM", 102, 110], ["patient", "ORGANISM", 112, 119], ["patient", "ORGANISM", 126, 133], ["heart", "ORGAN", 182, 187], ["immunoglobulin", "PROTEIN", 40, 54], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 102, 110], ["patient", "SPECIES", 112, 119], ["patient", "SPECIES", 126, 133], ["intravenous immunoglobulin therapy", "TREATMENT", 28, 62], ["progressive respiratory failure", "PROBLEM", 146, 177], ["heart failure", "PROBLEM", 182, 195], ["progressive", "OBSERVATION_MODIFIER", 146, 157], ["respiratory failure", "OBSERVATION", 158, 177], ["heart", "ANATOMY", 182, 187], ["failure", "OBSERVATION", 188, 195]]], ["The remaining ten patients recovered well.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["The major complications observed among these patients included septic shock (5/12, 42%), adult respiratory distress syndrome (5/12, 42%), liver failure (4/12, 33%), acute renal failure (4/12, 33%), severe preeclampsia (3/12, 25%), and stress ulcers (2/12, 17%).", [["respiratory", "ANATOMY", 95, 106], ["liver", "ANATOMY", 138, 143], ["renal", "ANATOMY", 171, 176], ["stress ulcers", "ANATOMY", 235, 248], ["septic shock", "DISEASE", 63, 75], ["respiratory distress syndrome", "DISEASE", 95, 124], ["liver failure", "DISEASE", 138, 151], ["acute renal failure", "DISEASE", 165, 184], ["preeclampsia", "DISEASE", 205, 217], ["stress ulcers", "DISEASE", 235, 248], ["patients", "ORGANISM", 45, 53], ["liver", "ORGAN", 138, 143], ["renal", "ORGAN", 171, 176], ["ulcers", "PATHOLOGICAL_FORMATION", 242, 248], ["patients", "SPECIES", 45, 53], ["The major complications", "PROBLEM", 0, 23], ["septic shock", "PROBLEM", 63, 75], ["adult respiratory distress syndrome", "PROBLEM", 89, 124], ["liver failure", "PROBLEM", 138, 151], ["acute renal failure", "PROBLEM", 165, 184], ["severe preeclampsia", "PROBLEM", 198, 217], ["stress ulcers", "PROBLEM", 235, 248], ["major", "OBSERVATION_MODIFIER", 4, 9], ["complications", "OBSERVATION", 10, 23], ["septic shock", "OBSERVATION", 63, 75], ["respiratory distress syndrome", "OBSERVATION", 95, 124], ["liver", "ANATOMY", 138, 143], ["failure", "OBSERVATION", 144, 151], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["renal", "ANATOMY", 171, 176], ["failure", "OBSERVATION", 177, 184], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["preeclampsia", "OBSERVATION", 205, 217], ["stress ulcers", "OBSERVATION", 235, 248]]], ["Patient 4 was diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), and patient 10 was diagnosed with thrombotic thrombocytopenic purpura (TTP).", [["SIADH", "DISEASE", 94, 99], ["thrombotic thrombocytopenic purpura", "DISEASE", 136, 171], ["TTP", "DISEASE", 173, 176], ["antidiuretic hormone", "GENE_OR_GENE_PRODUCT", 72, 92], ["patient", "ORGANISM", 106, 113], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 106, 113], ["the syndrome", "PROBLEM", 29, 41], ["inappropriate secretion of antidiuretic hormone", "PROBLEM", 45, 92], ["SIADH", "PROBLEM", 94, 99], ["thrombotic thrombocytopenic purpura", "PROBLEM", 136, 171], ["TTP", "PROBLEM", 173, 176], ["antidiuretic hormone", "OBSERVATION", 72, 92], ["thrombotic", "OBSERVATION_MODIFIER", 136, 146], ["thrombocytopenic purpura", "OBSERVATION", 147, 171], ["TTP", "OBSERVATION", 173, 176]]], ["(100) Cough -- (17 Of the 4 patients who presented during their second trimester, 3 patients (patients 1, 3, and 4) chose to terminate their pregnancies after they had recovered from pneumonia for social reasons.", [["pneumonia", "DISEASE", 183, 192], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 94, 102], ["Cough", "PROBLEM", 6, 11], ["pneumonia", "PROBLEM", 183, 192], ["pneumonia", "OBSERVATION", 183, 192]]], ["Patient 2 experienced intrauterine fetal death and spontaneous miscarriage 40 days after the diagnosis of H7N9 pneumonia.", [["intrauterine fetal", "ANATOMY", 22, 40], ["intrauterine fetal death", "DISEASE", 22, 46], ["miscarriage", "DISEASE", 63, 74], ["pneumonia", "DISEASE", 111, 120], ["fetal", "ORGAN", 35, 40], ["Patient", "SPECIES", 0, 7], ["H7N9", "SPECIES", 106, 110], ["intrauterine fetal death", "PROBLEM", 22, 46], ["spontaneous miscarriage", "PROBLEM", 51, 74], ["H7N9 pneumonia", "PROBLEM", 106, 120], ["fetal", "ANATOMY", 35, 40], ["death", "OBSERVATION", 41, 46], ["H7N9", "OBSERVATION_MODIFIER", 106, 110], ["pneumonia", "OBSERVATION", 111, 120]]], ["After the miscarriage, the progression of multiple organ dysfunction syndrome (MODS) ceased, and she recovered well.", [["organ", "ANATOMY", 51, 56], ["miscarriage", "DISEASE", 10, 21], ["multiple organ dysfunction syndrome", "DISEASE", 42, 77], ["MODS", "DISEASE", 79, 83], ["organ", "ORGAN", 51, 56], ["the miscarriage", "PROBLEM", 6, 21], ["multiple organ dysfunction syndrome", "PROBLEM", 42, 77], ["MODS", "PROBLEM", 79, 83], ["miscarriage", "OBSERVATION", 10, 21], ["progression", "OBSERVATION_MODIFIER", 27, 38], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["organ", "OBSERVATION", 51, 56], ["dysfunction syndrome", "OBSERVATION", 57, 77]]], ["Of the 8 patients who presented during their third trimester, patient 5 had spontaneous preterm labor on the first day of admission, and she delivered a baby with severe asphyxia (Apgar score of 2 at 1 min) who died after several hours.", [["preterm labor", "DISEASE", 88, 101], ["asphyxia", "DISEASE", 170, 178], ["patients", "ORGANISM", 9, 17], ["patient", "ORGANISM", 62, 69], ["patients", "SPECIES", 9, 17], ["patient", "SPECIES", 62, 69], ["spontaneous preterm labor", "PROBLEM", 76, 101], ["severe asphyxia", "PROBLEM", 163, 178], ["Apgar score", "TEST", 180, 191], ["labor", "OBSERVATION", 96, 101], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["asphyxia", "OBSERVATION", 170, 178]]], ["Patient 6 had preterm delivery 30 days after recovery.", [["Patient", "SPECIES", 0, 7]]], ["Patient 8 experienced intrauterine death at presentation.", [["intrauterine", "ANATOMY", 22, 34], ["intrauterine death", "DISEASE", 22, 40], ["Patient", "SPECIES", 0, 7], ["intrauterine death", "PROBLEM", 22, 40]]], ["The other 5 patients, whose gestational ages ranged from 31 weeks to 38 weeks, underwent emergency Cesarean section as soon as the diagnosis of severe pneumonia was made.", [["pneumonia", "DISEASE", 151, 160], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["emergency Cesarean section", "TREATMENT", 89, 115], ["severe pneumonia", "PROBLEM", 144, 160], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["pneumonia", "OBSERVATION", 151, 160]]], ["After delivery, the ventilator settings were downregulated for 4 patients, but for patient 11, who had H1N1 pneumonia, no improvement was observed.", [["pneumonia", "DISEASE", 108, 117], ["patients", "ORGANISM", 65, 73], ["patient", "ORGANISM", 83, 90], ["patients", "SPECIES", 65, 73], ["patient", "SPECIES", 83, 90], ["delivery", "TREATMENT", 6, 14], ["the ventilator settings", "TREATMENT", 16, 39], ["H1N1 pneumonia", "PROBLEM", 103, 117], ["pneumonia", "OBSERVATION", 108, 117], ["no", "UNCERTAINTY", 119, 121], ["improvement", "OBSERVATION_MODIFIER", 122, 133]]], ["Although ECMO was used, her cardiorespiratory condition worsened, and she died 21 days later.", [["ECMO", "TREATMENT", 9, 13], ["her cardiorespiratory condition", "PROBLEM", 24, 55], ["worsened", "OBSERVATION_MODIFIER", 56, 64]]], ["Her newborn infant had mild asphyxia (Apgar score of 7 at 1 min) but recovered well after primary resuscitation.DiscussionThe risk of pneumonia during pregnancy appears to be lowest during the first trimester [2] .", [["asphyxia", "DISEASE", 28, 36], ["pneumonia", "DISEASE", 134, 143], ["infant", "SPECIES", 12, 18], ["mild asphyxia", "PROBLEM", 23, 36], ["Apgar score", "TEST", 38, 49], ["primary resuscitation", "TREATMENT", 90, 111], ["pneumonia", "PROBLEM", 134, 143], ["pregnancy", "PROBLEM", 151, 160], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["asphyxia", "OBSERVATION", 28, 36], ["pneumonia", "OBSERVATION", 134, 143]]], ["Advanced gestational age has been proven to be an independent maternal risk factor for pneumonia [6] .", [["pneumonia", "DISEASE", 87, 96], ["pneumonia", "PROBLEM", 87, 96], ["pneumonia", "OBSERVATION", 87, 96]]], ["Other risk factors for pneumonia in pregnancy include anemia, asthma, smoking, and the use of antepartum corticosteroids and tocolytic agents [8] [9] [10] .", [["pneumonia", "DISEASE", 23, 32], ["anemia", "DISEASE", 54, 60], ["asthma", "DISEASE", 62, 68], ["smoking", "CHEMICAL", 70, 77], ["corticosteroids", "CHEMICAL", 105, 120], ["corticosteroids", "SIMPLE_CHEMICAL", 105, 120], ["tocolytic agents [8] [9] [10]", "SIMPLE_CHEMICAL", 125, 154], ["Other risk factors", "PROBLEM", 0, 18], ["pneumonia in pregnancy", "PROBLEM", 23, 45], ["anemia", "PROBLEM", 54, 60], ["asthma", "PROBLEM", 62, 68], ["antepartum corticosteroids", "TREATMENT", 94, 120], ["tocolytic agents", "TREATMENT", 125, 141], ["pneumonia", "OBSERVATION", 23, 32], ["anemia", "OBSERVATION", 54, 60], ["asthma", "OBSERVATION", 62, 68]]], ["In this case series, all the patients presented during their second or third trimester with a mean gestational age of 30 weeks.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Six patients (6/12, 50%) had anemia at presentation.", [["anemia", "DISEASE", 29, 35], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["anemia", "PROBLEM", 29, 35], ["anemia", "OBSERVATION", 29, 35]]], ["Among these patients, five (5/6, 83%) had hemoglobin levels below 90 g/L. These findings highlighted the possibility of anemia and advanced gestational age as risk factors for severe pneumonia.DiscussionTwenty-five percent of our patients (3/12) had severe preeclampsia, which is much higher than reported prevalence of severe preeclampsia of 0.49% in China [11] .", [["anemia", "DISEASE", 120, 126], ["pneumonia", "DISEASE", 183, 192], ["preeclampsia", "DISEASE", 257, 269], ["preeclampsia", "DISEASE", 327, 339], ["patients", "ORGANISM", 12, 20], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 42, 52], ["patients", "ORGANISM", 230, 238], ["hemoglobin", "PROTEIN", 42, 52], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 230, 238], ["hemoglobin levels", "TEST", 42, 59], ["anemia", "PROBLEM", 120, 126], ["advanced gestational age", "PROBLEM", 131, 155], ["risk factors", "PROBLEM", 159, 171], ["severe pneumonia", "PROBLEM", 176, 192], ["severe preeclampsia", "PROBLEM", 250, 269], ["severe preeclampsia", "PROBLEM", 320, 339], ["highlighted the possibility of", "UNCERTAINTY", 89, 119], ["anemia", "OBSERVATION", 120, 126], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["pneumonia", "OBSERVATION", 183, 192], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["preeclampsia", "OBSERVATION", 257, 269], ["severe", "OBSERVATION_MODIFIER", 320, 326], ["preeclampsia", "OBSERVATION", 327, 339]]], ["Romanyuk et al. and Chen et al. also reported that women with pneumonia had a higher prevalence of preeclampsia/eclampsia than women without pneumonia [3, 12] .", [["pneumonia", "DISEASE", 62, 71], ["preeclampsia", "DISEASE", 99, 111], ["eclampsia", "DISEASE", 112, 121], ["pneumonia", "DISEASE", 141, 150], ["women", "ORGANISM", 51, 56], ["women", "ORGANISM", 127, 132], ["women", "SPECIES", 51, 56], ["women", "SPECIES", 127, 132], ["pneumonia", "PROBLEM", 62, 71], ["preeclampsia", "PROBLEM", 99, 111], ["eclampsia", "PROBLEM", 112, 121], ["pneumonia", "PROBLEM", 141, 150], ["pneumonia", "OBSERVATION", 62, 71], ["preeclampsia", "OBSERVATION", 99, 111], ["eclampsia", "OBSERVATION", 112, 121], ["pneumonia", "OBSERVATION", 141, 150]]], ["This increased incidence of preeclampsia/eclampsia might be the result of the pathophysiological changes associated with pneumonia.", [["preeclampsia", "DISEASE", 28, 40], ["eclampsia", "DISEASE", 41, 50], ["pneumonia", "DISEASE", 121, 130], ["preeclampsia", "PROBLEM", 28, 40], ["eclampsia", "PROBLEM", 41, 50], ["the pathophysiological changes", "PROBLEM", 74, 104], ["pneumonia", "PROBLEM", 121, 130], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["incidence", "OBSERVATION_MODIFIER", 15, 24], ["preeclampsia", "OBSERVATION", 28, 40], ["eclampsia", "OBSERVATION", 41, 50], ["pneumonia", "OBSERVATION", 121, 130]]], ["Severe pneumonia is characterized by hypoxemia, which subsequently causes placental hypoxia.", [["placental", "ANATOMY", 74, 83], ["pneumonia", "DISEASE", 7, 16], ["hypoxemia", "DISEASE", 37, 46], ["placental hypoxia", "DISEASE", 74, 91], ["placental", "ORGAN", 74, 83], ["Severe pneumonia", "PROBLEM", 0, 16], ["hypoxemia", "PROBLEM", 37, 46], ["placental hypoxia", "PROBLEM", 74, 91], ["pneumonia", "OBSERVATION", 7, 16], ["hypoxemia", "OBSERVATION", 37, 46], ["placental", "OBSERVATION_MODIFIER", 74, 83], ["hypoxia", "OBSERVATION", 84, 91]]], ["The hypoxic placenta releases antiangiogenic and proinflammatory factors that converge upon the maternal endothelium, inducing endothelial dysfunction, hypertension, and organ damage [13] .", [["hypoxic placenta", "ANATOMY", 4, 20], ["endothelium", "ANATOMY", 105, 116], ["endothelial", "ANATOMY", 127, 138], ["organ", "ANATOMY", 170, 175], ["endothelial dysfunction", "DISEASE", 127, 150], ["hypertension", "DISEASE", 152, 164], ["organ damage", "DISEASE", 170, 182], ["placenta", "ORGAN", 12, 20], ["endothelium", "TISSUE", 105, 116], ["endothelial", "TISSUE", 127, 138], ["organ", "ORGAN", 170, 175], ["proinflammatory factors", "PROTEIN", 49, 72], ["The hypoxic placenta releases antiangiogenic", "PROBLEM", 0, 44], ["proinflammatory factors", "PROBLEM", 49, 72], ["the maternal endothelium", "PROBLEM", 92, 116], ["endothelial dysfunction", "PROBLEM", 127, 150], ["hypertension", "PROBLEM", 152, 164], ["organ damage", "PROBLEM", 170, 182], ["hypoxic placenta", "OBSERVATION", 4, 20], ["antiangiogenic", "OBSERVATION_MODIFIER", 30, 44], ["endothelial dysfunction", "OBSERVATION", 127, 150], ["hypertension", "OBSERVATION", 152, 164]]], ["The three patients complicated with preeclampsia had significantly lower PaO 2 /FIO 2 ratios than those without preeclampsia (mean value: 118 vs 191, p = 0.004), and two of these patients died.", [["preeclampsia", "DISEASE", 36, 48], ["preeclampsia", "DISEASE", 112, 124], ["patients", "ORGANISM", 10, 18], ["FIO 2", "GENE_OR_GENE_PRODUCT", 80, 85], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 179, 187], ["preeclampsia", "PROBLEM", 36, 48], ["FIO 2 ratios", "TEST", 80, 92], ["preeclampsia", "PROBLEM", 112, 124], ["mean value", "TEST", 126, 136], ["preeclampsia", "OBSERVATION", 36, 48]]], ["Preeclampsia may cause pulmonary edema.", [["pulmonary", "ANATOMY", 23, 32], ["Preeclampsia", "DISEASE", 0, 12], ["pulmonary edema", "DISEASE", 23, 38], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 23, 38], ["Preeclampsia", "PROBLEM", 0, 12], ["pulmonary edema", "PROBLEM", 23, 38], ["may cause", "UNCERTAINTY", 13, 22], ["pulmonary", "ANATOMY", 23, 32], ["edema", "OBSERVATION", 33, 38]]], ["Of all obstetric causes of respiratory failure before delivery, severe preeclampsia is the leading cause [14] .", [["respiratory", "ANATOMY", 27, 38], ["respiratory failure", "DISEASE", 27, 46], ["preeclampsia", "DISEASE", 71, 83], ["all obstetric causes", "PROBLEM", 3, 23], ["respiratory failure", "PROBLEM", 27, 46], ["delivery", "TREATMENT", 54, 62], ["severe preeclampsia", "PROBLEM", 64, 83], ["respiratory failure", "OBSERVATION", 27, 46], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["preeclampsia", "OBSERVATION", 71, 83]]], ["A possible explanation for this outcome is that the pulmonary edema caused by severe preeclampsia aggravates the oxygen desaturation caused by pneumonia, predisposing the patient to require a mechanical ventilator.", [["pulmonary", "ANATOMY", 52, 61], ["pulmonary edema", "DISEASE", 52, 67], ["preeclampsia", "DISEASE", 85, 97], ["oxygen", "CHEMICAL", 113, 119], ["desaturation", "DISEASE", 120, 132], ["pneumonia", "DISEASE", 143, 152], ["oxygen", "CHEMICAL", 113, 119], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 52, 67], ["oxygen", "SIMPLE_CHEMICAL", 113, 119], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178], ["the pulmonary edema", "PROBLEM", 48, 67], ["severe preeclampsia", "PROBLEM", 78, 97], ["the oxygen desaturation", "PROBLEM", 109, 132], ["pneumonia", "PROBLEM", 143, 152], ["a mechanical ventilator", "TREATMENT", 190, 213], ["possible explanation for", "UNCERTAINTY", 2, 26], ["pulmonary", "ANATOMY", 52, 61], ["edema", "OBSERVATION", 62, 67], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["preeclampsia", "OBSERVATION", 85, 97], ["oxygen desaturation", "OBSERVATION", 113, 132], ["pneumonia", "OBSERVATION", 143, 152], ["mechanical ventilator", "OBSERVATION", 192, 213]]], ["Preeclampsia complicated with pneumonia may be an unfavorable predictive factor for a poor maternal outcome.", [["Preeclampsia", "DISEASE", 0, 12], ["pneumonia", "DISEASE", 30, 39], ["Preeclampsia", "PROBLEM", 0, 12], ["pneumonia", "PROBLEM", 30, 39], ["an unfavorable predictive factor", "PROBLEM", 47, 79], ["a poor maternal outcome", "PROBLEM", 84, 107], ["pneumonia", "OBSERVATION", 30, 39], ["unfavorable", "OBSERVATION_MODIFIER", 50, 61]]], ["Table 3 Maternal and fetal/neonatal outcomes Case 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 Proportion (%)Maternal outcomesDeath (17) Septic shock - (17) Fetal/neonatal outcomes (17) Preterm birth NA NA NA NAMaternal outcomesARDS adult respiratory distress syndrome, PE preeclampsia, IUD intrauterine death, CS cesarean section Initial misdiagnosis in pregnant patients is not uncommon.", [["fetal", "ANATOMY", 21, 26], ["intrauterine", "ANATOMY", 276, 288], ["shock", "DISEASE", 129, 134], ["NA", "CHEMICAL", 185, 187], ["NA", "CHEMICAL", 191, 193], ["respiratory distress syndrome", "DISEASE", 224, 253], ["PE preeclampsia", "DISEASE", 255, 270], ["intrauterine death", "DISEASE", 276, 294], ["misdiagnosis", "DISEASE", 324, 336], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 21, 26], ["patients", "ORGANISM", 349, 357], ["patients", "SPECIES", 349, 357], ["Maternal outcomesDeath", "TEST", 94, 116], ["Septic shock", "PROBLEM", 122, 134], ["Fetal/neonatal outcomes", "PROBLEM", 142, 165], ["Preterm birth", "PROBLEM", 171, 184], ["adult respiratory distress syndrome", "PROBLEM", 218, 253], ["PE preeclampsia", "PROBLEM", 255, 270], ["IUD intrauterine death", "PROBLEM", 272, 294], ["CS cesarean section", "TREATMENT", 296, 315], ["Septic shock", "OBSERVATION", 122, 134], ["respiratory distress", "OBSERVATION", 224, 244], ["PE", "OBSERVATION_MODIFIER", 255, 257], ["preeclampsia", "OBSERVATION", 258, 270]]], ["When reviewing the clinical data of these 12 patients, we observed that the initial clinical symptoms were similar to those in nonpregnant women, such as fever, cough, malaise, and dyspnea.", [["fever", "DISEASE", 154, 159], ["cough", "DISEASE", 161, 166], ["dyspnea", "DISEASE", 181, 188], ["patients", "ORGANISM", 45, 53], ["women", "ORGANISM", 139, 144], ["patients", "SPECIES", 45, 53], ["women", "SPECIES", 139, 144], ["the initial clinical symptoms", "PROBLEM", 72, 101], ["fever", "PROBLEM", 154, 159], ["cough", "PROBLEM", 161, 166], ["malaise", "PROBLEM", 168, 175], ["dyspnea", "PROBLEM", 181, 188]]], ["It is not easy to distinguish between symptoms related to physiological changes and more sinister symptoms of pneumonia during pregnancy.", [["pneumonia", "DISEASE", 110, 119], ["symptoms", "PROBLEM", 38, 46], ["physiological changes", "PROBLEM", 58, 79], ["pneumonia during pregnancy", "PROBLEM", 110, 136], ["pneumonia", "OBSERVATION", 110, 119]]], ["Patient 12 in this case series attended regular antenatal care visits at our hospital; this patient's pneumonia began with the symptoms of a common cold.", [["pneumonia", "DISEASE", 102, 111], ["patient", "ORGANISM", 92, 99], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 92, 99], ["this patient's pneumonia", "PROBLEM", 87, 111], ["the symptoms", "PROBLEM", 123, 135], ["a common cold", "PROBLEM", 139, 152], ["pneumonia", "OBSERVATION", 102, 111]]], ["Three days later, when she developed dyspnea, labor started.", [["dyspnea", "DISEASE", 37, 44], ["dyspnea", "PROBLEM", 37, 44], ["labor", "PROBLEM", 46, 51], ["dyspnea", "OBSERVATION", 37, 44]]], ["Her respiratory symptoms were intermixed with the discomfort of labor pain.", [["respiratory", "ANATOMY", 4, 15], ["labor pain", "DISEASE", 64, 74], ["Her respiratory symptoms", "PROBLEM", 0, 24], ["the discomfort of labor pain", "PROBLEM", 46, 74], ["respiratory", "ANATOMY", 4, 15]]], ["This made the early recognition of pneumonia more difficult.", [["pneumonia", "DISEASE", 35, 44], ["pneumonia", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 35, 44]]], ["It must be emphasized that close observation is very important; chest radiography should never be withheld from a pregnant woman in whom pneumonia is suspected since the radiation exposure through even multiple diagnostic X-ray procedures or chest CT rarely reaches the dose associated with fetal harm [15] .Maternal outcomesThere are limited publications regarding the timing of delivery.", [["chest", "ANATOMY", 64, 69], ["chest", "ANATOMY", 242, 247], ["fetal", "ANATOMY", 291, 296], ["pneumonia", "DISEASE", 137, 146], ["chest", "ORGANISM_SUBDIVISION", 64, 69], ["woman", "ORGANISM", 123, 128], ["fetal", "ORGANISM_SUBDIVISION", 291, 296], ["woman", "SPECIES", 123, 128], ["chest radiography", "TEST", 64, 81], ["pneumonia", "PROBLEM", 137, 146], ["the radiation exposure", "PROBLEM", 166, 188], ["multiple diagnostic X-ray procedures", "TREATMENT", 202, 238], ["chest CT", "TEST", 242, 250], ["delivery", "TREATMENT", 380, 388], ["pneumonia", "OBSERVATION", 137, 146], ["chest", "ANATOMY", 242, 247]]], ["Previous reviews and articles have noted that early delivery is beneficial and potentially life-saving for both mother and fetus [16, 17] .", [["fetus", "ANATOMY", 123, 128], ["fetus", "ORGAN", 123, 128]]], ["However, earlier on in gestation, the size of the uterus should not affect mechanical ventilation significantly, and the fetus may be nonviable at this younger gestational age.", [["uterus", "ANATOMY", 50, 56], ["fetus", "ANATOMY", 121, 126], ["uterus", "ORGAN", 50, 56], ["fetus", "ORGANISM", 121, 126], ["mechanical ventilation", "TREATMENT", 75, 97], ["size", "OBSERVATION_MODIFIER", 38, 42], ["uterus", "ANATOMY", 50, 56], ["should not affect", "UNCERTAINTY", 57, 74], ["mechanical ventilation", "OBSERVATION", 75, 97]]], ["Additionally, the risk of a surgical procedure for a patient in such a critical condition is extremely high.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["a surgical procedure", "TREATMENT", 26, 46], ["a critical condition", "PROBLEM", 69, 89], ["surgical", "OBSERVATION", 28, 36]]], ["In our case series, pregnancies were continued in 4 patients during 18 to 25 weeks of gestation; the 4 mothers all recovered from pneumonia, but one of them had a spontaneous miscarriage 40 days after the onset of illness.", [["pneumonia", "DISEASE", 130, 139], ["miscarriage", "DISEASE", 175, 186], ["illness", "DISEASE", 214, 221], ["patients", "ORGANISM", 52, 60], ["mothers", "ORGANISM", 103, 110], ["patients", "SPECIES", 52, 60], ["pneumonia", "PROBLEM", 130, 139], ["a spontaneous miscarriage", "PROBLEM", 161, 186], ["illness", "PROBLEM", 214, 221], ["pneumonia", "OBSERVATION", 130, 139]]], ["The other 3 pregnancies were uneventful, and live fetuses were discharged from the hospital.", [["fetuses", "ANATOMY", 50, 57], ["fetuses", "ORGANISM", 50, 57]]], ["Chang et al. and Liao et al. also reported cases of atypical pneumonia requiring mechanical ventilation during the second trimester without complications to either the mother or the newborn [18, 19] .", [["pneumonia", "DISEASE", 61, 70], ["atypical pneumonia", "PROBLEM", 52, 70], ["mechanical ventilation", "TREATMENT", 81, 103], ["complications", "PROBLEM", 140, 153], ["atypical", "OBSERVATION_MODIFIER", 52, 60], ["pneumonia", "OBSERVATION", 61, 70], ["mechanical ventilation", "OBSERVATION", 81, 103]]], ["However, during the third trimester, since elective delivery causes a 28% reduction in oxygen requirements within 24 h [17] , and since there is a high rate of adverse pregnancy outcomes in maternal pneumonia [3, 20] , most case series in the literature suggest an expeditious delivery after 28 weeks of gestation [1, 6] .", [["oxygen", "CHEMICAL", 87, 93], ["pneumonia", "DISEASE", 199, 208], ["oxygen", "CHEMICAL", 87, 93], ["oxygen", "SIMPLE_CHEMICAL", 87, 93], ["elective delivery", "TREATMENT", 43, 60], ["a 28% reduction in oxygen requirements", "TREATMENT", 68, 106], ["a high rate of adverse pregnancy outcomes", "PROBLEM", 145, 186], ["maternal pneumonia", "PROBLEM", 190, 208], ["an expeditious delivery", "TREATMENT", 262, 285], ["oxygen requirements", "OBSERVATION", 87, 106], ["pneumonia", "OBSERVATION", 199, 208]]], ["In our case series, 86% of our patients (6/7) who presented after 28 weeks of gestation with live fetuses underwent delivery soon after the diagnosis of severe pneumonia was made.", [["fetuses", "ANATOMY", 98, 105], ["pneumonia", "DISEASE", 160, 169], ["patients", "ORGANISM", 31, 39], ["fetuses", "ORGANISM", 98, 105], ["patients", "SPECIES", 31, 39], ["live fetuses", "PROBLEM", 93, 105], ["delivery", "TREATMENT", 116, 124], ["severe pneumonia", "PROBLEM", 153, 169], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["pneumonia", "OBSERVATION", 160, 169]]], ["Their fetal and maternal outcomes were mostly good, except for one neonatal death (patient 5) and one maternal death (patient 11).", [["fetal", "ANATOMY", 6, 11], ["death", "DISEASE", 76, 81], ["death", "DISEASE", 111, 116], ["fetal", "ANATOMICAL_SYSTEM", 6, 11], ["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 118, 125], ["one neonatal death", "PROBLEM", 63, 81], ["one maternal death", "PROBLEM", 98, 116]]], ["According to the reported cases in the literature and the experiences of our hospital, it seems reasonable to terminate pregnancies for patients in their third trimester and to continue pregnancies for those in their first or second trimester.Maternal outcomesOur study included only 12 patients, and it was a retrospective study.", [["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 287, 295], ["pregnancies", "TREATMENT", 186, 197], ["Our study", "TEST", 260, 269], ["a retrospective study", "TEST", 308, 329]]], ["These limitations should be taken into account when interpreting the results of the study.ConclusionsIn conclusion, severe pneumonia complicating pregnancy was associated with high maternal morbidity and mortality.", [["pneumonia", "DISEASE", 123, 132], ["the study", "TEST", 80, 89], ["severe pneumonia complicating pregnancy", "PROBLEM", 116, 155], ["high maternal morbidity", "PROBLEM", 176, 199], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["pneumonia", "OBSERVATION", 123, 132]]], ["High incidences of adverse fetal outcomes, such as intrauterine death, preterm birth and cesarean section, were also observed.", [["fetal", "ANATOMY", 27, 32], ["intrauterine", "ANATOMY", 51, 63], ["intrauterine death", "DISEASE", 51, 69], ["preterm birth", "DISEASE", 71, 84], ["fetal", "ANATOMICAL_SYSTEM", 27, 32], ["adverse fetal outcomes", "PROBLEM", 19, 41], ["intrauterine death", "PROBLEM", 51, 69], ["preterm birth", "PROBLEM", 71, 84], ["cesarean section", "TREATMENT", 89, 105], ["adverse fetal outcomes", "OBSERVATION", 19, 41]]], ["Anemia, advanced gestational age, and preeclampsia were associated with the severity of pneumonia.", [["Anemia", "DISEASE", 0, 6], ["preeclampsia", "DISEASE", 38, 50], ["pneumonia", "DISEASE", 88, 97], ["Anemia", "PROBLEM", 0, 6], ["advanced gestational age", "PROBLEM", 8, 32], ["preeclampsia", "PROBLEM", 38, 50], ["pneumonia", "PROBLEM", 88, 97], ["advanced", "OBSERVATION_MODIFIER", 8, 16], ["preeclampsia", "OBSERVATION", 38, 50], ["pneumonia", "OBSERVATION", 88, 97]]], ["Patients with dyspnea, fever and chest pain should be evaluated carefully; chest radiographs should be taken when the diagnosis of pneumonia is highly suspected.", [["chest", "ANATOMY", 33, 38], ["chest", "ANATOMY", 75, 80], ["dyspnea", "DISEASE", 14, 21], ["fever", "DISEASE", 23, 28], ["chest pain", "DISEASE", 33, 43], ["pneumonia", "DISEASE", 131, 140], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["dyspnea", "PROBLEM", 14, 21], ["fever", "PROBLEM", 23, 28], ["chest pain", "PROBLEM", 33, 43], ["chest radiographs", "TEST", 75, 92], ["pneumonia", "PROBLEM", 131, 140], ["dyspnea", "OBSERVATION", 14, 21], ["fever", "OBSERVATION", 23, 28], ["chest", "ANATOMY", 33, 38], ["chest", "ANATOMY", 75, 80], ["pneumonia", "OBSERVATION", 131, 140]]], ["Termination of pregnancy is recommended when respiratory function deteriorates progressively despite treatment for patients in their third trimester; it might be reasonable to continue pregnancies for those in their first or second trimester.", [["respiratory", "ANATOMY", 45, 56], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["respiratory function", "PROBLEM", 45, 65], ["treatment", "TREATMENT", 101, 110]]]], "b5d9ac891eceebbb139a9e367ab4cd7dbccb64f4": [["It has presented governments, healthcare services, and education facilities with wide-scale and complex logistical challenges on how to manage the rapid spread of the disease and minimise the projected human and economic costs.", [["human", "ORGANISM", 202, 207], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["wide-scale", "TREATMENT", 81, 91], ["the disease", "PROBLEM", 163, 174], ["disease", "OBSERVATION", 167, 174]]], ["Given that, to date, there is no vaccine to protect against COVID-19, non-pharmacological intervention is the only currently available means to reduce the spread of SARS-CoV-2, the virus that causes COVID-19, and \"flatten the curve\" of infection rates.", [["COVID-19", "CHEMICAL", 60, 68], ["SARS", "DISEASE", 165, 169], ["infection", "DISEASE", 236, 245], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV-2", "SPECIES", 165, 175], ["vaccine", "TREATMENT", 33, 40], ["COVID", "TEST", 60, 65], ["non-pharmacological intervention", "TREATMENT", 70, 102], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["the virus", "PROBLEM", 177, 186], ["COVID", "TEST", 199, 204], ["infection rates", "PROBLEM", 236, 251], ["infection", "OBSERVATION", 236, 245]]], ["In response, national and statewide governmental measures aimed at minimising transmission of the virus including \"stay at home\" orders, closure of businesses and places of congregation, and travel restrictions have had a substantive impact on mortality rates (Worldometer, 2020) .", [["statewide governmental measures", "TREATMENT", 26, 57], ["the virus", "PROBLEM", 94, 103], ["closure of businesses", "TREATMENT", 137, 158]]], ["As rates of infection dissipate in some countries, particularly in countries like Australia that have relatively low rates of daily infections, governments are now beginning to ease restrictions.", [["infection", "DISEASE", 12, 21], ["infections", "DISEASE", 132, 142], ["infection", "PROBLEM", 12, 21], ["infection", "OBSERVATION", 12, 21]]], ["However, preventive behaviors aimed at reducing infection rates remain highly pertinent given concerns over the potential for infection rates to rise again and fears of a \"second wave\".", [["infection", "DISEASE", 48, 57], ["infection", "DISEASE", 126, 135], ["preventive behaviors", "PROBLEM", 9, 29], ["reducing infection rates", "PROBLEM", 39, 63], ["infection rates", "PROBLEM", 126, 141], ["a \"second wave\"", "PROBLEM", 169, 184], ["infection", "OBSERVATION", 126, 135]]], ["Furthermore, some countries who are easing lockdown measures, such as some states in the US, still have high localised rates of infection, highlighting the imperative of ongoing performance of preventive behaviors to manage infection transmission.INTRODUCTIONBased on World Health Organization (WHO) recommendations (World Health Organization, 2020) and previous research on behaviors known to reduce virus transmission (Jefferson et al., 2011; Rabie & Curtis, 2006; Smith et al., 2015) , two key sets of COVID-19-related behaviors that may apply to the population as a whole have been proposed .", [["infection", "DISEASE", 128, 137], ["infection", "DISEASE", 224, 233], ["high localised rates of infection", "PROBLEM", 104, 137], ["infection transmission", "PROBLEM", 224, 246], ["COVID", "TEST", 505, 510], ["infection", "OBSERVATION", 128, 137]]], ["The first set is \"personal protective behaviors\" that are aimed at the individual in order to protect themselves or others (e.g. washing hands frequently, practicing respiratory hygiene).", [["respiratory", "ANATOMY", 166, 177]]], ["The second set involves behaviors aimed at ensuring physical distance between people (e.g. social distancing, stay at home orders).", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84]]], ["In the absence of direct evidence, knowledge to inform practice guidelines that governments and organisations can use to mobilise individuals into performing COVID-19 preventive behaviors has been gleaned from applying general principles from behavioral science and the models of behavior that underpin them (Lunn et al., 2020; Michie et al., 2020; British Psychological Society, 2020; West et al., 2020) as well as findings of previous empirical investigations in the psychological literature on similar health and risk behaviors (e.g. face mask use, handwashing, distancing; Chu et al., 2020; Reyes Fern andez et al., 2016; Zhang, Chung, et al., 2019; Zhang et al., 2020) .", [["general principles", "TREATMENT", 219, 237], ["previous empirical investigations", "TEST", 428, 461]]], ["Although this approach is potentially useful in structuring thinking and recommendations in urgent times, there is a pressing need for direct evidence that identifies the key determinants of these COVID-19 preventive behaviors and the processes involved.", [["these COVID", "TEST", 191, 202]]], ["This knowledge can then be used to inform development of effective interventions to promote uptake and adherence to these behaviors.", [["effective interventions", "TREATMENT", 57, 80]]], ["This is especially important given that individuals' beliefs may affect their adoption of non-pharmacological measures to prevent virus transmission (Teasdale et al., 2014) .INTRODUCTIONProminent among social cognition theories are dual-phase models which aim to provide a comprehensive theoretical account of health behavior uptake and participation, and the processes involved (Hagger, Cameron, Hamilton, Hankonen, & Lintunen, 2020; Hagger, Smith, Keech, Moyers, & Hamilton, 2020) .", [["non-pharmacological measures", "TREATMENT", 90, 118]]], ["The HAPA is an integrated model that combines features of stage, continuum, and dual-phase social cognition models.INTRODUCTIONA key feature of the model is the distinction made between motivational (where an individual is in a deliberative mindset while setting a goal/forming an intention) and volitional (where an individual is in an implementation mindset while pursuing their goal) phases involved in behavioral enactment.", [["HAPA", "DNA", 4, 8], ["stage, continuum", "PROBLEM", 58, 74]]], ["Intentions are proposed to be a function of three sets of belief-based constructs: outcome expectancies (beliefs that the target behavior will lead to outcomes that have utility for the individual, conceptually identical to an individual's attitudes toward the behavior), self-efficacy (beliefs in personal capacity to successfully perform the target behavior and overcome challenges and barriers to its performance), and risk perceptions (beliefs in the severity of a health condition that may arise from not performing the target behavior and personal vulnerability toward it).INTRODUCTIONIn the volitional phase of the HAPA, planning and action control strategies are important self-regulatory strategies that determine subsequent enactment of the target behavior (Schwarzer, 2008; Schwarzer & Hamilton, 2020) .", [["the HAPA", "TREATMENT", 618, 626], ["action control strategies", "TREATMENT", 641, 666], ["self-regulatory strategies", "TREATMENT", 681, 707]]], ["Two forms of planning are proposed: action planning, a task-facilitating strategy that relates to how individuals prepare themselves in performing a behavior, and coping planning, a distraction-inhibiting strategy that relates to how individuals prepare themselves in avoiding foreseen barriers and obstacles that may arise when performing a specific behavior, and potentially competing behaviors that may derail the behavior.", [["a distraction", "TREATMENT", 180, 193]]], ["In addition, action control, a self-regulatory strategy for promoting behavioral maintenance through the monitoring and evaluation of a behavior against a desired behavioral standard, is also an important direct determinant of behavior (Hamilton et al., 2018; Reyes Fern andez et al., 2016) .INTRODUCTIONBehavioral intention operates as a \"bridge\" between the motivational and volitional phases, while planning serves to link intentions with behavior.", [["action control", "TREATMENT", 13, 27], ["a self-regulatory strategy", "TREATMENT", 29, 55], ["promoting behavioral maintenance", "TREATMENT", 60, 92], ["the monitoring", "TEST", 101, 115], ["evaluation", "TEST", 120, 130]]], ["Previous research has provided support for the HAPA constructs in predicting health preventive behaviors, with prominent roles for outcome expectancies, forms of selfefficacy, planning and action control, with risk perceptions only relevant in certain contexts (see Schwarzer & Hamilton, 2020; .", [["HAPA constructs", "DNA", 47, 62], ["the HAPA constructs", "TREATMENT", 43, 62], ["action control", "TREATMENT", 189, 203]]], ["Furthermore, the model has been used as a basis for effective behavior change interventions aimed at promoting increased participation in health-related behaviors (Schwarzer & Hamilton, 2020) .The Present StudyGiven that social distancing is a key evidence-based behavior that will minimise transmission of SARS-CoV-2 if performed consistently at the population level, the aim of the present study was to apply the HAPA to identify the social cognition and self-regulatory determinants of this preventive behavior in samples of adults from two countries, Australia and the US.", [["SARS", "DISEASE", 307, 311], ["SARS-CoV-2", "ORGANISM", 307, 317], ["SARS-CoV", "SPECIES", 307, 315], ["effective behavior change interventions", "TREATMENT", 52, 91], ["CoV", "TEST", 312, 315], ["the US", "TEST", 569, 575], ["increased", "OBSERVATION_MODIFIER", 111, 120]]], ["Specifically, the current research aimed to identify potentially modifiable determinants that are reliably related to social distancing intentions and behavior, which may form targets of behavioral interventions to reduce COVID-19 infection rates, and, going forward, other communicable diseases transmitted through person-to-person contact.", [["infection", "DISEASE", 231, 240], ["communicable diseases", "DISEASE", 274, 295], ["person", "SPECIES", 316, 322], ["person", "SPECIES", 326, 332], ["behavioral interventions", "TREATMENT", 187, 211], ["COVID", "TEST", 222, 227], ["infection rates", "PROBLEM", 231, 246]]], ["The value of applying the HAPA is that it provides information on phase-relevant constructs in determining this important behavior.", [["HAPA", "DNA", 26, 30]]], ["Proposed predictions among model constructs are summarised diagrammatically in Figures 1 and 2 .", [["model constructs", "OBSERVATION", 27, 43]]], ["Figure 1 presents the HAPA predictions excluding effects of past social distancing behavior.The Present StudyIntention to perform social distancing was expected to be predicted by attitude (as a proxy for outcome expectancies), self-efficacy, and risk perceptions, and social distancing behavior was expected to be predicted by self-efficacy, intentions, action planning, coping planning, and action control.", [["coping planning", "TREATMENT", 372, 387], ["action control", "TREATMENT", 393, 407]]], ["In addition, intention was expected to predict action planning and coping planning such that the planning constructs mediate the intention-behavior relationship.", [["action planning", "TREATMENT", 47, 62], ["coping planning", "TREATMENT", 67, 82]]], ["Action control was proposed to predict behavior directly.", [["Action control", "TREATMENT", 0, 14]]], ["Although it is strictly a self-regulation technique aimed at facilitating better behavioral enactment, as proposed by the original HAPA (e.g. Schwarzer, 2008) , individuals who are effective at action control (i.e. self-monitoring) may also more likely form strong intentions.", [["a self-regulation technique", "TREATMENT", 24, 51]]], ["The coexistence of intention and action control within the same dataset allows this key question to be tested; which of the two factors may be more proximal to the behavioral outcome?", [["action control", "TREATMENT", 33, 47]]], ["Action control might not be a time-specific variable, and individuals may self-monitor their behaviors at any point in time (see Zhou et al., 2015) , even before goal setting.", [["Action control", "TREATMENT", 0, 14]]], ["Thus, examining the indirect (via intention) and direct effects of action control on behavior is intuitively meaningful, although not supported by the original HAPA, and tested in the present study.", [["action control", "TREATMENT", 67, 81], ["the present study", "TEST", 180, 197]]], ["Although model effects were expected to hold with the inclusion of past behavior, it was expected to attenuate the size of the proposed effects consistent with previous studies (Brown et al., 2020; Hagger et al., 2018) .", [["previous studies", "TEST", 160, 176], ["size", "OBSERVATION_MODIFIER", 115, 119], ["consistent with", "UNCERTAINTY", 144, 159]]], ["This was expected to be the case in the current study due to the relatively brief one-week follow up.", [["the current study", "TEST", 36, 53]]], ["The attenuation effect was proposed to model past decision making and effects of other unmeasured constructs on behavior.METHOD ParticipantsA sample of Australian (N = 495, 50.1% women) and US (N = 701, 48.9% women) residents were recruited via an online research panel company.", [["women", "ORGANISM", 179, 184], ["women", "ORGANISM", 209, 214], ["women", "SPECIES", 179, 184], ["women", "SPECIES", 209, 214], ["The attenuation effect", "PROBLEM", 0, 22], ["other unmeasured constructs on behavior", "PROBLEM", 81, 120], ["US", "TEST", 190, 192], ["attenuation effect", "OBSERVATION", 4, 22]]], ["To be eligible for inclusion, participants needed to be aged 18 years or older and were required to not be subject to formal quarantine for COVID-19.", [["participants", "SPECIES", 30, 42], ["COVID", "TEST", 140, 145]]], ["In addition to the inclusion criteria, participants were screened on the demographic characteristics of age, gender, and geographical region and quotas were imposed to ensure that the sample comprised similar proportions of these characteristics to the national population of each country.", [["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51]]], ["Sample characteristics are presented in Table S1 .", [["S1", "ANATOMY", 46, 48]]], ["Data were collected in April and May 2020 during which time residents throughout Australia and all states in the US were subject to \"stay at home\" orders to reduce transmission of the coronavirus.Design and ProcedureThe study adopted a prospective correlational design with self-report measures of HAPA constructs (attitudes, self-efficacy, risk perceptions, intentions, action planning, coping planning, and action control) and past engagement in social distancing behavior administered at an initial time-point (T1) in a survey administered using the Qualtrics TM online survey tool.", [["coronavirus", "DISEASE", 184, 195], ["coronavirus", "ORGANISM", 184, 195], ["HAPA constructs", "DNA", 298, 313], ["the coronavirus", "PROBLEM", 180, 195], ["Procedure", "TREATMENT", 207, 216], ["The study", "TEST", 216, 225], ["HAPA constructs", "TREATMENT", 298, 313], ["action planning", "TREATMENT", 371, 386], ["coping planning", "TREATMENT", 388, 403], ["action control", "TREATMENT", 409, 423]]], ["Participants were informed that they were participating in a survey on their social distancing behavior and were provided with an information sheet outlining study requirements.", [["Participants", "SPECIES", 0, 12]]], ["Participants were also provided with an information sheet providing instructions on how to complete the study measures.", [["Participants", "SPECIES", 0, 12], ["the study measures", "TEST", 100, 118]]], ["Social distancing (also known as 'physical distancing') is deliberately increasing the physical space between people to avoid spreading illness.", [["illness", "DISEASE", 136, 143], ["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["spreading illness", "PROBLEM", 126, 143]]], ["The World Health Organization and other world leading health authorities suggest that you should maintain at least a 1-2 m (3-6 feet) distance from other people to lessen the chances of getting infected with COVID-19.", [["COVID-19", "CHEMICAL", 208, 216], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160], ["COVID", "TEST", 208, 213]]], ["When answering the questions in this survey, think about your social distancing behavior (i.e. maintaining at least a 1-2 m (3-6 feet) distance from other people).\"", [["people", "SPECIES", 155, 161]]], ["One week later (T2), participants were contacted a second time by the panel company and were asked to self-report their social distancing behavior over the previous week using the same behavioral measure administered at T1.", [["participants", "SPECIES", 21, 33]]], ["Participants received a fixed sum of money for their participation based on expected completion time consistent with the panel company's published rates.", [["Participants", "SPECIES", 0, 12]]], ["Approval for study procedures was granted prior to data collection from the Griffith University Human Research Ethics Committee.MeasuresStudy measures were carried out on multi-item psychometric instruments developed using published guidelines and adapted for use with the target behavior in the current study (Schwarzer, 2008) .", [["Human", "ORGANISM", 96, 101], ["Human", "SPECIES", 96, 101], ["study procedures", "TEST", 13, 29], ["Study measures", "TEST", 136, 150], ["published guidelines", "TREATMENT", 223, 243]]], ["Participants provided their responses on scales with 7-point response options.", [["Participants", "SPECIES", 0, 12]]], ["Complete study measures are provided in Table S2 .MeasuresSocial Cognition Constructs.", [["Complete study measures", "TEST", 0, 23]]], ["Measures of attitudes, self-efficacy, risk perceptions, intentions, action planning, coping planning, and action control from the HAPA were developed according to guidelines (Schwarzer, 2007) .", [["coping planning", "TREATMENT", 85, 100]]], ["Attitude was measured using three semantic differential items in response to a common stem: \"My maintaining social distancing in the next week would be...\", followed by a series of bi-polar adjectives (e.g. (1) worthless -(7) valuable).", [["stem", "TISSUE", 86, 90], ["common stem", "ANATOMY", 79, 90]]], ["Participants were required to respond to the stem: \"In the next week, I have made a plan regarding...\", followed by the four items of the scale (e.g. \". . .when to maintain social distancing\") on Likert scales ranging from strongly disagree (1) to strongly agree (7).", [["Participants", "SPECIES", 0, 12], ["Likert scales", "TEST", 196, 209]]], ["Participants were required to respond to the stem: \"To keep my intention to maintain social distancing in the next week in difficult situations, I have made a plan...\", followed by the four items of the scale (e.g. \". . .what to do if something interferes with my goal of maintaining social distancing\") on Likert scales ranging from strongly disagree (1) to strongly agree (7).", [["Participants", "SPECIES", 0, 12], ["Likert scales", "TEST", 307, 320]]], ["Action control was measured using three items (e.g.", [["Action control", "TREATMENT", 0, 14]]], ["\"I have consistently monitored when, how often, and how to maintain social distancing\"), scored (1) strongly disagree to (7) strongly agree).MeasuresPast Behavior and Behavior.Participants self-reported their participation in the target behavior maintaining social distancing in relation to others to minimise transmission of the coronavirus that causes COVID-19.", [["coronavirus", "DISEASE", 330, 341], ["coronavirus", "ORGANISM", 330, 341], ["Participants", "SPECIES", 176, 188], ["the coronavirus", "PROBLEM", 326, 341], ["COVID", "TEST", 354, 359]]], ["The measure comprised two items prompting participants to report their frequency of social distancing behavior in the previous week: \"In the past week, how often did you maintain social distancing?\", scored (1) never to (7) always and \"In the past week, I maintained social distancing\", scored (1) false to (7) true.MeasuresDemographic Variables.", [["participants", "SPECIES", 42, 54]]], ["Participants self-reported their age in years, gender, employment status (currently unemployed/full time caregiver, currently full-time employed, part-time employed, on leave without pay/furloughed), marital status (married, widowed, separated/divorced, never married, in a de facto relationship), annual household income stratified by 11 income levels based on Australia and US national averages, and highest level of formal education (completed junior/lower/primary school, completed senior/high/secondary school, postschool vocational qualification/diploma, further education diploma, undergraduate university degree, postgraduate university degree).", [["Participants", "SPECIES", 0, 12]]], ["Binary income (low income versus middle/high income), 1 highest education level (completed school education only versus completed post-school education), and ethnicity (white/ Caucasian versus non-white) variables were computed for use in subsequent analyses.Data analysisHypothesised relations among HAPA constructs in the proposed model were tested in the Australia and US sample separately using single-indicator structural equation models implemented in the lavaan package in R (R Core Team, 2020; Rosseel, 2012) .", [["HAPA constructs", "DNA", 301, 316], ["ethnicity (white/ Caucasian versus non-white) variables", "PROBLEM", 158, 213], ["Data analysis", "TEST", 259, 272]]], ["We opted for single-indicator models over a full latent variable structural equation model due to the complexity of the model and the large number of parameters.", [["large", "OBSERVATION_MODIFIER", 134, 139]]], ["Participants reporting incomes of $400-$599 per week ($20,800-$31,199 per year) or below were classified as low income.Data analysisprovide an estimate of the measurement error of each variable in the model.", [["Participants", "SPECIES", 0, 12], ["Data analysisprovide", "TEST", 119, 139], ["the measurement error", "TEST", 155, 176]]], ["Simulation studies have demonstrated that parameter estimates and model fit of single-indicator models compare very favorably with full latent variable structural equation models, particularly when sample sizes are small (Savalei, 2019) .Data analysisWe freed parameters between the single-indicator latent variables according to our proposed model.", [["Simulation studies", "TEST", 0, 18], ["parameter estimates", "TEST", 42, 61], ["full latent variable structural equation models", "PROBLEM", 131, 178], ["structural equation", "OBSERVATION", 152, 171], ["sizes", "OBSERVATION_MODIFIER", 205, 210], ["small", "OBSERVATION_MODIFIER", 215, 220]]], ["The FIML approach is a preferred approach to handling missing data as simulation studies indicate that it leads to unbiased parameter estimates in structural equation modeling (Enders & Bandalos, 2001; Wothke, 1998) .Data analysisModel comparisons across the Australia and US samples were conducted using multigroup analyses.", [["simulation studies", "TEST", 70, 88], ["Data analysis", "TEST", 217, 230], ["US samples", "TEST", 273, 283], ["multigroup analyses", "TEST", 305, 324]]], ["An initial configural multisample model for the model excluding past behavior was estimated (Model 3), which provided evidence for the tenability of the model in accounting for the data across both samples.", [["the data", "TEST", 177, 185]]], ["This was followed by a restricted model in which the parameter estimates representing proposed relations among the HAPA constructs and behavior were constrained to equality across the two samples (Model 4).", [["HAPA constructs", "DNA", 115, 130], ["a restricted model", "TREATMENT", 21, 39], ["the HAPA constructs", "TREATMENT", 111, 130]]], ["This was established using a formal likelihood ratio test of the goodness-of-fit chi-square for the configural and constrained models (Byrne et al., 1989) .", [["a formal likelihood ratio test", "TEST", 27, 57], ["the goodness", "TEST", 61, 73]]], ["We also examined differences in the CFI; differences of less than .01 between values for the configural and constrained models have also been proposed as indicative of invariance of parameters (Cheung & Rensvold, 2002) .", [["CFI", "DNA", 36, 39], ["the CFI", "TEST", 32, 39], ["indicative of", "UNCERTAINTY", 154, 167]]], ["The configural (Model 5) and constrained (Model 6) multisample analyses were repeated for the model including past behavior.Data analysisModels were implemented using the maximum likelihood estimator with bootstrapped standard errors with 1,000 bootstrap replications.", [["constrained (Model 6) multisample analyses", "TEST", 29, 71], ["Data analysisModels", "TEST", 124, 143], ["1,000 bootstrap replications", "TREATMENT", 239, 267]]], ["Goodness of fit of the models with the data was evaluated using multiple criteria comparing the proposed model with the baseline model including the goodness-of-fit chi-square (v 2 ), the comparative fit index (CFI), the standardised root mean-squared of the residuals (SRMR), and the root mean square error of approximation (RMSEA) and its 90% confidence interval (90% CI).", [["the goodness", "TEST", 145, 157], ["the standardised root mean", "TEST", 217, 243], ["the residuals", "TEST", 255, 268], ["root", "OBSERVATION_MODIFIER", 234, 238], ["residuals", "OBSERVATION", 259, 268], ["root", "OBSERVATION_MODIFIER", 285, 289]]], ["Since the chi-square value is often statistically significant in complex models and has been shown to lead to the rejection of adequate models, we focused on the incremental fit indices.", [["the chi-square value", "TEST", 6, 26], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["rejection", "OBSERVATION", 114, 123]]], ["Specifically, values for the CFI should exceed 0.95, values for the SRMR should be less than or equal to 0.08, and values for the RMSEA should be below 0.05 with a narrow 90% confidence interval (Hu & Bentler, 1999) .", [["CFI", "DNA", 29, 32], ["the CFI", "TEST", 25, 32], ["the SRMR", "TEST", 64, 72], ["the RMSEA", "TEST", 126, 135]]], ["Data files, analysis scripts, and output are available online: https://osf.io/mrzex/ParticipantsAttrition across the two data collection occasions resulted in final sample sizes of 365 (M age = 49.78, SD = 16.89; 50.1% women; attrition rate 26.27%) and 440 (M age = 51.77, SD = 16.26; 46.6% women; attrition rate = 37.23%) participants retained at follow-up in the Australia and US samples, respectively.", [["women", "ORGANISM", 219, 224], ["women", "ORGANISM", 291, 296], ["women", "SPECIES", 219, 224], ["women", "SPECIES", 291, 296], ["participants", "SPECIES", 323, 335], ["Data files", "TEST", 0, 10], ["analysis scripts", "TEST", 12, 28], ["SD", "TEST", 201, 203], ["attrition rate", "TEST", 226, 240], ["SD", "TEST", 273, 275], ["attrition rate", "TEST", 298, 312], ["sizes", "OBSERVATION_MODIFIER", 172, 177]]], ["There were no missing data for the social cognition and behavior variables as participants could not advance through the survey without providing a response.", [["participants", "SPECIES", 78, 90], ["missing data", "PROBLEM", 14, 26], ["no", "UNCERTAINTY", 11, 13]]], ["There were a few instances of missing data for the demographic variables ranging from 0.5 per cent to 8.8 per cent in the Australia sample, and 0.9 per cent to 6.4 per cent in the US sample as participants could opt not to respond to these items as they represented personal data.", [["participants", "SPECIES", 193, 205], ["missing data", "PROBLEM", 30, 42], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["Missing data are reported in Table S3 .ParticipantsSample characteristics at follow-up are presented in Table S4 , and comparisons on study variables between those retained in the study at follow-up and those lost to attrition are presented in Table S3 .", [["Participants", "SPECIES", 39, 51], ["study variables", "TEST", 134, 149], ["the study", "TEST", 176, 185]]], ["Attrition analyses in the Australia sample revealed that participants lost to attrition were younger and were more likely to be non-white.", [["participants", "SPECIES", 57, 69], ["Attrition analyses", "TEST", 0, 18]]], ["However, there were no differences in proportion of gender, income, and education level.", [["no", "UNCERTAINTY", 20, 22]]], ["A MANOVA with the social cognition constructs and past behavior as dependent variables and attrition status (lost to attrition vs. included at follow-up) revealed no differences (Wilks' Lambda = 0.973, F(8) = 1.60, p = .115, partial g 2 = 0.026).", [["attrition status", "PROBLEM", 91, 107], ["Lambda", "TEST", 186, 192], ["F", "TEST", 202, 203], ["p", "TEST", 215, 216], ["partial g", "TEST", 225, 234], ["no", "UNCERTAINTY", 163, 165]]], ["Attrition analyses in the US sample also indicated that participants lost to attrition were younger, and more likely to be men, non-white, and lower educated, and have low income, than those remaining in the study at follow-up.", [["men", "ORGANISM", 123, 126], ["participants", "SPECIES", 56, 68], ["men", "SPECIES", 123, 126], ["Attrition analyses", "TEST", 0, 18], ["the study", "TEST", 204, 213]]], ["The MANOVA testing for differences on social cognition and past behavior variables among participants lost to attrition and those included at follow-up revealed statistically significant differences (Wilks' Lambda = 0.957, F(8) = 3.90, p < .001, partial g 2 = 0.043).", [["participants", "SPECIES", 89, 101], ["The MANOVA testing", "TEST", 0, 18], ["statistically significant differences", "PROBLEM", 161, 198], ["Lambda", "TEST", 207, 213], ["p", "TEST", 236, 237], ["partial g", "TEST", 246, 255]]], ["Follow-up tests revealed that mean values for past behavior, attitudes, intentions, and self-monitoring with respect to social distancing were significantly lower among participants lost to attrition compared to those retained at follow-up.", [["participants", "SPECIES", 169, 181], ["Follow-up tests", "TEST", 0, 15], ["mean values", "PROBLEM", 30, 41]]], ["However, effect sizes for these differences were small (ds < 0.23).", [["ds", "TEST", 56, 58], ["sizes", "OBSERVATION_MODIFIER", 16, 21], ["small", "OBSERVATION_MODIFIER", 49, 54]]], ["The total effect is computed as the sum of the indirect effects of the independent variable on the dependent variable through all model variables plus the direct effect.Preliminary AnalysesDescriptive statistics for study variables are presented in Table S4 .", [["study variables", "TEST", 216, 231], ["total", "OBSERVATION_MODIFIER", 4, 9], ["direct effect", "OBSERVATION", 155, 168]]], ["Participants reported high levels of intention (Australia sample, M = 6.54, SD = 0.66; US sample, M = 6.39, SD = 0.85) and behavior (Australia sample, M = 6.10, SD = 0.67; US sample, M = 6.40, SD = 0.97) with respect to social distancing.", [["Participants", "SPECIES", 0, 12], ["SD", "TEST", 76, 78], ["US sample", "TEST", 87, 96], ["M", "TEST", 98, 99], ["SD", "TEST", 108, 110], ["Australia sample", "TEST", 133, 149], ["M", "TEST", 151, 152], ["SD", "TEST", 161, 163], ["US sample", "TEST", 172, 181], ["M", "TEST", 183, 184], ["SD", "TEST", 193, 195]]], ["Internal consistency of the social cognition constructs was estimated using Revelle's (2018) omega and internal consistency of the behavior variables and risk perception was estimated using the Spearman-Brown as they comprised two items each.", [["omega", "TREATMENT", 93, 98], ["consistency", "OBSERVATION_MODIFIER", 9, 20]]], ["All constructs in both samples exhibited acceptable internal consistency, and these data were used to estimate measurement error in subsequent single-item structural equation models.", [["samples", "ANATOMY", 23, 30], ["All constructs in both samples", "TEST", 0, 30], ["these data", "TEST", 78, 88]]], ["Scale variance, descriptive statistics, and computed error variance terms used in structural equation models are also presented in Table S4 .", [["Scale variance", "TEST", 0, 14], ["descriptive statistics", "TEST", 16, 38], ["computed error variance", "TEST", 44, 67]]], ["Correlations among the model constructs and behavior and socio-demographic variables are presented in Table S5 .Structural Equation ModelsThe single-indicator structural equation models that excluded (Model 1) and included (Model 2) past behavior exhibited adequate model fit with the data for both the Australia and US samples (see Table S6 ).", [["the model constructs", "TEST", 19, 39], ["US samples", "TEST", 317, 327]]], ["Standardised parameter estimates and distribution statistics for each model in the Australia and US samples are presented in Tables 1 and 2, 2 respectively.", [["Standardised parameter estimates", "TEST", 0, 32], ["US samples", "TEST", 97, 107], ["distribution", "OBSERVATION_MODIFIER", 37, 49]]], ["Focusing first on the models excluding past behavior, intention and action control were statistically significant predictors of social distancing behavior in both samples, with no significant effects for self-efficacy, action planning, and coping planning.", [["action planning", "TREATMENT", 219, 234]]], ["There were also no significant effects of intention on action planning or coping planning in the Australia sample, while intention predicted both planning constructs in the US sample.", [["action planning", "TREATMENT", 55, 70], ["coping planning", "TREATMENT", 74, 89], ["the US sample", "TEST", 169, 182], ["no", "UNCERTAINTY", 16, 18], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["Self-efficacy and action control were significant predictors of intention in both samples, with attitudes predicting intention in the Australia sample only and risk perceptions predicting intention in the US sample, although the effect in the Australia sample fell short of statistical significance by a trivial margin (p = .077).", [["action control", "TREATMENT", 18, 32], ["the US sample", "TEST", 201, 214], ["the Australia sample", "TEST", 239, 259], ["trivial", "OBSERVATION_MODIFIER", 304, 311], ["margin", "OBSERVATION_MODIFIER", 312, 318]]], ["There were significant indirect effects of self-efficacy on behavior mediated by intention in both samples, and significant indirect effects of risk perceptions and action control on behavior mediated by intentions in the US sample only.", [["the US sample", "TEST", 218, 231], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["significant", "OBSERVATION_MODIFIER", 112, 123]]], ["Intention and action control had significant total effects on behavior in both samples, with a further total effect of self-efficacy in the US sample.", [["action control", "TREATMENT", 14, 28], ["significant total effects", "PROBLEM", 33, 58], ["the US sample", "TEST", 136, 149]]], ["Inclusion of past behavior led to an attenuation of model effects, consistent with previous research (Brown et al., 2020; Hagger et al., 2018) .", [["attenuation", "OBSERVATION_MODIFIER", 37, 48], ["model effects", "OBSERVATION", 52, 65], ["consistent with", "UNCERTAINTY", 67, 82]]], ["Notably, effects 2 Full parameter estimates for the models in the Australia and US samples are provided in Tables S7 and S8, respectively. of all HAPA constructs on behavior were reduced to a trivial size and were not statistically significant.", [["HAPA constructs", "DNA", 146, 161], ["US samples", "TEST", 80, 90], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["Effects of constructs on intentions remained with the same pattern as those in the model excluding past behavior for both samples, albeit with smaller effect sizes.", [["smaller effect sizes", "PROBLEM", 143, 163], ["smaller effect", "OBSERVATION_MODIFIER", 143, 157], ["sizes", "OBSERVATION_MODIFIER", 158, 163]]], ["The only exception was the action control-intention effect, which was reduced to a trivial size and non-significance in the US sample.", [["the US sample", "TEST", 120, 133], ["trivial", "OBSERVATION_MODIFIER", 83, 90], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["Past behavior predicted all model constructs with medium-to-large effect sizes in both samples.", [["samples", "ANATOMY", 87, 94], ["large", "OBSERVATION_MODIFIER", 60, 65], ["effect", "OBSERVATION_MODIFIER", 66, 72], ["sizes", "OBSERVATION_MODIFIER", 73, 78]]], ["3Multi-Group AnalysisComparisons of model fit across the Australia and US samples revealed adequate fit of the configural models excluding (Model 3) and including (Model 5) past behavior, lending support for the tenability of the proposed pattern of model effects across the samples (Table S6 ).", [["US samples", "TEST", 71, 81], ["adequate fit", "OBSERVATION", 91, 103], ["model effects", "OBSERVATION", 250, 263]]], ["Constraining regression coefficients to be invariant for the models including (Model 4) and excluding (Model 6) past behavior resulted in no significant change in model fit according to the goodness-of-fit chi-square and the CFI with differences in the CFI across models less than .01 (Table S6 ).", [["CFI", "DNA", 253, 256], ["Constraining regression coefficients", "PROBLEM", 0, 36], ["the models", "TEST", 57, 67], ["significant change in model fit", "PROBLEM", 141, 172], ["the goodness", "TEST", 186, 198], ["the CFI across models", "TEST", 249, 270], ["no", "UNCERTAINTY", 138, 140], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["change", "OBSERVATION", 153, 159]]], ["These findings suggested that any observed differences in the parameter estimates of the models across the Australia and US samples were relatively trivial.", [["US samples", "TEST", 121, 131], ["trivial", "OBSERVATION", 148, 155]]], ["This is consistent with the highly consistent pattern of effects in the models in each sample with relatively minor sample-specific variation.DISCUSSIONThe empirical literature has highlighted the imperative of non-pharmacological interventions in reducing the transmission of communicable viruses and preventing infection (Jefferson et al., 2011; Rabie & Curtis, 2006; Smith et al., 2015) .", [["communicable viruses", "DISEASE", 277, 297], ["infection", "DISEASE", 313, 322], ["non-pharmacological interventions", "TREATMENT", 211, 244], ["communicable viruses", "PROBLEM", 277, 297], ["infection", "PROBLEM", 313, 322], ["consistent with", "UNCERTAINTY", 8, 23], ["relatively", "OBSERVATION_MODIFIER", 99, 109], ["minor", "OBSERVATION_MODIFIER", 110, 115], ["specific variation", "OBSERVATION", 123, 141], ["communicable viruses", "OBSERVATION", 277, 297]]], ["In the context of the COVID-19 pandemic, participation in behaviors that prevent virus transmission is essential given the absence of a vaccine or clinically proven pharmacological therapy.", [["the COVID", "TEST", 18, 27], ["virus transmission", "TREATMENT", 81, 99], ["a vaccine", "TREATMENT", 134, 143], ["pharmacological therapy", "TREATMENT", 165, 188]]], ["Sustained, population-level participation in such behaviors is not only important to reduce infections in the current pandemic phase, but also in the phases of easing restrictions to avoid a potential \"second wave\" of infections.", [["infections", "DISEASE", 92, 102], ["infections", "DISEASE", 218, 228], ["infections", "PROBLEM", 92, 102], ["infections", "PROBLEM", 218, 228], ["infections", "OBSERVATION", 92, 102], ["infections", "OBSERVATION", 218, 228]]], ["There is a pressing need for evidence of potentially modifiable determinants of COVID-19 preventive behaviors, such as social distancing, 3 The social distancing behavior and past behavior variables were associated with large skewness and kurtosis values.", [["COVID", "TEST", 80, 85], ["large skewness and kurtosis values", "PROBLEM", 220, 254], ["large", "OBSERVATION_MODIFIER", 220, 225], ["skewness", "OBSERVATION", 226, 234]]], ["We checked to see whether the skewness and kurtosis values affected findings.", [["the skewness", "PROBLEM", 26, 38], ["kurtosis values affected findings", "PROBLEM", 43, 76]]], ["So, we re-estimated our structural equation models using a square root transformation of these variables.", [["square root transformation", "OBSERVATION", 59, 85]]], ["The reanalysis revealed virtually identical coefficients and the exact pattern of effects found for the analysis using the untransformed behavior variables.", [["The reanalysis", "TEST", 0, 14], ["the analysis", "TEST", 100, 112]]], ["Analysis scripts and output for this auxiliary analysis are available online: https://osf.io/mrzex/?view_only=3ae43e6fa81c48c6880e65d 068f5435b on which to base interventions promoting population level participation in these behaviors.DISCUSSIONThe current study aimed to address this need by identifying the theory based social cognition determinants of social distancing behavior, and the processes involved, in samples from Australia and the US.", [["Analysis scripts", "TEST", 0, 16], ["output", "TEST", 21, 27], ["this auxiliary analysis", "TEST", 32, 55], ["base interventions", "TREATMENT", 156, 174], ["The current study", "TEST", 245, 262], ["the US", "TEST", 441, 447]]], ["The study adopted a correlational prospective survey design guided by the HAPA.", [["The study", "TEST", 0, 9]]], ["Consistent with HAPA predictions, intention and action control were identified as significant direct predictors of social distancing behavior in both samples, while intention predicted action planning and coping planning in the US sample.", [["HAPA", "PROTEIN", 16, 20], ["HAPA predictions", "TREATMENT", 16, 32], ["action control", "TREATMENT", 48, 62], ["the US sample", "TEST", 224, 237]]], ["Further, self-efficacy and action control were identified as significant predictors of intention in both samples.", [["samples", "ANATOMY", 105, 112], ["action control", "TREATMENT", 27, 41]]], ["Attitudes and risk perceptions were additional predictors in the Australia and US samples, respectively.", [["US samples", "TEST", 79, 89]]], ["Significant indirect effects were also observed; self-efficacy predicted behavior mediated by intention in both samples, and risk perceptions and action control were found to predict behavior mediated by intentions in the US sample only.", [["Significant indirect effects", "PROBLEM", 0, 28], ["action control", "TREATMENT", 146, 160], ["the US sample", "TEST", 218, 231]]], ["Despite these limited differences, it should be noted that comparisons of the models across the Australia and US samples suggested that observed differences in parameter estimates across the samples were relatively trivial.", [["US samples", "TEST", 110, 120], ["the samples", "TEST", 187, 198], ["trivial", "OBSERVATION", 215, 222]]], ["Findings are consistent with the auxiliary assumption promulgated in the HAPA, and social cognition theories more generally, that the effects of the belief-based constructs reflect generalised processes that have a consistent pattern of effects across contexts, populations, and behaviors.", [["generalised processes", "PROBLEM", 181, 202], ["consistent with", "UNCERTAINTY", 13, 28]]], ["In sum, the current findings indicate that individuals' social distancing behavior is a function of both motivational and volitional processes, and this provides formative data on potential targets for behavioral interventions aimed at promoting participation in this preventive behavior.Theoretical ImplicationsResults of this study provide qualified support for the application of the HAPA, with its focus on constructs that represent dual phases of action.", [["behavioral interventions", "TREATMENT", 202, 226], ["this study", "TEST", 323, 333], ["the application of the HAPA", "TREATMENT", 364, 391], ["dual phases", "OBSERVATION", 437, 448]]], ["Findings demonstrate a prominent role for self-efficacy as the key determinant of intentions, and intentions as the key determinant of behavior across both samples.", [["prominent", "OBSERVATION_MODIFIER", 23, 32]]], ["These findings are in line with applications of the HAPA in multiple health behavioral contexts , as well as research on social cognition constructs more broadly (Hamilton, van Dongen, & Hagger, 2020; McEachan et al., 2011) .", [["HAPA", "CHEMICAL", 52, 56], ["the HAPA", "TREATMENT", 48, 56]]], ["The pervasive effect of intention on behavior is also aligned with a substantive literature on social cognition theories demonstrating intentions as the pre-eminent determinant of behavior (Hamilton, van Dongen, et al., 2020; McEachan et al., 2011) .", [["pervasive", "OBSERVATION_MODIFIER", 4, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20]]], ["Overall, these effects suggest that social distancing behavior should be conceptualised as a reasoned action.Theoretical ImplicationsHowever, the current study also demonstrated a prominent role for constructs representing volitional processes in the enactment of behavior.", [["the current study", "TEST", 142, 159], ["volitional processes", "PROBLEM", 223, 243], ["prominent", "OBSERVATION_MODIFIER", 180, 189], ["volitional processes", "OBSERVATION", 223, 243]]], ["In particular, action control, a construct reflecting individuals' application of key self-regulatory skills to enact behavior, was a consistent predictor of both intentions and behavior across the samples.", [["action control", "TREATMENT", 15, 29]]], ["Individuals possessing these skills are not only more likely to form intentions to perform social distancing behaviors, but are also more likely to engage in the behavior through, for example, an automatic process.", [["an automatic process", "PROBLEM", 193, 213]]], ["Specifically, the direct effect not mediated by intentions suggests that individuals with good action control might be more effective in structuring their environment or forming habits that promote enactment of social distancing without the need for extensive deliberation or weighing up of options.", [["extensive deliberation", "TREATMENT", 250, 272]]], ["Research has suggested that individuals possessing these skills are effective in controlling their actions more broadly, but also that such skills can be acquired or learned (Gardner, 2015; Gardner et al., 2020) , which provides a potential avenue for intervention: training people to be more effective in regulating their own actions.Theoretical ImplicationsInterestingly, current research shows that risk perceptions have small effects on intentions and subsequent behavior.", [["people", "ORGANISM", 275, 281], ["people", "SPECIES", 275, 281], ["intervention", "TREATMENT", 252, 264], ["training people", "TREATMENT", 266, 281], ["small", "OBSERVATION_MODIFIER", 424, 429]]], ["Risk perceptions had small but significant effects in the US sample, and a small effect which fell short of statistical significance in the Australia sample.", [["the US sample", "TEST", 54, 67], ["a small effect", "PROBLEM", 73, 87], ["small", "OBSERVATION_MODIFIER", 21, 26], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["small", "OBSERVATION_MODIFIER", 75, 80]]], ["This pattern of effects is consistent with applications of the HAPA and other social cognition models like protection motivation theory, which found relatively modest or null effects of risk perceptions on intentions and behavior (Zhang, Chung, et al., 2019) .", [["the HAPA", "TREATMENT", 59, 67], ["consistent with", "UNCERTAINTY", 27, 42]]], ["In the context of COVID-19 prevention and social distancing behavior, it is common knowledge that the infection will not have serious consequences for the majority of the population, and is likely only to be serious for those with underlying conditions or impaired immunity, or the elderly.", [["infection", "DISEASE", 102, 111], ["impaired immunity", "DISEASE", 256, 273], ["COVID-19 prevention", "TREATMENT", 18, 37], ["the infection", "PROBLEM", 98, 111], ["underlying conditions", "PROBLEM", 231, 252], ["impaired immunity", "PROBLEM", 256, 273], ["infection", "OBSERVATION", 102, 111]]], ["Instead, it seems that self-efficacy and action control are more pervasive and consistent determinants of behavior, and these may be more pertinent targets for intervention.Theoretical ImplicationsAction and coping planning were expected to mediate intention-behavior effects in the current model, such that planning is an important part of the process of intention enactment for social distancing.", [["action control", "TREATMENT", 41, 55], ["intervention", "TREATMENT", 160, 172], ["coping planning", "TREATMENT", 208, 223]]], ["These findings are not, however, unique, and previous research has demonstrated considerable variability in the role of planning in intention enactment, and effect sizes are often small (Rhodes et al., 2020; .", [["considerable", "OBSERVATION_MODIFIER", 80, 92], ["variability", "OBSERVATION_MODIFIER", 93, 104], ["sizes", "OBSERVATION_MODIFIER", 164, 169], ["small", "OBSERVATION_MODIFIER", 180, 185]]], ["Taken together, it seems that volitional processes such as action control are far more pervasive in promoting social distancing intentions and behavior.Theoretical ImplicationsIntroduction of past behavior in the current model had marked influences on the size of model effects, rendering effects of almost all model constructs on intentions and behavior trivial and not statistically significant.", [["volitional processes", "PROBLEM", 30, 50], ["action control", "TREATMENT", 59, 73], ["marked", "OBSERVATION_MODIFIER", 231, 237], ["size", "OBSERVATION_MODIFIER", 256, 260]]], ["Nevertheless, the residual effect of past behavior may provide some indication of unmeasured constructs on subsequent behavior, particularly those that bypass effects of intentions and are more likely rooted in non-conscious processes that lead to behavior, such as implicit attitudes or motives.Practical ImplicationsResearch applying social cognition models like the HAPA provides useful guidance for the development of future behavioral interventions aimed at promoting social distancing behaviors.", [["unmeasured constructs", "PROBLEM", 82, 103], ["behavioral interventions", "TREATMENT", 429, 453], ["residual", "OBSERVATION_MODIFIER", 18, 26], ["effect", "OBSERVATION_MODIFIER", 27, 33], ["bypass", "OBSERVATION", 152, 158], ["more likely", "UNCERTAINTY", 189, 200]]], ["Although participants' intentions toward, and actual participation in, social distancing behavior were relatively high, scores and variability estimates suggested that some participants were reporting lapses in their social distancing behavior.", [["participants", "SPECIES", 9, 21], ["participants", "SPECIES", 173, 185]]], ["Such lapses present considerable risks to coronavirus transmission, particularly in areas of high prevalence where the likelihood of contact with infected persons is substantially elevated.", [["coronavirus", "DISEASE", 42, 53], ["coronavirus", "ORGANISM", 42, 53], ["persons", "ORGANISM", 155, 162], ["persons", "SPECIES", 155, 162], ["Such lapses", "PROBLEM", 0, 11], ["coronavirus transmission", "PROBLEM", 42, 66], ["substantially elevated", "PROBLEM", 166, 188], ["coronavirus", "OBSERVATION", 42, 53], ["high prevalence", "OBSERVATION_MODIFIER", 93, 108], ["elevated", "OBSERVATION_MODIFIER", 180, 188]]], ["Our research provides some indication of the constructs that should be targeted for change and also the types of behavior change techniques that make up the content of interventions (Hagger, Cameron, et al, 2020; Hagger, Smith, et al., 2020; Kok et al., 2016) .", [["behavior change techniques", "TREATMENT", 113, 139]]], ["Based on current findings, strategies to promote self-efficacy should be foremost in potential targets of interventions to promote intentions and behavior.", [["interventions", "TREATMENT", 106, 119]]], ["Interventions that have manipulated mastery experience (i.e. practicing a behavior) and vicarious experience (i.e. observing a model performing the behavior) have been shown to be successful in strengthening self-efficacy, as have interventions that provide feedback on past or others' performance (Warner & French, 2020) .", [["Interventions", "TREATMENT", 0, 13], ["interventions", "TREATMENT", 231, 244]]], ["Tailoring of these strategies could also be considered and targeted at uptake of the behavior for those that have not already adopted the behavior (e.g. demonstration of appropriate social distance when in line to purchase goods) or at maintenance of the behavior (e.g. developing a rule of thumb on keeping an appropriate social distance every time when in line to purchase goods).Practical ImplicationsAction control was another key determinant of intentions and behavior.", [["thumb", "ORGANISM_SUBDIVISION", 291, 296], ["Practical ImplicationsAction control", "TREATMENT", 382, 418], ["thumb", "ANATOMY", 291, 296]]], ["This suggests that it is important that individuals acquire monitoring and self-regulatory strategies with respect to their social distancing behavior.", [["self-regulatory strategies", "TREATMENT", 75, 101]]], ["For example, action control involves consistent monitoring as to whether an individual follows through on their intentions for the target behavior (Schwarzer & Hamilton, 2020) .", [["action control", "TREATMENT", 13, 27]]], ["Monitoring helps identify discrepancies in behavior (e.g. not being at an appropriate social distance when in line to purchase goods), and noting a discrepancy can trigger taking additional action to ensure goals are achieved (e.g. adjusting the distance) or for disengaging from the goal (e.g. abandoning the goods and leaving the shop) (Webb & de Bruin, 2020) .", [["discrepancies in behavior", "PROBLEM", 26, 51]]], ["In order to promote better action control, interventions may prompt self-monitoring (e.g. through selfobservation of social distancing behavior) or be monitored by others (e.g. shop attendant prompts an individual to increase their social distance).Practical ImplicationsGiven that constructs such as attitudes and risk perceptions were not strong, consistent determinants of social distancing behavior, strategies targeting change in these constructs may not be at the forefront of behavioral interventions to promote social distancing.", [["interventions", "TREATMENT", 43, 56], ["behavioral interventions", "TREATMENT", 483, 507]]], ["Strategies aimed at promoting attitude change and increased risk perceptions usually involve information provision (e.g. providing information about health consequences, highlighting the pros over the cons of social distancing) and communication-persuasion (e.g. using credible sources to deliver messages, using framing/reframing methods) about the importance of maintaining social distancing (Hamilton & Johnson, 2020) .", [["Strategies", "TREATMENT", 0, 10]]], ["However, reviews suggest that such strategies relate more to short-term change rather than sustained, longer-term impact on behavior (Jepson et al., 2010) .", [["short-term change", "PROBLEM", 61, 78]]], ["Another approach could be the use of fear appeals which seek to arouse negative emotional reactions in order to promote self-protective motivation and action (Kok et al., 2016) .", [["emotional reactions", "PROBLEM", 80, 99]]], ["However, caution is needed when using fear appeals to attempt to change behavior as excessively heightened fear may be counter-productive in motivating individuals to engage in preventive behaviors (Kok et al., 2018; Lin, 2020) , and may even be counter-productive because they are responses aimed at mitigating fear, such as avoidance or denial, neither of which may manage the risk itself (Hagger et al., 2017; Leventhal et al., 1998) .", [["excessively heightened fear", "PROBLEM", 84, 111]]], ["There is evidence that messages that highlight risk but also provide coping information to increase self-efficacy (Kok et al., 2018) and that use positive prosocial language (Heffner et al., 2020) may be effective because they are more readily accepted and prevent defensive and avoidant reactions.", [["defensive and avoidant reactions", "PROBLEM", 265, 297]]], ["However, current evidence suggests that interventions targeting change in attitudes and risk perception are unlikely to be enough to promote social distancing.Strengths, Limitations, and Avenues for Future ResearchThe present research has a number of strengths including focus on social distancing, a key preventive behavior aimed at reducing transmission of SARS-CoV-2 to prevent COVID-19 infections; adoption of a fit-for-purpose theoretical model, the HAPA, that provides a set of a priori predictions on the motivational and volitional determinants of the target behavior; recruitment of samples from two countries, Australia and the US, with key demographic characteristics that closely match those of the population; and the use of prospective study design and structural equation modelling techniques.", [["SARS", "DISEASE", 359, 363], ["infections", "DISEASE", 390, 400], ["SARS-CoV-2", "ORGANISM", 359, 369], ["SARS-CoV", "SPECIES", 359, 367], ["interventions", "TREATMENT", 40, 53], ["COVID-19 infections", "PROBLEM", 381, 400], ["the US", "TEST", 634, 640], ["prospective study", "TEST", 738, 755], ["structural equation modelling techniques", "TEST", 767, 807]]], ["A number of limitations to the current data should also be noted.", [["the current data", "TEST", 27, 43]]], ["That there was substantive attrition at follow-up in both samples is an important limitation.", [["samples", "ANATOMY", 58, 65], ["substantive attrition", "PROBLEM", 15, 36], ["attrition", "OBSERVATION_MODIFIER", 27, 36]]], ["Non-trivial attrition could result in selection bias.", [["Non-trivial attrition", "PROBLEM", 0, 21]]], ["For example, participants who are more motivated or engaged may be overrepresented in the sample.", [["participants", "SPECIES", 13, 25]]], ["In the current study, participants were provided with multiple reminders to complete measures at follow-up, but more intensive recruitment and incentivisation of non-responders may have further minimised attrition rates.", [["participants", "SPECIES", 22, 34], ["the current study", "TEST", 3, 20]]], ["It should be noted that participant drop-out affected the demographic profile of the samples, particularly among underrepresented groups.", [["samples", "ANATOMY", 85, 92]]], ["This is particularly relevant to the current context given data indicating that COVID-19 infection and mortality rates are higher in underrepresented minority and socioeconomic groups (CDC, 2020) .", [["infection", "DISEASE", 89, 98], ["COVID-19", "ORGANISM", 80, 88], ["COVID", "TEST", 80, 85], ["infection", "PROBLEM", 89, 98], ["mortality rates", "TEST", 103, 118], ["infection", "OBSERVATION", 89, 98]]], ["A potential solution would be to oversample in underrepresented groups in which attrition rates are likely to be high and should be considered in future research.", [["A potential solution", "TREATMENT", 0, 20]]], ["However, the samples were not stratified by salient demographic or socioeconomic variables.", [["the samples", "TEST", 9, 20]]], ["The current samples cannot be characterised as representative of the Australian or US population.", [["samples", "ANATOMY", 12, 19]]], ["Taking these biases into account, the current findings should not be considered directly generalisable to the broader population.Strengths, Limitations, and Avenues for Future ResearchIn addition, the current study adopted a prospective design, which provided a basis for the temporal ordering of constructs in the model.", [["the current study", "TEST", 197, 214]]], ["However, the correlational design of the current study means that inferences of causality are based on theory rather than the data.", [["the current study", "TEST", 37, 54]]], ["Furthermore, the current design did not permit modeling of the stability or change in model constructs over time.", [["stability", "OBSERVATION", 63, 72]]], ["The latter represents an important caveat when utilising current data as a basis for intervention.", [["intervention", "TREATMENT", 85, 97]]], ["Future research should aim to adopt cross-lagged panel designs that model change in constructs over time, and utilise intervention or experimental designs that target change in model constructs and observe their effects on behavior.", [["model change in constructs", "PROBLEM", 68, 94], ["utilise intervention", "TREATMENT", 110, 130], ["experimental designs", "TREATMENT", 134, 154], ["target change in model constructs", "TREATMENT", 160, 193]]], ["Also, the study was conducted over a one-week period.", [["the study", "TEST", 6, 15]]], ["Although this is a relatively brief follow-up period, it was considered appropriate given the high speed of virus transmission and the need for prompt adoption of social distancing in the population to prevent widespread infection.", [["infection", "DISEASE", 221, 230], ["virus transmission", "TREATMENT", 108, 126], ["widespread infection", "PROBLEM", 210, 230], ["widespread", "OBSERVATION_MODIFIER", 210, 220], ["infection", "OBSERVATION", 221, 230]]], ["The current results, however, do not confirm the extent to which model constructs predict social distancing over a longer period, and long-term follow-up would be necessary to support the application of the HAPA in accounting for maintenance of social distancing, which is especially important as lockdown restrictions ease in order to prevent a \"second wave\" of infection.", [["infection", "DISEASE", 363, 372], ["the HAPA", "TREATMENT", 203, 211], ["infection", "PROBLEM", 363, 372], ["infection", "OBSERVATION", 363, 372]]], ["The present study also relied exclusively on self-report measures which may introduce additional error variance through recall bias and socially desirable responding.", [["The present study", "TEST", 0, 17]]], ["Future studies may consider verification of behavioral data with non-self-report data such as the use of GPS mapping of mobile phones or using observation to verify rates of social distancing behavior in particular contexts (e.g. workplaces, grocery stores).", [["Future studies", "TEST", 0, 14], ["behavioral data", "TEST", 44, 59], ["GPS mapping", "TEST", 105, 116], ["mobile phones", "TREATMENT", 120, 133]]], ["It might also be useful for future studies to investigate the role of social factors, as suggested in the HAPA, on social distancing behavior.", [["future studies", "TEST", 28, 42]]], ["This is particularly important given the considerable potential for \"social\" influences to affect individuals' behavior in minimising person-to-person contact with others outside the individual's immediate household.", [["person", "SPECIES", 134, 140], ["person", "SPECIES", 144, 150]]], ["Precedence for these effects comes from previous research which has found that pressure from important others and moral obligation toward others predicts adherence to COVID-19 preventive behaviors, including social distancing (Hagger, Cameron, et al, 2020; Hagger, Smith, et al., 2020; Lin et al., 2020) .", [["COVID", "TEST", 167, 172], ["pressure", "OBSERVATION_MODIFIER", 79, 87]]], ["Finally, this research was conducted during a period when it is likely that participants were already engaging in social distancing and, thus, already had substantive experience with the behavior, indicated by the high scale mean scores for past behavior (M = 6.5 on a 7-point scale) in both samples.", [["samples", "ANATOMY", 292, 299], ["participants", "SPECIES", 76, 88]]], ["This likely explains the substantive effect of past behavior in attenuating model effects and the need for longitudinal designs or using methods such as ecological momentary assessment that capture moment-by-moment changes over time in behavior.CONCLUSIONGiven the urgent need for populations to adopt COVID-19 preventive behaviors, such as social distancing, the present study applied the HAPA to predict key motivational and volitional determinants of social distancing behavior in samples across two different countries, Australia and the US.", [["longitudinal designs", "TREATMENT", 107, 127], ["methods", "TREATMENT", 137, 144], ["ecological momentary assessment", "TEST", 153, 184], ["COVID", "TEST", 302, 307], ["the present study", "TEST", 360, 377], ["the US", "TEST", 538, 544], ["substantive", "OBSERVATION_MODIFIER", 25, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43]]], ["Overall, the current findings provide qualified support for some of the core proposed effects among the motivational and volitional factors in the model, as well as their effects on individuals' social distancing behavior.", [["qualified support", "TREATMENT", 38, 55]]], ["The current study fills a knowledge gap in the literature on the social psychological processes that guide social distancing behavior in an unprecedented context of a pandemic and suggests that the motivational and volitional constructs of self-efficacy, intention, and action control, in particular, may have utility in explaining this important COVID-19 preventive behavior.", [["The current study", "TEST", 0, 17], ["action control", "TREATMENT", 270, 284]]], ["Despite the correlational design, the current findings suggest multiple potential routes to behavioral performance that can serve as a basis for the development of intervention and enable further testing of effects of the techniques on both behavior change and the targeted theory constructs.SUPPORTING INFORMATIONAdditional supporting information may be found online in the Supporting Information section at the end of the article.", [["intervention", "TREATMENT", 164, 176], ["further testing", "TEST", 188, 203], ["the techniques", "TREATMENT", 218, 232]]]], "PMC7191113": [], "PMC7509627": [["Social and Behavioral Determinants of Health and Predictive AnalyticsSince the Health Information Technology for Economic and Clinical Health act of 2009, the majority of US health care systems have adopted electronic health records (EHRs) for patient care [1].", [["patient", "ORGANISM", 244, 251], ["patient", "SPECIES", 244, 251]]], ["Faced with increased financial incentives to improve population health, care coordination, and quality of care, health care providers and payers now use EHRs and other digital data sources to understand how past associations and trends in their patient populations can be used to forecast health care\u2013related outcomes, a component of the widely known strategy of predictive analytics [1,2].Social and Behavioral Determinants of Health and Predictive AnalyticsPredictive analytics uses extensive data, modeling, and algorithms to predict individual and population events and has a long history in commercial industries [3].", [["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 245, 252]]], ["For better or worse, commercial industries have developed innovative techniques to mine demographic, socioeconomic, and consumer behavior data as part of the forecasting and analytics process.", [["innovative techniques", "TREATMENT", 58, 79]]], ["These institutions use such data to make predictions for various goals, such as determining ideal customers for specific products or services and how much institutions should offer to whom [4].Social and Behavioral Determinants of Health and Predictive AnalyticsThere are 2 broad approaches to predictive analytics.", [["predictive analytics", "TEST", 294, 314]]], ["The modeling and simulation approach is used to test hypotheses or assess the consequences of scenarios where the rules of the models are developed from theories.", [["simulation approach", "TREATMENT", 17, 36]]], ["Such models also employ data to initialize variables, to calibrate free parameters, or for validation.", [["validation", "TEST", 91, 101]]], ["Alternatively, predictive analytics may also use machine learning in which models are exclusively built from data via algorithms and tested on data that mirror the calibration and validation steps of modeling and simulation, respectively.", [["the calibration", "TEST", 160, 175]]], ["On the basis of the specific prediction goal, different types of data and methods are required and thus have different associated limitations and challenges.Social and Behavioral Determinants of Health and Predictive AnalyticsIn health care, the same techniques are used with different goals.", [["methods", "TREATMENT", 74, 81], ["Predictive AnalyticsIn health care", "TREATMENT", 206, 240]]], ["Over the last decade, health insurance plans have ramped up the use of predictive analytics, employing patient demographics, insurance claims data, and clinical characteristics derived from EHRs to create statistical models of future health care risks and resource utilization [6].", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["These data science techniques generally involve larger and more complex databases but represent an application of traditional statistical forecasting methods using a wide range of techniques such as deep neural networks, natural language processing (NLP), random forest, and decision tree algorithms [7,8].Social and Behavioral Determinants of Health and Predictive AnalyticsThe growing awareness of associations between social and behavioral factors and health has led predictive modeling to explore the incorporation of social and behavioral determinants of health (SBDH) into forecasting [9,10].", [["neural networks", "ANATOMY", 204, 219], ["neural networks", "MULTI-TISSUE_STRUCTURE", 204, 219], ["a wide range of techniques", "TREATMENT", 164, 190], ["deep neural networks", "TREATMENT", 199, 219], ["larger", "OBSERVATION_MODIFIER", 48, 54], ["growing", "OBSERVATION_MODIFIER", 379, 386]]], ["At the community level, characteristics of neighborhoods, such as food access and transportation, play significant roles in health outcomes, morbidity, and mortality [13-15].Social and Behavioral Determinants of Health and Predictive AnalyticsAlthough SBDH factors have been incorporated in the predictive modeling process to forecast health care\u2013related outcomes, there are limitations related to the use of such factors.", [["SBDH factors", "PROTEIN", 252, 264], ["morbidity", "PROBLEM", 141, 150], ["SBDH factors", "PROBLEM", 252, 264], ["such factors", "TREATMENT", 409, 421]]], ["For instance, machine learning methods are not generally developed to capture changing SBDH factors.", [["SBDH factors", "GENE_OR_GENE_PRODUCT", 87, 99], ["SBDH factors", "PROTEIN", 87, 99], ["machine learning methods", "TREATMENT", 14, 38], ["changing SBDH factors", "PROBLEM", 78, 99]]], ["They mainly address the stationary distributions of the SBDH factors.", [["SBDH factors", "GENE_OR_GENE_PRODUCT", 56, 68], ["SBDH factors", "PROTEIN", 56, 68], ["the SBDH factors", "PROBLEM", 52, 68]]], ["A change in the data requires providing longitudinal data to the model to perform time series modeling and to capture these changes.", [["A change in the data", "PROBLEM", 0, 20], ["change", "OBSERVATION_MODIFIER", 2, 8]]], ["If a change in the distribution of data is necessary (eg, to reflect potential trends in SBDH over time), then the approach of modeling and simulation may be used to explore various scenarios.", [["a change", "PROBLEM", 3, 11], ["change", "OBSERVATION_MODIFIER", 5, 11]]], ["An example is the common use of event-driven simulations in health care research [16].Social and Behavioral Determinants of Health and Predictive AnalyticsA growing crop of initiatives uses SBDH to predict health care use in the United States [17].", [["SBDH", "CHEMICAL", 190, 194]]], ["Although the methods and evidence underlying these new models that incorporate SBDH are nascent and have not shown improved predictions over traditional clinical measures, the medical community\u2019s interest in SBDH needs in conjunction with predictive analytics continues to increase [18,19].Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsBolstered by the initiatives of the national organizations, incorporation of SBDH into predictive models could help to (1) identify patients and populations who need more resources, (2) improve health care reimbursement for providers who serve patients with social needs, (3) reduce health and health care disparities, and (4) improve the quality of health care.Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsPredictive analytics and SBDH risk segmentation could facilitate efforts to identify patients who would benefit from more resources and targeted services.", [["SBDH", "GENE_OR_GENE_PRODUCT", 79, 83], ["patients", "ORGANISM", 597, 605], ["patients", "ORGANISM", 709, 717], ["patients", "ORGANISM", 1087, 1095], ["patients", "SPECIES", 597, 605], ["patients", "SPECIES", 709, 717], ["patients", "SPECIES", 1087, 1095], ["the methods", "TEST", 9, 20], ["traditional clinical measures", "TREATMENT", 141, 170], ["predictive analytics", "TEST", 239, 259], ["SBDH risk segmentation", "PROBLEM", 1027, 1049]]], ["This may lessen the resource burden of universal social risk screening or social care delivery [26].", [["social care delivery", "TREATMENT", 74, 94]]], ["For example, a systematic risk analysis could help identify patients with modifiable social risks at a higher risk of poor medical outcomes.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["a systematic risk analysis", "TEST", 13, 39], ["poor medical outcomes", "PROBLEM", 118, 139]]], ["In addition to using SBDH-sensitive analytics to identify vulnerable individuals, this approach could also help health care organizations or partner agencies identify disadvantaged communities, such as neighborhoods with food deserts [26,30].", [["SBDH", "CHEMICAL", 21, 25], ["SBDH", "SIMPLE_CHEMICAL", 21, 25], ["SBDH", "TEST", 21, 25], ["vulnerable individuals", "PROBLEM", 58, 80]]], ["A health care system truly desiring to maximize its impact on the health of a community could more effectively increase food access at the neighborhood level by working with farmers\u2019 markets and grocery stores in addition to individual-level interventions.Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsUnder the present federal regulations for Medicaid-managed care, social and behavioral services such as care coordination are reimbursed through capitation.", [["individual-level interventions", "TREATMENT", 225, 255]]], ["Predictive analytics and SBDH risk segmentation could support new payment models to adequately reflect the medical and social complexity of patients [31].", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["Predictive analytics", "TEST", 0, 20], ["SBDH risk segmentation", "PROBLEM", 25, 47]]], ["Beyond capitated or global payments, contextualizing patients with their SBDH needs enables health care payers to more accurately assess providers\u2019 care for vulnerable populations who require more health care resources, thus impacting their fee-for-service payments [27].", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Present Medicaid-managed care regulations could support value-added services that would not be reimbursed under capitation alone but would address the health needs of members, such as interventions that assess environmental triggers of asthma [31].", [["asthma", "DISEASE", 236, 242], ["interventions", "TREATMENT", 184, 197], ["asthma", "PROBLEM", 236, 242]]], ["Several states (eg, Rhode Island, Minnesota, and Oregon) have adopted the Accountable Care Organization models that reward health care providers for addressing their Medicaid populations\u2019 SBDH with adjusted payment structures [32,33].", [["SBDH", "DISEASE", 188, 192]]], ["Patient protection laws in the United States regarding insurance denials and premium payments should be upheld to ensure that SBDH risk segmentation does not increase the burden of health care costs to disadvantaged populations [34].Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsIdentifying and accounting for the increased risk of poor health outcomes and associated health care utilization is critical to the elimination of disparities in care for vulnerable populations.", [["Patient", "SPECIES", 0, 7], ["premium payments", "TREATMENT", 77, 93], ["SBDH risk segmentation", "PROBLEM", 126, 148], ["vulnerable populations", "PROBLEM", 579, 601]]], ["The spread of COVID-19 across the United States and worldwide is a great example of how predictive modeling could help health care systems and public health officials address health disparities and potentially change the course of the pandemic.", [["COVID-19", "CHEMICAL", 14, 22], ["COVID", "TEST", 14, 19], ["spread", "OBSERVATION_MODIFIER", 4, 10]]], ["The COVID-19 pandemic has highlighted long-standing health disparities [35,36]; neighborhoods with the highest proportion of racial and ethnic minorities and people living in poverty are experiencing higher rates of hospitalization and death [37-40].", [["death", "DISEASE", 236, 241], ["people", "ORGANISM", 158, 164], ["people", "SPECIES", 158, 164], ["The COVID", "TEST", 0, 9]]], ["In response, several research teams have started to include information on SBDH in predictive modeling and assessment of COVID-19\u2013related risk and outcomes [39,41].Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsExclusion of SBDH-related variables in risk-adjusted reimbursement models would result in lower reimbursement for patients with greater social needs, which dissuades providers from caring for these patients in capitated systems [42].", [["patients", "ORGANISM", 453, 461], ["patients", "ORGANISM", 537, 545], ["patients", "SPECIES", 453, 461], ["patients", "SPECIES", 537, 545], ["assessment", "TEST", 107, 117], ["COVID", "TEST", 121, 126], ["reimbursement models", "TREATMENT", 392, 412]]], ["Employing SBDH in risk-adjusted capitated payment models could translate into improved health care policy by supporting organizations to more effectively meet the needs of individuals and communities with greater social needs.Potential Benefits of Including Social and Behavioral Determinants in Predictive Models ::: The Rationale for Including Social and Behavioral Determinants in Predictive ModelsBeyond payment adjustment, stratifying patients by their SBDH risk levels could reveal health disparities as well as promote health care quality by establishing a mechanism to fairly evaluate providers\u2019 care of patients with social disadvantages [42].", [["SBDH", "CHEMICAL", 10, 14], ["patients", "ORGANISM", 440, 448], ["patients", "ORGANISM", 612, 620], ["patients", "SPECIES", 440, 448], ["patients", "SPECIES", 612, 620], ["payment adjustment", "TREATMENT", 408, 426]]], ["Health systems and payers could further evaluate the quality of health care by developing specific SBDH-dependent quality indicators that bolster equity in health care across the range of patients served [42].Diversity of Data Sources ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsA wide range of SBDH variables and data sources are used in predictive models and no guidelines exist to distinguish which variables and data sources would best improve the performance of the predictive model.", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["SBDH variables", "PROBLEM", 340, 354]]], ["A rapid review of social, behavioral, and environmental determinants of health used with clinical data identified 744 variables among 178 articles, in which the majority of articles included socioeconomic and material conditions [48].", [["clinical data", "TEST", 89, 102]]], ["In one systematic review of predictive models using EHR data, 36 of the 106 unique studies included SBDH data in one of their final predictive models [58].", [["EHR data", "TEST", 52, 60], ["SBDH data", "TEST", 100, 109]]], ["The same systematic review included behavioral determinants in 30 of these EHR-based predictive models.", [["behavioral determinants", "TEST", 36, 59]]], ["However, 12 of these studies\u2019 behavioral variables were limited to tobacco use or smoking alone [58].", [["smoking", "CHEMICAL", 82, 89], ["tobacco", "ORGANISM", 67, 74], ["tobacco", "SPECIES", 67, 74], ["these studies", "TEST", 15, 28], ["behavioral variables", "PROBLEM", 30, 50]]], ["As another case example, a Kaiser predictive model that uses race and ethnicity as one variable to develop a hypoglycemia risk model omitted race in their final, simpler model on finding that race was not one of the strongest predictors of hypoglycemia compared with clinical factors [59].Diversity of Data Sources ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsIn addition to survey-collected data aggregated at the geographic level, academic centers are expanding this community-level framework to include geocentric data such as transit data, which contains data on access to transportation [60], the Environmental Protection Agency\u2019s Air Quality Index data [61], and food desert data from the United States Department of Agriculture\u2019s Food Access Research Atlas [62].Diversity of Data Sources ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsAs expected with predictive models, the performance of a model varies depending on the selected SBDH variables and data sources [43,44].", [["hypoglycemia", "DISEASE", 109, 121], ["hypoglycemia", "DISEASE", 240, 252], ["a hypoglycemia risk", "PROBLEM", 107, 126], ["hypoglycemia", "PROBLEM", 240, 252], ["geocentric data", "TEST", 550, 565], ["transit data", "TEST", 574, 586], ["a model varies", "PROBLEM", 983, 997]]], ["When analyzing SBDH variables, the diversity of data sources has implications for a model\u2019s ability to address challenges associated with SBDH, such as accurately assessing the temporal duration of SBDH and determining the spatial-level effects of population-level SBDH data.", [["SBDH", "PROTEIN", 15, 19], ["SBDH variables", "PROBLEM", 15, 29], ["SBDH", "PROBLEM", 138, 142], ["SBDH", "PROBLEM", 198, 202], ["level SBDH data", "TEST", 259, 274]]], ["Researchers need to critically analyze SBDH variables and data sources to ensure the selection of variables and high-quality data sources that accurately and authentically capture SBDH factors to be tested.Diversity of Health Outcomes ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsHealth care\u2013based predictive models that integrate SBDH risk factors have been used to forecast a wide range of health care\u2013relevant endpoints.", [["SBDH factors", "GENE_OR_GENE_PRODUCT", 180, 192], ["SBDH factors", "PROTEIN", 180, 192], ["SBDH risk factors", "PROTEIN", 375, 392], ["SBDH factors", "PROBLEM", 180, 192], ["SBDH risk factors", "PROBLEM", 375, 392]]], ["There is no consensus on which health outcomes are the most appropriate to predict with specific SBDH factors.", [["SBDH factors", "GENE_OR_GENE_PRODUCT", 97, 109], ["SBDH factors", "PROTEIN", 97, 109], ["no", "UNCERTAINTY", 9, 11]]], ["For example, the Centers for Disease Control and Prevention (CDC), the CDC Foundation, and the Robert Wood Johnson Foundation collaboratively created 500 Cities, a tool that uses community-level socioeconomic characteristics to predict city-level health behaviors, mortality, and morbidity [65,66].Diversity of Health Outcomes ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsSimilar to challenges related to data sources, the diversity of health outcomes as the endpoint for the predictive models will impact assessing the performance of their methods and determining the best methods to address specific SBDH variables or to set the stage for standardized guidelines for specific SBDH variables and outcomes.Lack of Transparency ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsMany predictive models that incorporate SBDH data have been developed and are used in the private sector and are therefore not only proprietary but also unavailable for public review and scrutiny.", [["Disease Control", "TREATMENT", 29, 44], ["standardized guidelines", "TREATMENT", 685, 708], ["Transparency", "OBSERVATION", 758, 770]]], ["One company relies exclusively on consumer data, rather than medical data, to develop as many as 70 different models to predict patients at risk for general poor health and high health care costs [67].", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136]]], ["For example, one commercial model developer described a case study using its socioeconomic score model to predict the risk of common chronic diseases, highlighting the score\u2019s successful prediction in the top 10% and bottom 10% of the score risk data, although it did not describe how the model performed in the remaining 80% of the population covered [68].Lack of Transparency ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsHowever, the lack of transparency also extends to the academic sector.", [["chronic diseases", "DISEASE", 133, 149], ["a case study", "TEST", 54, 66], ["common chronic diseases", "PROBLEM", 126, 149], ["the score risk data", "TEST", 231, 250], ["common", "OBSERVATION_MODIFIER", 126, 132], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["diseases", "OBSERVATION", 141, 149], ["Transparency", "OBSERVATION", 365, 377]]], ["When data used for a data-driven model, source code, and the model itself are not made open source, the derived models cannot be replicated, a problem known as the reproducibility crisis in machine learning [69].", [["a data", "TEST", 19, 25], ["the reproducibility crisis", "PROBLEM", 160, 186]]], ["Without the training data and code, the reproducibility of machine learning is dismal.Lack of Transparency ::: Present State of Including Social and Behavioral Determinants in Predictive AnalyticsGiven the relative novelty of SBDH in predictive analytics and the lack of standardization around data sources and outcomes assessed as well as challenges related to transparency of models in the private sector, models that incorporate SBDH factors are fraught with questions about accuracy.", [["SBDH factors", "PROTEIN", 432, 444], ["the training data", "TEST", 8, 25], ["dismal", "OBSERVATION_MODIFIER", 79, 85], ["Transparency", "OBSERVATION", 94, 106]]], ["The lack of transparency makes it very difficult to assure model accuracy, precludes replicability, and portends clinicians\u2019 mistrust of these models.", [["transparency", "OBSERVATION", 12, 24]]], ["Such challenges highlight the need for greater transparency in model development and sharing across institutions.Develop Consensus on Transparency, Privacy Protection, and Ethical Uses of SBDH Data in Predictive Models ::: Privacy Standards, Patient Consent, and Ethical Use of Social and Behavioral Determinants Data ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsAs expected, many consumers are unsettled by the unregulated use of personal and commercial information to predict sensitive behaviors or health outcomes [4].", [["Privacy Protection", "TREATMENT", 148, 166]]], ["An example of such unregulated use of personal information is Google\u2019s acquisition of large amounts of personal health data, from hospitals and clinics across 21 US states, used to predict health and health care use, undisclosed to patients and other parties [73,74].", [["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240]]], ["Social determinants cover sensitive topics, such as poverty, substance misuse, food insecurity, and homelessness.", [["substance misuse", "DISEASE", 61, 77], ["food insecurity", "DISEASE", 79, 94], ["homelessness", "DISEASE", 100, 112]]], ["Similarly, individuals may be concerned about the social, employment, and legal effects of revealing SBDH when their data are not protected [75].Develop Consensus on Transparency, Privacy Protection, and Ethical Uses of SBDH Data in Predictive Models ::: Privacy Standards, Patient Consent, and Ethical Use of Social and Behavioral Determinants Data ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsTo address such concerns, there needs to be an established discourse leading to a national consensus and clear guidelines regarding the ethical use of patients\u2019 SBDH data in the context of a health care predictive model [76].", [["patients", "ORGANISM", 577, 585], ["patients", "SPECIES", 577, 585], ["Privacy Protection", "TREATMENT", 180, 198]]], ["Lack of transparency in methods, applications, and data protection results in little accountability to ensure that SBDH risk predictions are not used to achieve profits at the expense of health care quality or access, such as using SBDH data to exclude vulnerable patients from a health intervention to ensure greater health care profits [76,77].", [["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["data protection", "TEST", 51, 66], ["SBDH risk predictions", "PROBLEM", 115, 136], ["SBDH data", "TEST", 232, 241], ["a health intervention", "TREATMENT", 278, 299], ["transparency", "OBSERVATION_MODIFIER", 8, 20]]], ["Establishing robust and meaningful national guidelines for using SBDH data will require insights from a variety of clinical, social science, and technical perspectives as well as views of patients, community members, policy makers, and ethicists.", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196]]], ["In particular, patients should participate and be involved in the research that is developing models to safeguard the ethical and transparent use of patient data [78].", [["patients", "ORGANISM", 15, 23], ["patient", "ORGANISM", 149, 156], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 149, 156]]], ["Without the perspectives of patients and community members at the forefront of these discussions, rather than moving to a new level of health care equity and access, SBDH predictive analytics could easily slide into domains that many would consider inappropriate use, especially given a special concern and focus on the highest risk members of our communities [76].Create Guidelines to Reduce Inherent Bias in Predictive Models ::: Privacy Standards, Patient Consent, and Ethical Use of Social and Behavioral Determinants Data ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsOne important ethical and technical challenge of SBDH analytics, mostly in the application of statistical modeling, is ingrained model bias.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["SBDH analytics", "TREATMENT", 652, 666]]], ["For instance, vulnerable patients, such as those with more social and behavioral risk factors, may not be adequately represented in the data sources used to build the predictive model, leading to the model\u2019s inaccurate predictions for these individuals.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["behavioral risk factors", "PROBLEM", 70, 93], ["vulnerable", "OBSERVATION_MODIFIER", 14, 24]]], ["Therefore, being at risk for bias from the original sample is normally corrected in a standard process [79].Create Guidelines to Reduce Inherent Bias in Predictive Models ::: Privacy Standards, Patient Consent, and Ethical Use of Social and Behavioral Determinants Data ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsThe data sources might also lack information on the key SBDH variables that affect the desired outcomes.", [["bias", "PROBLEM", 29, 33]]], ["An example of this challenge might be a predictive model that focuses on health care utilization as the desired outcome and lacks data on health care access for vulnerable populations.", [["this challenge", "TREATMENT", 14, 28], ["vulnerable populations", "PROBLEM", 161, 183]]], ["A model with such ingrained bias would thus underestimate the actual requirement for the greater amount of health care resources necessary to achieve the same health outcomes once these individuals have access to health care [42].", [["A model with such ingrained bias", "PROBLEM", 0, 32], ["health care resources", "TREATMENT", 107, 128]]], ["Recently, this situation was observed in a study by Obermeyer et al [80] who assessed a large, commercial health plan\u2019s predictive algorithm.", [["a study", "TEST", 41, 48], ["predictive algorithm", "TEST", 120, 140], ["large", "OBSERVATION_MODIFIER", 88, 93]]], ["The model systematically underestimated the health needs of African American patients by assuming that health care costs served as an adequate proxy for health needs.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["The bias arose because the unequal access to care among African American patients resulted in less money spent caring for those patients compared with White patients.Create Guidelines to Reduce Inherent Bias in Predictive Models ::: Privacy Standards, Patient Consent, and Ethical Use of Social and Behavioral Determinants Data ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsAlthough many researchers use health care utilization and costs as outcomes for SBDH research, models with these outcomes, proxied for health needs, are biased in that the data underrepresents those with lower access to health care.", [["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 157, 165]]], ["In recognition of the ingrained model bias, one approach might be to develop guidelines that recommend stratifying the population for key SBDH risk factors.", [["SBDH risk factors", "PROTEIN", 138, 155], ["key SBDH risk factors", "PROBLEM", 134, 155]]], ["Therefore, separate models would assess health care utilization for each stratum, taking into account unmeasured SBDH risk factors impacting health care utilization (eg, socioeconomic status, which defines insurance type and access to health care).Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsThe future of SBDH-centric predictive modeling faces several challenges related to data sources and model design.", [["SBDH-centric predictive modeling faces", "TREATMENT", 521, 559]]], ["Although ubiquitous, this information is captured inconsistently and depends on the use of NLP to render the data useful in analytics [81,82].", [["NLP", "TREATMENT", 91, 94], ["the data", "TEST", 105, 113]]], ["When NLP is utilized, the SBDH language in the health record may not describe the level of SBDH precisely enough to accurately determine social risk as social determinants such as neighborhood disadvantage may need to reach a threshold to have a significant impact on health-related outcomes [83].Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsAnother important challenge is related to the use of population-level SBDH variables and whether such variables are interpreted as proxies for individual-level factors that cannot be measured, such as low household income, or represent population-level spatial elements, such as a high concentration of low household income in a neighborhood [84].", [["NLP", "PROTEIN", 5, 8], ["population-level SBDH variables", "TEST", 609, 640], ["individual-level factors", "PROBLEM", 699, 723]]], ["In contrast, geospatial models investigate population-level elements based on the principle of spatial autocorrelation, meaning that data located close together are interrelated by nature [85].", [["level elements", "PROBLEM", 54, 68]]], ["Addressing this challenge is critical to the interpretation of models and requires sufficiently transparent models that allow the proper distinction between the two implications of the population-level SBDH variables.Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsThere are also several technical challenges related to the analytic approach, spanning the choice of analytic model, data sources, discriminatory power, and SBDH temporality.", [["SBDH", "GENE_OR_GENE_PRODUCT", 202, 206], ["SBDH variables", "PROTEIN", 202, 216], ["the population", "TEST", 181, 195], ["SBDH temporality", "PROBLEM", 633, 649]]], ["Statistical models, spatial analysis, and machine learning have all been used alone and in combination with various SBDH predictive models.", [["SBDH", "PROTEIN", 116, 120], ["spatial analysis", "TEST", 20, 36]]], ["However, not all machine learning techniques, which range from transparent decision tree algorithms to unsupervised neural networks, are appropriate for use with SBDH predictive models.", [["neural networks", "ANATOMY", 116, 131], ["neural networks", "MULTI-TISSUE_STRUCTURE", 116, 131]]], ["Models should instead reflect appropriate domain expertise as well as appropriate machine learning techniques.", [["appropriate machine learning techniques", "TREATMENT", 70, 109]]], ["Moreover, for techniques that depend on unsupervised neural networks, there are long-standing controversies regarding the disadvantages of nontransparent, one-of-a-kind models versus more readily explainable logistic regression models [7,86].Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsThere are also challenges related to using SBDH data at the geographic level in predictive modeling, which are often needed to identify SBDH on a population level and for community-level interventions [26].", [["neural networks", "ANATOMY", 53, 68], ["neural networks", "MULTI-TISSUE_STRUCTURE", 53, 68], ["SBDH", "CANCER", 637, 641], ["SBDH data", "TEST", 544, 553], ["community-level interventions", "TREATMENT", 672, 701]]], ["Furthermore, analyzing SBDH data at different geographic levels (eg, census block group, census tract, county, and state) is methodologically complex.Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsThe discriminatory power to distinguish patients with and without social needs also poses a challenge in nongeospatial modeling with the potential to introduce higher-than-desirable false positives and/or negatives [74].", [["patients", "ORGANISM", 449, 457], ["SBDH", "PROTEIN", 23, 27], ["patients", "SPECIES", 449, 457], ["analyzing SBDH data", "TEST", 13, 32], ["a challenge in nongeospatial modeling", "TREATMENT", 499, 536]]], ["For instance, a study of food security among Medicare patients using clinical data and a needs assessment survey could not accurately predict which patients would benefit from a referral to community resources [88].", [["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 148, 156], ["a study", "TEST", 14, 21], ["clinical data", "TEST", 69, 82], ["a needs assessment survey", "TEST", 87, 112]]], ["Similarly, a predictive model that uses random forest decision methods applied to socioeconomic data did not improve referral rates to community services once at-risk patients were identified [28].", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["random forest decision methods", "TREATMENT", 40, 70]]], ["When SBDH data are operationalized in a poorly functioning algorithm, these false positives and negatives indicate that a health system spends unnecessary resources evaluating several patients not at high risk, whereas groups of patients needing social services remain unidentified [74,89].", [["patients", "ORGANISM", 184, 192], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 229, 237], ["these false positives", "TEST", 70, 91]]], ["To address this phenomenon, algorithms may need to be tested with new data as predictive analytics methods that use SBDH risk data have evidenced limited generalizability outside of the original sample data where the model was developed [26,46].Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsWithin a model\u2019s discriminatory power is the challenge of temporality in analytic models.", [["this phenomenon", "PROBLEM", 11, 26]]], ["Specifically, further research and development are necessary to determine how to capture changing social risk factors related to changing life circumstances throughout a person\u2019s life or epoch [90].", [["person", "SPECIES", 170, 176]]], ["For example, by structural design, a model may overlook an individual\u2019s loss of income through unemployment or community changes not reflected in neighborhood data [74].", [["community changes", "PROBLEM", 111, 128]]], ["Thus, time-oriented models will be better able to elucidate the persistence or amelioration of disparities.Determine Best Practice Guidelines for SBDH Data Sources and Predictive Model Design As Well As Open-Source Access ::: Technical Challenges Associated With Data Sources and Analytics ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsFurther guidance on analytic challenges, such as optimizing the appropriate separation of high- and low-risk cases, will be crucial as part of future, wide-scale dissemination of SBDH-focused predictive modeling tools.", [["SBDH", "CHEMICAL", 545, 549], ["SBDH", "SIMPLE_CHEMICAL", 545, 549], ["amelioration of disparities", "PROBLEM", 79, 106], ["analytic challenges", "TREATMENT", 386, 405], ["SBDH", "PROBLEM", 545, 549]]], ["To advance predictive analytics and increase generalizability across the United States, there should also be open-source SBDH resources for methods and databases that leverage previous SBDH research and development [91,92].", [["predictive analytics", "TEST", 11, 31]]], ["The lack of standardization of SBDH data and collection processes prevents the interoperability and integration of modeling into diverse platforms [91,92] and impacts the creation of SBDH products for EHRs [94].", [["SBDH products", "PROTEIN", 183, 196], ["standardization of SBDH data", "TEST", 12, 40], ["collection processes", "PROBLEM", 45, 65], ["the creation of SBDH products", "TREATMENT", 167, 196]]], ["For greater interoperability, we need a standard, practical coding system for SBDH factors that goes beyond vendor-specific coding [91,92].", [["SBDH factors", "PROTEIN", 78, 90], ["a standard, practical coding system", "TREATMENT", 38, 73], ["SBDH factors", "PROBLEM", 78, 90]]], ["Such an endeavor is presently being pioneered by the Social Interventions Research and Evaluation Network through the HL7 Gravity Project [95].Support National Shared Research and Development to Advance SBDH Predictive Model Development and Application ::: Expanding the Knowledge Base to Inform Best Practice Guidelines ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsIn recognition of the emerging field of SBDH predictive analytics, steps toward developing consensus and further evaluative work are needed to produce best practice guidelines for the use of SBDH data in predictive modeling [91].", [["Evaluation", "TEST", 87, 97], ["SBDH data", "TEST", 588, 597]]], ["There is wide variability in the choice of data sources, risk factors, targeted outcomes, geographic levels, and analytic approaches in the SBDH predictive models.", [["wide variability", "PROBLEM", 9, 25], ["geographic levels", "TEST", 90, 107], ["wide", "OBSERVATION_MODIFIER", 9, 13], ["variability", "OBSERVATION_MODIFIER", 14, 25]]], ["At present, there is a very limited understanding of the impact of these parameters on the effectiveness of the SBDH predictive model.", [["the SBDH predictive model", "TREATMENT", 108, 133]]], ["Best practice guidelines should include transparency of model validation methods for various outcomes to ensure that modeling methods can be replicated in other populations [91].", [["Best practice guidelines", "TREATMENT", 0, 24], ["modeling methods", "TREATMENT", 117, 133]]], ["The use of SBDH variables in predictive modeling is relatively new.", [["SBDH variables in predictive modeling", "PROBLEM", 11, 48], ["predictive modeling", "OBSERVATION", 29, 48], ["relatively", "OBSERVATION_MODIFIER", 52, 62], ["new", "OBSERVATION_MODIFIER", 63, 66]]], ["Developing consensus might be premature in such circumstances and evaluative work must occur beforehand.", [["premature in such circumstances", "PROBLEM", 30, 61], ["might be", "UNCERTAINTY", 21, 29], ["premature", "OBSERVATION_MODIFIER", 30, 39]]], ["Such discourse would facilitate data sharing, create open-source tools and algorithms, and set expectations.Establish a National Agenda to Create a Shared Evidence Base Regarding the Importance of SBDH Factors and the Best Approach for Including SBDH in Analytics ::: Expanding the Knowledge Base to Inform Best Practice Guidelines ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsAlthough the methods and analyses addressing SBDH have matured substantially over the past decades, an expanded data infrastructure and more research are necessary to gain a full understanding of how SBDH manifests throughout a person\u2019s life [96].", [["SBDH", "DISEASE", 608, 612], ["person", "SPECIES", 636, 642], ["algorithms", "TEST", 75, 85]]], ["Rather, they are often intended to give health systems or insurers a leg-up over their competition in achieving financial or pay-for-performance targets.", [["leg", "ORGANISM_SUBDIVISION", 69, 72], ["leg", "ANATOMY", 69, 72]]], ["There should be a national agenda to develop and share technology and human resources and strategies to support efficient data extraction, evidence-based development, and effective analytics and reporting within and across institutions in the United States [92].", [["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["efficient data extraction", "TREATMENT", 112, 137]]], ["Such shared desire would be an incentive for them to participate in the development of a shared evidence base, resulting in the creation of better predictive models.Conclusions ::: Recommendations to Address Challenges and Improve SBDH Predictive ModelsIn the face of great challenges and perhaps even greater benefits, we have identified a series of potential approaches for advancing the present state of predictive analytics within the SBDH context.", [["SBDH", "CANCER", 439, 443]]], ["The future of predictive modeling involving SBDH will require key stakeholders\u2014including policy makers, payers, providers, researchers and analysts, patients, and their advocates\u2014to reach a consensus regarding ethical frameworks, data sharing, technical parameters, and model transparency.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["transparency", "OBSERVATION_MODIFIER", 276, 288]]]], "d5358516f0fcf89924ec27594bbbb135fec0bc46": [["IntroductionControlled release systems have been used in many fields, especially in recent years.", [["IntroductionControlled release systems", "TREATMENT", 0, 38]]], ["The main areas are the pharmaceutical industry, medicine, cosmetics and environment.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["pharmaceutical industry", "OBSERVATION", 23, 46]]], ["These release systems enable the release of the active substance at the preferred conditions and speed and at same time can be used with natural or synthetic polymers, which are selected according to the application place and purpose Especially, embedding, physical absorption, hydrogen bonding and electrostatic interactions play an active role between the active substance to be released and the support material [1] .", [["hydrogen", "CHEMICAL", 278, 286], ["hydrogen", "SIMPLE_CHEMICAL", 278, 286], ["natural or synthetic polymers", "TREATMENT", 137, 166], ["hydrogen bonding", "TREATMENT", 278, 294], ["electrostatic interactions", "TREATMENT", 299, 325]]], ["Therefore the interaction of the active substances to be selected with the appropriate polymers, and the release of these substances from organo-hydrogels, which are polymeric material, are among popular topics recently [2] [3] [4] .", [["organo-hydrogels", "SIMPLE_CHEMICAL", 138, 154], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 220, 231], ["the active substances", "TREATMENT", 29, 50], ["the appropriate polymers", "TREATMENT", 71, 95], ["these substances", "TREATMENT", 116, 132], ["organo-hydrogels", "TREATMENT", 138, 154]]], ["Organo-hydrogels consist of low molecular weight materials or polymeric materials that are classified as physical and chemical organo-hydrogels.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 127, 143], ["Organo-hydrogels", "TREATMENT", 0, 16], ["low molecular weight materials", "PROBLEM", 28, 58], ["polymeric materials", "PROBLEM", 62, 81], ["low molecular", "OBSERVATION_MODIFIER", 28, 41]]], ["Chemical polymeric organohydrogels are three-dimensional macromolecular structures that absorb water and organic solvents which are more suitable for use in a variety of research including chemistry, biotechnology, medicine and pharmaceuticals [3, [5] [6] [7] [8] .IntroductionThe peppermint (Mentha species) plant is included in the Lamiaceae family and contains essential oils such as peppermint essential oil, menthol, pulegon, p-menthon, isopulegon, verbenone, p-pinene, limonene, a-terpineol, b-bourbonen and menthyl acetate [9] .", [["oils", "ANATOMY", 374, 378], ["3, [5] [6] [7", "CHEMICAL", 245, 258], ["menthol", "CHEMICAL", 413, 420], ["pulegon, p-menthon, isopulegon, verbenone, p-pinene, limonene, a-terpineol, b-bourbonen and menthyl acetate", "CHEMICAL", 422, 529], ["menthol", "CHEMICAL", 413, 420], ["pulegon", "CHEMICAL", 422, 429], ["p-menthon", "CHEMICAL", 431, 440], ["isopulegon", "CHEMICAL", 442, 452], ["verbenone", "CHEMICAL", 454, 463], ["p-pinene", "CHEMICAL", 465, 473], ["limonene", "CHEMICAL", 475, 483], ["a-terpineol", "CHEMICAL", 485, 496], ["b-bourbonen", "CHEMICAL", 498, 509], ["menthyl acetate", "CHEMICAL", 514, 529], ["water", "SIMPLE_CHEMICAL", 95, 100], ["[3, [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 244, 263], ["peppermint", "ORGANISM", 281, 291], ["Mentha species", "ORGANISM", 293, 307], ["peppermint essential oil", "SIMPLE_CHEMICAL", 387, 411], ["menthol", "SIMPLE_CHEMICAL", 413, 420], ["pulegon", "SIMPLE_CHEMICAL", 422, 429], ["p-menthon", "SIMPLE_CHEMICAL", 431, 440], ["isopulegon", "SIMPLE_CHEMICAL", 442, 452], ["verbenone", "SIMPLE_CHEMICAL", 454, 463], ["p-pinene", "SIMPLE_CHEMICAL", 465, 473], ["limonene", "SIMPLE_CHEMICAL", 475, 483], ["a-terpineol", "SIMPLE_CHEMICAL", 485, 496], ["b-bourbonen", "SIMPLE_CHEMICAL", 498, 509], ["menthyl acetate [9]", "SIMPLE_CHEMICAL", 514, 533], ["Chemical polymeric organohydrogels", "TREATMENT", 0, 34], ["organic solvents", "TREATMENT", 105, 121], ["The peppermint (Mentha species", "TREATMENT", 277, 307], ["essential oils", "TREATMENT", 364, 378], ["menthol", "TREATMENT", 413, 420], ["pulegon", "TREATMENT", 422, 429], ["p-menthon", "TREATMENT", 431, 440], ["isopulegon", "TREATMENT", 442, 452], ["verbenone", "TREATMENT", 454, 463], ["p-pinene", "TREATMENT", 465, 473], ["limonene", "TREATMENT", 475, 483], ["a-terpineol", "TREATMENT", 485, 496], ["b-bourbonen", "TREATMENT", 498, 509], ["menthyl acetate", "TREATMENT", 514, 529], ["polymeric organohydrogels", "OBSERVATION", 9, 34]]], ["Medically, peppermint contains active ingredients which affect spasm and degassing, asthma, flu, bronchitis and cough blocker, migraine, insomnia and dizziness, as well as vitamin C, vitamin A and manganese and acts as an antimicrobial and diuretic.", [["spasm", "DISEASE", 63, 68], ["degassing", "DISEASE", 73, 82], ["asthma", "DISEASE", 84, 90], ["flu", "DISEASE", 92, 95], ["bronchitis", "DISEASE", 97, 107], ["cough", "DISEASE", 112, 117], ["migraine", "DISEASE", 127, 135], ["insomnia", "DISEASE", 137, 145], ["dizziness", "DISEASE", 150, 159], ["vitamin C", "CHEMICAL", 172, 181], ["vitamin A", "CHEMICAL", 183, 192], ["manganese", "CHEMICAL", 197, 206], ["vitamin C", "CHEMICAL", 172, 181], ["vitamin A", "CHEMICAL", 183, 192], ["manganese", "CHEMICAL", 197, 206], ["vitamin C", "SIMPLE_CHEMICAL", 172, 181], ["vitamin A", "SIMPLE_CHEMICAL", 183, 192], ["manganese", "SIMPLE_CHEMICAL", 197, 206], ["diuretic", "SIMPLE_CHEMICAL", 240, 248], ["active ingredients", "PROBLEM", 31, 49], ["spasm", "PROBLEM", 63, 68], ["asthma", "PROBLEM", 84, 90], ["flu", "PROBLEM", 92, 95], ["bronchitis", "PROBLEM", 97, 107], ["cough blocker", "PROBLEM", 112, 125], ["migraine", "PROBLEM", 127, 135], ["insomnia", "PROBLEM", 137, 145], ["dizziness", "PROBLEM", 150, 159], ["vitamin C", "TREATMENT", 172, 181], ["vitamin A", "TREATMENT", 183, 192], ["manganese", "TREATMENT", 197, 206], ["an antimicrobial", "TREATMENT", 219, 235], ["diuretic", "TREATMENT", 240, 248], ["active", "OBSERVATION_MODIFIER", 31, 37], ["asthma", "OBSERVATION", 84, 90], ["bronchitis", "OBSERVATION", 97, 107]]], ["Vitamin A is an antioxidant and is important for manganese, fat and protein metabolism while helping prevent cancer, while Vitamin C helps reduce the damage from free radicals in the body.", [["cancer", "ANATOMY", 109, 115], ["body", "ANATOMY", 183, 187], ["Vitamin A", "CHEMICAL", 0, 9], ["manganese", "CHEMICAL", 49, 58], ["cancer", "DISEASE", 109, 115], ["Vitamin C", "CHEMICAL", 123, 132], ["Vitamin A", "CHEMICAL", 0, 9], ["manganese", "CHEMICAL", 49, 58], ["Vitamin C", "CHEMICAL", 123, 132], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["manganese", "SIMPLE_CHEMICAL", 49, 58], ["fat", "TISSUE", 60, 63], ["cancer", "CANCER", 109, 115], ["Vitamin C", "SIMPLE_CHEMICAL", 123, 132], ["free radicals", "SIMPLE_CHEMICAL", 162, 175], ["body", "ORGANISM_SUBDIVISION", 183, 187], ["Vitamin A", "TREATMENT", 0, 9], ["manganese, fat and protein metabolism", "TREATMENT", 49, 86], ["cancer", "PROBLEM", 109, 115], ["Vitamin C", "TREATMENT", 123, 132], ["the damage from free radicals in the body", "PROBLEM", 146, 187], ["cancer", "OBSERVATION", 109, 115], ["free radicals", "OBSERVATION", 162, 175], ["body", "ANATOMY", 183, 187]]], ["Different mint types have been used both as a folk remedy and in the pharmaceutical, food, perfumery, cosmetics and industry since ancient times because of various physiological effects in people, such as antimicrobial, antispasmodic, choleretic, and carminative properties [9] [10] [11] [12] .", [["people", "ORGANISM", 189, 195], ["choleretic", "SIMPLE_CHEMICAL", 235, 245], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 274, 292], ["people", "SPECIES", 189, 195], ["a folk remedy", "TREATMENT", 44, 57], ["various physiological effects", "PROBLEM", 156, 185], ["antimicrobial, antispasmodic", "TREATMENT", 205, 233], ["choleretic, and carminative properties", "TREATMENT", 235, 273]]], ["Medicines containing active ingredients from peppermint include colpermin (187 mg Menthol), Salonpas (3% menthol), Camfolin (10%), and Otrivine menthol (0.10%) [13, 14] .", [["colpermin", "CHEMICAL", 64, 73], ["Menthol", "CHEMICAL", 82, 89], ["Salonpas", "CHEMICAL", 92, 100], ["menthol", "CHEMICAL", 105, 112], ["Camfolin", "CHEMICAL", 115, 123], ["Otrivine menthol", "CHEMICAL", 135, 151], ["colpermin", "CHEMICAL", 64, 73], ["Menthol", "CHEMICAL", 82, 89], ["Salonpas", "CHEMICAL", 92, 100], ["menthol", "CHEMICAL", 105, 112], ["Camfolin", "CHEMICAL", 115, 123], ["Otrivine menthol", "CHEMICAL", 135, 151], ["peppermint", "SIMPLE_CHEMICAL", 45, 55], ["colpermin", "SIMPLE_CHEMICAL", 64, 73], ["Menthol", "SIMPLE_CHEMICAL", 82, 89], ["Salonpas", "SIMPLE_CHEMICAL", 92, 100], ["menthol", "SIMPLE_CHEMICAL", 105, 112], ["Camfolin", "SIMPLE_CHEMICAL", 115, 123], ["Otrivine menthol", "SIMPLE_CHEMICAL", 135, 151], ["Medicines", "TREATMENT", 0, 9], ["active ingredients from peppermint", "TREATMENT", 21, 55], ["colpermin", "TREATMENT", 64, 73], ["Salonpas (3% menthol)", "TREATMENT", 92, 113], ["Camfolin", "TREATMENT", 115, 123], ["Otrivine menthol", "TREATMENT", 135, 151], ["active", "OBSERVATION_MODIFIER", 21, 27]]], ["Essential oils, which are among the various active ingredients in peppermint species, are used in the polymer and industrial fields [15] [16] [17] [18] [19] [20] [21] .IntroductionParacetamol (acetaminophen) is a drug active substance that is used as an alternative drug in aspirin-sensitive patients and has antipyretic effect.", [["Essential oils", "ANATOMY", 0, 14], ["Paracetamol", "CHEMICAL", 180, 191], ["acetaminophen", "CHEMICAL", 193, 206], ["aspirin", "CHEMICAL", 274, 281], ["[15] [16] [17] [18] [19] [20]", "CHEMICAL", 132, 161], ["Paracetamol", "CHEMICAL", 180, 191], ["acetaminophen", "CHEMICAL", 193, 206], ["aspirin", "CHEMICAL", 274, 281], ["[15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 132, 166], ["Paracetamol", "SIMPLE_CHEMICAL", 180, 191], ["acetaminophen", "SIMPLE_CHEMICAL", 193, 206], ["aspirin", "SIMPLE_CHEMICAL", 274, 281], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["IntroductionParacetamol (acetaminophen)", "TREATMENT", 168, 207], ["a drug active substance", "TREATMENT", 211, 234], ["an alternative drug in aspirin", "TREATMENT", 251, 281], ["antipyretic effect", "TREATMENT", 309, 327], ["oils", "OBSERVATION", 10, 14], ["various", "OBSERVATION_MODIFIER", 36, 43], ["active", "OBSERVATION_MODIFIER", 44, 50], ["ingredients", "OBSERVATION_MODIFIER", 51, 62], ["peppermint species", "OBSERVATION", 66, 84]]], ["Although its analgesic effect is mild J o u r n a l P r e -p r o o f compared to new generation analgesics, it has almost no side effects in the gastrointestinal tract, is reliability and is safe for use in pregnant women, which ensures that paracetamol is always at the forefront as a classic analgesic [22] .", [["gastrointestinal tract", "ANATOMY", 145, 167], ["paracetamol", "CHEMICAL", 242, 253], ["paracetamol", "CHEMICAL", 242, 253], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 145, 167], ["women", "ORGANISM", 216, 221], ["paracetamol", "SIMPLE_CHEMICAL", 242, 253], ["women", "SPECIES", 216, 221], ["new generation analgesics", "TREATMENT", 81, 106], ["side effects in the gastrointestinal tract", "PROBLEM", 125, 167], ["paracetamol", "TREATMENT", 242, 253], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["gastrointestinal tract", "ANATOMY", 145, 167]]], ["Many publications recommend and apply antipyretic therapy such as paracetamol for first-line treatment of fever caused by Prolonged release of paracetamol may be an alternative drug for first-line treatment of fever caused by COVID-19 [23] [24] [25] .IntroductionCarboplatin cis-Diammine (1,1-cyclobutanedicarboxylato) platinum (II) is a 2nd generation platinum compound.", [["paracetamol", "CHEMICAL", 66, 77], ["fever", "DISEASE", 106, 111], ["paracetamol", "CHEMICAL", 143, 154], ["fever", "DISEASE", 210, 215], ["COVID-19 [23] [24]", "CHEMICAL", 226, 244], ["Carboplatin cis-Diammine", "CHEMICAL", 263, 287], ["1,1-cyclobutanedicarboxylato", "CHEMICAL", 289, 317], ["platinum", "CHEMICAL", 319, 327], ["II", "CHEMICAL", 329, 331], ["platinum", "CHEMICAL", 353, 361], ["paracetamol", "CHEMICAL", 66, 77], ["paracetamol", "CHEMICAL", 143, 154], ["COVID-19", "CHEMICAL", 226, 234], ["Carboplatin cis-Diammine", "CHEMICAL", 263, 287], ["1,1-cyclobutanedicarboxylato", "CHEMICAL", 289, 317], ["platinum (II)", "CHEMICAL", 319, 332], ["platinum", "CHEMICAL", 353, 361], ["paracetamol", "SIMPLE_CHEMICAL", 66, 77], ["paracetamol", "SIMPLE_CHEMICAL", 143, 154], ["COVID-19 [23] [24] [25]", "SIMPLE_CHEMICAL", 226, 249], ["Carboplatin cis-Diammine", "SIMPLE_CHEMICAL", 263, 287], ["1,1-cyclobutanedicarboxylato) platinum (II", "SIMPLE_CHEMICAL", 289, 331], ["platinum compound", "SIMPLE_CHEMICAL", 353, 370], ["antipyretic therapy", "TREATMENT", 38, 57], ["paracetamol", "TREATMENT", 66, 77], ["first-line treatment", "TREATMENT", 82, 102], ["fever", "PROBLEM", 106, 111], ["paracetamol", "TREATMENT", 143, 154], ["an alternative drug", "TREATMENT", 162, 181], ["first-line treatment", "TREATMENT", 186, 206], ["fever", "PROBLEM", 210, 215], ["COVID", "TEST", 226, 231], ["IntroductionCarboplatin cis-Diammine (1,1-cyclobutanedicarboxylato) platinum (II)", "TREATMENT", 251, 332], ["a 2nd generation platinum compound", "TREATMENT", 336, 370]]], ["It is designed to stop the growth of cancer cells and kill them.", [["cancer cells", "ANATOMY", 37, 49], ["cancer", "DISEASE", 37, 43], ["cancer cells", "CELL", 37, 49], ["cancer cells", "CELL_TYPE", 37, 49], ["cancer cells", "PROBLEM", 37, 49], ["cancer", "OBSERVATION", 37, 43]]], ["It is effective on carboplatin DNA.", [["carboplatin", "CHEMICAL", 19, 30], ["carboplatin", "CHEMICAL", 19, 30], ["carboplatin", "SIMPLE_CHEMICAL", 19, 30], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["carboplatin DNA", "TREATMENT", 19, 34], ["effective", "OBSERVATION_MODIFIER", 6, 15]]], ["Adenine and guanine are linked to the DNA from the N-7 position by a covalent ligament.", [["Adenine", "CHEMICAL", 0, 7], ["guanine", "CHEMICAL", 12, 19], ["Adenine", "CHEMICAL", 0, 7], ["guanine", "CHEMICAL", 12, 19], ["Adenine", "SIMPLE_CHEMICAL", 0, 7], ["guanine", "SIMPLE_CHEMICAL", 12, 19], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["ligament", "TISSUE", 78, 86], ["N-7 position", "DNA", 51, 63], ["Adenine and guanine", "TREATMENT", 0, 19], ["covalent ligament", "OBSERVATION", 69, 86]]], ["As a result of the formation of DNA addition products, DNA synthesis and transcription are inhibited and the cell cannot divide.", [["cell", "ANATOMY", 109, 113], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["cell", "CELL", 109, 113], ["DNA addition products", "PROTEIN", 32, 53], ["DNA addition products", "TREATMENT", 32, 53], ["DNA synthesis", "TREATMENT", 55, 68], ["transcription", "TREATMENT", 73, 86]]], ["Binding to DNA and cytoplasmic proteins can result in cytotoxic effects.", [["cytoplasmic", "ANATOMY", 19, 30], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["cytoplasmic", "ORGANISM_SUBSTANCE", 19, 30], ["cytoplasmic proteins", "PROTEIN", 19, 39], ["Binding to DNA", "PROBLEM", 0, 14], ["cytoplasmic proteins", "PROBLEM", 19, 39], ["cytotoxic effects", "PROBLEM", 54, 71], ["cytotoxic effects", "OBSERVATION", 54, 71]]], ["Broad-spectrum carboplatin is a frequently used chemotherapeutic agent for the treatment of childhood cancers.", [["childhood cancers", "ANATOMY", 92, 109], ["carboplatin", "CHEMICAL", 15, 26], ["cancers", "DISEASE", 102, 109], ["carboplatin", "CHEMICAL", 15, 26], ["carboplatin", "SIMPLE_CHEMICAL", 15, 26], ["childhood cancers", "CANCER", 92, 109], ["Broad-spectrum carboplatin", "TREATMENT", 0, 26], ["chemotherapeutic agent", "TREATMENT", 48, 70], ["childhood cancers", "PROBLEM", 92, 109], ["cancers", "OBSERVATION", 102, 109]]], ["It is used for the treatment of osteosarcoma, hepatoblastoma, neuroblastoma, germ cell tumors, central nervous system tumors, head and neck cancers [26, 27] .IntroductionIn fact, the main purpose of this research is to synthesize organo-hydrogels in a novel form that has the properties of both organogels and hydrogels.", [["osteosarcoma", "ANATOMY", 32, 44], ["hepatoblastoma", "ANATOMY", 46, 60], ["neuroblastoma", "ANATOMY", 62, 75], ["germ cell tumors", "ANATOMY", 77, 93], ["central nervous system tumors", "ANATOMY", 95, 124], ["head and neck cancers", "ANATOMY", 126, 147], ["osteosarcoma", "DISEASE", 32, 44], ["hepatoblastoma", "DISEASE", 46, 60], ["neuroblastoma", "DISEASE", 62, 75], ["germ cell tumors", "DISEASE", 77, 93], ["central nervous system tumors", "DISEASE", 95, 124], ["head and neck cancers", "DISEASE", 126, 147], ["osteosarcoma", "CANCER", 32, 44], ["hepatoblastoma", "CANCER", 46, 60], ["neuroblastoma", "CANCER", 62, 75], ["germ cell tumors", "CANCER", 77, 93], ["central nervous system tumors", "CANCER", 95, 124], ["head and neck cancers", "CANCER", 126, 147], ["organogels", "SIMPLE_CHEMICAL", 295, 305], ["the treatment", "TREATMENT", 15, 28], ["osteosarcoma", "PROBLEM", 32, 44], ["hepatoblastoma", "PROBLEM", 46, 60], ["neuroblastoma", "PROBLEM", 62, 75], ["germ cell tumors", "PROBLEM", 77, 93], ["central nervous system tumors", "PROBLEM", 95, 124], ["head and neck cancers", "PROBLEM", 126, 147], ["hydrogels", "TREATMENT", 237, 246], ["both organogels", "TREATMENT", 290, 305], ["hydrogels", "TREATMENT", 310, 319], ["osteosarcoma", "OBSERVATION", 32, 44], ["hepatoblastoma", "OBSERVATION", 46, 60], ["neuroblastoma", "OBSERVATION", 62, 75], ["germ cell tumors", "OBSERVATION", 77, 93], ["central", "ANATOMY_MODIFIER", 95, 102], ["nervous system", "ANATOMY", 103, 117], ["tumors", "OBSERVATION", 118, 124], ["head", "ANATOMY", 126, 130], ["neck", "ANATOMY", 135, 139], ["cancers", "OBSERVATION", 140, 147]]], ["At the same time, the swelling behavior of these organo-hydrogels in different solvent environments, biocompatibility properties, and their effects on the release of the drug active substance were examined and enhanced.", [["swelling", "DISEASE", 22, 30], ["organo-hydrogels", "SIMPLE_CHEMICAL", 49, 65], ["the swelling behavior", "PROBLEM", 18, 39], ["these organo-hydrogels", "TREATMENT", 43, 65], ["biocompatibility properties", "TREATMENT", 101, 128], ["swelling", "OBSERVATION", 22, 30]]], ["In this study, organo-hydrogels containing agar-based peppermint oil were synthesized using two different crosslinkers, MBA and GA.", [["peppermint oil", "ANATOMY", 54, 68], ["MBA", "CHEMICAL", 120, 123], ["GA", "CHEMICAL", 128, 130], ["organo-hydrogels", "SIMPLE_CHEMICAL", 15, 31], ["peppermint", "ORGANISM", 54, 64], ["oil", "ORGANISM_SUBSTANCE", 65, 68], ["MBA", "SIMPLE_CHEMICAL", 120, 123], ["GA", "SIMPLE_CHEMICAL", 128, 130], ["this study", "TEST", 3, 13], ["organo-hydrogels", "TREATMENT", 15, 31], ["agar-based peppermint oil", "TREATMENT", 43, 68]]], ["Characterization of synthesized gel, hydrogels and organo-hydrogels was carried out with FTIR and SEM.", [["synthesized gel, hydrogels", "TREATMENT", 20, 46], ["organo-hydrogels", "TREATMENT", 51, 67]]], ["The swelling properties were examined in DI water, tap water, ethanol, acetone, ethanol/water, acetone/water, and gasoline and the usability of polymers as an effective sorbent was investigated.", [["swelling", "DISEASE", 4, 12], ["ethanol, acetone, ethanol/water, acetone/water", "CHEMICAL", 62, 108], ["gasoline", "CHEMICAL", 114, 122], ["ethanol", "CHEMICAL", 62, 69], ["acetone", "CHEMICAL", 71, 78], ["ethanol", "CHEMICAL", 80, 87], ["acetone", "CHEMICAL", 95, 102], ["gasoline", "CHEMICAL", 114, 122], ["ethanol", "SIMPLE_CHEMICAL", 62, 69], ["acetone", "SIMPLE_CHEMICAL", 71, 78], ["ethanol", "SIMPLE_CHEMICAL", 80, 87], ["water", "SIMPLE_CHEMICAL", 88, 93], ["acetone", "SIMPLE_CHEMICAL", 95, 102], ["water", "SIMPLE_CHEMICAL", 103, 108], ["gasoline", "SIMPLE_CHEMICAL", 114, 122], ["The swelling properties", "PROBLEM", 0, 23], ["ethanol", "TREATMENT", 62, 69], ["acetone", "TREATMENT", 71, 78], ["ethanol", "TREATMENT", 80, 87], ["acetone", "TREATMENT", 95, 102], ["water", "TREATMENT", 103, 108], ["gasoline", "TREATMENT", 114, 122], ["polymers", "TREATMENT", 144, 152], ["an effective sorbent", "TREATMENT", 156, 176], ["swelling", "OBSERVATION", 4, 12]]], ["Additionally, the fundamental purpose of the study to investigate the ability of the synthesized gel, hydrogels and organo-hydrogels as antioxidants with blood clotting and hemolysis properties and their potential use as paracetamol and carboplatin carrier/delivery systems.IntroductionJ o u r n a l P r e -p r o o fReagentsGlycerol (G), agar (99%), N, N, methylenebisacrylamide (MBA, 99%), glutaraldehyde (GA, 25% v/v), ethanol, acetone, calcium chloride (CaCl 2 ), sodium hydroxide (NaOH) and hydrochloric acid (HCl) (36.5-38% v/v) were purchased from Sigma; ammonium persulfate (APS) (98%) was purchased from Merck.", [["blood", "ANATOMY", 154, 159], ["hemolysis", "DISEASE", 173, 182], ["paracetamol", "CHEMICAL", 221, 232], ["carboplatin", "CHEMICAL", 237, 248], ["Glycerol", "CHEMICAL", 324, 332], ["N, N, methylenebisacrylamide", "CHEMICAL", 350, 378], ["MBA", "CHEMICAL", 380, 383], ["glutaraldehyde", "CHEMICAL", 391, 405], ["GA", "CHEMICAL", 407, 409], ["ethanol", "CHEMICAL", 421, 428], ["acetone", "CHEMICAL", 430, 437], ["calcium chloride", "CHEMICAL", 439, 455], ["CaCl 2", "CHEMICAL", 457, 463], ["sodium hydroxide", "CHEMICAL", 467, 483], ["NaOH", "CHEMICAL", 485, 489], ["hydrochloric acid", "CHEMICAL", 495, 512], ["HCl", "CHEMICAL", 514, 517], ["ammonium persulfate", "CHEMICAL", 561, 580], ["APS", "CHEMICAL", 582, 585], ["paracetamol", "CHEMICAL", 221, 232], ["carboplatin", "CHEMICAL", 237, 248], ["Glycerol", "CHEMICAL", 324, 332], ["N", "CHEMICAL", 350, 351], ["methylenebisacrylamide", "CHEMICAL", 356, 378], ["MBA", "CHEMICAL", 380, 383], ["glutaraldehyde", "CHEMICAL", 391, 405], ["ethanol", "CHEMICAL", 421, 428], ["acetone", "CHEMICAL", 430, 437], ["calcium chloride", "CHEMICAL", 439, 455], ["CaCl 2", "CHEMICAL", 457, 463], ["sodium hydroxide", "CHEMICAL", 467, 483], ["NaOH", "CHEMICAL", 485, 489], ["hydrochloric acid", "CHEMICAL", 495, 512], ["HCl", "CHEMICAL", 514, 517], ["ammonium persulfate", "CHEMICAL", 561, 580], ["organo-hydrogels", "SIMPLE_CHEMICAL", 116, 132], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["paracetamol", "SIMPLE_CHEMICAL", 221, 232], ["carboplatin", "SIMPLE_CHEMICAL", 237, 248], ["Glycerol", "SIMPLE_CHEMICAL", 324, 332], ["G", "SIMPLE_CHEMICAL", 334, 335], ["N, N, methylenebisacrylamide", "SIMPLE_CHEMICAL", 350, 378], ["MBA", "SIMPLE_CHEMICAL", 380, 383], ["glutaraldehyde", "SIMPLE_CHEMICAL", 391, 405], ["GA", "SIMPLE_CHEMICAL", 407, 409], ["v/v)", "SIMPLE_CHEMICAL", 415, 419], ["ethanol", "SIMPLE_CHEMICAL", 421, 428], ["acetone", "SIMPLE_CHEMICAL", 430, 437], ["calcium chloride", "SIMPLE_CHEMICAL", 439, 455], ["CaCl 2 )", "SIMPLE_CHEMICAL", 457, 465], ["sodium hydroxide", "SIMPLE_CHEMICAL", 467, 483], ["NaOH", "SIMPLE_CHEMICAL", 485, 489], ["hydrochloric acid", "SIMPLE_CHEMICAL", 495, 512], ["HCl", "SIMPLE_CHEMICAL", 514, 517], ["ammonium persulfate", "SIMPLE_CHEMICAL", 561, 580], ["APS", "SIMPLE_CHEMICAL", 582, 585], ["the study", "TEST", 41, 50], ["the synthesized gel", "TREATMENT", 81, 100], ["hydrogels", "TREATMENT", 102, 111], ["organo-hydrogels", "TREATMENT", 116, 132], ["antioxidants", "TREATMENT", 136, 148], ["blood clotting", "TREATMENT", 154, 168], ["hemolysis properties", "TREATMENT", 173, 193], ["paracetamol", "TREATMENT", 221, 232], ["carboplatin carrier/delivery systems", "TREATMENT", 237, 273], ["IntroductionJ", "TEST", 274, 287], ["a l P r e", "TREATMENT", 296, 305], ["fReagentsGlycerol", "TREATMENT", 315, 332], ["agar", "TEST", 338, 342], ["methylenebisacrylamide", "TREATMENT", 356, 378], ["glutaraldehyde (GA", "TREATMENT", 391, 409], ["ethanol", "TREATMENT", 421, 428], ["acetone", "TREATMENT", 430, 437], ["calcium chloride (CaCl", "TREATMENT", 439, 461], ["sodium hydroxide (NaOH)", "TREATMENT", 467, 490], ["hydrochloric acid", "TREATMENT", 495, 512], ["ammonium persulfate (APS)", "TREATMENT", 561, 586]]], ["In terms of analytical grade, all reagents were of the highest cleanliness available, and they were used without additional purification.", [["all reagents", "TREATMENT", 30, 42], ["additional purification", "TREATMENT", 113, 136]]], ["Peppermint oil (PmO), gasoline, paracetamol and carboplatin were procured from local suppliers.ReagentsDistilled water (DI, 18.2 M\u03a9 cm; Human I) was also employed from the beginning to the end of this study.Agar-Glycerol-based gels, hydrogels and organo-hydrogels synthesisAgar-Glycerol-based gel and hydrogels were synthesized via free radical polymerization in emulsion according to the preparation method given in Table 1 [8] .", [["PmO", "CHEMICAL", 16, 19], ["gasoline", "CHEMICAL", 22, 30], ["paracetamol", "CHEMICAL", 32, 43], ["carboplatin", "CHEMICAL", 48, 59], ["Glycerol", "CHEMICAL", 212, 220], ["Agar-", "CHEMICAL", 273, 278], ["Glycerol", "CHEMICAL", 278, 286], ["gasoline", "CHEMICAL", 22, 30], ["paracetamol", "CHEMICAL", 32, 43], ["carboplatin", "CHEMICAL", 48, 59], ["Glycerol", "CHEMICAL", 212, 220], ["Glycerol", "CHEMICAL", 278, 286], ["Peppermint", "SIMPLE_CHEMICAL", 0, 10], ["oil", "ORGANISM_SUBSTANCE", 11, 14], ["PmO", "SIMPLE_CHEMICAL", 16, 19], ["gasoline", "SIMPLE_CHEMICAL", 22, 30], ["paracetamol", "SIMPLE_CHEMICAL", 32, 43], ["carboplatin", "SIMPLE_CHEMICAL", 48, 59], ["Agar-Glycerol", "SIMPLE_CHEMICAL", 207, 220], ["organo-hydrogels", "SIMPLE_CHEMICAL", 247, 263], ["Agar-Glycerol", "SIMPLE_CHEMICAL", 273, 286], ["Human", "SPECIES", 136, 141], ["Peppermint oil (PmO)", "TREATMENT", 0, 20], ["gasoline", "TREATMENT", 22, 30], ["paracetamol", "TREATMENT", 32, 43], ["carboplatin", "TREATMENT", 48, 59], ["this study", "TEST", 196, 206], ["Agar", "TEST", 207, 211], ["Glycerol-based gels", "TREATMENT", 212, 231], ["hydrogels", "TREATMENT", 233, 242], ["organo-hydrogels synthesisAgar", "TREATMENT", 247, 277], ["Glycerol-based gel and hydrogels", "TREATMENT", 278, 310], ["free radical polymerization in emulsion", "TREATMENT", 332, 371], ["the preparation method", "TREATMENT", 385, 407]]], ["Briefly, gel and hydrogel were synthesized as follows with batch polymerization reactions were conducted in 20 mL flasks.", [["gel and hydrogel", "TREATMENT", 9, 25], ["batch polymerization reactions", "TREATMENT", 59, 89]]], ["Agar (2% w/v) solution was prepared by dissolving agar in water at 80 \uf0b0C. Firstly, 2 mL of agar solution and 0.04 mL of glycerol were added to the 20 mL flask and homogenized by vigorous mixing (at 2500 rpm and 15 min).", [["glycerol", "CHEMICAL", 120, 128], ["glycerol", "CHEMICAL", 120, 128], ["glycerol", "SIMPLE_CHEMICAL", 120, 128], ["Agar (2% w/v) solution", "TREATMENT", 0, 22], ["agar solution", "TREATMENT", 91, 104], ["glycerol", "TREATMENT", 120, 128]]], ["Secondly, MBA (0.1%) or glutaraldehyde reagent (0.5 mL of glutaraldehyde (25% v/v) + 0.5 mL of ethanol + 0.1 mL of hydrochloric acid) was added as crosslinker and further homogenized.", [["MBA", "CHEMICAL", 10, 13], ["glutaraldehyde", "CHEMICAL", 24, 38], ["glutaraldehyde", "CHEMICAL", 58, 72], ["ethanol", "CHEMICAL", 95, 102], ["hydrochloric acid", "CHEMICAL", 115, 132], ["MBA", "CHEMICAL", 10, 13], ["glutaraldehyde", "CHEMICAL", 24, 38], ["glutaraldehyde", "CHEMICAL", 58, 72], ["ethanol", "CHEMICAL", 95, 102], ["hydrochloric acid", "CHEMICAL", 115, 132], ["MBA", "SIMPLE_CHEMICAL", 10, 13], ["glutaraldehyde reagent", "SIMPLE_CHEMICAL", 24, 46], ["glutaraldehyde", "SIMPLE_CHEMICAL", 58, 72], ["ethanol", "SIMPLE_CHEMICAL", 95, 102], ["hydrochloric acid", "SIMPLE_CHEMICAL", 115, 132], ["glutaraldehyde reagent", "TREATMENT", 24, 46], ["glutaraldehyde", "TREATMENT", 58, 72], ["ethanol", "TREATMENT", 95, 102], ["hydrochloric acid)", "TREATMENT", 115, 133]]], ["In this study, the polymer with no cross-linker used during synthesis was named gel and polymer synthesized using crosslinker was named hydrogel [28] .", [["this study", "TEST", 3, 13], ["the polymer", "TREATMENT", 15, 26], ["cross-linker", "TREATMENT", 35, 47], ["synthesis", "TREATMENT", 60, 69], ["gel and polymer synthesized using crosslinker", "TREATMENT", 80, 125]]], ["Gel and hydrogel compositions are given in Table 2 .", [["Gel and hydrogel compositions", "TREATMENT", 0, 29], ["hydrogel compositions", "OBSERVATION", 8, 29]]], ["Finally, the polymerization reaction was initiated by the addition of the initiator solution APS (0.1 mol% in proportion to total monomer amount) in 100 \u00b5L DI water.", [["APS", "DISEASE", 93, 96], ["APS", "SIMPLE_CHEMICAL", 93, 96], ["the polymerization reaction", "PROBLEM", 9, 36], ["the initiator solution APS", "TREATMENT", 70, 96]]], ["Reaction temperatures were maintained at 25 \u00b0C with a temperature-controlled hot plate.", [["Reaction temperatures", "TEST", 0, 21], ["a temperature", "TEST", 52, 65]]], ["Immediately afterwards, the solution was transferred into a plastic petri with 35 mm diameter and was allowed to polymerize for 4 h.", [["the solution", "TREATMENT", 24, 36], ["a plastic petri with 35 mm diameter", "TREATMENT", 58, 93]]], ["Obtained AG gels were stored at 25 \u00b0C for further uses.Agar-Glycerol-based gels, hydrogels and organo-hydrogels synthesisFor the preparation of organo-hydrogels, the above method was used (Table 1) Table 2 .", [["Agar-Glycerol", "CHEMICAL", 55, 68], ["Glycerol", "CHEMICAL", 60, 68], ["Agar-Glycerol", "SIMPLE_CHEMICAL", 55, 68], ["organo-hydrogels", "SIMPLE_CHEMICAL", 95, 111], ["organo-hydrogels", "SIMPLE_CHEMICAL", 144, 160], ["AG gels", "TREATMENT", 9, 16], ["Agar", "TEST", 55, 59], ["Glycerol-based gels", "TREATMENT", 60, 79], ["hydrogels", "TREATMENT", 81, 90], ["organo-hydrogels synthesis", "TREATMENT", 95, 121], ["organo-hydrogels", "TREATMENT", 144, 160], ["the above method", "TREATMENT", 162, 178]]], ["Finally, the polymerization reaction was initiated with the addition of the initiator solution APS in 100 \u00b5L DI water.", [["APS", "DISEASE", 95, 98], ["APS", "SIMPLE_CHEMICAL", 95, 98], ["the polymerization reaction", "PROBLEM", 9, 36], ["the initiator solution APS", "TREATMENT", 72, 98]]], ["Reaction temperatures were maintained at 25 \u00b0C with a temperature-controlled hot plate.", [["Reaction temperatures", "TEST", 0, 21], ["a temperature", "TEST", 52, 65]]], ["Then, the solution was transferred to a plastic petri with 35 mm diameter and was allowed to polymerize.", [["the solution", "TREATMENT", 6, 18], ["a plastic petri with 35 mm diameter", "TREATMENT", 38, 73]]], ["The gel, hydrogels and organohydrogels were kept in DI water and washing water was renewed every 2 h for 8 h to eliminate unreactive monomers.", [["organohydrogels", "SIMPLE_CHEMICAL", 23, 38], ["The gel", "TREATMENT", 0, 7], ["hydrogels", "TREATMENT", 9, 18], ["organohydrogels", "TREATMENT", 23, 38], ["washing water", "TREATMENT", 65, 78], ["unreactive monomers", "OBSERVATION", 122, 141]]], ["The synthesized gel, hydrogels, p(AG-m-PmO) and p(AG-g-PmO) organo-hydrogels were dried in the oven at 40 \u00baC until a constant weight was achieved and stored at 4 \u00baC for further use.Organo-hydrogel synthesis containing paracetamol and carboplatinParacetamol and carboplatin drugs were added directly into the organo-hydrogels during their synthesis [29] .", [["AG-m-PmO", "CHEMICAL", 34, 42], ["paracetamol", "CHEMICAL", 218, 229], ["carboplatinParacetamol", "CHEMICAL", 234, 256], ["carboplatin", "CHEMICAL", 261, 272], ["paracetamol", "CHEMICAL", 218, 229], ["carboplatinParacetamol", "CHEMICAL", 234, 256], ["carboplatin", "CHEMICAL", 261, 272], ["AG-m-PmO", "SIMPLE_CHEMICAL", 34, 42], ["p(AG-g-PmO", "SIMPLE_CHEMICAL", 48, 58], ["organo-hydrogels", "SIMPLE_CHEMICAL", 60, 76], ["paracetamol", "SIMPLE_CHEMICAL", 218, 229], ["carboplatinParacetamol", "SIMPLE_CHEMICAL", 234, 256], ["carboplatin", "SIMPLE_CHEMICAL", 261, 272], ["The synthesized gel", "TREATMENT", 0, 19], ["hydrogels", "TREATMENT", 21, 30], ["p(AG-m-PmO", "TREATMENT", 32, 42], ["p(AG-g-PmO", "TREATMENT", 48, 58], ["organo-hydrogels", "TREATMENT", 60, 76], ["a constant weight", "TEST", 115, 132], ["Organo-hydrogel synthesis", "TREATMENT", 181, 206], ["paracetamol", "TREATMENT", 218, 229], ["carboplatinParacetamol", "TREATMENT", 234, 256], ["carboplatin drugs", "TREATMENT", 261, 278]]], ["The synthesis of drug-loaded organo-hydrogels was the same as the synthesis procedure for the organo-hydrogels described above.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 29, 45], ["organo-hydrogels", "SIMPLE_CHEMICAL", 94, 110], ["drug-loaded organo-hydrogels", "TREATMENT", 17, 45], ["the synthesis procedure", "TREATMENT", 62, 85], ["the organo-hydrogels", "TREATMENT", 90, 110]]], ["In addition to the reaction mixture mentioned above, 50 ppm 1mL paracetamol/carboplatin drug was added.", [["paracetamol", "CHEMICAL", 64, 75], ["carboplatin", "CHEMICAL", 76, 87], ["paracetamol", "CHEMICAL", 64, 75], ["carboplatin", "CHEMICAL", 76, 87], ["paracetamol", "SIMPLE_CHEMICAL", 64, 75], ["carboplatin", "SIMPLE_CHEMICAL", 76, 87], ["the reaction mixture", "TREATMENT", 15, 35], ["paracetamol/carboplatin drug", "TREATMENT", 64, 92]]], ["Thus, drugs from the -OH group in the structure of paracetamol and the -NH 3 group of carboplatin are physically bound to organo-hydrogels and drug-loaded organo-hydrogels were synthesized.Swelling analysisSwelling assays were carried out with certain amounts of dried gel, hydrogels, and organohydrogels placed in water, ethanol, acetone, ethanol/ID water (1:1), acetone/ID water (1:1) and gasoline and at different pHs (2.0-12.0) for 24 h.", [["paracetamol", "CHEMICAL", 51, 62], ["carboplatin", "CHEMICAL", 86, 97], ["ethanol", "CHEMICAL", 322, 329], ["acetone", "CHEMICAL", 331, 338], ["ethanol", "CHEMICAL", 340, 347], ["acetone", "CHEMICAL", 364, 371], ["gasoline", "CHEMICAL", 391, 399], ["OH", "CHEMICAL", 22, 24], ["paracetamol", "CHEMICAL", 51, 62], ["NH 3", "CHEMICAL", 72, 76], ["carboplatin", "CHEMICAL", 86, 97], ["ethanol", "CHEMICAL", 322, 329], ["acetone", "CHEMICAL", 331, 338], ["ethanol", "CHEMICAL", 340, 347], ["acetone", "CHEMICAL", 364, 371], ["gasoline", "CHEMICAL", 391, 399], ["paracetamol", "SIMPLE_CHEMICAL", 51, 62], ["carboplatin", "SIMPLE_CHEMICAL", 86, 97], ["organo-hydrogels", "SIMPLE_CHEMICAL", 122, 138], ["organo-hydrogels", "SIMPLE_CHEMICAL", 155, 171], ["organohydrogels", "SIMPLE_CHEMICAL", 289, 304], ["water", "SIMPLE_CHEMICAL", 315, 320], ["ethanol", "SIMPLE_CHEMICAL", 322, 329], ["acetone", "SIMPLE_CHEMICAL", 331, 338], ["ethanol", "SIMPLE_CHEMICAL", 340, 347], ["acetone", "SIMPLE_CHEMICAL", 364, 371], ["gasoline", "SIMPLE_CHEMICAL", 391, 399], ["drugs", "TREATMENT", 6, 11], ["paracetamol", "TREATMENT", 51, 62], ["carboplatin", "TREATMENT", 86, 97], ["physically bound", "PROBLEM", 102, 118], ["organo-hydrogels", "TREATMENT", 122, 138], ["drug-loaded organo-hydrogels", "TREATMENT", 143, 171], ["Swelling analysis", "TEST", 189, 206], ["Swelling assays", "TEST", 206, 221], ["dried gel", "TREATMENT", 263, 272], ["hydrogels", "TREATMENT", 274, 283], ["organohydrogels", "TREATMENT", 289, 304], ["ethanol", "TREATMENT", 322, 329], ["acetone", "TREATMENT", 331, 338], ["ethanol/ID water", "TREATMENT", 340, 356], ["acetone/ID water", "TREATMENT", 364, 380], ["gasoline", "TREATMENT", 391, 399]]], ["Swelling tests were performed at room temperature of 25 \u00baC [7, 30] .Fourier Transform Infrared Spectroscopy (FTIR) analysisFourier Transform Infrared Spectroscopy (FTIR) (Thermo, model Nicolet iS10 Spectrometer, USA) was used for FTIR analysis.", [["Swelling tests", "TEST", 0, 14], ["Infrared Spectroscopy", "TEST", 86, 107], ["Infrared Spectroscopy", "TEST", 141, 162], ["FTIR analysis", "TEST", 230, 243]]], ["The analysis was performed to investigate the functional groups and possible interactions between all chemicals utilized to synthesize the gel, hydrogels and organo-hydrogels.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 158, 174], ["The analysis", "TEST", 0, 12], ["all chemicals", "TREATMENT", 98, 111], ["the gel", "TREATMENT", 135, 142], ["hydrogels", "TREATMENT", 144, 153], ["organo-hydrogels", "TREATMENT", 158, 174]]], ["The gel, hydrogels, and organo-hydrogels were crushed to obtain a powder then placed on the ATR sample plate.", [["ATR", "CHEMICAL", 92, 95], ["organo-hydrogels", "SIMPLE_CHEMICAL", 24, 40], ["The gel, hydrogels", "TREATMENT", 0, 18], ["organo-hydrogels", "TREATMENT", 24, 40], ["a powder", "TREATMENT", 64, 72], ["the ATR sample plate", "TREATMENT", 88, 108]]], ["The spectral range was investigated from 4000 to 650 cm -1 with a resolution of 4 cm -1 .Scanning Electron Microscopy (SEM) analysisSEM Ultra Field emission-Energy Dispersive Spectroscopy X-ray (ZEISS, model FESEM-EDX, Germany) was used to monitor the morphological properties of the gel, hydrogels and organo-hydrogels.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 303, 319], ["The spectral range", "TEST", 0, 18], ["Scanning Electron Microscopy", "TEST", 89, 117], ["Ultra Field emission", "TEST", 136, 156], ["Dispersive Spectroscopy", "TEST", 164, 187], ["model FESEM", "TEST", 202, 213], ["hydrogels", "PROBLEM", 289, 298], ["organo-hydrogels", "TREATMENT", 303, 319], ["4000 to 650 cm", "OBSERVATION_MODIFIER", 41, 55], ["4 cm", "OBSERVATION_MODIFIER", 80, 84]]], ["The samples were scanned using a voltage of 15 and 20 kV.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["a voltage", "TEST", 31, 40]]], ["The surfaces of the gel, hydrogels, and organo-hydrogels were coated with gold before analysis.Blood clotting and hemolysis analysisFirstly, organo-hydrogels, AG, p(AG-m), and p(AG-g) were separately added to flat bottom falcon tubes and placed in a shaking water bath (swb) at 37.5 \u00b0C. Then, freshly prepared 0.24 mL of 0.2 M calcium chloride solution and 3 mL blood was added to each falcon tube.", [["Blood", "ANATOMY", 95, 100], ["blood", "ANATOMY", 362, 367], ["hemolysis", "DISEASE", 114, 123], ["AG", "CHEMICAL", 159, 161], ["calcium chloride", "CHEMICAL", 327, 343], ["calcium chloride", "CHEMICAL", 327, 343], ["organo-hydrogels", "SIMPLE_CHEMICAL", 40, 56], ["Blood", "ORGANISM_SUBSTANCE", 95, 100], ["organo-hydrogels", "SIMPLE_CHEMICAL", 141, 157], ["AG", "SIMPLE_CHEMICAL", 159, 161], ["AG-m", "SIMPLE_CHEMICAL", 165, 169], ["AG-g", "SIMPLE_CHEMICAL", 178, 182], ["calcium chloride", "SIMPLE_CHEMICAL", 327, 343], ["blood", "ORGANISM_SUBSTANCE", 362, 367], ["tube", "TISSUE", 393, 397], ["hydrogels", "TREATMENT", 25, 34], ["organo-hydrogels", "TREATMENT", 40, 56], ["analysis", "TEST", 86, 94], ["Blood clotting", "TEST", 95, 109], ["hemolysis analysisFirstly", "PROBLEM", 114, 139], ["organo", "TEST", 141, 147], ["AG", "TEST", 159, 161], ["AG", "TEST", 165, 167], ["AG", "TEST", 178, 180], ["flat bottom falcon tubes", "TREATMENT", 209, 233], ["a shaking water bath", "TREATMENT", 248, 268], ["0.2 M calcium chloride solution", "TREATMENT", 321, 352], ["each falcon tube", "TREATMENT", 381, 397], ["surfaces", "OBSERVATION_MODIFIER", 4, 12], ["gel", "ANATOMY", 20, 23], ["hydrogels", "OBSERVATION", 25, 34], ["clotting", "OBSERVATION", 101, 109], ["hemolysis", "OBSERVATION", 114, 123], ["falcon tube", "OBSERVATION", 386, 397]]], ["The solution containing 0.27 mL calcium chloride blood mix was added dropwise to the surface of the gel, hydrogels, and organo-hydrogels.", [["blood", "ANATOMY", 49, 54], ["surface", "ANATOMY", 85, 92], ["calcium chloride", "CHEMICAL", 32, 48], ["calcium chloride", "CHEMICAL", 32, 48], ["calcium chloride", "SIMPLE_CHEMICAL", 32, 48], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["organo-hydrogels", "SIMPLE_CHEMICAL", 120, 136], ["The solution", "TREATMENT", 0, 12], ["0.27 mL calcium chloride blood mix", "TREATMENT", 24, 58], ["hydrogels", "TREATMENT", 105, 114], ["organo-hydrogels", "TREATMENT", 120, 136]]], ["Next the samples were incubated for 10 minutes in a swb at 37.5 \u00b0C. Afterwards, 10 mL of ID water was slowly added to the samples and diluted with water.", [["samples", "ANATOMY", 9, 16], ["samples", "ANATOMY", 122, 129], ["the samples", "TEST", 5, 16], ["ID water", "TREATMENT", 89, 97]]], ["Then the samples were centrifuged at 545 rpm for a minute and the supernatant portion of the samples was carefully separated.", [["samples", "ANATOMY", 9, 16], ["supernatant", "ANATOMY", 66, 77], ["samples", "ANATOMY", 93, 100], ["the samples", "TEST", 5, 16], ["the samples", "TEST", 89, 100]]], ["The supernatant was then diluted by adding 40 mL of ID water.", [["supernatant", "ANATOMY", 4, 15], ["ID water", "TREATMENT", 52, 60]]], ["As the control group, 0.27 mL of calcium chloride containing blood was added into 50 mL of ID water.", [["blood", "ANATOMY", 61, 66], ["calcium chloride", "CHEMICAL", 33, 49], ["calcium chloride", "CHEMICAL", 33, 49], ["calcium chloride", "SIMPLE_CHEMICAL", 33, 49], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["calcium chloride containing blood", "TREATMENT", 33, 66], ["ID water", "TREATMENT", 91, 99]]], ["The prepared solutions were incubated for 1 hour in a swb at 37.5 \u00b0C. At the end of the period, the absorbance values of the samples were measured at 542 nm using a UV-Vis spectrophotometer (Thermo Genesys 10S).", [["samples", "ANATOMY", 125, 132], ["the absorbance values", "TEST", 96, 117], ["the samples", "TEST", 121, 132], ["a UV-Vis spectrophotometer", "TREATMENT", 163, 189]]], ["The blood clothing index (BCI) of the samples was calculated using Eq 1 BCI = (A samples /A ctrl )100 (2) that A sample is the absorbance value of organo-hydrogels in contact with blood samples, A positive control is the absorbance value measured using 0.2 mL blood sample and distilled water and A negative control is the absorbance value measured using 0.2 mL blood sample and saline [31] [32] [33] .Antioxidant analysisTo evaluate the antioxidant activity, Folin-Ciocalteu [34] [35] [36] and ABTS [35, 37] methods were applied as explained in the literature.Paracetamol and Carboplatin release studiesSynthesized drug-loaded gel, hydrogels and organo-hydrogels were used as controlled release systems for paracetamol (painkiller) and carboplatin (an anti-cancer agent), which are frequently used in the medical field.", [["blood", "ANATOMY", 4, 9], ["samples", "ANATOMY", 38, 45], ["blood samples", "ANATOMY", 180, 193], ["blood sample", "ANATOMY", 260, 272], ["blood sample", "ANATOMY", 362, 374], ["Folin-Ciocalteu", "CHEMICAL", 460, 475], ["ABTS", "CHEMICAL", 495, 499], ["Paracetamol", "CHEMICAL", 561, 572], ["Carboplatin", "CHEMICAL", 577, 588], ["paracetamol", "CHEMICAL", 708, 719], ["painkiller", "CHEMICAL", 721, 731], ["carboplatin", "CHEMICAL", 737, 748], ["ABTS", "CHEMICAL", 495, 499], ["Paracetamol", "CHEMICAL", 561, 572], ["Carboplatin", "CHEMICAL", 577, 588], ["paracetamol", "CHEMICAL", 708, 719], ["carboplatin", "CHEMICAL", 737, 748], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["organo-hydrogels", "SIMPLE_CHEMICAL", 147, 163], ["blood samples", "ORGANISM_SUBSTANCE", 180, 193], ["blood", "ORGANISM_SUBSTANCE", 260, 265], ["blood", "ORGANISM_SUBSTANCE", 362, 367], ["saline [31] [32] [33]", "SIMPLE_CHEMICAL", 379, 400], ["Folin-Ciocalteu", "SIMPLE_CHEMICAL", 460, 475], ["ABTS", "SIMPLE_CHEMICAL", 495, 499], ["Paracetamol", "SIMPLE_CHEMICAL", 561, 572], ["Carboplatin", "SIMPLE_CHEMICAL", 577, 588], ["organo-hydrogels", "SIMPLE_CHEMICAL", 647, 663], ["paracetamol", "SIMPLE_CHEMICAL", 708, 719], ["painkiller", "SIMPLE_CHEMICAL", 721, 731], ["carboplatin", "SIMPLE_CHEMICAL", 737, 748], ["The blood clothing index", "TEST", 0, 24], ["the samples", "TEST", 34, 45], ["BCI", "TEST", 72, 75], ["A samples /A ctrl )", "TEST", 79, 98], ["A sample", "TEST", 111, 119], ["the absorbance value", "TEST", 123, 143], ["organo-hydrogels", "PROBLEM", 147, 163], ["blood samples", "TEST", 180, 193], ["the absorbance value", "TEST", 217, 237], ["blood sample", "TEST", 260, 272], ["the absorbance value", "TEST", 319, 339], ["Antioxidant analysisTo", "TEST", 402, 424], ["ABTS", "TEST", 495, 499], ["methods", "TREATMENT", 509, 516], ["Paracetamol", "TREATMENT", 561, 572], ["Carboplatin release studies", "TREATMENT", 577, 604], ["Synthesized drug-loaded gel", "TREATMENT", 604, 631], ["hydrogels", "TREATMENT", 633, 642], ["organo-hydrogels", "TREATMENT", 647, 663], ["paracetamol (painkiller)", "TREATMENT", 708, 732], ["carboplatin", "TREATMENT", 737, 748], ["an anti-cancer agent", "TREATMENT", 750, 770]]], ["The gel, hydrogels and organo-hydrogels loaded with a certain amount (50 ppm (6)) [39] , were used to identify the release kinetics.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 23, 39], ["The gel", "TREATMENT", 0, 7], ["hydrogels", "TREATMENT", 9, 18], ["organo-hydrogels", "TREATMENT", 23, 39]]], ["These equations are given in Table 3 .Results and DiscussionIn the synthesis of AG gel, the agar solution and glycerol were bonded to each other with weak hydrogen bonds without any crosslinker [28] .", [["AG gel", "CHEMICAL", 80, 86], ["glycerol", "CHEMICAL", 110, 118], ["glycerol", "CHEMICAL", 110, 118], ["hydrogen", "CHEMICAL", 155, 163], ["AG", "SIMPLE_CHEMICAL", 80, 82], ["glycerol", "SIMPLE_CHEMICAL", 110, 118], ["the synthesis of AG gel", "TREATMENT", 63, 86], ["the agar solution", "TREATMENT", 88, 105], ["glycerol", "TREATMENT", 110, 118]]], ["The structure obtained by hydrogenstrong bridge bonds between the -NH and -OH groups on the agar molecule and the -OH groups on the glycerol was called gel.", [["the -NH and -OH", "CHEMICAL", 62, 77], ["glycerol", "CHEMICAL", 132, 140], ["NH", "CHEMICAL", 67, 69], ["OH", "CHEMICAL", 75, 77], ["OH", "CHEMICAL", 115, 117], ["glycerol", "CHEMICAL", 132, 140], ["hydrogenstrong", "SIMPLE_CHEMICAL", 26, 40], ["-NH", "SIMPLE_CHEMICAL", 66, 69], ["-OH", "SIMPLE_CHEMICAL", 74, 77], ["glycerol", "SIMPLE_CHEMICAL", 132, 140], ["the glycerol", "TREATMENT", 128, 140]]], ["In the synthesis of p(AG-m) and p(AG-g) hydrogels, the structure obtained by adding crosslinking agent to the agar solution and glycerol medium was called hydrogel [43, 44] .", [["glycerol", "CHEMICAL", 128, 136], ["glycerol", "CHEMICAL", 128, 136], ["p(AG-g) hydrogels", "SIMPLE_CHEMICAL", 32, 49], ["glycerol", "SIMPLE_CHEMICAL", 128, 136], ["p(AG-g) hydrogels", "TREATMENT", 32, 49], ["crosslinking agent", "TREATMENT", 84, 102], ["the agar solution", "TREATMENT", 106, 123], ["glycerol medium", "TREATMENT", 128, 143]]], ["In the synthesis of p(AG-m-PmO) and p(AG-g-PmO) organohydrogels, strong hydrogen bonds were formed between the -OH groups on peppermint and glycerol molecules and the -OH groups in the agar structure.", [["glycerol", "CHEMICAL", 140, 148], ["p(AG-m-PmO)", "CHEMICAL", 20, 31], ["p(AG-g-PmO", "CHEMICAL", 36, 46], ["hydrogen", "CHEMICAL", 72, 80], ["OH", "CHEMICAL", 112, 114], ["glycerol", "CHEMICAL", 140, 148], ["OH", "CHEMICAL", 168, 170], ["AG-m-PmO", "SIMPLE_CHEMICAL", 22, 30], ["p(AG-g-PmO", "SIMPLE_CHEMICAL", 36, 46], ["hydrogen bonds", "SIMPLE_CHEMICAL", 72, 86], ["peppermint", "SIMPLE_CHEMICAL", 125, 135], ["glycerol molecules", "SIMPLE_CHEMICAL", 140, 158], ["AG", "TEST", 22, 24], ["AG", "TEST", 38, 40], ["organohydrogels", "PROBLEM", 48, 63], ["strong hydrogen bonds", "PROBLEM", 65, 86], ["peppermint and glycerol molecules", "TREATMENT", 125, 158], ["hydrogen bonds", "OBSERVATION", 72, 86], ["agar structure", "OBSERVATION", 185, 199]]], ["At the same time, the crosslinking agent was added to the reaction medium and crosslinking was provided between peppermint oil, agar and glycerol [45] [46] [47] .", [["glycerol", "CHEMICAL", 137, 145], ["glycerol", "CHEMICAL", 137, 145], ["peppermint", "SIMPLE_CHEMICAL", 112, 122], ["oil", "ORGANISM_SUBSTANCE", 123, 126], ["glycerol [45] [46] [47]", "SIMPLE_CHEMICAL", 137, 160], ["the crosslinking agent", "TREATMENT", 18, 40], ["the reaction medium and crosslinking", "TREATMENT", 54, 90]]], ["Thus, the structure including both hydrogen bonds and cross-linked was called organo-hydrogel.", [["hydrogen", "CHEMICAL", 35, 43], ["hydrogen bonds", "SIMPLE_CHEMICAL", 35, 49], ["organo-hydrogel", "TREATMENT", 78, 93], ["hydrogen bonds", "OBSERVATION", 35, 49]]], ["By increasing the amount of peppermint oil added to the structure, both physical and chemical bonding was strengthened.", [["oil", "ANATOMY", 39, 42], ["oil", "ORGANISM_SUBSTANCE", 39, 42], ["peppermint oil", "TREATMENT", 28, 42], ["amount", "OBSERVATION_MODIFIER", 18, 24], ["peppermint oil", "OBSERVATION", 28, 42]]], ["In the synthesis of drug-loaded organo-hydrogels, drugs were added to the reaction medium in the final stage of the synthesis.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 32, 48], ["organo-hydrogels", "TREATMENT", 32, 48], ["drugs", "TREATMENT", 50, 55], ["the reaction medium", "PROBLEM", 70, 89]]], ["These drugs were physically attached or trapped in the structure of organohydrogels.", [["organohydrogels", "SIMPLE_CHEMICAL", 68, 83], ["These drugs", "TREATMENT", 0, 11]]], ["These gel, hydrogels and organo-hydrogels were subjected to the following analyses.Swelling propertiesThe swelling ability of a polymeric gel is determined by the interaction between the functional groups in its structure and the solvent used.", [["swelling", "DISEASE", 106, 114], ["organo-hydrogels", "SIMPLE_CHEMICAL", 25, 41], ["These gel", "TREATMENT", 0, 9], ["hydrogels", "TREATMENT", 11, 20], ["organo-hydrogels", "TREATMENT", 25, 41], ["Swelling properties", "PROBLEM", 83, 102], ["The swelling", "PROBLEM", 102, 114], ["a polymeric gel", "TREATMENT", 126, 141], ["swelling", "OBSERVATION", 106, 114]]], ["Push and pull between polymer chains is affected by non-covalent electrostatic, hydrophobic, Van der Waals, and hydrogen bonding.Swelling propertiesHydrophobic interactions are physical crosslinker interactions and this affects the swelling behavior of the gel [48] .Swelling propertiesSwelling of gel, hydrogels and organo-hydrogels in different media such as water-organic solvent mixtures can be controlled by the solvent composition as well as crosslinker dosage.Swelling propertiesThe change in percent swelling of gel, hydrogels and organo-hydrogels as a function of solvent concentration in water-organic solvent mixtures are shown in Figure 2 .", [["swelling", "DISEASE", 508, 516], ["hydrogen", "CHEMICAL", 112, 120], ["hydrogen", "SIMPLE_CHEMICAL", 112, 120], ["organo-hydrogels", "SIMPLE_CHEMICAL", 317, 333], ["water-organic solvent mixtures", "SIMPLE_CHEMICAL", 361, 391], ["crosslinker", "SIMPLE_CHEMICAL", 448, 459], ["water", "SIMPLE_CHEMICAL", 598, 603], ["Push and pull between polymer chains", "TREATMENT", 0, 36], ["hydrogen bonding", "TREATMENT", 112, 128], ["Swelling properties", "PROBLEM", 129, 148], ["Hydrophobic interactions", "PROBLEM", 148, 172], ["physical crosslinker interactions", "PROBLEM", 177, 210], ["Swelling properties", "PROBLEM", 267, 286], ["Swelling of gel", "PROBLEM", 286, 301], ["hydrogels", "TREATMENT", 303, 312], ["organo-hydrogels in different media", "TREATMENT", 317, 352], ["water-organic solvent mixtures", "TREATMENT", 361, 391], ["the solvent composition", "TREATMENT", 413, 436], ["Swelling properties", "PROBLEM", 467, 486], ["The change in percent swelling of gel", "PROBLEM", 486, 523], ["hydrogels", "TREATMENT", 525, 534], ["organo-hydrogels", "TREATMENT", 539, 555], ["a function of solvent concentration in water-organic solvent mixtures", "TREATMENT", 559, 628], ["Hydrophobic", "OBSERVATION_MODIFIER", 148, 159], ["Swelling", "OBSERVATION", 286, 294], ["change", "OBSERVATION_MODIFIER", 490, 496], ["percent", "OBSERVATION_MODIFIER", 500, 507], ["swelling", "OBSERVATION", 508, 516]]], ["After the AG gel was crosslinked, the ID water absorption capacity increased by 16% for p(AG-m) andSwelling properties27% for p(AG-g), and tap water absorption capacity increased by 35% for p(AG-g) and 68%Swelling propertiesfor p(AG-m).", [["AG", "CHEMICAL", 10, 12], ["AG", "SIMPLE_CHEMICAL", 10, 12], ["the AG gel", "TREATMENT", 6, 16], ["the ID water absorption capacity", "TREATMENT", 34, 66], ["Swelling", "PROBLEM", 99, 107], ["AG", "TEST", 128, 130], ["tap water absorption capacity", "TEST", 139, 168], ["AG", "TEST", 192, 194]]], ["When organo-hydrogels were compared among themselves, p(AG-g-PmO) 1 organo-hydrogel has higher water absorption capacity than other organo-hydrogels and has 106.6% swelling ratio in ID water.", [["swelling", "DISEASE", 164, 172], ["organo-hydrogels", "SIMPLE_CHEMICAL", 5, 21], ["AG-g-PmO) 1 organo-hydrogel", "SIMPLE_CHEMICAL", 56, 83], ["organo-hydrogels", "SIMPLE_CHEMICAL", 132, 148], ["organo-hydrogels", "TREATMENT", 5, 21], ["AG", "TEST", 56, 58], ["organo-hydrogel", "TREATMENT", 68, 83], ["higher water absorption capacity", "PROBLEM", 88, 120], ["other organo-hydrogels", "PROBLEM", 126, 148], ["% swelling ratio", "PROBLEM", 162, 178], ["swelling", "OBSERVATION", 164, 172]]], ["It was observed that the S% of organo-hydrogels Organo-hydrogels, AG, p(AG-m), and p(AG-g) were prepared by free radical polymerization in emulsion media and the FTIR spectra are shown in Figure 3 .", [["AG, p(AG-m", "CHEMICAL", 66, 76], ["organo-hydrogels", "SIMPLE_CHEMICAL", 31, 47], ["Organo-hydrogels", "SIMPLE_CHEMICAL", 48, 64], ["AG", "SIMPLE_CHEMICAL", 66, 68], ["AG-m)", "SIMPLE_CHEMICAL", 72, 77], ["p(AG-g)", "SIMPLE_CHEMICAL", 83, 90], ["free radical", "SIMPLE_CHEMICAL", 108, 120], ["the S", "TEST", 21, 26], ["organo", "TEST", 31, 37], ["hydrogels", "PROBLEM", 55, 64], ["AG", "TEST", 66, 68], ["AG", "TEST", 85, 87], ["free radical polymerization in emulsion media", "TREATMENT", 108, 153], ["the FTIR spectra", "TEST", 158, 174]]], ["Peaks which formed at 3400 cm -1 , 2900 cm -1 , 1643 cm -1 ,1370 cm -1 and 1070 cm -1 -930 cm -1 wavelengths belonged to agar and these peaks are associated with -OH, methoxyl group, -NH, ester sulfate and anhydrousgalactose bonds, respectively [54, 55] .", [["OH", "CHEMICAL", 163, 165], ["methoxyl", "CHEMICAL", 167, 175], ["ester sulfate", "CHEMICAL", 188, 201], ["anhydrousgalactose", "CHEMICAL", 206, 224], ["OH", "CHEMICAL", 163, 165], ["methoxyl", "CHEMICAL", 167, 175], ["NH", "CHEMICAL", 184, 186], ["ester sulfate", "CHEMICAL", 188, 201], ["anhydrousgalactose", "CHEMICAL", 206, 224], ["-OH", "SIMPLE_CHEMICAL", 162, 165], ["methoxyl group, -NH, ester sulfate", "SIMPLE_CHEMICAL", 167, 201], ["anhydrousgalactose bonds", "SIMPLE_CHEMICAL", 206, 230], ["Peaks", "PROBLEM", 0, 5], ["agar", "TEST", 121, 125], ["3400 cm", "OBSERVATION_MODIFIER", 22, 29], ["2900 cm", "OBSERVATION_MODIFIER", 35, 42], ["1370 cm", "OBSERVATION_MODIFIER", 60, 67]]], ["Glycerol peaks formed at 3600-3000 cm -1 , 2930 cm -1 , 1637 cm -1 ,1397 cm -1 and 1032 cm -1 wavelengths and these peaks belong to -OH, -C-H, -C-C, CH and C-O bonds, respectively [56] .", [["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "CHEMICAL", 0, 8], ["OH", "CHEMICAL", 133, 135], ["C", "CHEMICAL", 138, 139], ["H", "CHEMICAL", 140, 141], ["C", "CHEMICAL", 144, 145], ["C", "CHEMICAL", 146, 147], ["CH", "CHEMICAL", 149, 151], ["C-O", "CHEMICAL", 156, 159], ["Glycerol", "SIMPLE_CHEMICAL", 0, 8], ["-OH", "SIMPLE_CHEMICAL", 132, 135], ["-C-H, -C-C", "SIMPLE_CHEMICAL", 137, 147], ["C-O bonds", "SIMPLE_CHEMICAL", 156, 165], ["Glycerol peaks", "TEST", 0, 14], ["these peaks", "TEST", 110, 121], ["OH", "TEST", 133, 135], ["C", "TEST", 144, 145], ["peaks", "OBSERVATION_MODIFIER", 9, 14]]], ["Peppermint oil had a band peak at 3600-3000 cm Considering the peaks in the organo-hydrogel, the peaks at 2922 cm -1 -2853 cm -1 and 1653 cm -1 expanded and deepened, and the peak depth at 1037 cm -1 increased.", [["Peppermint oil", "ANATOMY", 0, 14], ["oil", "ORGANISM_SUBSTANCE", 11, 14], ["Peppermint oil", "TREATMENT", 0, 14], ["a band peak", "TEST", 19, 30], ["the peak depth", "TEST", 171, 185], ["band peak", "OBSERVATION_MODIFIER", 21, 30], ["3000 cm", "OBSERVATION_MODIFIER", 39, 46], ["peaks", "OBSERVATION_MODIFIER", 97, 102], ["deepened", "OBSERVATION_MODIFIER", 157, 165], ["peak", "OBSERVATION_MODIFIER", 175, 179], ["depth", "OBSERVATION_MODIFIER", 180, 185], ["increased", "OBSERVATION_MODIFIER", 200, 209]]], ["The changes in these peaks indicate that PmO entered the structure of the organo-hydrogel.SEM analysisThe surface morphologies of the synthesized materials were monitored by SEM and are shown in Figures 4a and 4b .", [["surface", "ANATOMY", 106, 113], ["PmO", "CHEMICAL", 41, 44], ["PmO", "CHEMICAL", 41, 44], ["PmO", "SIMPLE_CHEMICAL", 41, 44], ["PmO", "PROTEIN", 41, 44], ["The changes in these peaks", "PROBLEM", 0, 26], ["the organo-hydrogel", "TREATMENT", 70, 89], ["SEM analysis", "TEST", 90, 102], ["PmO", "OBSERVATION", 41, 44], ["surface", "OBSERVATION_MODIFIER", 106, 113]]], ["Figure 4a shows the surface image of p(AG-g-PmO) organohydrogels.", [["surface", "ANATOMY", 20, 27], ["PmO", "CHEMICAL", 44, 47], ["PmO", "PROTEIN", 44, 47], ["the surface image", "TEST", 16, 33], ["AG", "TEST", 39, 41], ["organohydrogels", "PROBLEM", 49, 64]]], ["As clearly seen, the intertwined mesh surface can be seen after polymerization was completed.", [["mesh surface", "ANATOMY", 33, 45], ["polymerization", "TREATMENT", 64, 78], ["mesh", "OBSERVATION", 33, 37]]], ["Figure 4b shows that as the peppermint oil content in p(AG-g-PmO) organohydrogel increased, the mesh structure opened and the oil globules penetrated better on and into the surface.", [["oil", "ANATOMY", 39, 42], ["oil globules", "ANATOMY", 126, 138], ["surface", "ANATOMY", 173, 180], ["p(AG-g-PmO", "CHEMICAL", 54, 64], ["oil globules", "ORGANISM_SUBSTANCE", 126, 138], ["surface", "CELLULAR_COMPONENT", 173, 180], ["Figure 4b", "TEST", 0, 9], ["the peppermint oil content", "TEST", 24, 50], ["AG", "TEST", 56, 58], ["organohydrogel", "TREATMENT", 66, 80], ["the mesh structure", "TREATMENT", 92, 110], ["the oil globules", "TREATMENT", 122, 138], ["mesh structure", "OBSERVATION", 96, 110], ["oil", "OBSERVATION_MODIFIER", 126, 129], ["globules", "OBSERVATION_MODIFIER", 130, 138], ["penetrated", "OBSERVATION_MODIFIER", 139, 149], ["better", "OBSERVATION_MODIFIER", 150, 156], ["surface", "ANATOMY_MODIFIER", 173, 180]]], ["The p(AG-g-PmO) 3 organo-hydrogels surface image is intertwined on the surface and vice versa, the p(AG-m-PmO) 3 organo-hydrogels surface is flatter with a background of fat globules.Blood clotting and hemolysis analysisBiocompatibility means there is no reaction in tissue with the presence of the material.", [["surface", "ANATOMY", 71, 78], ["fat globules", "ANATOMY", 170, 182], ["Blood", "ANATOMY", 183, 188], ["tissue", "ANATOMY", 267, 273], ["hemolysis", "DISEASE", 202, 211], ["p(AG-g-PmO) 3", "CHEMICAL", 4, 17], ["p(AG-m-PmO) 3", "CHEMICAL", 99, 112], ["surface", "CELLULAR_COMPONENT", 71, 78], ["fat globules", "TISSUE", 170, 182], ["Blood", "ORGANISM_SUBSTANCE", 183, 188], ["tissue", "TISSUE", 267, 273], ["The p(AG-g-PmO)", "TREATMENT", 0, 15], ["organo-hydrogels surface image", "TREATMENT", 18, 48], ["the p(AG-m-PmO)", "TEST", 95, 110], ["fat globules", "PROBLEM", 170, 182], ["Blood clotting", "TEST", 183, 197], ["hemolysis analysis", "TEST", 202, 220], ["reaction in tissue", "PROBLEM", 255, 273], ["flatter", "OBSERVATION_MODIFIER", 141, 148], ["fat globules", "OBSERVATION", 170, 182], ["clotting", "OBSERVATION", 189, 197], ["hemolysis", "OBSERVATION", 202, 211], ["Biocompatibility", "OBSERVATION_MODIFIER", 220, 236], ["no", "UNCERTAINTY", 252, 254], ["reaction", "OBSERVATION", 255, 263]]], ["That is to say chemical interactions of materials and body fluids and whether the physiological consequences of this interaction harm the body.", [["body fluids", "ANATOMY", 54, 65], ["body", "ANATOMY", 138, 142], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["body fluids", "TREATMENT", 54, 65], ["body", "ANATOMY", 138, 142]]], ["One focus of our study was how to eliminate and minimize unwanted interactions.", [["our study", "TEST", 13, 22]]], ["In fact, it is desired and ideal that this property of J o u r n a l P r e -p r o o f organo-hydrogels can be determined by in vitro tests.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 86, 102], ["organo-hydrogels", "TREATMENT", 86, 102], ["vitro tests", "TEST", 127, 138]]], ["For this reason, blood compatibility tests are important.", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["blood compatibility tests", "TEST", 17, 42]]], ["In this study, hemolysis and blood clotting tests were performed to determine blood compatibility of organo-hydrogel [58, 59] .", [["blood", "ANATOMY", 29, 34], ["blood", "ANATOMY", 78, 83], ["hemolysis", "DISEASE", 15, 24], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["organo-hydrogel", "SIMPLE_CHEMICAL", 101, 116], ["this study", "TEST", 3, 13], ["hemolysis", "TEST", 15, 24], ["blood clotting tests", "TEST", 29, 49]]], ["Hemolysis was calculated for AG, p(AG-m), p(AG-g), PmO and organo-hydrogels at a concentration of 5 mg/mL and is given Figure 5a .", [["Hemolysis", "DISEASE", 0, 9], ["PmO", "CHEMICAL", 51, 54], ["AG", "SIMPLE_CHEMICAL", 29, 31], ["AG-g", "SIMPLE_CHEMICAL", 44, 48], ["PmO", "SIMPLE_CHEMICAL", 51, 54], ["organo-hydrogels", "SIMPLE_CHEMICAL", 59, 75], ["Hemolysis", "TEST", 0, 9], ["AG", "TEST", 29, 31], ["AG", "TEST", 35, 37], ["AG", "TEST", 44, 46], ["PmO", "TEST", 51, 54], ["organo-hydrogels", "TREATMENT", 59, 75]]], ["It is stated that the hemolysis rate is not hemolytic up to 5% [58, 59] Therefore, it was concluded that organo-hydrogels were blood compatible at this rate.", [["blood", "ANATOMY", 127, 132], ["hemolysis", "DISEASE", 22, 31], ["hemolytic", "DISEASE", 44, 53], ["organo-hydrogels", "SIMPLE_CHEMICAL", 105, 121], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["the hemolysis rate", "TEST", 18, 36], ["hemolytic", "PROBLEM", 44, 53], ["organo-hydrogels", "TREATMENT", 105, 121]]], ["As organo-hydrogels were synthesized with peppermint oil, there was a slight increase in % hemolysis for organohydrogel, which increased from 0.3% to 1.4%, meaning organo-hydrogels containing essential oil did not have a negative effect on hemolysis.Blood clotting and hemolysis analysisAnother method of evaluating the blood compatibility of organo-hydrogels is to determine the organo-hydrogel Blood Clotting Index (BCI).", [["oil", "ANATOMY", 202, 205], ["Blood", "ANATOMY", 250, 255], ["blood", "ANATOMY", 320, 325], ["hemolysis", "DISEASE", 91, 100], ["organohydrogel", "CHEMICAL", 105, 119], ["hemolysis", "DISEASE", 240, 249], ["hemolysis", "DISEASE", 269, 278], ["organo-hydrogels", "SIMPLE_CHEMICAL", 3, 19], ["peppermint", "ORGANISM", 42, 52], ["oil", "ORGANISM_SUBSTANCE", 53, 56], ["organohydrogel", "SIMPLE_CHEMICAL", 105, 119], ["organo-hydrogels", "SIMPLE_CHEMICAL", 164, 180], ["oil", "ORGANISM_SUBSTANCE", 202, 205], ["Blood", "ORGANISM_SUBSTANCE", 250, 255], ["blood", "ORGANISM_SUBSTANCE", 320, 325], ["organo-hydrogels", "TREATMENT", 3, 19], ["peppermint oil", "TREATMENT", 42, 56], ["a slight increase in % hemolysis", "PROBLEM", 68, 100], ["organohydrogel", "TREATMENT", 105, 119], ["meaning organo-hydrogels", "TREATMENT", 156, 180], ["hemolysis", "PROBLEM", 240, 249], ["Blood clotting", "TEST", 250, 264], ["hemolysis analysis", "TEST", 269, 287], ["the blood compatibility", "TEST", 316, 339], ["organo-hydrogels", "TREATMENT", 343, 359], ["the organo", "TEST", 376, 386], ["slight", "OBSERVATION_MODIFIER", 70, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["% hemolysis", "OBSERVATION", 89, 100], ["negative effect", "OBSERVATION_MODIFIER", 221, 236], ["hemolysis", "OBSERVATION", 240, 249], ["clotting", "OBSERVATION", 256, 264], ["hemolysis", "OBSERVATION", 269, 278]]], ["Therefore, the BCI's of organo-hydrogels are shown in Figure 5b .", [["the BCI", "TEST", 11, 18], ["organo-hydrogels", "TREATMENT", 24, 40]]], ["In Figure 5b , 5 mg/mL organo-hydrogel blood clotting indices were between 4.8% and 8.2%.", [["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["organo", "TEST", 23, 29], ["hydrogel blood clotting indices", "TEST", 30, 61]]], ["For blood contact applications with these organo-hydrogel, the gel amount should be less than 5 mg/mL.Antioxidant analysisThe antioxidant activity of PmO, p (AG-m), p(AG-g) and organo-hydrogels is given in Table 4 as gallic acid equivalent value.", [["blood", "ANATOMY", 4, 9], ["PmO, p (AG-m", "CHEMICAL", 150, 162], ["gallic acid", "CHEMICAL", 217, 228], ["PmO", "CHEMICAL", 150, 153], ["p (AG-m), p(AG-g)", "CHEMICAL", 155, 172], ["gallic acid", "CHEMICAL", 217, 228], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["PmO", "SIMPLE_CHEMICAL", 150, 153], ["AG-m", "SIMPLE_CHEMICAL", 158, 162], ["AG-g)", "SIMPLE_CHEMICAL", 167, 172], ["organo-hydrogels", "SIMPLE_CHEMICAL", 177, 193], ["gallic acid", "SIMPLE_CHEMICAL", 217, 228], ["blood contact applications", "TREATMENT", 4, 30], ["these organo-hydrogel, the gel amount", "TREATMENT", 36, 73], ["Antioxidant analysis", "TEST", 102, 122], ["AG", "TEST", 167, 169], ["organo-hydrogels", "TREATMENT", 177, 193]]], ["The PmO, p(AG-m), p(AG-g) and organo-hydrogels reduction capacity can be used to determine the antioxidant activity.", [["PmO, p(AG-m), p(AG-g)", "CHEMICAL", 4, 25], ["PmO", "SIMPLE_CHEMICAL", 4, 7], ["AG-m", "SIMPLE_CHEMICAL", 11, 15], ["AG-g", "SIMPLE_CHEMICAL", 20, 24], ["organo-hydrogels", "SIMPLE_CHEMICAL", 30, 46], ["AG", "TEST", 20, 22], ["organo-hydrogels reduction capacity", "TREATMENT", 30, 65]]], ["When Table 4 is analyzed, as the concentration of the substance increases, the reduction power also increases due to the absorbents.", [["the reduction power", "TREATMENT", 75, 94], ["the absorbents", "TREATMENT", 117, 131]]], ["When these values are considered, organo-hydrogels show higher antioxidant activity than other gels [9, 10] .Paracetamol and Carboplatin release studiesEnvironmentally sensitive systems release drugs in response to a change in the environmental conditions such as solvent, temperature and pH.", [["Paracetamol", "CHEMICAL", 109, 120], ["Carboplatin", "CHEMICAL", 125, 136], ["Paracetamol", "CHEMICAL", 109, 120], ["Carboplatin", "CHEMICAL", 125, 136], ["organo-hydrogels", "SIMPLE_CHEMICAL", 34, 50], ["Paracetamol", "SIMPLE_CHEMICAL", 109, 120], ["Carboplatin", "SIMPLE_CHEMICAL", 125, 136], ["these values", "TEST", 5, 17], ["organo-hydrogels", "TREATMENT", 34, 50], ["Paracetamol", "TREATMENT", 109, 120], ["Carboplatin release studies", "TREATMENT", 125, 152], ["Environmentally sensitive systems release drugs", "TREATMENT", 152, 199], ["a change in the environmental conditions", "PROBLEM", 215, 255]]], ["To perform drug release of paracetamol-and carboplatin-loaded organo-hydrogels, gastric, intestinal, oral blood and skin media were imitated in vitro.", [["gastric", "ANATOMY", 80, 87], ["intestinal", "ANATOMY", 89, 99], ["oral blood", "ANATOMY", 101, 111], ["skin", "ANATOMY", 116, 120], ["paracetamol", "CHEMICAL", 27, 38], ["carboplatin", "CHEMICAL", 43, 54], ["paracetamol", "CHEMICAL", 27, 38], ["carboplatin", "CHEMICAL", 43, 54], ["paracetamol", "SIMPLE_CHEMICAL", 27, 38], ["carboplatin", "SIMPLE_CHEMICAL", 43, 54], ["organo-hydrogels", "SIMPLE_CHEMICAL", 62, 78], ["gastric", "MULTI-TISSUE_STRUCTURE", 80, 87], ["intestinal", "MULTI-TISSUE_STRUCTURE", 89, 99], ["oral blood", "ORGANISM_SUBSTANCE", 101, 111], ["skin", "ORGAN", 116, 120], ["paracetamol", "TREATMENT", 27, 38], ["carboplatin", "TREATMENT", 43, 54], ["organo-hydrogels", "TREATMENT", 62, 78], ["oral blood and skin media", "TREATMENT", 101, 126], ["gastric", "ANATOMY", 80, 87], ["intestinal", "ANATOMY", 89, 99], ["skin", "ANATOMY", 116, 120]]], ["Thus, release analyses were conducted in different pH environments.", [["release analyses", "TEST", 6, 22]]], ["For example, some organo-hydrogels shrink at the pH of the stomach, while they swell at intestinal pH and release the drug.", [["stomach", "ANATOMY", 59, 66], ["intestinal", "ANATOMY", 88, 98], ["stomach", "ORGAN", 59, 66], ["intestinal", "ORGAN", 88, 98], ["some organo-hydrogels", "PROBLEM", 13, 34], ["some", "OBSERVATION_MODIFIER", 13, 17], ["organo", "OBSERVATION", 18, 24], ["hydrogels shrink", "OBSERVATION", 25, 41], ["stomach", "ANATOMY", 59, 66], ["intestinal", "ANATOMY", 88, 98]]], ["For some organo-hydrogels, the opposite is true.", [["some organo-hydrogels", "TREATMENT", 4, 25], ["hydrogels", "OBSERVATION", 16, 25], ["true", "OBSERVATION_MODIFIER", 43, 47]]], ["Some organo-hydrogels release drugs at a pH of 5.5 on the skin surface, while others release drugs in body fluids at a pH of 7.4 [62] .Journal Pre-proofAnother focus of our study was to investigate the paracetamol and carboplatin release capacities of the new biocompatible gel, hydrogels and organo-hydrogels.", [["skin surface", "ANATOMY", 58, 70], ["body fluids", "ANATOMY", 102, 113], ["paracetamol", "CHEMICAL", 202, 213], ["carboplatin", "CHEMICAL", 218, 229], ["paracetamol", "CHEMICAL", 202, 213], ["carboplatin", "CHEMICAL", 218, 229], ["organo-hydrogels", "SIMPLE_CHEMICAL", 5, 21], ["skin", "ORGAN", 58, 62], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["paracetamol", "SIMPLE_CHEMICAL", 202, 213], ["carboplatin", "SIMPLE_CHEMICAL", 218, 229], ["organo-hydrogels", "SIMPLE_CHEMICAL", 293, 309], ["Some organo-hydrogels release drugs", "TREATMENT", 0, 35], ["a pH", "TEST", 39, 43], ["the skin surface", "TREATMENT", 54, 70], ["a pH", "TEST", 117, 121], ["our study", "TEST", 169, 178], ["the paracetamol and carboplatin release capacities", "TREATMENT", 198, 248], ["the new biocompatible gel", "TREATMENT", 252, 277], ["hydrogels", "TREATMENT", 279, 288], ["organo-hydrogels", "TREATMENT", 293, 309], ["skin", "ANATOMY", 58, 62], ["new", "OBSERVATION_MODIFIER", 256, 259], ["biocompatible gel", "OBSERVATION", 260, 277]]], ["Paracetamol and carboplatin loading amounts in gel, hydrogels and organo-hydrogels were determined as 50 ppm.", [["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 16, 27], ["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 16, 27], ["Paracetamol", "SIMPLE_CHEMICAL", 0, 11], ["carboplatin", "SIMPLE_CHEMICAL", 16, 27], ["organo-hydrogels", "SIMPLE_CHEMICAL", 66, 82], ["Paracetamol", "TREATMENT", 0, 11], ["carboplatin loading amounts in gel", "TREATMENT", 16, 50], ["hydrogels", "TREATMENT", 52, 61], ["organo-hydrogels", "TREATMENT", 66, 82]]], ["Figure 6 shows the drug release behaviors of gel, hydrogels and organo-hydrogels at 37.5 \u00baC.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 64, 80], ["gel, hydrogels", "TREATMENT", 45, 59], ["organo-hydrogels", "TREATMENT", 64, 80]]], ["Due to the difference in concentration of the release event, while the solvent enters the gel, hydrogels and organo-hydrogel structure, the loaded drug switches to the solvent medium.", [["hydrogels", "TREATMENT", 95, 104], ["organo-hydrogel structure", "TREATMENT", 109, 134], ["the loaded drug", "TREATMENT", 136, 151], ["the solvent medium", "TREATMENT", 164, 182]]], ["The release analyses of paracetamol loaded on gel, hydrogels and organo-hydrogels were conducted separately at body temperature (37.5\u00b0C), at different pH values (2.0, 5.5, 7.4, 8.0) and release results are given in Figure 6 .", [["body", "ANATOMY", 111, 115], ["paracetamol", "CHEMICAL", 24, 35], ["paracetamol", "CHEMICAL", 24, 35], ["paracetamol", "SIMPLE_CHEMICAL", 24, 35], ["organo-hydrogels", "SIMPLE_CHEMICAL", 65, 81], ["body", "ORGANISM_SUBDIVISION", 111, 115], ["paracetamol loaded on gel", "TREATMENT", 24, 49], ["hydrogels", "TREATMENT", 51, 60], ["organo-hydrogels", "TREATMENT", 65, 81], ["body temperature", "TEST", 111, 127], ["different pH values", "TEST", 141, 160]]], ["As seen in Figure 6 (a-c), all organo-hydrogels released paracetamol slowly.", [["paracetamol", "CHEMICAL", 57, 68], ["paracetamol", "CHEMICAL", 57, 68], ["organo-hydrogels", "SIMPLE_CHEMICAL", 31, 47], ["paracetamol", "SIMPLE_CHEMICAL", 57, 68], ["all organo-hydrogels", "TREATMENT", 27, 47], ["paracetamol", "TREATMENT", 57, 68]]], ["Moreover, AG, p(AG-m) and p(AG-g) had maximum paracetamol release of 8.0% at pH 8.0, 7.8% at pH 2.0 and 8.2% at pH 2.0, respectively.", [["AG", "CHEMICAL", 10, 12], ["paracetamol", "CHEMICAL", 46, 57], ["paracetamol", "CHEMICAL", 46, 57], ["AG", "SIMPLE_CHEMICAL", 10, 12], ["paracetamol", "SIMPLE_CHEMICAL", 46, 57], ["AG", "TEST", 10, 12], ["AG", "TEST", 16, 18], ["AG", "TEST", 28, 30], ["maximum paracetamol release", "TEST", 38, 65], ["pH", "TEST", 77, 79], ["pH", "TEST", 93, 95], ["pH", "TEST", 112, 114]]], ["The amount of paracetamol released from the p(AG-m-PmO) organo-hydrogel system is given in Table 5 .", [["paracetamol", "CHEMICAL", 14, 25], ["AG-m-PmO", "CHEMICAL", 46, 54], ["paracetamol", "CHEMICAL", 14, 25], ["p(AG-m-PmO", "CHEMICAL", 44, 54], ["paracetamol", "SIMPLE_CHEMICAL", 14, 25], ["paracetamol", "TREATMENT", 14, 25], ["the p(AG-m-PmO) organo-hydrogel system", "TREATMENT", 40, 78], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["paracetamol", "OBSERVATION_MODIFIER", 14, 25]]], ["The highest paracetamol release amounts occurred at pH 2.0.", [["paracetamol", "CHEMICAL", 12, 23], ["paracetamol", "CHEMICAL", 12, 23], ["paracetamol", "SIMPLE_CHEMICAL", 12, 23], ["The highest paracetamol release amounts", "TREATMENT", 0, 39], ["pH", "TEST", 52, 54], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["When paracetamol release was compared between p(AG-m-PmO) organo-hydrogels, it appeared that the minimum release was from the p(AG-m-PmO) 1 organo-hydrogel.", [["paracetamol", "CHEMICAL", 5, 16], ["paracetamol", "CHEMICAL", 5, 16], ["p(AG-m-PmO)", "CHEMICAL", 126, 137], ["paracetamol", "SIMPLE_CHEMICAL", 5, 16], ["paracetamol release", "TREATMENT", 5, 24], ["AG", "TEST", 48, 50], ["organo-hydrogels", "TREATMENT", 58, 74], ["organo-hydrogel", "TREATMENT", 140, 155]]], ["The amounts of paracetamol released from the p(AG-g-PmO) organo-hydrogel system are given in Table 5 .Journal Pre-proofThe highest paracetamol release rates occurred at pH 7.4 and pH 8.0.", [["paracetamol", "CHEMICAL", 15, 26], ["AG-g-PmO", "CHEMICAL", 47, 55], ["paracetamol", "CHEMICAL", 131, 142], ["paracetamol", "CHEMICAL", 15, 26], ["PmO", "CHEMICAL", 52, 55], ["paracetamol", "CHEMICAL", 131, 142], ["paracetamol", "SIMPLE_CHEMICAL", 15, 26], ["paracetamol", "SIMPLE_CHEMICAL", 131, 142], ["paracetamol", "TREATMENT", 15, 26], ["the p(AG-g-PmO)", "TREATMENT", 41, 56], ["organo-hydrogel system", "TREATMENT", 57, 79], ["The highest paracetamol release rates", "TEST", 119, 156], ["pH", "TEST", 169, 171], ["pH", "TEST", 180, 182], ["amounts", "OBSERVATION_MODIFIER", 4, 11]]], ["When paracetamol release was compared between p(AG-g-PmO) organo-hydrogels, it was shown that the minimum release was from p(AG-g-PmO) 1 organo-hydrogel.", [["paracetamol", "CHEMICAL", 5, 16], ["paracetamol", "CHEMICAL", 5, 16], ["PmO", "CHEMICAL", 53, 56], ["paracetamol", "SIMPLE_CHEMICAL", 5, 16], ["paracetamol release", "TREATMENT", 5, 24], ["AG", "TEST", 48, 50], ["organo-hydrogels", "TREATMENT", 58, 74], ["AG", "TEST", 125, 127], ["organo-hydrogel", "TREATMENT", 137, 152]]], ["The highest cumulative paracetamol release from organo-hydrogels was observed in organo-hydrogels synthesized with GA crosslinker.", [["paracetamol", "CHEMICAL", 23, 34], ["GA crosslinker", "CHEMICAL", 115, 129], ["paracetamol", "CHEMICAL", 23, 34], ["paracetamol", "SIMPLE_CHEMICAL", 23, 34], ["organo-hydrogels", "SIMPLE_CHEMICAL", 48, 64], ["organo-hydrogels", "SIMPLE_CHEMICAL", 81, 97], ["GA crosslinker", "SIMPLE_CHEMICAL", 115, 129], ["The highest cumulative paracetamol release", "TREATMENT", 0, 42], ["organo-hydrogels", "TREATMENT", 48, 64], ["organo-hydrogels", "TREATMENT", 81, 97], ["GA crosslinker", "TREATMENT", 115, 129]]], ["Paracetamol release can be controlled by crosslinker type and changing the amount of peppermint oil in the organo-hydrogels.Journal Pre-proofAccording to Figure 6 and Table 5 , the highest carboplatin release between gels, hydrogels and organo-hydrogels was observed from organo-hydrogels.", [["oil", "ANATOMY", 96, 99], ["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 189, 200], ["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 189, 200], ["Paracetamol", "SIMPLE_CHEMICAL", 0, 11], ["carboplatin", "SIMPLE_CHEMICAL", 189, 200], ["organo-hydrogels", "SIMPLE_CHEMICAL", 237, 253], ["organo-hydrogels", "SIMPLE_CHEMICAL", 272, 288], ["Paracetamol release", "TREATMENT", 0, 19], ["peppermint oil", "TREATMENT", 85, 99], ["the organo-hydrogels", "TREATMENT", 103, 123], ["the highest carboplatin release between gels", "TREATMENT", 177, 221], ["hydrogels", "TREATMENT", 223, 232], ["organo-hydrogels", "TREATMENT", 237, 253], ["organo-hydrogels", "TREATMENT", 272, 288]]], ["The results showed that there was a high rate of carboplatin release from organo-hydrogels, both synthesized by MBA and synthesized by GA agent.", [["carboplatin", "CHEMICAL", 49, 60], ["MBA", "CHEMICAL", 112, 115], ["GA", "CHEMICAL", 135, 137], ["carboplatin", "CHEMICAL", 49, 60], ["carboplatin", "SIMPLE_CHEMICAL", 49, 60], ["organo-hydrogels", "SIMPLE_CHEMICAL", 74, 90], ["MBA", "SIMPLE_CHEMICAL", 112, 115], ["GA", "SIMPLE_CHEMICAL", 135, 137], ["carboplatin release", "TREATMENT", 49, 68], ["organo-hydrogels", "TREATMENT", 74, 90]]], ["AG, p(AG-m) and p(AG-g) maximum carboplatin release was 1.7%, 1.6%, and 2.5% at pH 7.4, respectively.", [["carboplatin", "CHEMICAL", 32, 43], ["carboplatin", "CHEMICAL", 32, 43], ["AG", "SIMPLE_CHEMICAL", 0, 2], ["carboplatin", "SIMPLE_CHEMICAL", 32, 43], ["AG", "TEST", 0, 2], ["AG", "TEST", 18, 20], ["maximum carboplatin release", "TREATMENT", 24, 51], ["pH", "TEST", 80, 82]]], ["The maximum carboplatin release was found to be 100% for p(AG-m-PMO) 3 and 99.4% for p(AG-g-PMO) 1 (Table 5 ).", [["carboplatin", "CHEMICAL", 12, 23], ["carboplatin", "CHEMICAL", 12, 23], ["carboplatin", "SIMPLE_CHEMICAL", 12, 23], ["The maximum carboplatin release", "TREATMENT", 0, 31], ["AG", "TEST", 59, 61], ["AG", "TEST", 87, 89]]], ["When the release results were evaluated according to the amount of peppermint oil, it was clearly observed that the amount of release increased as the amount of peppermint oil increased in organohydrogels cross-linked with MBA.", [["oil", "ANATOMY", 172, 175], ["MBA", "CHEMICAL", 223, 226], ["MBA", "CHEMICAL", 223, 226], ["oil", "ORGANISM_SUBSTANCE", 78, 81], ["organohydrogels", "SIMPLE_CHEMICAL", 189, 204], ["MBA", "SIMPLE_CHEMICAL", 223, 226], ["peppermint oil", "TREATMENT", 67, 81], ["peppermint oil", "TREATMENT", 161, 175], ["amount", "OBSERVATION_MODIFIER", 151, 157], ["peppermint", "OBSERVATION_MODIFIER", 161, 171], ["oil", "OBSERVATION_MODIFIER", 172, 175], ["increased", "OBSERVATION_MODIFIER", 176, 185]]], ["It was determined that the increase in the amount of peppermint did not affect the release amount from organo-hydrogels connected with GA reagent.", [["GA", "CHEMICAL", 135, 137], ["organo-hydrogels", "SIMPLE_CHEMICAL", 103, 119], ["GA reagent", "SIMPLE_CHEMICAL", 135, 145], ["organo-hydrogels", "TREATMENT", 103, 119], ["GA reagent", "TREATMENT", 135, 145], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["amount", "OBSERVATION_MODIFIER", 43, 49]]], ["It was evident that the p(AG-g-PmO) 3 (paracetamol) and p(AG-m-PmO) 3J o u r n a l P r e -p r o o fJournal Pre-proof (carboplatin) organo-hydrogels had higher release capacity than the other organo-hydrogels.J o u r n a l P r e -p r o o fMoreover some of the other reported material in the literature include HC50SA50Ca0.5 (40% paracetamol), HC50SA50Zn0.5 (30% paracetamol), HC50SA50Cu0.5 (38% paracetamol), HC75SA25 (80% paracetamol), HC50SA50 (90% paracetamol) and HC25SA75 (100% paracetamol) [63] , carboxylated lignin (70% paracetamol), lignin tablet (70% paracetamol) and non-lignin tablet (70% paracetamol) [64] , and pure drug (100% Carboplatin), CP-loaded PEGylated MWCNTs (95% carboplatin) and enteric-coated PEGylated MWCNTs (95% carboplatin) [26] so on.J o u r n a l P r e -p r o o fThe release kinetics of the synthesized organo-hydrogels were investigated to obtain the most appropriate release model for the data obtained.", [["paracetamol", "CHEMICAL", 39, 50], ["carboplatin", "CHEMICAL", 118, 129], ["HC50SA50Ca0.5", "CHEMICAL", 309, 322], ["paracetamol", "CHEMICAL", 328, 339], ["HC50SA50Z", "CHEMICAL", 342, 351], ["paracetamol", "CHEMICAL", 361, 372], ["HC50SA50Cu0.5", "CHEMICAL", 375, 388], ["paracetamol", "CHEMICAL", 394, 405], ["HC75SA25", "CHEMICAL", 408, 416], ["paracetamol", "CHEMICAL", 422, 433], ["HC50SA50", "CHEMICAL", 436, 444], ["paracetamol", "CHEMICAL", 450, 461], ["HC25SA75", "CHEMICAL", 467, 475], ["paracetamol", "CHEMICAL", 482, 493], ["carboxylated lignin", "CHEMICAL", 502, 521], ["paracetamol", "CHEMICAL", 527, 538], ["lignin tablet", "CHEMICAL", 541, 554], ["paracetamol", "CHEMICAL", 560, 571], ["non-lignin tablet", "CHEMICAL", 577, 594], ["paracetamol", "CHEMICAL", 600, 611], ["Carboplatin", "CHEMICAL", 640, 651], ["CP", "CHEMICAL", 654, 656], ["MWCNTs", "CHEMICAL", 674, 680], ["carboplatin", "CHEMICAL", 686, 697], ["MWCNTs", "CHEMICAL", 728, 734], ["carboplatin", "CHEMICAL", 740, 751], ["p(AG-g-PmO) 3", "CHEMICAL", 24, 37], ["paracetamol", "CHEMICAL", 39, 50], ["p(AG-m-PmO", "CHEMICAL", 56, 66], ["carboplatin", "CHEMICAL", 118, 129], ["HC50SA50Ca0.5", "CHEMICAL", 309, 322], ["paracetamol", "CHEMICAL", 328, 339], ["paracetamol", "CHEMICAL", 361, 372], ["HC50SA50Cu0.5", "CHEMICAL", 375, 388], ["paracetamol", "CHEMICAL", 394, 405], ["HC75SA25", "CHEMICAL", 408, 416], ["paracetamol", "CHEMICAL", 422, 433], ["HC50SA50", "CHEMICAL", 436, 444], ["paracetamol", "CHEMICAL", 450, 461], ["HC25SA75", "CHEMICAL", 467, 475], ["paracetamol", "CHEMICAL", 482, 493], ["paracetamol", "CHEMICAL", 527, 538], ["paracetamol", "CHEMICAL", 560, 571], ["paracetamol", "CHEMICAL", 600, 611], ["Carboplatin", "CHEMICAL", 640, 651], ["carboplatin", "CHEMICAL", 686, 697], ["carboplatin", "CHEMICAL", 740, 751], ["paracetamol", "SIMPLE_CHEMICAL", 39, 50], ["AG-m-PmO", "SIMPLE_CHEMICAL", 58, 66], ["carboplatin", "SIMPLE_CHEMICAL", 118, 129], ["organo-hydrogels", "SIMPLE_CHEMICAL", 131, 147], ["organo-hydrogels", "SIMPLE_CHEMICAL", 191, 207], ["HC50SA50Ca0.5", "SIMPLE_CHEMICAL", 309, 322], ["paracetamol", "SIMPLE_CHEMICAL", 328, 339], ["paracetamol", "SIMPLE_CHEMICAL", 361, 372], ["HC50SA50Cu0.5", "SIMPLE_CHEMICAL", 375, 388], ["paracetamol", "SIMPLE_CHEMICAL", 394, 405], ["HC75SA25", "SIMPLE_CHEMICAL", 408, 416], ["paracetamol", "SIMPLE_CHEMICAL", 422, 433], ["HC50SA50", "SIMPLE_CHEMICAL", 436, 444], ["paracetamol", "SIMPLE_CHEMICAL", 450, 461], ["HC25SA75", "SIMPLE_CHEMICAL", 467, 475], ["paracetamol", "SIMPLE_CHEMICAL", 482, 493], ["carboxylated lignin", "SIMPLE_CHEMICAL", 502, 521], ["paracetamol", "SIMPLE_CHEMICAL", 527, 538], ["lignin", "SIMPLE_CHEMICAL", 541, 547], ["paracetamol", "SIMPLE_CHEMICAL", 560, 571], ["non-lignin", "SIMPLE_CHEMICAL", 577, 587], ["paracetamol", "SIMPLE_CHEMICAL", 600, 611], ["Carboplatin", "SIMPLE_CHEMICAL", 640, 651], ["CP", "SIMPLE_CHEMICAL", 654, 656], ["PEGylated MWCNTs", "SIMPLE_CHEMICAL", 664, 680], ["carboplatin", "SIMPLE_CHEMICAL", 686, 697], ["enteric-coated PEGylated MWCNTs", "SIMPLE_CHEMICAL", 703, 734], ["carboplatin", "SIMPLE_CHEMICAL", 740, 751], ["organo-hydrogels", "SIMPLE_CHEMICAL", 834, 850], ["the p(AG-g-PmO)", "TREATMENT", 20, 35], ["paracetamol", "TEST", 39, 50], ["AG", "TEST", 58, 60], ["PmO", "TEST", 63, 66], ["fJournal Pre-proof (carboplatin", "TREATMENT", 98, 129], ["organo-hydrogels", "TREATMENT", 131, 147], ["higher release capacity", "PROBLEM", 152, 175], ["the other organo-hydrogels", "PROBLEM", 181, 207], ["HC50SA50Ca0.5", "TEST", 309, 322], ["paracetamol", "TEST", 328, 339], ["HC50SA50Zn", "TREATMENT", 342, 352], ["paracetamol", "TREATMENT", 361, 372], ["paracetamol", "TEST", 394, 405], ["HC75SA25", "TEST", 408, 416], ["paracetamol", "TEST", 422, 433], ["HC50SA50", "TEST", 436, 444], ["paracetamol", "TREATMENT", 450, 461], ["HC25SA75 (100% paracetamol)", "TREATMENT", 467, 494], ["carboxylated lignin", "TREATMENT", 502, 521], ["paracetamol", "TREATMENT", 527, 538], ["lignin tablet (70% paracetamol)", "TREATMENT", 541, 572], ["non-lignin tablet (70% paracetamol)", "TREATMENT", 577, 612], ["pure drug", "TREATMENT", 624, 633], ["CP-loaded PEGylated MWCNTs", "TREATMENT", 654, 680], ["carboplatin", "TREATMENT", 686, 697], ["enteric-coated PEGylated MWCNTs (95% carboplatin)", "TREATMENT", 703, 752], ["The release kinetics", "TREATMENT", 794, 814], ["the synthesized organo-hydrogels", "TREATMENT", 818, 850], ["the data", "TEST", 918, 926]]], ["Mathematical models play an important role in predicting the release mechanism in organo-hydrogels and provide more general information to improve their mechanisms.", [["organo-hydrogels", "TREATMENT", 82, 98]]], ["Common kinetic model equations were applied to determine the release kinetics of the drug from organo-hydrogels (Table 6 -7).", [["Common kinetic model equations", "TREATMENT", 0, 30], ["organo-hydrogels", "TREATMENT", 95, 111], ["kinetic model equations", "OBSERVATION", 7, 30]]], ["The drug release data from organo-hydrogels were processed with these kinetic models to investigate release kinetics and systems.", [["organo-hydrogels", "SIMPLE_CHEMICAL", 27, 43], ["organo-hydrogels", "TREATMENT", 27, 43], ["these kinetic models", "TREATMENT", 64, 84]]], ["The paracetamol release from organo-hydrogels revealed a very high R-square with HM and KPM.", [["paracetamol", "CHEMICAL", 4, 15], ["paracetamol", "CHEMICAL", 4, 15], ["paracetamol", "SIMPLE_CHEMICAL", 4, 15], ["organo-hydrogels", "SIMPLE_CHEMICAL", 29, 45], ["The paracetamol release", "TREATMENT", 0, 23], ["organo-hydrogels", "TEST", 29, 45], ["KPM", "TREATMENT", 88, 91]]], ["The n values calculated with the KPM method to determine the paracetamol release mechanisms of organo-hydrogels are given in Table 6 .", [["paracetamol", "CHEMICAL", 61, 72], ["paracetamol", "CHEMICAL", 61, 72], ["paracetamol", "SIMPLE_CHEMICAL", 61, 72], ["organo-hydrogels", "SIMPLE_CHEMICAL", 95, 111], ["The n values", "TEST", 0, 12], ["the KPM method", "TREATMENT", 29, 43], ["the paracetamol release mechanisms", "TREATMENT", 57, 91], ["organo-hydrogels", "TREATMENT", 95, 111]]], ["When the n values of paracetamol release were examined, it was determined that other organo-hydrogels excluding p(AG-m-PMO) 3 organo-hydrogel released in accordance with the Fick type release law.", [["paracetamol", "CHEMICAL", 21, 32], ["AG-m-PMO", "CHEMICAL", 114, 122], ["paracetamol", "CHEMICAL", 21, 32], ["p(AG-m-PMO) 3", "CHEMICAL", 112, 125], ["paracetamol", "SIMPLE_CHEMICAL", 21, 32], ["organo-hydrogels", "SIMPLE_CHEMICAL", 85, 101], ["AG-m-PMO) 3 organo-hydrogel", "SIMPLE_CHEMICAL", 114, 141], ["paracetamol release", "TREATMENT", 21, 40], ["other organo-hydrogels", "PROBLEM", 79, 101], ["AG", "TEST", 114, 116], ["organo-hydrogel", "TREATMENT", 126, 141]]], ["In the Fick type release mechanism, n values are less than 0.45 and release is controlled by the diffusion rate of water into the organo-hydrogel.", [["water", "SIMPLE_CHEMICAL", 115, 120], ["n values", "TEST", 36, 44]]], ["Carboplatin release from organo-hydrogels revealed a very high R-square with the ZoM, HM and KPM.J o u r n a l P r e -p r o o fThe n values calculated with KPM for organo-hydrogels are shown in Table 7 J o u r n a l P r e -p r o o f Table 3 .", [["Carboplatin", "CHEMICAL", 0, 11], ["Carboplatin", "CHEMICAL", 0, 11], ["Carboplatin", "SIMPLE_CHEMICAL", 0, 11], ["organo-hydrogels", "SIMPLE_CHEMICAL", 25, 41], ["ZoM", "SIMPLE_CHEMICAL", 81, 84], ["KPM", "SIMPLE_CHEMICAL", 156, 159], ["organo-hydrogels", "SIMPLE_CHEMICAL", 164, 180], ["Carboplatin release", "TREATMENT", 0, 19], ["organo", "TEST", 25, 31], ["KPM", "TEST", 93, 96], ["The n values", "TEST", 127, 139], ["KPM", "TEST", 156, 159], ["organo-hydrogels", "TREATMENT", 164, 180]]], ["Total phenol content values.", [["phenol", "CHEMICAL", 6, 12], ["phenol", "CHEMICAL", 6, 12], ["phenol", "SIMPLE_CHEMICAL", 6, 12], ["Total phenol content values", "TEST", 0, 27]]], ["Paracetamol and carboplatin % release values.", [["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 16, 27], ["Paracetamol", "CHEMICAL", 0, 11], ["carboplatin", "CHEMICAL", 16, 27], ["Paracetamol", "SIMPLE_CHEMICAL", 0, 11], ["carboplatin", "SIMPLE_CHEMICAL", 16, 27], ["Paracetamol", "TREATMENT", 0, 11], ["carboplatin % release values", "TEST", 16, 44]]], ["Release kinetics and mechanism for paracetamol release.", [["paracetamol", "CHEMICAL", 35, 46], ["paracetamol", "CHEMICAL", 35, 46], ["paracetamol", "SIMPLE_CHEMICAL", 35, 46], ["paracetamol release", "TREATMENT", 35, 54]]], ["Release kinetics and mechanism for carboplatin release J o u r n a l P r e -p r o o f Table Legends Table 1 Codes of different organo-hydrogelOrgano-hydrogel CodeAgar J o u r n a l P r e -p r o o f Table 3 .", [["carboplatin", "CHEMICAL", 35, 46], ["carboplatin", "CHEMICAL", 35, 46], ["carboplatin", "SIMPLE_CHEMICAL", 35, 46], ["organo-hydrogel", "SIMPLE_CHEMICAL", 127, 142], ["carboplatin release", "TREATMENT", 35, 54], ["different organo-hydrogel", "TREATMENT", 117, 142], ["Organo", "TEST", 142, 148]]], ["Mathematical models for drug release.", [["drug release", "TREATMENT", 24, 36]]], ["J o u r n a l P r e -p r o o f Fickian diffusion mechanism n \u2264 0.45, non-Fickian (anomalous) diffusion mechanism.0.45 < n < 0.89 J o u r n a l P r e -p r o o f", [["r o o f Fickian", "CHEMICAL", 23, 38], ["Fickian diffusion mechanism", "TEST", 31, 58], ["non-Fickian (anomalous) diffusion mechanism", "PROBLEM", 69, 112]]]], "9027b4d1324273bed34f667f3d61d2536e9fd316": [["IntroductionSevere fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease recently discovered in China [1] [2] [3] [4] [5] .", [["fever", "DISEASE", 19, 24], ["thrombocytopenia syndrome", "DISEASE", 30, 55], ["SFTS", "DISEASE", 57, 61], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 126, 145], ["fever", "PROBLEM", 19, 24], ["thrombocytopenia syndrome", "PROBLEM", 30, 55], ["SFTS", "PROBLEM", 57, 61], ["an emerging infectious disease", "PROBLEM", 66, 96], ["thrombocytopenia syndrome", "OBSERVATION", 30, 55], ["infectious", "OBSERVATION", 78, 88]]], ["The causative agent of this illness, severe fever with thrombocytopenia syndrome virus (SFTSV), was identified as a novel tickborne Bunynavirus in genus Phlebovirus; it is also named Huaiyangshan virus, since the original cases were identified in the Huaiyangshan Mountains in 2009 [1, 6, 7] .", [["fever", "DISEASE", 44, 49], ["thrombocytopenia syndrome", "DISEASE", 55, 80], ["Bunynavirus", "CHEMICAL", 132, 143], ["Huaiyangshan virus", "ORGANISM", 183, 201], ["severe fever with thrombocytopenia syndrome virus", "SPECIES", 37, 86], ["SFTSV", "SPECIES", 88, 93], ["Huaiyangshan virus", "SPECIES", 183, 201], ["this illness", "PROBLEM", 23, 35], ["severe fever", "PROBLEM", 37, 49], ["thrombocytopenia syndrome virus", "PROBLEM", 55, 86], ["SFTSV", "PROBLEM", 88, 93], ["a novel tickborne Bunynavirus in genus Phlebovirus", "PROBLEM", 114, 164], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["fever", "OBSERVATION", 44, 49], ["thrombocytopenia", "OBSERVATION", 55, 71], ["genus Phlebovirus", "OBSERVATION", 147, 164]]], ["It was reported that SFTSV can be transmitted in several ways: 1) patients can be infected through a tick bite; the virus has been detected in Haemaphysalis longicornis ticks [1, 7] and/or 2) through personto-person transmission via contact with blood from patients with SFTS [8] .", [["blood", "ANATOMY", 246, 251], ["SFTSV", "CHEMICAL", 21, 26], ["tick bite", "DISEASE", 101, 110], ["SFTS", "DISEASE", 271, 275], ["SFTSV", "GENE_OR_GENE_PRODUCT", 21, 26], ["patients", "ORGANISM", 66, 74], ["Haemaphysalis longicornis ticks", "ORGANISM", 143, 174], ["blood", "ORGANISM_SUBSTANCE", 246, 251], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 66, 74], ["Haemaphysalis longicornis", "SPECIES", 143, 168], ["person", "SPECIES", 209, 215], ["patients", "SPECIES", 257, 265], ["SFTSV", "SPECIES", 21, 26], ["Haemaphysalis longicornis", "SPECIES", 143, 168], ["SFTSV", "PROBLEM", 21, 26], ["a tick bite", "PROBLEM", 99, 110], ["the virus", "PROBLEM", 112, 121], ["SFTSV", "OBSERVATION", 21, 26], ["infected", "OBSERVATION", 82, 90]]], ["Sporadic and clustered SFTS endemics have been documented in at least six provinces in Northeastern, Eastern, and Central China since 2009 [1, 3, 9] .IntroductionThe typical clinical presentation of SFTS is acute fever and thrombocytopenia (platelet count less than 100,000/ml), in addition to other non-specific features including muscle pain, severe malaise, nausea, vomiting, and diarrhea [1, 3, [6] [7] [8] .", [["platelet", "ANATOMY", 241, 249], ["muscle", "ANATOMY", 332, 338], ["SFTS", "DISEASE", 199, 203], ["fever", "DISEASE", 213, 218], ["thrombocytopenia", "DISEASE", 223, 239], ["muscle pain", "DISEASE", 332, 343], ["nausea", "DISEASE", 361, 367], ["vomiting", "DISEASE", 369, 377], ["diarrhea", "DISEASE", 383, 391], ["SFTS", "CANCER", 199, 203], ["platelet", "CELL", 241, 249], ["muscle", "ORGAN", 332, 338], ["Sporadic and clustered SFTS endemics", "PROBLEM", 0, 36], ["SFTS", "PROBLEM", 199, 203], ["acute fever", "PROBLEM", 207, 218], ["thrombocytopenia", "PROBLEM", 223, 239], ["platelet count", "TEST", 241, 255], ["other non-specific features", "PROBLEM", 294, 321], ["muscle pain", "PROBLEM", 332, 343], ["severe malaise", "PROBLEM", 345, 359], ["nausea", "PROBLEM", 361, 367], ["vomiting", "PROBLEM", 369, 377], ["diarrhea", "PROBLEM", 383, 391], ["clustered", "OBSERVATION_MODIFIER", 13, 22], ["SFTS", "OBSERVATION", 23, 27], ["Central", "ANATOMY_MODIFIER", 114, 121], ["SFTS", "OBSERVATION", 199, 203], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["fever", "OBSERVATION", 213, 218], ["thrombocytopenia", "OBSERVATION", 223, 239], ["muscle", "ANATOMY", 332, 338], ["severe", "OBSERVATION_MODIFIER", 345, 351], ["malaise", "OBSERVATION", 352, 359]]], ["A high mortality rate (ranging from 12%-30%) has been reported for SFTSV-infected patients [1, 6, 9] .", [["SFTSV-infected", "DISEASE", 67, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["SFTSV", "SPECIES", 67, 72], ["A high mortality rate", "PROBLEM", 0, 21], ["SFTSV", "PROBLEM", 67, 72], ["high", "OBSERVATION_MODIFIER", 2, 6], ["infected", "OBSERVATION", 73, 81]]], ["The exact mechanism of SFTSV pathogenesis remains unclear but it is generally suspected that immunopathology plays a key role [10, 11] .", [["SFTSV", "DISEASE", 23, 28], ["immunopathology", "DISEASE", 93, 108], ["SFTSV", "CANCER", 23, 28], ["SFTSV pathogenesis", "PROBLEM", 23, 41], ["SFTSV", "OBSERVATION", 23, 28]]], ["As with other viral infections, immune activation and exaggerated cytokine production in the form of cytokine storm can potentially drive the SFTS disease process.", [["viral infections", "DISEASE", 14, 30], ["SFTS", "CANCER", 142, 146], ["cytokine", "PROTEIN", 66, 74], ["cytokine", "PROTEIN", 101, 109], ["other viral infections", "PROBLEM", 8, 30], ["immune activation", "PROBLEM", 32, 49], ["exaggerated cytokine production", "PROBLEM", 54, 85], ["cytokine storm", "TREATMENT", 101, 115], ["the SFTS disease process", "PROBLEM", 138, 162], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["exaggerated", "OBSERVATION_MODIFIER", 54, 65], ["cytokine production", "OBSERVATION", 66, 85], ["cytokine storm", "OBSERVATION", 101, 115], ["SFTS", "OBSERVATION", 142, 146]]], ["Several studies reported that SFTSV infection could lead to elevated levels of serum cytokines, which might contribute to disease severity and clinical outcome [6, 12, 13] .", [["serum", "ANATOMY", 79, 84], ["SFTSV infection", "DISEASE", 30, 45], ["SFTSV", "SIMPLE_CHEMICAL", 30, 35], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["serum cytokines", "PROTEIN", 79, 94], ["SFTSV", "SPECIES", 30, 35], ["Several studies", "TEST", 0, 15], ["SFTSV infection", "PROBLEM", 30, 45], ["elevated levels of serum cytokines", "PROBLEM", 60, 94], ["disease severity", "PROBLEM", 122, 138], ["SFTSV", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45]]], ["In separate reports it was shown that the viral infection induced CD3+CD8+ and CD3+CD4+ T cell population changes [11, 14] .", [["CD3+CD8+ and CD3+CD4+ T cell", "ANATOMY", 66, 94], ["infection", "DISEASE", 48, 57], ["CD3", "GENE_OR_GENE_PRODUCT", 66, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["CD3", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["CD3", "PROTEIN", 66, 69], ["CD8", "PROTEIN", 70, 73], ["CD3", "PROTEIN", 79, 82], ["CD4", "PROTEIN", 83, 86], ["the viral infection", "PROBLEM", 38, 57], ["CD3", "TEST", 66, 69], ["CD8", "TEST", 70, 73], ["CD3", "TEST", 79, 82], ["CD4", "TEST", 83, 86], ["T cell population changes", "PROBLEM", 88, 113], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57], ["T cell population", "OBSERVATION", 88, 105]]], ["However, almost all of the previous reports showed data collected at one or two time points of the disease process rather than determining dynamic changes in key lab test results and immunological markers incurred during the critical clinical period shortly after infection.IntroductionIn the current report, changes in SFTSV viral load, platelets and white blood cell counts, levels of key serum enzymes, cytokine profile and changes in two important T subset populations, were measured every other day during the first 10-15 days of hospitalization for four deceased patients and twenty-nine survivors diagnosed with SFTSV infection.", [["platelets", "ANATOMY", 338, 347], ["white blood cell", "ANATOMY", 352, 368], ["serum", "ANATOMY", 391, 396], ["infection", "DISEASE", 264, 273], ["SFTSV infection", "DISEASE", 619, 634], ["SFTSV", "ORGANISM", 320, 325], ["platelets", "CELL", 338, 347], ["white blood cell", "CELL", 352, 368], ["serum", "ORGANISM_SUBSTANCE", 391, 396], ["T subset populations", "CELL", 452, 472], ["patients", "ORGANISM", 569, 577], ["platelets", "CELL_TYPE", 338, 347], ["serum enzymes", "PROTEIN", 391, 404], ["cytokine", "PROTEIN", 406, 414], ["T subset populations", "CELL_TYPE", 452, 472], ["patients", "SPECIES", 569, 577], ["SFTSV", "SPECIES", 320, 325], ["SFTSV", "SPECIES", 619, 624], ["the disease process", "PROBLEM", 95, 114], ["immunological markers", "TEST", 183, 204], ["infection", "PROBLEM", 264, 273], ["SFTSV viral load", "TEST", 320, 336], ["platelets", "TEST", 338, 347], ["white blood cell counts", "TEST", 352, 375], ["levels", "TEST", 377, 383], ["key serum enzymes", "TEST", 387, 404], ["cytokine profile", "TEST", 406, 422], ["SFTSV infection", "PROBLEM", 619, 634], ["disease", "OBSERVATION", 99, 106], ["infection", "OBSERVATION", 264, 273], ["SFTSV", "OBSERVATION", 320, 325], ["viral load", "OBSERVATION", 326, 336], ["SFTSV infection", "OBSERVATION", 619, 634]]], ["Information learned from the current study provide a better understanding on the relationship between clinical disease progression and key clinical lab and immunological parameters.", [["clinical disease progression", "PROBLEM", 102, 130]]], ["Such information is also useful to guide a more in-depth investigation on the mechanisms of SFTSV pathogenesis.ParticipantsBetween May 2011 and July 2013, thirty-three patients (16 males and 17 females) (Table 1) , with confirmed SFTSV infection based on diagnostic guidelines from the Chinese Ministry of Health [15] , were admitted to the Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.", [["SFTSV", "DISEASE", 92, 97], ["SFTSV infection", "DISEASE", 230, 245], ["Infectious Diseases", "DISEASE", 355, 374], ["SFTSV", "CANCER", 92, 97], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["SFTSV", "SPECIES", 230, 235], ["SFTSV pathogenesis", "PROBLEM", 92, 110], ["SFTSV infection", "PROBLEM", 230, 245], ["SFTSV", "OBSERVATION", 92, 97], ["SFTSV", "ANATOMY", 230, 235], ["infection", "OBSERVATION", 236, 245], ["Infectious", "OBSERVATION", 355, 365]]], ["These patients were from the rural areas of three Eastern China provinces (17 patients from Anhui, 16 patients from Jiangsu, and 1 from Shandong).", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 102, 110]]], ["There was no geographical connection between the four patients who died (2 from Anhui and 2 from Jiangsu).", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["no", "UNCERTAINTY", 10, 12], ["geographical", "OBSERVATION_MODIFIER", 13, 25], ["connection", "OBSERVATION", 26, 36]]], ["In addition to the SFTSV-infected patients, thirtytwo healthy volunteers (21 males and 11 females) were also enrolled in this study (Table 1) to serve as normal controls.", [["SFTSV-infected", "DISEASE", 19, 33], ["SFTSV", "GENE_OR_GENE_PRODUCT", 19, 24], ["patients", "ORGANISM", 34, 42], ["volunteers", "ORGANISM", 62, 72], ["patients", "SPECIES", 34, 42], ["this study", "TEST", 121, 131], ["SFTSV", "OBSERVATION", 19, 24], ["infected", "OBSERVATION_MODIFIER", 25, 33]]], ["Written informed consent was obtained from all participants and the study was approved by the Institutional Review Board at First Affiliated Hospital of Nanjing Medical University.Sample collection and processingAll SFTSV-infected patients received standard antiviral and standard support treatments after admission to the hospital based on SFTS treatment guidelines from the Chinese Ministry of Health.", [["SFTSV-infected", "DISEASE", 216, 230], ["patients", "ORGANISM", 231, 239], ["participants", "SPECIES", 47, 59], ["patients", "SPECIES", 231, 239], ["the study", "TEST", 64, 73], ["Sample collection", "TEST", 180, 197], ["standard antiviral", "TREATMENT", 249, 267], ["standard support treatments", "TREATMENT", 272, 299], ["SFTS treatment guidelines", "TREATMENT", 341, 366], ["All", "OBSERVATION_MODIFIER", 212, 215], ["SFTSV", "OBSERVATION", 216, 221], ["infected", "OBSERVATION_MODIFIER", 222, 230]]], ["Individual identification codes were given to each participant and blood samples were collected under identification codes.", [["blood samples", "ANATOMY", 67, 80], ["blood samples", "ORGANISM_SUBSTANCE", 67, 80], ["participant", "SPECIES", 51, 62], ["blood samples", "TEST", 67, 80]]], ["For SFTSV-infected patients, samples were collected during hospitalization at Days 5, 7, 9, 11, 13 , and 15 after onset of fever while blood samples from healthy donors were collected at a single time point at the time of enrollment.Lab tests and assaysBlood cell and platelet counts were measured by Japanese SYSMEX XE2100 fully-automatic blood cell analyzer.", [["samples", "ANATOMY", 29, 36], ["blood samples", "ANATOMY", 135, 148], ["Blood cell", "ANATOMY", 253, 263], ["platelet", "ANATOMY", 268, 276], ["blood cell", "ANATOMY", 340, 350], ["SFTSV-infected", "DISEASE", 4, 18], ["fever", "DISEASE", 123, 128], ["SFTSV", "GENE_OR_GENE_PRODUCT", 4, 9], ["patients", "ORGANISM", 19, 27], ["samples", "CANCER", 29, 36], ["blood samples", "ORGANISM_SUBSTANCE", 135, 148], ["donors", "ORGANISM", 162, 168], ["Blood cell", "CELL", 253, 263], ["platelet", "CELL", 268, 276], ["blood cell", "CELL", 340, 350], ["patients", "SPECIES", 19, 27], ["SFTSV", "SPECIES", 4, 9], ["SFTSV", "PROBLEM", 4, 9], ["samples", "TEST", 29, 36], ["fever", "PROBLEM", 123, 128], ["blood samples", "TEST", 135, 148], ["healthy donors", "PROBLEM", 154, 168], ["Lab tests", "TEST", 233, 242], ["assays", "TEST", 247, 253], ["Blood cell", "TEST", 253, 263], ["platelet counts", "TEST", 268, 283], ["Japanese SYSMEX", "TEST", 301, 316], ["automatic blood cell analyzer", "TEST", 330, 359], ["infected", "OBSERVATION_MODIFIER", 10, 18], ["fever", "OBSERVATION", 123, 128], ["platelet counts", "OBSERVATION", 268, 283]]], ["Japanese Olympus AU5400 fully-automatic biochemical detector was used to determine levels of alanine transaminase (ALT), aspartate transaminase (AST), lactic dehydrogenase (LDH), and creatine kinase (CK).Lab tests and assaysThe TaqMan real-time fluorescent quantitative PCR method was used to detect SFTSV viral load.", [["alanine", "CHEMICAL", 93, 100], ["aspartate", "CHEMICAL", 121, 130], ["creatine", "CHEMICAL", 183, 191], ["alanine", "CHEMICAL", 93, 100], ["aspartate", "CHEMICAL", 121, 130], ["creatine", "CHEMICAL", 183, 191], ["alanine transaminase", "GENE_OR_GENE_PRODUCT", 93, 113], ["ALT", "SIMPLE_CHEMICAL", 115, 118], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 121, 143], ["AST", "SIMPLE_CHEMICAL", 145, 148], ["lactic dehydrogenase", "GENE_OR_GENE_PRODUCT", 151, 171], ["LDH", "GENE_OR_GENE_PRODUCT", 173, 176], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 183, 198], ["CK", "GENE_OR_GENE_PRODUCT", 200, 202], ["alanine transaminase", "PROTEIN", 93, 113], ["ALT", "PROTEIN", 115, 118], ["aspartate transaminase", "PROTEIN", 121, 143], ["AST", "PROTEIN", 145, 148], ["lactic dehydrogenase", "PROTEIN", 151, 171], ["LDH", "PROTEIN", 173, 176], ["creatine kinase", "PROTEIN", 183, 198], ["CK", "PROTEIN", 200, 202], ["SFTSV", "SPECIES", 300, 305], ["Japanese Olympus", "TEST", 0, 16], ["automatic biochemical detector", "TEST", 30, 60], ["alanine transaminase", "TEST", 93, 113], ["ALT", "TEST", 115, 118], ["aspartate transaminase", "TEST", 121, 143], ["AST", "TEST", 145, 148], ["lactic dehydrogenase", "TEST", 151, 171], ["LDH)", "TEST", 173, 177], ["creatine kinase", "TEST", 183, 198], ["CK", "TEST", 200, 202], ["Lab tests", "TEST", 204, 213], ["assays", "TEST", 218, 224], ["The TaqMan", "TEST", 224, 234], ["fluorescent quantitative PCR method", "TEST", 245, 280], ["SFTSV viral load", "PROBLEM", 300, 316], ["SFTSV viral load", "OBSERVATION", 300, 316]]], ["The virus RNA was extracted from the plasma samples using a RNA extraction kit and RT-PCR amplification was conducted immediately on the fluorescent quantitative PCR detector (ABI StepOne Plus).", [["plasma samples", "ANATOMY", 37, 51], ["plasma samples", "ORGANISM_SUBSTANCE", 37, 51], ["virus RNA", "RNA", 4, 13], ["The virus RNA", "PROBLEM", 0, 13], ["the plasma samples", "TEST", 33, 51], ["a RNA extraction kit", "TREATMENT", 58, 78], ["RT-PCR amplification", "TREATMENT", 83, 103], ["virus RNA", "OBSERVATION", 4, 13]]], ["SFTSV RNA was detected with the specific primers targeting the highly conserved region of SFTSV L, M, and S genes [1, 16] .Lab tests and assaysThe RT-PCR reaction system was in a volume of 25 ml; reaction conditions were 50uC for 15 min with 1 cycle; 95uC for 15 min with 1 cycle; 94uC for 15 sec, 55uC for 45 sec, and 55uC with 45 cycles.", [["SFTSV", "GENE_OR_GENE_PRODUCT", 0, 5], ["SFTSV L", "GENE_OR_GENE_PRODUCT", 90, 97], ["SFTSV RNA", "RNA", 0, 9], ["SFTSV L, M, and S genes", "DNA", 90, 113], ["SFTSV", "SPECIES", 0, 5], ["SFTSV RNA", "PROBLEM", 0, 9], ["the specific primers", "TEST", 28, 48], ["Lab tests", "TEST", 123, 132], ["assays", "TEST", 137, 143], ["The RT-PCR reaction system", "TEST", 143, 169], ["reaction conditions", "PROBLEM", 196, 215], ["SFTSV", "OBSERVATION", 90, 95]]], ["Fluorescent signals were collected by FAM channel.Lab tests and assaysLymphocyte subpopulations and T cell activation profiles in patients' PBMC were analyzed by flow cytometry with florescentconjugated T cell surface markers: florescent-conjugated mouse anti-human CD3-PerCP Cy5.5, CTLA-4-PE, CD4-FITC, CD28-PE, CD8-PE, CD69-FITC, CD25-PE, CD56-PE, HLA-DR-FITC, and isotype controls: mouse IgG1-PE and mouse IgG1-FITC (BD Bioscience, CA, USA).", [["assaysLymphocyte", "ANATOMY", 64, 80], ["T cell", "ANATOMY", 100, 106], ["PBMC", "ANATOMY", 140, 144], ["T cell surface", "ANATOMY", 203, 217], ["FITC", "CHEMICAL", 298, 302], ["FITC", "CHEMICAL", 326, 330], ["FITC", "CHEMICAL", 414, 418], ["FAM", "SIMPLE_CHEMICAL", 38, 41], ["assaysLymphocyte subpopulations", "CELL", 64, 95], ["T cell", "CELL", 100, 106], ["patients", "ORGANISM", 130, 138], ["PBMC", "CELL", 140, 144], ["T cell", "CELL", 203, 209], ["mouse", "ORGANISM", 249, 254], ["CD3", "GENE_OR_GENE_PRODUCT", 266, 269], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 283, 289], ["PE", "SIMPLE_CHEMICAL", 290, 292], ["CD4", "GENE_OR_GENE_PRODUCT", 294, 297], ["FITC", "GENE_OR_GENE_PRODUCT", 298, 302], ["CD28", "GENE_OR_GENE_PRODUCT", 304, 308], ["PE", "SIMPLE_CHEMICAL", 309, 311], ["CD8-PE", "GENE_OR_GENE_PRODUCT", 313, 319], ["CD69", "GENE_OR_GENE_PRODUCT", 321, 325], ["FITC", "GENE_OR_GENE_PRODUCT", 326, 330], ["CD25-PE", "GENE_OR_GENE_PRODUCT", 332, 339], ["CD56", "GENE_OR_GENE_PRODUCT", 341, 345], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 350, 356], ["FITC", "GENE_OR_GENE_PRODUCT", 357, 361], ["mouse", "ORGANISM", 385, 390], ["IgG1-PE", "GENE_OR_GENE_PRODUCT", 391, 398], ["mouse", "ORGANISM", 403, 408], ["IgG1-FITC", "GENE_OR_GENE_PRODUCT", 409, 418], ["PBMC", "CELL_TYPE", 140, 144], ["florescentconjugated T cell surface markers", "PROTEIN", 182, 225], ["florescent-conjugated mouse anti-human CD3", "PROTEIN", 227, 269], ["PerCP", "PROTEIN", 270, 275], ["CTLA", "PROTEIN", 283, 287], ["PE", "PROTEIN", 290, 292], ["CD4", "PROTEIN", 294, 297], ["FITC", "PROTEIN", 298, 302], ["CD28", "PROTEIN", 304, 308], ["PE", "PROTEIN", 309, 311], ["CD8", "PROTEIN", 313, 316], ["PE", "PROTEIN", 317, 319], ["CD69", "PROTEIN", 321, 325], ["FITC", "PROTEIN", 326, 330], ["CD25", "PROTEIN", 332, 336], ["PE", "PROTEIN", 337, 339], ["CD56", "PROTEIN", 341, 345], ["PE", "PROTEIN", 346, 348], ["HLA", "PROTEIN", 350, 353], ["DR", "PROTEIN", 354, 356], ["FITC", "PROTEIN", 357, 361], ["IgG1", "PROTEIN", 391, 395], ["mouse IgG1", "PROTEIN", 403, 413], ["FITC", "PROTEIN", 414, 418], ["patients", "SPECIES", 130, 138], ["mouse", "SPECIES", 249, 254], ["mouse", "SPECIES", 385, 390], ["mouse", "SPECIES", 403, 408], ["mouse", "SPECIES", 249, 254], ["mouse", "SPECIES", 385, 390], ["mouse", "SPECIES", 403, 408], ["Fluorescent signals", "TEST", 0, 19], ["Lab tests", "TEST", 50, 59], ["assaysLymphocyte subpopulations", "TEST", 64, 95], ["T cell activation profiles", "TEST", 100, 126], ["patients' PBMC", "TEST", 130, 144], ["flow cytometry", "TEST", 162, 176], ["florescent", "TEST", 227, 237], ["CD3", "TEST", 266, 269], ["PerCP", "TEST", 270, 275], ["Cy", "TEST", 276, 278], ["CTLA", "TEST", 283, 287], ["PE", "PROBLEM", 290, 292], ["CD4", "TEST", 294, 297], ["FITC", "TEST", 298, 302], ["CD28", "TEST", 304, 308], ["PE", "PROBLEM", 309, 311], ["CD8", "TEST", 313, 316], ["PE", "TEST", 317, 319], ["CD69", "TEST", 321, 325], ["FITC", "TEST", 326, 330], ["CD25", "TEST", 332, 336], ["PE", "TEST", 337, 339], ["CD56", "TEST", 341, 345], ["PE", "TEST", 346, 348], ["HLA", "TEST", 350, 353], ["DR", "TEST", 354, 356], ["FITC", "TEST", 357, 361], ["isotype controls", "TEST", 367, 383], ["mouse IgG1", "TEST", 385, 395], ["PE", "PROBLEM", 396, 398], ["mouse IgG1", "TEST", 403, 413], ["PE", "OBSERVATION", 290, 292], ["PE", "OBSERVATION", 309, 311], ["PE", "OBSERVATION", 317, 319], ["CD25", "ANATOMY", 332, 336], ["PE", "OBSERVATION", 337, 339], ["PE", "OBSERVATION", 346, 348], ["PE", "OBSERVATION", 396, 398]]], ["Cell populations were analyzed with FACS Calibur Flow Cytometer and CellQuest software (BD BioScience).Lab tests and assaysSerum cytokines were detected using Human Th1/Th2/Th17 Cytometric Bead Array (CBA) Kit (BD BioScience) according to the manufacturer's instructions.", [["Cell", "ANATOMY", 0, 4], ["Cell populations", "CELL", 0, 16], ["Human", "ORGANISM", 159, 164], ["assaysSerum cytokines", "PROTEIN", 117, 138], ["Th17", "PROTEIN", 173, 177], ["Human", "SPECIES", 159, 164], ["Human", "SPECIES", 159, 164], ["Cell populations", "TEST", 0, 16], ["Lab tests", "TEST", 103, 112], ["assaysSerum cytokines", "TEST", 117, 138], ["Human Th1/Th2/Th17 Cytometric Bead Array (CBA) Kit (BD BioScience", "TREATMENT", 159, 224]]], ["The flow cytometer (FACS Caliber) was used to detect IL-2, IL-4, IL-6, IL-10, TNF -a, IFN-c, and IL-17A levels in the serum.", [["serum", "ANATOMY", 118, 123], ["IL-2", "GENE_OR_GENE_PRODUCT", 53, 57], ["IL-4", "GENE_OR_GENE_PRODUCT", 59, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 65, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 71, 76], ["TNF -a", "GENE_OR_GENE_PRODUCT", 78, 84], ["IFN-c", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL-17A", "GENE_OR_GENE_PRODUCT", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["TNF", "PROTEIN", 78, 81], ["IFN", "PROTEIN", 86, 89], ["The flow cytometer", "TEST", 0, 18], ["IL", "TEST", 53, 55], ["IL", "TEST", 59, 61], ["IL", "TEST", 65, 67], ["IL", "TEST", 71, 73], ["TNF", "TEST", 78, 81], ["IFN", "TEST", 86, 89], ["IL", "TEST", 97, 99], ["flow cytometer", "OBSERVATION", 4, 18], ["serum", "ANATOMY", 118, 123]]], ["The detection sensitivity of each cytokine was 2.5 pg/ml.Statistical analysisThe results were analyzed using statistical software SPSS17.0 for Windows (SPPS, an IBM Company).", [["cytokine", "PROTEIN", 34, 42], ["each cytokine", "TEST", 29, 42], ["Statistical analysis", "TEST", 57, 77]]], ["Mann-Whitney U nonparametric test, Student's t-test, or Rank-sum test, where appropriate, were used to compare the mean value of any two groups (deceased patients vs. survivors, or infected groups vs. normal control group), with p,0.05 considered statistically significant.ResultsDuring the period from May 2011 and July 2013, 33 patients with laboratory-confirmed SFTSV infection were admitted to Jiangsu People's Hospital, Nanjing, China.", [["SFTSV infection", "DISEASE", 365, 380], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 330, 338], ["SFTSV", "SPECIES", 365, 370], ["Student's t-test", "TEST", 35, 51], ["Rank-sum test", "TEST", 56, 69], ["infected groups vs", "PROBLEM", 181, 199], ["SFTSV infection", "PROBLEM", 365, 380], ["SFTSV", "ANATOMY", 365, 370], ["infection", "OBSERVATION", 371, 380]]], ["These patients share the similar clinic manifestations of SFTS, including acute fever (.38uC), weakness, anorexia, nausea and vomiting, as well as disturbance of consciousness, ecchymosis, and gastrointestinal hemorrhage for those in critical condition (Table 1) , as well as the hallmark thrombocytopenia (platelet count ,4610 9 /L).", [["gastrointestinal", "ANATOMY", 193, 209], ["platelet", "ANATOMY", 307, 315], ["SFTS", "DISEASE", 58, 62], ["acute fever", "DISEASE", 74, 85], ["weakness", "DISEASE", 95, 103], ["anorexia", "DISEASE", 105, 113], ["nausea", "DISEASE", 115, 121], ["vomiting", "DISEASE", 126, 134], ["disturbance of consciousness", "DISEASE", 147, 175], ["ecchymosis", "DISEASE", 177, 187], ["gastrointestinal hemorrhage", "DISEASE", 193, 220], ["thrombocytopenia", "DISEASE", 289, 305], ["patients", "ORGANISM", 6, 14], ["SFTS", "CANCER", 58, 62], ["gastrointestinal", "ORGANISM_SUBDIVISION", 193, 209], ["platelet", "CELL", 307, 315], ["patients", "SPECIES", 6, 14], ["SFTS", "PROBLEM", 58, 62], ["acute fever", "PROBLEM", 74, 85], ["weakness", "PROBLEM", 95, 103], ["anorexia", "PROBLEM", 105, 113], ["nausea", "PROBLEM", 115, 121], ["vomiting", "PROBLEM", 126, 134], ["disturbance of consciousness", "PROBLEM", 147, 175], ["ecchymosis", "PROBLEM", 177, 187], ["gastrointestinal hemorrhage", "PROBLEM", 193, 220], ["the hallmark thrombocytopenia", "PROBLEM", 276, 305], ["platelet count", "TEST", 307, 321], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["fever", "OBSERVATION", 80, 85], ["weakness", "OBSERVATION", 95, 103], ["anorexia", "OBSERVATION", 105, 113], ["ecchymosis", "OBSERVATION", 177, 187], ["gastrointestinal", "ANATOMY", 193, 209], ["hemorrhage", "OBSERVATION", 210, 220], ["hallmark", "OBSERVATION_MODIFIER", 280, 288], ["thrombocytopenia", "OBSERVATION", 289, 305]]], ["At admission, all patients enrolled in this study had confirmed positive SFTSV in blood samples determined by reversetranscriptase polymerase chain reaction (RT-PCR) with designated primers for SFTSV L, M, S genes.", [["blood samples", "ANATOMY", 82, 95], ["patients", "ORGANISM", 18, 26], ["SFTSV", "GENE_OR_GENE_PRODUCT", 73, 78], ["blood samples", "ORGANISM_SUBSTANCE", 82, 95], ["SFTSV L", "GENE_OR_GENE_PRODUCT", 194, 201], ["SFTSV L, M, S genes", "DNA", 194, 213], ["patients", "SPECIES", 18, 26], ["this study", "TEST", 39, 49], ["positive SFTSV in blood samples", "PROBLEM", 64, 95], ["reversetranscriptase polymerase chain reaction", "PROBLEM", 110, 156], ["RT-PCR", "TEST", 158, 164], ["SFTSV", "PROBLEM", 194, 199], ["SFTSV", "OBSERVATION", 73, 78]]], ["During hospitalization, all patients received similar treatment based on guidelines from the Chinese Ministry of Health [15] .", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["similar treatment", "TREATMENT", 46, 63]]], ["Four died within 1-3 days after admission (7-9 days after onset of fever) and 29 patients recovered from the illness.", [["fever", "DISEASE", 67, 72], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["fever", "PROBLEM", 67, 72], ["the illness", "PROBLEM", 105, 116]]], ["The length between symptom onset to admission did not contribute to the mortality as those deceased were admitted on Day 7 of symptom onset while the median time of admission for those who survived was 6 days (range 3-10 days) ( Table 1 ).", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["There was no gender bias for the deceased (2 males/2 females) and survivors (14 males/16 females) patients.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["gender bias", "PROBLEM", 13, 24], ["no", "UNCERTAINTY", 10, 12]]], ["On the other hand, the median age of the deceased patients (70 years) was notably older than the median age of survivors (59 years), but not statistically significant due to a small sample size (Table 1) .", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["small", "OBSERVATION_MODIFIER", 176, 181], ["size", "OBSERVATION_MODIFIER", 189, 193]]], ["While all patients had easily detectable SFTSV in their blood, SFTSV viral load among survivors peaked shortly after admission (within 7-11 days of symptom onset) and then dropped rapidly during the remaining period of the study (Fig. 1A) .", [["blood", "ANATOMY", 56, 61], ["patients", "ORGANISM", 10, 18], ["SFTSV", "CANCER", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "SPECIES", 10, 18], ["easily detectable SFTSV in their blood", "PROBLEM", 23, 61], ["SFTSV viral load", "PROBLEM", 63, 79], ["the study", "TEST", 219, 228], ["SFTSV", "OBSERVATION", 41, 46]]], ["In contrast, three out of four deceased patients who were admitted on Day 7 of disease onset died within three days of admission with much higher levels of viral load while one of the deceased patients had similar levels of viral load to those who survived (Fig. 1A) .", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 193, 201], ["viral load", "PROBLEM", 156, 166], ["viral load", "PROBLEM", 224, 234], ["viral load", "OBSERVATION", 156, 166], ["viral load", "OBSERVATION", 224, 234]]], ["When the viral loads on Day 9 for both groups were compared, the mean log viral load for the deceased patients (8.85, range 6.67-9.76) was about 1000 fold higher than the mean log viral load in the survivors (5.92, range 2.66-7.94) (p,0.0001) (Fig. 1B) .ResultsAs indicated by the namesake of this disease, platelet (PLT) counts in all SFTSV-infected patients were low when the diagnosis was made, as evidenced by levels half of the normal range (100-300610 9 /L).", [["platelet", "ANATOMY", 307, 315], ["PLT", "ANATOMY", 317, 320], ["SFTSV-infected", "DISEASE", 336, 350], ["patients", "ORGANISM", 102, 110], ["platelet", "CELL", 307, 315], ["PLT", "CELL", 317, 320], ["SFTSV", "GENE_OR_GENE_PRODUCT", 336, 341], ["patients", "ORGANISM", 351, 359], ["platelet", "CELL_TYPE", 307, 315], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 351, 359], ["the viral loads", "TEST", 5, 20], ["the mean log viral load", "TEST", 61, 84], ["the mean log viral load", "TEST", 167, 190], ["this disease", "PROBLEM", 293, 305], ["platelet", "TEST", 307, 315], ["PLT) counts", "TEST", 317, 328], ["all SFTSV", "TEST", 332, 341], ["infected", "OBSERVATION_MODIFIER", 342, 350], ["normal range", "OBSERVATION_MODIFIER", 433, 445]]], ["The level of drop in PTL was similar between deceased patients and survivors ( Fig. 2A) .", [["PTL", "CANCER", 21, 24], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["drop in PTL", "PROBLEM", 13, 24], ["drop", "OBSERVATION_MODIFIER", 13, 17], ["PTL", "OBSERVATION", 21, 24]]], ["After patients were admitted to hospital, their PLT levels improved steadily, partially due to treatment.", [["patients", "ORGANISM", 6, 14], ["PLT", "PROTEIN", 48, 51], ["patients", "SPECIES", 6, 14], ["their PLT levels", "TEST", 42, 58], ["treatment", "TREATMENT", 95, 104]]], ["PLT levels returned to a normal range on Day 13 among the survivors while those who died did so before Day 9 of disease onset with low PLT levels.ResultsParallel to PLT, white blood cell (WBC) counts were also below the normal range (4.0-9.0610 9 /L) between 5-6 days after onset of fever but returned to normal around Day 9, earlier than PLT (Fig. 2B) .", [["white blood cell", "ANATOMY", 170, 186], ["WBC", "ANATOMY", 188, 191], ["fever", "DISEASE", 283, 288], ["PLT", "GENE_OR_GENE_PRODUCT", 0, 3], ["PLT", "GENE_OR_GENE_PRODUCT", 135, 138], ["PLT", "CELL", 165, 168], ["white blood cell", "CELL", 170, 186], ["WBC", "CELL", 188, 191], ["PLT", "PROTEIN", 0, 3], ["PLT", "PROTEIN", 135, 138], ["PLT", "CELL_TYPE", 165, 168], ["PLT", "PROTEIN", 339, 342], ["PLT levels", "TEST", 0, 10], ["disease onset", "PROBLEM", 112, 125], ["low PLT levels", "PROBLEM", 131, 145], ["PLT", "TEST", 165, 168], ["white blood cell", "TEST", 170, 186], ["WBC", "TEST", 188, 191], ["counts", "TEST", 193, 199], ["fever", "PROBLEM", 283, 288], ["PLT", "TEST", 339, 342], ["normal range", "OBSERVATION_MODIFIER", 25, 37], ["fever", "OBSERVATION", 283, 288], ["normal", "OBSERVATION", 305, 311]]], ["Interestingly, those who died had WBC counts within normal range, albeit at the lower end of the normal range.", [["WBC", "ANATOMY", 34, 37], ["WBC", "CELL", 34, 37], ["WBC counts", "TEST", 34, 44], ["normal range", "OBSERVATION_MODIFIER", 52, 64], ["lower", "ANATOMY_MODIFIER", 80, 85], ["normal range", "OBSERVATION", 97, 109]]], ["It is likely that these patients were admitted on Day 7, slightly later than many of the other patients, and their WBC went up further after admission.ResultsSFTSV-infected patients had acute tissue damage as indicated by multiple elevated key serum enzymes (Fig. 2C-F) .", [["WBC", "ANATOMY", 115, 118], ["tissue", "ANATOMY", 192, 198], ["serum", "ANATOMY", 244, 249], ["ResultsSFTSV-infected", "DISEASE", 151, 172], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 95, 103], ["WBC", "CELL", 115, 118], ["patients", "ORGANISM", 173, 181], ["tissue", "TISSUE", 192, 198], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["serum enzymes", "PROTEIN", 244, 257], ["Fig. 2C-F", "PROTEIN", 259, 268], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 173, 181], ["their WBC", "TEST", 109, 118], ["ResultsSFTSV", "TEST", 151, 163], ["acute tissue damage", "PROBLEM", 186, 205], ["multiple elevated key serum enzymes", "PROBLEM", 222, 257], ["is likely", "UNCERTAINTY", 3, 12], ["infected", "OBSERVATION", 164, 172], ["acute tissue", "OBSERVATION_MODIFIER", 186, 198], ["damage", "OBSERVATION", 199, 205]]], ["ALT, AST, CK, and LDH were all highly elevated in both deceased patients and survivors; levels in the deceased patients were significantly higher than those in the survivors (Fig. 2C-F, Table 2 ).", [["ALT", "SIMPLE_CHEMICAL", 0, 3], ["AST", "SIMPLE_CHEMICAL", 5, 8], ["CK", "GENE_OR_GENE_PRODUCT", 10, 12], ["LDH", "GENE_OR_GENE_PRODUCT", 18, 21], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 111, 119], ["ALT", "PROTEIN", 0, 3], ["AST", "PROTEIN", 5, 8], ["CK", "PROTEIN", 10, 12], ["LDH", "PROTEIN", 18, 21], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 111, 119], ["ALT", "TEST", 0, 3], ["AST", "TEST", 5, 8], ["CK", "TEST", 10, 12], ["LDH", "TEST", 18, 21], ["levels", "TEST", 88, 94]]], ["Our analysis further demonstrated that peak elevations were at the time of admission, about 5 days after the onset of symptoms.", [["Our analysis", "TEST", 0, 12], ["peak elevations", "PROBLEM", 39, 54], ["symptoms", "PROBLEM", 118, 126], ["peak", "OBSERVATION_MODIFIER", 39, 43], ["elevations", "OBSERVATION_MODIFIER", 44, 54]]], ["AST, CK, and LDH levels gradually declined among the survivors while ALT levels remained elevated for a longer time.", [["AST", "SIMPLE_CHEMICAL", 0, 3], ["CK", "GENE_OR_GENE_PRODUCT", 5, 7], ["LDH", "GENE_OR_GENE_PRODUCT", 13, 16], ["ALT", "SIMPLE_CHEMICAL", 69, 72], ["AST", "PROTEIN", 0, 3], ["CK", "PROTEIN", 5, 7], ["LDH", "PROTEIN", 13, 16], ["ALT", "PROTEIN", 69, 72], ["AST", "TEST", 0, 3], ["CK", "TEST", 5, 7], ["LDH levels", "TEST", 13, 23], ["ALT levels", "TEST", 69, 79], ["elevated", "PROBLEM", 89, 97]]], ["All four patients died before Day 9 from symptom onset while all these biomarkers were highly elevated.ResultsBecause it is suspected that virus-induced immunopathology may be involved in the tissue damage observed in both clinical presentation and abnormal lab tests, changes in important T cell subsets in SFTSV-infected patients were measured.", [["tissue", "ANATOMY", 192, 198], ["T cell", "ANATOMY", 290, 296], ["immunopathology", "DISEASE", 153, 168], ["SFTSV-infected", "DISEASE", 308, 322], ["patients", "ORGANISM", 9, 17], ["tissue", "TISSUE", 192, 198], ["T cell", "CELL", 290, 296], ["SFTSV", "GENE_OR_GENE_PRODUCT", 308, 313], ["patients", "ORGANISM", 323, 331], ["T cell subsets", "CELL_TYPE", 290, 304], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 323, 331], ["symptom onset", "PROBLEM", 41, 54], ["all these biomarkers", "TEST", 61, 81], ["highly elevated", "PROBLEM", 87, 102], ["virus", "PROBLEM", 139, 144], ["the tissue damage", "PROBLEM", 188, 205], ["abnormal lab tests", "PROBLEM", 249, 267], ["SFTSV", "PROBLEM", 308, 313], ["cell subsets", "OBSERVATION", 292, 304], ["infected", "OBSERVATION_MODIFIER", 314, 322]]], ["Both CD8+/ CD69+ and CD4+/CD69+ T cells were significantly elevated early in infection (Fig. 3A and 3B ).", [["CD8+/ CD69+ and CD4+/CD69+ T cells", "ANATOMY", 5, 39], ["infection", "DISEASE", 77, 86], ["CD8", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD69", "GENE_OR_GENE_PRODUCT", 11, 15], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD69", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD8", "PROTEIN", 5, 8], ["CD69", "PROTEIN", 11, 15], ["CD4", "PROTEIN", 21, 24], ["CD69", "PROTEIN", 26, 30], ["T cells", "CELL_TYPE", 32, 39], ["Both CD8", "TEST", 0, 8], ["CD69", "TEST", 11, 15], ["CD4", "TEST", 21, 24], ["CD69", "TEST", 26, 30], ["T cells", "PROBLEM", 32, 39], ["significantly elevated", "PROBLEM", 45, 67], ["infection", "PROBLEM", 77, 86], ["infection", "OBSERVATION", 77, 86]]], ["At Day 9 after disease onset, mean percentages of CD4+/CD69+ T cells were 3.62% in survivors and 10.52% in later deceased patients while the normal control group was 1.12%.", [["CD4+/CD69+ T cells", "ANATOMY", 50, 68], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD69", "GENE_OR_GENE_PRODUCT", 55, 59], ["patients", "ORGANISM", 122, 130], ["CD4", "PROTEIN", 50, 53], ["CD69", "PROTEIN", 55, 59], ["T cells", "CELL_TYPE", 61, 68], ["patients", "SPECIES", 122, 130], ["disease onset", "PROBLEM", 15, 28], ["mean percentages", "TEST", 30, 46], ["CD4", "TEST", 50, 53], ["CD69", "TEST", 55, 59], ["T cells", "TEST", 61, 68]]], ["CD8+/CD69+ T cells were 3.02% in survivors and 11.15% in later deceased patients while the normal control group was 0.51%.", [["CD8+/CD69+ T cells", "ANATOMY", 0, 18], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD69", "GENE_OR_GENE_PRODUCT", 5, 9], ["patients", "ORGANISM", 72, 80], ["CD8", "PROTEIN", 0, 3], ["CD69", "PROTEIN", 5, 9], ["T cells", "CELL_TYPE", 11, 18], ["patients", "SPECIES", 72, 80], ["CD8", "TEST", 0, 3], ["CD69", "TEST", 5, 9], ["T cells", "TEST", 11, 18], ["survivors", "TEST", 33, 42]]], ["Elevations in these T cells in later deceased patients were significantly higher than the elevation observed in survivors (p = 0.045 for CD4+/CD69+ T cells and p = 0.009 for CD8+/CD69+ T cells).", [["T cells", "ANATOMY", 20, 27], ["CD4+/CD69+ T cells", "ANATOMY", 137, 155], ["CD8+/CD69+ T cells", "ANATOMY", 174, 192], ["T cells", "CELL", 20, 27], ["patients", "ORGANISM", 46, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 137, 140], ["CD69", "GENE_OR_GENE_PRODUCT", 142, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 174, 177], ["CD69", "GENE_OR_GENE_PRODUCT", 179, 183], ["T cells", "CELL_TYPE", 20, 27], ["CD4", "PROTEIN", 137, 140], ["CD69", "PROTEIN", 142, 146], ["T cells", "CELL_TYPE", 148, 155], ["CD8", "PROTEIN", 174, 177], ["CD69", "PROTEIN", 179, 183], ["T cells", "CELL_TYPE", 185, 192], ["patients", "SPECIES", 46, 54], ["Elevations in these T cells", "PROBLEM", 0, 27], ["CD4", "TEST", 137, 140], ["CD69", "TEST", 142, 146], ["T cells", "TEST", 148, 155], ["p", "TEST", 160, 161], ["CD8", "TEST", 174, 177], ["CD69", "TEST", 179, 183], ["significantly", "OBSERVATION_MODIFIER", 60, 73], ["higher", "OBSERVATION_MODIFIER", 74, 80], ["elevation", "OBSERVATION", 90, 99]]], ["These T cells gradually returned to normal levels in survivors around 2 weeks after disease onset.ResultsHLA-DR+ T cells were also measured ( Fig. 3C and 3D ).", [["T cells", "ANATOMY", 6, 13], ["ResultsHLA-DR+ T cells", "ANATOMY", 98, 120], ["T cells", "CELL", 6, 13], ["ResultsHLA-DR", "GENE_OR_GENE_PRODUCT", 98, 111], ["T cells", "CELL_TYPE", 6, 13], ["ResultsHLA-DR+ T cells", "CELL_LINE", 98, 120], ["These T cells", "TEST", 0, 13], ["disease onset", "PROBLEM", 84, 97], ["ResultsHLA", "TEST", 98, 108]]], ["The deceased patients had an early elevation of CD8+/HLA-DR+ T cells while these cells went up later among survivors, reaching peak levels at Day 13 after disease onset before coming down, although remaining higher than the normal control group (p,0.001).", [["CD8+/HLA-DR+ T cells", "ANATOMY", 48, 68], ["cells", "ANATOMY", 81, 86], ["patients", "ORGANISM", 13, 21], ["CD8", "GENE_OR_GENE_PRODUCT", 48, 51], ["cells", "CELL", 81, 86], ["CD8", "PROTEIN", 48, 51], ["DR", "PROTEIN", 57, 59], ["T cells", "CELL_TYPE", 61, 68], ["patients", "SPECIES", 13, 21], ["an early elevation", "PROBLEM", 26, 44], ["CD8", "TEST", 48, 51], ["HLA", "TEST", 53, 56], ["T cells", "PROBLEM", 61, 68], ["these cells", "PROBLEM", 75, 86], ["peak levels", "TEST", 127, 138], ["disease onset", "PROBLEM", 155, 168], ["early", "OBSERVATION_MODIFIER", 29, 34], ["elevation", "OBSERVATION_MODIFIER", 35, 44], ["higher", "OBSERVATION_MODIFIER", 208, 214], ["normal", "OBSERVATION", 224, 230]]], ["In contrast, CD4+/HLA-DR+ CD4 T cells went up at the same time for both survivors and deceased patients, and the levels continued to go up through the entire study period for survivors and were also much higher than observed for the normal control group (p = 0.039).", [["CD4+/HLA-DR+ CD4 T cells", "ANATOMY", 13, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 95, 103], ["CD4", "PROTEIN", 13, 16], ["DR", "PROTEIN", 22, 24], ["CD4 T cells", "CELL_TYPE", 26, 37], ["patients", "SPECIES", 95, 103], ["CD4", "TEST", 13, 16], ["HLA", "TEST", 18, 21], ["CD4 T cells", "PROBLEM", 26, 37], ["the levels", "TEST", 109, 119]]], ["CTLA4+ T cells showed a different pattern.", [["CTLA4+ T cells", "ANATOMY", 0, 14], ["CTLA4", "GENE_OR_GENE_PRODUCT", 0, 5], ["CTLA4", "PROTEIN", 0, 5], ["T cells", "CELL_TYPE", 7, 14], ["CTLA4+ T cells", "TEST", 0, 14], ["different pattern", "OBSERVATION", 24, 41]]], ["Both CD8+/ CTLA4+ and CD4+/CTLA4+T cells went up around Day 11-13 from disease onset ( Fig. 3E and 3F ) and continued to go higher than observed in the normal control group during the remaining study period (p,0.001).", [["CD8+/ CTLA4+", "ANATOMY", 5, 17], ["CD4+/CTLA4+T cells", "ANATOMY", 22, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 5, 8], ["CTLA4", "GENE_OR_GENE_PRODUCT", 11, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 22, 25], ["CTLA4", "GENE_OR_GENE_PRODUCT", 27, 32], ["CD8", "PROTEIN", 5, 8], ["CTLA4", "PROTEIN", 11, 16], ["CD4", "PROTEIN", 22, 25], ["CTLA4", "PROTEIN", 27, 32], ["T cells", "CELL_TYPE", 33, 40], ["Both CD8", "TEST", 0, 8], ["CTLA4", "TEST", 11, 16], ["CD4", "TEST", 22, 25], ["CTLA4", "TEST", 27, 32], ["T cells", "TEST", 33, 40], ["CTLA4", "ANATOMY", 11, 16], ["CTLA4", "ANATOMY", 27, 32], ["normal", "OBSERVATION", 152, 158]]], ["For deceased patients, they died around Day 9 so CTLA4+ T cell levels were not significantly elevated.", [["T cell", "ANATOMY", 56, 62], ["patients", "ORGANISM", 13, 21], ["CTLA4", "GENE_OR_GENE_PRODUCT", 49, 54], ["T cell", "CELL", 56, 62], ["CTLA4", "PROTEIN", 49, 54], ["patients", "SPECIES", 13, 21], ["T cell levels", "TEST", 56, 69], ["significantly elevated", "PROBLEM", 79, 101]]], ["CD28+ T cells were also measured but no significant differences were observed between SFTSV-infected patients and healthy donors (data not shown).ResultsSpecific cytokines were measured further to identify those that may be involved in the pathogenesis of SFTS.", [["CD28+ T cells", "ANATOMY", 0, 13], ["SFTSV-infected", "DISEASE", 86, 100], ["SFTS", "DISEASE", 256, 260], ["CD28", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 101, 109], ["donors", "ORGANISM", 122, 128], ["SFTS", "CANCER", 256, 260], ["CD28", "PROTEIN", 0, 4], ["T cells", "CELL_TYPE", 6, 13], ["cytokines", "PROTEIN", 162, 171], ["patients", "SPECIES", 101, 109], ["CD28", "TEST", 0, 4], ["T cells", "TEST", 6, 13], ["significant differences", "PROBLEM", 40, 63], ["ResultsSpecific cytokines", "TEST", 146, 171], ["SFTS", "PROBLEM", 256, 260], ["no", "UNCERTAINTY", 37, 39], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["SFTS", "OBSERVATION", 256, 260]]], ["Among the seven cytokines measured in this study, there were no significant differences for IL-2, IL-4, TNF-a, or IL-17A in serum samples between SFTSV-infected patients (both deceased and survivors) and the normal control group (Fig. 4A) .", [["serum samples", "ANATOMY", 124, 137], ["SFTSV-infected", "DISEASE", 146, 160], ["IL-2", "GENE_OR_GENE_PRODUCT", 92, 96], ["IL-4", "GENE_OR_GENE_PRODUCT", 98, 102], ["TNF-a", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-17A", "GENE_OR_GENE_PRODUCT", 114, 120], ["serum samples", "ORGANISM_SUBSTANCE", 124, 137], ["SFTSV", "ORGANISM", 146, 151], ["patients", "ORGANISM", 161, 169], ["cytokines", "PROTEIN", 16, 25], ["TNF", "PROTEIN", 104, 107], ["IL-17A", "PROTEIN", 114, 120], ["patients", "SPECIES", 161, 169], ["this study", "TEST", 38, 48], ["IL", "TEST", 92, 94], ["IL", "TEST", 98, 100], ["TNF", "TEST", 104, 107], ["IL", "TEST", 114, 116], ["serum samples", "TEST", 124, 137], ["SFTSV", "TEST", 146, 151], ["no", "UNCERTAINTY", 61, 63], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["SFTSV", "ANATOMY", 146, 151], ["normal", "OBSERVATION", 208, 214]]], ["However, significant elevations of serum IL-6, IL-10, and IFN-c were discovered in deceased patients, not only compared to the normal control group but also to survivors (Fig. 4B) .", [["serum", "ANATOMY", 35, 40], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-10", "GENE_OR_GENE_PRODUCT", 47, 52], ["IFN-c", "GENE_OR_GENE_PRODUCT", 58, 63], ["patients", "ORGANISM", 92, 100], ["serum IL-6", "PROTEIN", 35, 45], ["IL", "PROTEIN", 47, 49], ["IFN", "PROTEIN", 58, 61], ["patients", "SPECIES", 92, 100], ["significant elevations", "PROBLEM", 9, 31], ["serum IL", "TEST", 35, 43], ["IL", "TEST", 47, 49], ["IFN", "TEST", 58, 61], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["elevations", "OBSERVATION_MODIFIER", 21, 31]]], ["For survivors, both IL-6 and IL-10 were elevated but significantly only compared to the normal control group for IL-10 ( Fig. 4B, Table 2 ).", [["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 113, 118], ["IL-6", "PROTEIN", 20, 24], ["IL", "PROTEIN", 29, 31], ["IL", "PROTEIN", 113, 115], ["survivors", "TEST", 4, 13], ["both IL", "TEST", 15, 22], ["IL", "TEST", 29, 31], ["IL", "TEST", 113, 115]]], ["IFN-c was actually lower in the survivors compared to the normal control group (Fig. 4B) .", [["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "PROTEIN", 0, 3], ["IFN", "TEST", 0, 3], ["lower", "OBSERVATION_MODIFIER", 19, 24]]], ["When the kinetics of these three elevated cytokines were monitored, IL-6 and IL-10 levels showed an upward trend for the deceased patients; however, in survivors, levels slowly returned to normal levels (Fig. 5) .", [["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 77, 82], ["patients", "ORGANISM", 130, 138], ["cytokines", "PROTEIN", 42, 51], ["patients", "SPECIES", 130, 138], ["these three elevated cytokines", "PROBLEM", 21, 51], ["IL", "TEST", 68, 70], ["IL", "TEST", 77, 79], ["levels", "TEST", 163, 169]]], ["IFN-c went down for both deceased patients and survivors.DiscussionSFTS, which has a 12-30% mortality rate, is one of the most severe emerging human infectious diseases in China after severe acute respiratory syndrome (SARS) and avian influenza in the new millennium.", [["infectious diseases", "DISEASE", 149, 168], ["acute respiratory syndrome", "DISEASE", 191, 217], ["SARS", "DISEASE", 219, 223], ["avian influenza", "DISEASE", 229, 244], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 34, 42], ["human", "ORGANISM", 143, 148], ["IFN", "PROTEIN", 0, 3], ["patients", "SPECIES", 34, 42], ["human", "SPECIES", 143, 148], ["avian influenza", "SPECIES", 229, 244], ["human", "SPECIES", 143, 148], ["human infectious diseases", "PROBLEM", 143, 168], ["severe acute respiratory syndrome", "PROBLEM", 184, 217], ["SARS", "PROBLEM", 219, 223], ["avian influenza in the new millennium", "PROBLEM", 229, 266], ["infectious", "OBSERVATION", 149, 159], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["respiratory syndrome", "OBSERVATION", 197, 217]]], ["While previous studies have documented the overall levels of viral load, changes in key lab results, and certain immunological biomarkers in SFTS patients at a few select time points, there is no report on the concurrent measurement of key abnormal findings over the critical acute phase of SFTS after infection, and no further analysis to relate these dynamic changes to the severity and course of the disease.DiscussionAlthough thrombocytopenia is a key abnormal finding in SFTS, its levels in both deceased patients and survivors were very similar in our analysis, and thus, may not be directly related to disease severity and death.", [["SFTS", "DISEASE", 141, 145], ["SFTS", "DISEASE", 291, 295], ["infection", "DISEASE", 302, 311], ["thrombocytopenia", "DISEASE", 430, 446], ["death", "DISEASE", 630, 635], ["patients", "ORGANISM", 146, 154], ["SFTS", "CANCER", 291, 295], ["SFTS", "CANCER", 476, 480], ["patients", "ORGANISM", 510, 518], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 510, 518], ["previous studies", "TEST", 6, 22], ["viral load", "PROBLEM", 61, 71], ["key abnormal findings", "PROBLEM", 236, 257], ["infection", "PROBLEM", 302, 311], ["further analysis", "TEST", 320, 336], ["the disease", "PROBLEM", 399, 410], ["thrombocytopenia", "PROBLEM", 430, 446], ["a key abnormal finding in SFTS", "PROBLEM", 450, 480], ["our analysis", "TEST", 554, 566], ["disease severity", "PROBLEM", 609, 625], ["death", "PROBLEM", 630, 635], ["viral load", "OBSERVATION", 61, 71], ["acute phase", "OBSERVATION_MODIFIER", 276, 287], ["infection", "OBSERVATION", 302, 311], ["disease", "OBSERVATION", 403, 410], ["thrombocytopenia", "OBSERVATION", 430, 446]]], ["In contrast, the level of SFTSV viremia is correlated to disease severity with significantly higher levels in the deceased patients than in the survivors when measured on Days 7-9 after onset of fever.", [["viremia", "DISEASE", 32, 39], ["fever", "DISEASE", 195, 200], ["SFTSV", "GENE_OR_GENE_PRODUCT", 26, 31], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["SFTSV viremia", "PROBLEM", 26, 39], ["disease severity", "PROBLEM", 57, 73], ["fever", "PROBLEM", 195, 200], ["SFTSV viremia", "OBSERVATION", 26, 39], ["significantly", "OBSERVATION_MODIFIER", 79, 92], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["levels", "OBSERVATION_MODIFIER", 100, 106], ["fever", "OBSERVATION", 195, 200]]], ["Viral loads gradually dropped among survivors during the recovery phase.", [["Viral", "ORGANISM", 0, 5], ["Viral loads", "TEST", 0, 11]]], ["The finding is consistent with other reports that the SFTSV viral load is related to disease severity [6] .", [["SFTSV viral", "ORGANISM", 54, 65], ["SFTSV", "SPECIES", 54, 59], ["the SFTSV viral load", "PROBLEM", 50, 70], ["disease severity", "PROBLEM", 85, 101], ["consistent with", "UNCERTAINTY", 15, 30], ["SFTSV", "OBSERVATION", 54, 59], ["viral load", "OBSERVATION", 60, 70]]], ["SFTSV infection causes tissue injury and organ damage, which can lead to elevated serum enzymatic markers and death.", [["tissue", "ANATOMY", 23, 29], ["organ", "ANATOMY", 41, 46], ["serum", "ANATOMY", 82, 87], ["SFTSV", "CHEMICAL", 0, 5], ["infection", "DISEASE", 6, 15], ["tissue injury", "DISEASE", 23, 36], ["organ damage", "DISEASE", 41, 53], ["death", "DISEASE", 110, 115], ["tissue", "TISSUE", 23, 29], ["organ", "ORGAN", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["serum enzymatic markers", "PROTEIN", 82, 105], ["SFTSV", "SPECIES", 0, 5], ["SFTSV infection", "PROBLEM", 0, 15], ["tissue injury", "PROBLEM", 23, 36], ["organ damage", "PROBLEM", 41, 53], ["elevated serum enzymatic markers", "PROBLEM", 73, 105], ["death", "PROBLEM", 110, 115], ["infection", "OBSERVATION", 6, 15], ["injury", "OBSERVATION", 30, 36], ["organ", "ANATOMY", 41, 46], ["damage", "OBSERVATION", 47, 53]]], ["In all SFTSV-infected patients, ALT, AST, LDH, and CK were all elevated above the normal range especially during the acute phase of the disease, and their peak levels in deceased patients were significantly higher than in survivors, which is similar to other reports [6, 14] [10].", [["SFTSV-infected", "DISEASE", 7, 21], ["SFTSV", "GENE_OR_GENE_PRODUCT", 7, 12], ["patients", "ORGANISM", 22, 30], ["ALT", "SIMPLE_CHEMICAL", 32, 35], ["AST", "SIMPLE_CHEMICAL", 37, 40], ["LDH", "GENE_OR_GENE_PRODUCT", 42, 45], ["CK", "GENE_OR_GENE_PRODUCT", 51, 53], ["patients", "ORGANISM", 179, 187], ["ALT", "PROTEIN", 32, 35], ["AST", "PROTEIN", 37, 40], ["LDH", "PROTEIN", 42, 45], ["CK", "PROTEIN", 51, 53], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 179, 187], ["SFTSV", "SPECIES", 7, 12], ["all SFTSV", "TEST", 3, 12], ["ALT", "TEST", 32, 35], ["AST", "TEST", 37, 40], ["LDH", "TEST", 42, 45], ["CK", "TEST", 51, 53], ["the disease", "PROBLEM", 132, 143], ["their peak levels", "TEST", 149, 166], ["all", "OBSERVATION_MODIFIER", 3, 6], ["SFTSV", "OBSERVATION", 7, 12], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["LDH", "ANATOMY", 42, 45], ["normal range", "OBSERVATION_MODIFIER", 82, 94], ["disease", "OBSERVATION", 136, 143], ["significantly", "OBSERVATION_MODIFIER", 193, 206], ["higher", "OBSERVATION_MODIFIER", 207, 213]]], ["On the other hand, our kinetics analysis discovered that ALT was the last one to come down while AST, LDH and CK started to decrease among survivors very early after their admission to the hospital.", [["ALT", "SIMPLE_CHEMICAL", 57, 60], ["AST", "SIMPLE_CHEMICAL", 97, 100], ["LDH", "GENE_OR_GENE_PRODUCT", 102, 105], ["CK", "GENE_OR_GENE_PRODUCT", 110, 112], ["AST", "PROTEIN", 97, 100], ["LDH", "PROTEIN", 102, 105], ["CK", "PROTEIN", 110, 112], ["our kinetics analysis", "TEST", 19, 40], ["ALT", "TEST", 57, 60], ["AST", "TEST", 97, 100], ["LDH", "TEST", 102, 105], ["CK", "TEST", 110, 112]]], ["These lab tests may serve great value for the clinical prognosis of SFTSV-infected patients.", [["SFTSV-infected", "DISEASE", 68, 82], ["SFTSV", "CANCER", 68, 73], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["SFTSV", "SPECIES", 68, 73], ["These lab tests", "TEST", 0, 15], ["SFTSV", "PROBLEM", 68, 73], ["SFTSV", "OBSERVATION", 68, 73], ["infected", "OBSERVATION", 74, 82]]], ["The human immune system responds powerfully to a major viral infection such as SFTSV.", [["immune system", "ANATOMY", 10, 23], ["viral infection", "DISEASE", 55, 70], ["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["a major viral infection", "PROBLEM", 47, 70], ["SFTSV", "PROBLEM", 79, 84], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70], ["SFTSV", "OBSERVATION", 79, 84]]], ["Previous studies found that total CD3+ T cells and total CD4+ T cells were decreased in SFTSVinfected patients, more so during acute phase infection, in severe cases, and in those who eventually die from the disease [11] .", [["CD3+ T cells", "ANATOMY", 34, 46], ["CD4+ T cells", "ANATOMY", 57, 69], ["infection", "DISEASE", 139, 148], ["CD3", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["patients", "ORGANISM", 102, 110], ["CD3", "PROTEIN", 34, 37], ["T cells", "CELL_TYPE", 39, 46], ["CD4+ T cells", "CELL_TYPE", 57, 69], ["patients", "SPECIES", 102, 110], ["Previous studies", "TEST", 0, 16], ["total CD3", "TEST", 28, 37], ["T cells", "PROBLEM", 39, 46], ["total CD4", "TEST", 51, 60], ["T cells", "PROBLEM", 62, 69], ["acute phase infection", "PROBLEM", 127, 148], ["the disease", "PROBLEM", 204, 215], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["acute phase", "OBSERVATION_MODIFIER", 127, 138], ["infection", "OBSERVATION", 139, 148], ["severe", "OBSERVATION_MODIFIER", 153, 159]]], ["At the same time, there is no significant change in CD8+ T cells [11, 14] .", [["CD8+ T cells", "ANATOMY", 52, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 52, 55], ["CD8", "PROTEIN", 52, 55], ["T cells", "CELL_TYPE", 57, 64], ["significant change in CD8+ T cells", "PROBLEM", 30, 64], ["no", "UNCERTAINTY", 27, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["change", "OBSERVATION", 42, 48]]], ["Because the measurement of serum cytokines in SFTSV-infected patients in previous studies actually showed increased levels consistent with a cytokine storm as expected in a typical major viral infection, the above data of total T cells was surprising.", [["serum", "ANATOMY", 27, 32], ["T cells", "ANATOMY", 228, 235], ["SFTSV-infected", "DISEASE", 46, 60], ["viral infection", "DISEASE", 187, 202], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["SFTSV", "GENE_OR_GENE_PRODUCT", 46, 51], ["patients", "ORGANISM", 61, 69], ["T cells", "CELL", 228, 235], ["serum cytokines", "PROTEIN", 27, 42], ["cytokine", "PROTEIN", 141, 149], ["total T cells", "CELL_TYPE", 222, 235], ["patients", "SPECIES", 61, 69], ["serum cytokines", "TEST", 27, 42], ["SFTSV", "PROBLEM", 46, 51], ["previous studies", "TEST", 73, 89], ["increased levels", "PROBLEM", 106, 122], ["a cytokine storm", "PROBLEM", 139, 155], ["a typical major viral infection", "PROBLEM", 171, 202], ["total T cells", "PROBLEM", 222, 235], ["SFTSV", "OBSERVATION", 46, 51], ["infected", "OBSERVATION_MODIFIER", 52, 60], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["consistent with", "UNCERTAINTY", 123, 138], ["cytokine storm", "OBSERVATION", 141, 155], ["typical", "OBSERVATION_MODIFIER", 173, 180], ["major", "OBSERVATION_MODIFIER", 181, 186], ["viral", "OBSERVATION_MODIFIER", 187, 192], ["infection", "OBSERVATION", 193, 202]]], ["In the current study, change within subpopulations of T cells was investigated and profound T cell activation was discovered.DiscussionThree subsets of T cells (CD69+, HLA-DR+ and CTLA4+) were found elevated in SFTSV-infected patients but their changes happened at different phases of progression of the disease.", [["T cells", "ANATOMY", 54, 61], ["T cell", "ANATOMY", 92, 98], ["T cells", "ANATOMY", 152, 159], ["SFTSV-infected", "DISEASE", 211, 225], ["T cells", "CELL", 54, 61], ["T cell", "CELL", 92, 98], ["T cells", "CELL", 152, 159], ["CD69", "GENE_OR_GENE_PRODUCT", 161, 165], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 168, 174], ["CTLA4", "GENE_OR_GENE_PRODUCT", 180, 185], ["SFTSV", "CANCER", 211, 216], ["patients", "ORGANISM", 226, 234], ["T cells", "CELL_TYPE", 54, 61], ["T cells", "CELL_TYPE", 152, 159], ["CD69", "PROTEIN", 161, 165], ["HLA", "PROTEIN", 168, 171], ["DR", "PROTEIN", 172, 174], ["CTLA4", "PROTEIN", 180, 185], ["patients", "SPECIES", 226, 234], ["SFTSV", "SPECIES", 211, 216], ["the current study", "TEST", 3, 20], ["T cells", "PROBLEM", 54, 61], ["profound T cell activation", "PROBLEM", 83, 109], ["T cells", "TEST", 152, 159], ["CD69", "TEST", 161, 165], ["HLA", "TEST", 168, 171], ["DR", "TEST", 172, 174], ["CTLA4", "TEST", 180, 185], ["SFTSV", "PROBLEM", 211, 216], ["the disease", "PROBLEM", 300, 311], ["subpopulations", "OBSERVATION_MODIFIER", 36, 50], ["profound", "OBSERVATION_MODIFIER", 83, 91], ["T cell activation", "OBSERVATION", 92, 109], ["elevated", "OBSERVATION_MODIFIER", 199, 207], ["SFTSV", "OBSERVATION", 211, 216], ["infected", "OBSERVATION_MODIFIER", 217, 225], ["progression", "OBSERVATION_MODIFIER", 285, 296], ["disease", "OBSERVATION", 304, 311]]], ["CD69 molecule is a human transmembrane C-Type lectin protein and T cell early activation marker; CD69+ T cells (both CD8+ and CD4+) were elevated during the acute phase of SFTSV infection with significant activation in the deceased patients compared to the survivors at time points of the peak viremia.", [["transmembrane", "ANATOMY", 25, 38], ["T cell", "ANATOMY", 65, 71], ["CD69+ T cells", "ANATOMY", 97, 110], ["CD8+", "ANATOMY", 117, 121], ["infection", "DISEASE", 178, 187], ["viremia", "DISEASE", 294, 301], ["CD69", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 19, 24], ["C-Type lectin", "GENE_OR_GENE_PRODUCT", 39, 52], ["T cell", "CELL", 65, 71], ["CD69", "GENE_OR_GENE_PRODUCT", 97, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 126, 129], ["SFTSV", "CANCER", 172, 177], ["patients", "ORGANISM", 232, 240], ["CD69 molecule", "PROTEIN", 0, 13], ["human transmembrane C-Type lectin protein", "PROTEIN", 19, 60], ["T cell early activation marker", "PROTEIN", 65, 95], ["CD69", "PROTEIN", 97, 101], ["T cells", "CELL_TYPE", 103, 110], ["CD8", "PROTEIN", 117, 120], ["CD4", "PROTEIN", 126, 129], ["human", "SPECIES", 19, 24], ["patients", "SPECIES", 232, 240], ["human", "SPECIES", 19, 24], ["SFTSV", "SPECIES", 172, 177], ["CD69 molecule", "TEST", 0, 13], ["a human transmembrane C", "TEST", 17, 40], ["Type lectin protein", "TEST", 41, 60], ["T cell early activation marker", "TEST", 65, 95], ["CD69", "TEST", 97, 101], ["T cells", "TEST", 103, 110], ["CD8", "TEST", 117, 120], ["CD4", "TEST", 126, 129], ["SFTSV infection", "PROBLEM", 172, 187], ["the peak viremia", "PROBLEM", 285, 301], ["acute phase", "OBSERVATION_MODIFIER", 157, 168], ["SFTSV infection", "OBSERVATION", 172, 187], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["activation", "OBSERVATION", 205, 215], ["peak viremia", "OBSERVATION", 289, 301]]], ["This T cell subpopulation in survivors gradually decreased to normal levels and was comparable to healthy donors in 2 weeks.DiscussionIn contrast, HLA-DR+ (a MHC class II cell surface receptor) and CTLA4+ (a member of the immunoglobulin superfamily on the surface of helper T cells) T cells (both CD4+ and CD8+) were elevated during the recovery phase (after the peak viremia) in the survivors.", [["T cell", "ANATOMY", 5, 11], ["cell surface", "ANATOMY", 171, 183], ["surface", "ANATOMY", 256, 263], ["helper T cells", "ANATOMY", 267, 281], ["T cells", "ANATOMY", 283, 290], ["CD4+", "ANATOMY", 297, 301], ["viremia", "DISEASE", 368, 375], ["T cell", "CELL", 5, 11], ["donors", "ORGANISM", 106, 112], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 147, 153], ["MHC class II cell surface receptor", "GENE_OR_GENE_PRODUCT", 158, 192], ["CTLA4", "GENE_OR_GENE_PRODUCT", 198, 203], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 222, 236], ["surface", "CELLULAR_COMPONENT", 256, 263], ["helper T cells", "CELL", 267, 281], ["T cells", "CELL", 283, 290], ["CD4", "GENE_OR_GENE_PRODUCT", 297, 300], ["CD8", "GENE_OR_GENE_PRODUCT", 306, 309], ["T cell subpopulation", "CELL_TYPE", 5, 25], ["HLA", "PROTEIN", 147, 150], ["DR", "PROTEIN", 151, 153], ["MHC class II cell surface receptor", "PROTEIN", 158, 192], ["CTLA4", "PROTEIN", 198, 203], ["immunoglobulin superfamily", "PROTEIN", 222, 248], ["helper T cells", "CELL_TYPE", 267, 281], ["T cells", "CELL_TYPE", 283, 290], ["CD4", "PROTEIN", 297, 300], ["CD8", "PROTEIN", 306, 309], ["CTLA4", "TEST", 198, 203], ["T cells", "TEST", 283, 290], ["CD4", "TEST", 297, 300], ["CD8", "TEST", 306, 309], ["the peak viremia", "PROBLEM", 359, 375], ["subpopulation", "OBSERVATION_MODIFIER", 12, 25]]], ["These cells were low and only measured during the acute phase of infection for the deceased patients; however, HLA-DR+/CD8+ T cells were significantly elevated.DiscussionAn increase in HLA-DR+ T cells is often in response to antigen binding and signaling.", [["cells", "ANATOMY", 6, 11], ["HLA-DR+/CD8+", "ANATOMY", 111, 123], ["T cells", "ANATOMY", 124, 131], ["HLA-DR+ T cells", "ANATOMY", 185, 200], ["infection", "DISEASE", 65, 74], ["cells", "CELL", 6, 11], ["patients", "ORGANISM", 92, 100], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 111, 117], ["CD8", "GENE_OR_GENE_PRODUCT", 119, 122], ["T cells", "CELL", 124, 131], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 185, 191], ["DR", "PROTEIN", 115, 117], ["CD8", "PROTEIN", 119, 122], ["T cells", "CELL_TYPE", 124, 131], ["HLA-DR+ T cells", "CELL_LINE", 185, 200], ["patients", "SPECIES", 92, 100], ["These cells", "TEST", 0, 11], ["infection", "PROBLEM", 65, 74], ["HLA", "TEST", 111, 114], ["T cells", "TEST", 124, 131], ["significantly elevated", "PROBLEM", 137, 159], ["HLA", "TEST", 185, 188], ["antigen binding", "TEST", 225, 240], ["low", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 65, 74]]], ["These cells bind to antigens on the surface of B cells, stimulating B cell proliferation.", [["cells", "ANATOMY", 6, 11], ["surface", "ANATOMY", 36, 43], ["B cells", "ANATOMY", 47, 54], ["B cell", "ANATOMY", 68, 74], ["cells", "CELL", 6, 11], ["surface", "CELLULAR_COMPONENT", 36, 43], ["B cells", "CELL", 47, 54], ["B cell", "CELL", 68, 74], ["antigens", "PROTEIN", 20, 28], ["B cells", "CELL_TYPE", 47, 54], ["These cells bind", "PROBLEM", 0, 16], ["B cells", "TREATMENT", 47, 54], ["stimulating B cell proliferation", "PROBLEM", 56, 88], ["B cells", "OBSERVATION", 47, 54], ["stimulating B cell proliferation", "OBSERVATION", 56, 88]]], ["CTLA4 is a T-cell costimulatory molecule on antigen-presenting cells and transmits an inhibitory signal to T cells.", [["T-cell", "ANATOMY", 11, 17], ["antigen-presenting cells", "ANATOMY", 44, 68], ["T cells", "ANATOMY", 107, 114], ["CTLA4", "GENE_OR_GENE_PRODUCT", 0, 5], ["T-cell costimulatory", "GENE_OR_GENE_PRODUCT", 11, 31], ["cells", "CELL", 63, 68], ["T cells", "CELL", 107, 114], ["CTLA4", "PROTEIN", 0, 5], ["T-cell costimulatory molecule", "PROTEIN", 11, 40], ["antigen-presenting cells", "CELL_TYPE", 44, 68], ["T cells", "CELL_TYPE", 107, 114]]], ["HLA-DR and CTLA4 may serve as upregulation markers in the recovery phase and may have a role in checking and re-balancing the lymphocytes once the viral infection is under control.", [["lymphocytes", "ANATOMY", 126, 137], ["viral infection", "DISEASE", 147, 162], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 0, 6], ["CTLA4", "GENE_OR_GENE_PRODUCT", 11, 16], ["lymphocytes", "CELL", 126, 137], ["DR", "PROTEIN", 4, 6], ["CTLA4", "PROTEIN", 11, 16], ["lymphocytes", "CELL_TYPE", 126, 137], ["CTLA4", "TREATMENT", 11, 16], ["upregulation markers", "TEST", 30, 50], ["the lymphocytes", "PROBLEM", 122, 137], ["the viral infection", "PROBLEM", 143, 162], ["lymphocytes", "ANATOMY", 126, 137], ["viral", "OBSERVATION_MODIFIER", 147, 152], ["infection", "OBSERVATION", 153, 162]]], ["Taken together, our data imply that an increase inCD69+ T cells may be related to pathogenesis while a late increase in HLA-DR+ and CTLA4+ T cells may indicate the induction of protective immune responses.DiscussionAs reported in SARS [17] and pandemic influenza cases [18, 19] , patients infected with SFTSV also mounted an exaggerated immune response; furthermore, cytokine storm (hypercytokinemia) was responsible for significant damage to body tissues and organs, potentially resulting in death.", [["T cells", "ANATOMY", 56, 63], ["T cells", "ANATOMY", 139, 146], ["body tissues", "ANATOMY", 443, 455], ["organs", "ANATOMY", 460, 466], ["SARS", "DISEASE", 230, 234], ["influenza", "DISEASE", 253, 262], ["hypercytokinemia", "DISEASE", 383, 399], ["death", "DISEASE", 493, 498], ["inCD69", "GENE_OR_GENE_PRODUCT", 48, 54], ["T cells", "CELL", 56, 63], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 120, 126], ["CTLA4", "GENE_OR_GENE_PRODUCT", 132, 137], ["T cells", "CELL", 139, 146], ["patients", "ORGANISM", 280, 288], ["body tissues", "TISSUE", 443, 455], ["organs", "ORGAN", 460, 466], ["inCD69", "PROTEIN", 48, 54], ["T cells", "CELL_TYPE", 56, 63], ["DR", "PROTEIN", 124, 126], ["CTLA4", "PROTEIN", 132, 137], ["T cells", "CELL_TYPE", 139, 146], ["cytokine", "PROTEIN", 367, 375], ["patients", "SPECIES", 280, 288], ["SFTSV", "SPECIES", 303, 308], ["pathogenesis", "PROBLEM", 82, 94], ["a late increase", "PROBLEM", 101, 116], ["HLA", "TEST", 120, 123], ["CTLA4", "PROBLEM", 132, 137], ["pandemic influenza cases", "PROBLEM", 244, 268], ["SFTSV", "PROBLEM", 303, 308], ["an exaggerated immune response", "PROBLEM", 322, 352], ["cytokine storm (hypercytokinemia", "PROBLEM", 367, 399], ["significant damage to body tissues", "PROBLEM", 421, 455], ["death", "PROBLEM", 493, 498], ["may be related to", "UNCERTAINTY", 64, 81], ["late", "OBSERVATION_MODIFIER", 103, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["SFTSV", "OBSERVATION", 303, 308], ["exaggerated", "OBSERVATION_MODIFIER", 325, 336], ["immune response", "OBSERVATION", 337, 352], ["significant", "OBSERVATION_MODIFIER", 421, 432], ["damage", "OBSERVATION", 433, 439], ["body tissues", "ANATOMY", 443, 455], ["organs", "ANATOMY", 460, 466]]], ["In our study, both proinflammatory cytokines (such as IL-6 and IFN-c) and antiinflammatory cytokines (such as IL-10) were elevated in SFTSVinfected patients and levels were dramatically higher in the deceased patients, which is similar to reports by other groups [6, 10] .", [["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["IFN-c", "GENE_OR_GENE_PRODUCT", 63, 68], ["IL-10", "GENE_OR_GENE_PRODUCT", 110, 115], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 209, 217], ["proinflammatory cytokines", "PROTEIN", 19, 44], ["IL-6", "PROTEIN", 54, 58], ["IFN", "PROTEIN", 63, 66], ["antiinflammatory cytokines", "PROTEIN", 74, 100], ["IL", "PROTEIN", 110, 112], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 209, 217], ["our study", "TEST", 3, 12], ["both proinflammatory cytokines", "TREATMENT", 14, 44], ["IL", "TEST", 54, 56], ["IFN-c)", "TREATMENT", 63, 69], ["antiinflammatory cytokines", "TREATMENT", 74, 100], ["IL", "TEST", 110, 112], ["proinflammatory cytokines", "OBSERVATION", 19, 44], ["dramatically", "OBSERVATION_MODIFIER", 173, 185], ["higher", "OBSERVATION_MODIFIER", 186, 192]]], ["More significantly, IL-6 and IL-10 were persistently elevated in the deceased patients while levels trended down in survivors, indicating the possibility of using them as biomarkers to monitor the progression of the disease.", [["IL-6", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["patients", "ORGANISM", 78, 86], ["IL-6", "PROTEIN", 20, 24], ["IL", "PROTEIN", 29, 31], ["patients", "SPECIES", 78, 86], ["IL", "TEST", 20, 22], ["IL", "TEST", 29, 31], ["persistently elevated", "PROBLEM", 40, 61], ["levels", "TEST", 93, 99], ["biomarkers", "TEST", 171, 181], ["the disease", "PROBLEM", 212, 223], ["elevated", "OBSERVATION_MODIFIER", 53, 61], ["disease", "OBSERVATION", 216, 223]]], ["Levels of IL-2, IL-4, TNFa, and IL-17A were similar to normal healthy donors; this finding is somewhat different from previous reports showing that TNF-a was significantly elevated in SFTS-infected patients, especially deceased patients [6, 10] .", [["SFTS-infected", "DISEASE", 184, 197], ["IL-2", "GENE_OR_GENE_PRODUCT", 10, 14], ["IL-4", "GENE_OR_GENE_PRODUCT", 16, 20], ["TNFa", "GENE_OR_GENE_PRODUCT", 22, 26], ["IL-17A", "GENE_OR_GENE_PRODUCT", 32, 38], ["donors", "ORGANISM", 70, 76], ["TNF", "GENE_OR_GENE_PRODUCT", 148, 151], ["SFTS", "CANCER", 184, 188], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 228, 236], ["TNFa", "PROTEIN", 22, 26], ["IL-17A", "PROTEIN", 32, 38], ["TNF", "PROTEIN", 148, 151], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 228, 236], ["Levels", "TEST", 0, 6], ["IL", "TEST", 10, 12], ["IL", "TEST", 16, 18], ["TNFa", "TEST", 22, 26], ["IL", "TEST", 32, 34], ["TNF", "TEST", 148, 151], ["significantly elevated in SFTS", "PROBLEM", 158, 188]]], ["It is not clear what may have contributed to this difference but timing of sample collection and different assay kits are potential factors influencing the final results of measurement.", [["sample", "ANATOMY", 75, 81], ["this difference", "PROBLEM", 45, 60], ["sample collection", "PROBLEM", 75, 92], ["different assay kits", "TEST", 97, 117]]], ["In conclusion, the current study identified concurrent patterns of dynamic changes for viral load, PLT, key serum enzymes, major T cell subsets and unique cytokines in SFTS patients, further extending our understanding of this high risk, emerging viral infection, which was discovered only a few years ago.", [["serum", "ANATOMY", 108, 113], ["T cell", "ANATOMY", 129, 135], ["SFTS", "ANATOMY", 168, 172], ["SFTS", "DISEASE", 168, 172], ["viral infection", "DISEASE", 247, 262], ["PLT", "GENE_OR_GENE_PRODUCT", 99, 102], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["T cell", "CELL", 129, 135], ["patients", "ORGANISM", 173, 181], ["PLT", "PROTEIN", 99, 102], ["serum enzymes", "PROTEIN", 108, 121], ["major T cell subsets", "CELL_TYPE", 123, 143], ["cytokines", "PROTEIN", 155, 164], ["patients", "SPECIES", 173, 181], ["the current study", "TEST", 15, 32], ["dynamic changes", "PROBLEM", 67, 82], ["viral load", "TEST", 87, 97], ["PLT", "TEST", 99, 102], ["key serum enzymes", "TEST", 104, 121], ["major T cell subsets", "PROBLEM", 123, 143], ["emerging viral infection", "PROBLEM", 238, 262], ["cell subsets", "OBSERVATION", 131, 143], ["viral", "OBSERVATION_MODIFIER", 247, 252], ["infection", "OBSERVATION", 253, 262]]], ["Findings on the involvement of CD69+ as well as HLA-DR+ and CTLA4+ T cells in SFTSV infection will lead more targeted research on the mechanism of pathogenesis in the coming future.", [["T cells", "ANATOMY", 67, 74], ["infection", "DISEASE", 84, 93], ["CD69", "GENE_OR_GENE_PRODUCT", 31, 35], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 48, 54], ["CTLA4", "GENE_OR_GENE_PRODUCT", 60, 65], ["T cells", "CELL", 67, 74], ["SFTSV", "ORGANISM", 78, 83], ["CD69", "PROTEIN", 31, 35], ["DR", "PROTEIN", 52, 54], ["CTLA4", "PROTEIN", 60, 65], ["T cells", "CELL_TYPE", 67, 74], ["SFTSV", "SPECIES", 78, 83], ["CD69", "TEST", 31, 35], ["HLA", "TEST", 48, 51], ["CTLA4", "PROBLEM", 60, 65], ["T cells", "PROBLEM", 67, 74], ["SFTSV infection", "PROBLEM", 78, 93], ["CTLA4", "OBSERVATION", 60, 65], ["SFTSV infection", "OBSERVATION", 78, 93]]]], "18cb299ffe4605032e106ecc23f4d7db73f60e9e": [["IntroductionThe recent emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in Wuhan, China in late 2019 and its subsequent spread to the rest of the world has created a pandemic situation unprecedented in modern history [1] [2] [3] [4] .", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 43, 81], ["SARS", "DISEASE", 83, 87], ["SARS-CoV-2", "ORGANISM", 83, 93], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 240, 255], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2", "SPECIES", 36, 93], ["Severe Acute Respiratory Syndrome", "PROBLEM", 36, 69], ["Coronavirus (SARS", "PROBLEM", 70, 87], ["a pandemic situation", "PROBLEM", 187, 207], ["Severe", "OBSERVATION_MODIFIER", 36, 42], ["Acute", "OBSERVATION_MODIFIER", 43, 48], ["Respiratory Syndrome", "OBSERVATION", 49, 69]]], ["SARS-CoV-2 is a betacoronavirus closely related to SARS-CoV, however, significant differences in the spike glycoprotein (SGP) are present in SARS-CoV-2 that may drive differences in the attachment and entry process.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "ORGANISM", 0, 10], ["betacoronavirus", "CANCER", 16, 31], ["SARS-CoV", "ORGANISM", 51, 59], ["spike glycoprotein", "GENE_OR_GENE_PRODUCT", 101, 119], ["SGP", "GENE_OR_GENE_PRODUCT", 121, 124], ["SARS-CoV-2", "ORGANISM", 141, 151], ["spike glycoprotein", "PROTEIN", 101, 119], ["SGP", "PROTEIN", 121, 124], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 141, 149], ["a betacoronavirus", "PROBLEM", 14, 31], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["the spike glycoprotein (SGP)", "PROBLEM", 97, 125], ["significant", "OBSERVATION_MODIFIER", 70, 81]]], ["In SARS-CoV, the SGP binds to its cognate receptor, human angiotensin converting enzyme 2 (hACE2).", [["SARS", "DISEASE", 3, 7], ["angiotensin", "CHEMICAL", 58, 69], ["SARS-CoV", "ORGANISM", 3, 11], ["SGP", "GENE_OR_GENE_PRODUCT", 17, 20], ["human", "ORGANISM", 52, 57], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 58, 89], ["hACE2", "GENE_OR_GENE_PRODUCT", 91, 96], ["SGP", "PROTEIN", 17, 20], ["cognate receptor", "PROTEIN", 34, 50], ["human angiotensin converting enzyme 2", "PROTEIN", 52, 89], ["hACE2", "PROTEIN", 91, 96], ["human", "SPECIES", 52, 57], ["SARS-CoV", "SPECIES", 3, 11], ["human", "SPECIES", 52, 57], ["SARS", "PROBLEM", 3, 7], ["the SGP binds", "PROBLEM", 13, 26], ["human angiotensin converting enzyme", "TEST", 52, 87]]], ["The bound virus is then endocytosed into the cell, where SGP is acted upon by the endosomal protease TMPRSS2 to allow envelope fusion and viral entry 5 .IntroductionWhile ACE2 has been confidently identified as the viral receptor, many viruses (including some betacoronaviruses) will use cellular polysaccharides as cellular attachment co-receptors, allowing the virus to adhere to the surface of the cell and increasing the local concentration of viral particles to increase effective infection rates.IntroductionSequence analysis of SGP of SARS-CoV-2 suggests that this virus has evolved to have additional potential glycosaminoglycan (GAG) binding domains compared to SARS-CoV 6, 7 .", [["cell", "ANATOMY", 45, 49], ["endosomal", "ANATOMY", 82, 91], ["cellular", "ANATOMY", 288, 296], ["cellular", "ANATOMY", 316, 324], ["surface", "ANATOMY", 386, 393], ["cell", "ANATOMY", 401, 405], ["infection", "DISEASE", 486, 495], ["SARS", "DISEASE", 542, 546], ["glycosaminoglycan", "CHEMICAL", 619, 636], ["SARS", "DISEASE", 671, 675], ["cell", "CELL", 45, 49], ["SGP", "GENE_OR_GENE_PRODUCT", 57, 60], ["endosomal", "CELLULAR_COMPONENT", 82, 91], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 101, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 171, 175], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 260, 277], ["cellular", "CELL", 288, 296], ["cellular", "CELL", 316, 324], ["surface", "CELLULAR_COMPONENT", 386, 393], ["cell", "CELL", 401, 405], ["SGP", "GENE_OR_GENE_PRODUCT", 535, 538], ["SARS-CoV-2", "ORGANISM", 542, 552], ["glycosaminoglycan", "SIMPLE_CHEMICAL", 619, 636], ["GAG", "SIMPLE_CHEMICAL", 638, 641], ["SGP", "PROTEIN", 57, 60], ["endosomal protease", "PROTEIN", 82, 100], ["TMPRSS2", "PROTEIN", 101, 108], ["ACE2", "PROTEIN", 171, 175], ["viral receptor", "PROTEIN", 215, 229], ["cellular attachment co-receptors", "PROTEIN", 316, 348], ["SGP", "PROTEIN", 535, 538], ["glycosaminoglycan (GAG) binding domains", "PROTEIN", 619, 658], ["SARS-CoV", "SPECIES", 542, 550], ["SARS-CoV", "SPECIES", 671, 679], ["The bound virus", "PROBLEM", 0, 15], ["the endosomal protease TMPRSS2", "TREATMENT", 78, 108], ["envelope fusion", "TREATMENT", 118, 133], ["ACE2", "TREATMENT", 171, 175], ["the viral receptor", "PROBLEM", 211, 229], ["many viruses", "PROBLEM", 231, 243], ["some betacoronaviruses", "TREATMENT", 255, 277], ["cellular polysaccharides", "TREATMENT", 288, 312], ["cellular attachment co-receptors", "TREATMENT", 316, 348], ["the virus", "PROBLEM", 359, 368], ["increasing the local concentration of viral particles", "TREATMENT", 410, 463], ["effective infection rates", "PROBLEM", 476, 501], ["IntroductionSequence analysis", "TEST", 502, 531], ["SARS", "PROBLEM", 542, 546], ["CoV", "TEST", 547, 550], ["this virus", "PROBLEM", 567, 577], ["potential glycosaminoglycan (GAG) binding domains", "PROBLEM", 609, 658], ["SARS", "TEST", 671, 675], ["CoV", "TEST", 676, 679], ["bound virus", "OBSERVATION", 4, 15], ["viruses", "OBSERVATION", 236, 243], ["viral particles", "OBSERVATION", 448, 463], ["increase", "OBSERVATION_MODIFIER", 467, 475], ["effective", "OBSERVATION_MODIFIER", 476, 485], ["infection", "OBSERVATION", 486, 495]]], ["GAGs are a family of linear sulfated polysaccharides found on the surface of virtually all mammalian cells, and commonly includes chondroitin sulfate (CS) and heparan sulfate (HS) .", [["surface", "ANATOMY", 66, 73], ["cells", "ANATOMY", 101, 106], ["chondroitin sulfate", "CHEMICAL", 130, 149], ["heparan sulfate", "CHEMICAL", 159, 174], ["chondroitin sulfate", "CHEMICAL", 130, 149], ["heparan sulfate", "CHEMICAL", 159, 174], ["GAGs", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 66, 73], ["mammalian cells", "CELL", 91, 106], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 130, 149], ["CS", "SIMPLE_CHEMICAL", 151, 153], ["heparan sulfate", "SIMPLE_CHEMICAL", 159, 174], ["HS", "SIMPLE_CHEMICAL", 176, 178], ["mammalian cells", "CELL_TYPE", 91, 106], ["linear sulfated polysaccharides", "TREATMENT", 21, 52], ["chondroitin sulfate", "TREATMENT", 130, 149], ["heparan sulfate", "TREATMENT", 159, 174], ["mammalian cells", "OBSERVATION", 91, 106]]], ["Previous studies using isolated SARS-CoV-2 SGP monomer or trimer and surface plasmon resonance (SPR) have shown that SARS-CoV-2 SGP has high affinity to heparin 6, 7 , a specialized member of the HS family that is highly sulfated and commonly used clinically as an anti-coagulant drug.", [["heparin", "CHEMICAL", 153, 160], ["SARS-CoV-2 SGP", "GENE_OR_GENE_PRODUCT", 117, 131], ["heparin 6", "SIMPLE_CHEMICAL", 153, 162], ["SARS-CoV-2 SGP monomer", "PROTEIN", 32, 54], ["SARS-CoV-2 SGP", "PROTEIN", 117, 131], ["Previous studies", "TEST", 0, 16], ["isolated SARS", "TEST", 23, 36], ["CoV", "TEST", 37, 40], ["surface plasmon resonance", "TEST", 69, 94], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["heparin", "TREATMENT", 153, 160], ["an anti-coagulant drug", "TREATMENT", 262, 284]]], ["It was also reported that heparin was capable of inhibiting infection of SARS-CoV-2 in Vero cell culture in a concentration-dependent fashion 7 .", [["cell culture", "ANATOMY", 92, 104], ["heparin", "CHEMICAL", 26, 33], ["infection", "DISEASE", 60, 69], ["SARS", "DISEASE", 73, 77], ["heparin", "SIMPLE_CHEMICAL", 26, 33], ["Vero cell", "CELL", 87, 96], ["Vero cell culture", "CELL_LINE", 87, 104], ["SARS-CoV", "SPECIES", 73, 81], ["heparin", "TREATMENT", 26, 33], ["inhibiting infection of SARS", "PROBLEM", 49, 77], ["CoV", "TEST", 78, 81], ["Vero cell culture", "TEST", 87, 104]]], ["These results support a model of SARS-CoV-2 attachment and entry illustrated in Figure 1 , where SARS-CoV-2 initially binds to HS in the nasal epithelium glycocalyx, then subsequently binds hACE2 and is endocytosed.IntroductionHowever, little work has been done in this area due in part to safety concerns of the assay.", [["nasal epithelium glycocalyx", "ANATOMY", 137, 164], ["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["HS", "GENE_OR_GENE_PRODUCT", 127, 129], ["nasal epithelium glycocalyx", "TISSUE", 137, 164], ["hACE2", "GENE_OR_GENE_PRODUCT", 190, 195], ["SARS-CoV-2", "DNA", 97, 107], ["HS", "DNA", 127, 129], ["hACE2", "PROTEIN", 190, 195], ["SARS", "PROBLEM", 33, 37], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["the assay", "TEST", 309, 318], ["nasal epithelium", "ANATOMY", 137, 153], ["glycocalyx", "ANATOMY_MODIFIER", 154, 164]]], ["Due to the highly transmissible and pathogenic nature of SARS-CoV-2, handling of live virus requires biosafety level 3 (BSL3) containment 8 .", [["SARS", "DISEASE", 57, 61], ["SARS-CoV-2", "ORGANISM", 57, 67], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61]]], ["Thus, only facilities equipped with BSL-3 can safely study neutralizing responses using live virus.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 36, 41]]], ["A safer way is needed to study viral inhibitors and immunological responses in a practical, reproducible surrogate assay that effectively replaces the need for the live SARS-CoV-2 to extend this capability to non-BSL-3 laboratories that are more widely available.", [["study viral inhibitors", "TREATMENT", 25, 47]]], ["Here, we report the development and use of a high titer lentivirus pseudotyped with SARS-CoV-2 SPG to screen potential inhibitors in a lower biosafety level laboratory.", [["lentivirus", "ORGANISM", 56, 66], ["lentivirus", "SPECIES", 56, 66], ["SARS-CoV", "SPECIES", 84, 92], ["a high titer lentivirus pseudotyped", "TREATMENT", 43, 78], ["potential inhibitors", "TREATMENT", 109, 129]]], ["Since the backbone of this virus consists of a non-replicating lentivirus, it poses no risk of infection to the personnel involved, and attachment and entry can be measured by detectable fluorescence intensity directly correlating with the efficiency of transduction.", [["infection", "DISEASE", 95, 104], ["lentivirus", "ORGANISM", 63, 73], ["this virus", "PROBLEM", 22, 32], ["a non-replicating lentivirus", "TREATMENT", 45, 73], ["infection", "PROBLEM", 95, 104], ["virus", "OBSERVATION", 27, 32], ["non-replicating", "OBSERVATION_MODIFIER", 47, 62], ["lentivirus", "OBSERVATION", 63, 73], ["no risk of", "UNCERTAINTY", 84, 94], ["infection", "OBSERVATION", 95, 104]]], ["Using this lentiviral system, we test the ability of various sulfated polysaccharides to inhibit pseudotyped viral attachment and entry.", [["lentiviral", "ORGANISM", 11, 21], ["pseudotyped", "ORGANISM", 97, 108], ["this lentiviral system", "TREATMENT", 6, 28], ["various sulfated polysaccharides", "TREATMENT", 53, 85], ["pseudotyped viral attachment", "TREATMENT", 97, 125]]], ["We find several sulfated polysaccharides with potent anti-SARS-CoV-2 activity.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 68], ["several sulfated polysaccharides", "TREATMENT", 8, 40], ["potent anti-SARS", "TREATMENT", 46, 62]]], ["We demonstrate that SPR can be performed using pseudotyped lentiviral virions, presenting a more biologically-relevant context for biophysical analysis than isolated SGP protein.IntroductionWe discuss implications of these findings for both SARS-CoV-2 studies and potential clinical applications.SARS-CoV-2 Spike protein can be efficiently pseudotyped on a lentiviral vectorWe used a third generation lentiviral vector (pLV) 9,10 to pseudotype SARS-CoV-2 SPG for the purpose of these studies.", [["SARS", "DISEASE", 241, 245], ["lentiviral", "ORGANISM", 59, 69], ["SGP", "GENE_OR_GENE_PRODUCT", 166, 169], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 296, 306], ["pseudotyped", "ORGANISM", 340, 351], ["lentiviral", "ORGANISM", 357, 367], ["lentiviral", "ORGANISM", 401, 411], ["SGP protein", "PROTEIN", 166, 177], ["SARS-CoV-2 Spike protein", "PROTEIN", 296, 320], ["pseudotyped lentiviral virions", "TREATMENT", 47, 77], ["biophysical analysis", "TEST", 131, 151], ["isolated SGP protein", "PROBLEM", 157, 177], ["these findings", "TEST", 217, 231], ["both SARS", "TEST", 236, 245], ["SARS", "TEST", 296, 300], ["CoV", "TEST", 301, 304], ["Spike protein", "PROBLEM", 307, 320], ["efficiently pseudotyped", "PROBLEM", 328, 351], ["a lentiviral vectorWe", "TREATMENT", 355, 376], ["a third generation lentiviral vector", "TREATMENT", 382, 418], ["pseudotype SARS", "TEST", 433, 448], ["these studies", "TEST", 478, 491]]], ["Both VSV-G and SARS-CoV-2 spike glycoprotein pseudotyped pLV efficiently, although, VSV-G was much more efficient, as expected ( Figure S1 , Supplementary Information).", [["VSV-G", "ORGANISM", 5, 10], ["SARS-CoV-2", "ORGANISM", 15, 25], ["pseudotyped", "ORGANISM", 45, 56], ["pLV", "GENE_OR_GENE_PRODUCT", 57, 60], ["VSV-G", "GENE_OR_GENE_PRODUCT", 84, 89], ["VSV-G and SARS-CoV-2 spike glycoprotein pseudotyped pLV", "DNA", 5, 60], ["SARS-CoV", "SPECIES", 15, 23], ["VSV", "SPECIES", 84, 87], ["Both VSV", "TEST", 0, 8], ["G", "TEST", 9, 10], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["glycoprotein pseudotyped pLV", "TREATMENT", 32, 60], ["VSV", "TEST", 84, 87]]], ["The success of pseudotyping was assessed by the expression of green fluorescent protein (gfp) since pLV backbone incorporates the gene encoding for gfp.pLV-S transduction inhibited by some sulfated polysaccharidesWe tested the ability of twelve different polysaccharides to inhibit pLV-S transduction inAnti-SARS-CoV-2 IC50 determination for heparin derivativesTo test the potency and efficacy of these sulfated glycans, we performed concentrationdependent pseudotypes pLV-S infection assays to determine IC50 values for UFH, A.B.C.L. variegatus Sulfated FucanUFH-de6S, enoxaparin, enoxaparin-de6S, enoxaparin-deNS, enoxaparin-fully-deS, L.L. variegatus Sulfated Fucanvar SF and B. occ.", [["pLV-S", "CHEMICAL", 282, 287], ["heparin", "CHEMICAL", 342, 349], ["UFH", "CHEMICAL", 521, 524], ["enoxaparin", "CHEMICAL", 570, 580], ["enoxaparin", "CHEMICAL", 582, 592], ["de6S", "CHEMICAL", 593, 597], ["enoxaparin", "CHEMICAL", 599, 609], ["deNS", "CHEMICAL", 610, 614], ["enoxaparin", "CHEMICAL", 616, 626], ["enoxaparin", "CHEMICAL", 570, 580], ["enoxaparin-de6S", "CHEMICAL", 582, 597], ["enoxaparin-deNS", "CHEMICAL", 599, 614], ["enoxaparin", "CHEMICAL", 616, 626], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 62, 87], ["gfp", "GENE_OR_GENE_PRODUCT", 89, 92], ["gfp.pLV-S", "GENE_OR_GENE_PRODUCT", 148, 157], ["pLV-S", "GENE_OR_GENE_PRODUCT", 282, 287], ["heparin derivatives", "SIMPLE_CHEMICAL", 342, 361], ["UFH", "SIMPLE_CHEMICAL", 521, 524], ["FucanUFH-de6S", "SIMPLE_CHEMICAL", 555, 568], ["enoxaparin", "SIMPLE_CHEMICAL", 570, 580], ["enoxaparin-de6S", "SIMPLE_CHEMICAL", 582, 597], ["enoxaparin-deNS", "SIMPLE_CHEMICAL", 599, 614], ["enoxaparin", "SIMPLE_CHEMICAL", 616, 626], ["-fully-deS", "SIMPLE_CHEMICAL", 626, 636], ["B. occ", "ORGANISM", 679, 685], ["green fluorescent protein", "PROTEIN", 62, 87], ["gfp", "PROTEIN", 89, 92], ["pLV backbone", "PROTEIN", 100, 112], ["gfp.pLV", "PROTEIN", 148, 155], ["A.B.C.L. variegatus", "SPECIES", 526, 545], ["L.L. variegatus", "SPECIES", 638, 653], ["B. occ", "SPECIES", 679, 685], ["pseudotyping", "PROBLEM", 15, 27], ["green fluorescent protein (gfp", "PROBLEM", 62, 92], ["pLV backbone", "TREATMENT", 100, 112], ["gfp.pLV-S transduction", "TREATMENT", 148, 170], ["some sulfated polysaccharides", "TREATMENT", 184, 213], ["pLV", "TEST", 282, 285], ["inAnti-SARS", "TEST", 301, 312], ["CoV", "TEST", 313, 316], ["heparin derivatives", "TREATMENT", 342, 361], ["these sulfated glycans", "TREATMENT", 397, 419], ["concentrationdependent pseudotypes pLV", "TREATMENT", 434, 472], ["S infection assays", "PROBLEM", 473, 491], ["IC50 values", "TEST", 505, 516], ["UFH", "TREATMENT", 521, 524], ["variegatus Sulfated FucanUFH", "TREATMENT", 535, 563], ["de6S", "TREATMENT", 564, 568], ["enoxaparin", "TREATMENT", 570, 580], ["enoxaparin", "TREATMENT", 582, 592], ["de6S", "TREATMENT", 593, 597], ["enoxaparin", "TREATMENT", 599, 609], ["deNS", "TREATMENT", 610, 614], ["enoxaparin", "TREATMENT", 616, 626], ["deNS", "ANATOMY", 610, 614]]], ["Because of the role of avidity often found in protein-GAG interactions, IC50 values were measured in terms of mg/L. We tested pLV-S transduction rates at inhibitor concentrations ranging from 500 mg/L to 5 \u00b5g/L, with results shown inEnoxaparin-deNS No activity Enoxaparin-fully-deSNo activitySPR measurements of pLV-S binding affinityDirect binding measurements of pLV-S for surface immobilized heparin were made Table 1 .SPR measurements of pLV-S binding affinityconcentrations of the pLV-S virion were determined from an estimated molecular weight for pLV-S of 250 MDa.", [["surface", "ANATOMY", 375, 382], ["inEnoxaparin", "CHEMICAL", 231, 243], ["Enoxaparin", "CHEMICAL", 261, 271], ["heparin", "CHEMICAL", 395, 402], ["inEnoxaparin", "CHEMICAL", 231, 243], ["Enoxaparin", "CHEMICAL", 261, 271], ["GAG", "SIMPLE_CHEMICAL", 54, 57], ["inEnoxaparin", "SIMPLE_CHEMICAL", 231, 243], ["Enoxaparin", "SIMPLE_CHEMICAL", 261, 271], ["pLV-S", "SIMPLE_CHEMICAL", 312, 317], ["pLV-S", "SIMPLE_CHEMICAL", 365, 370], ["heparin", "SIMPLE_CHEMICAL", 395, 402], ["pLV-S", "GENE_OR_GENE_PRODUCT", 442, 447], ["pLV", "PROTEIN", 312, 315], ["pLV", "PROTEIN", 365, 368], ["pLV", "PROTEIN", 442, 445], ["pLV", "PROTEIN", 486, 489], ["pLV", "PROTEIN", 554, 557], ["IC50 values", "TEST", 72, 83], ["pLV-S transduction rates at inhibitor concentrations", "TREATMENT", 126, 178], ["inEnoxaparin", "TREATMENT", 231, 243], ["activity Enoxaparin", "TREATMENT", 252, 271], ["pLV", "TEST", 312, 315], ["Direct binding measurements", "TEST", 334, 361], ["pLV", "TREATMENT", 365, 368], ["surface immobilized heparin", "TREATMENT", 375, 402], ["SPR measurements", "TEST", 422, 438], ["pLV", "TEST", 442, 445], ["an estimated molecular weight", "TEST", 520, 549], ["pLV", "TEST", 554, 557], ["pLV", "OBSERVATION", 442, 445], ["pLV", "ANATOMY", 486, 489]]], ["This molecular weight was based on the similarity of pLV to another enveloped retrovirus (Rous sarcoma virus) having a diameter of ~100 nm 13 and an estimated mass of 250 MDa 14 .", [["Rous sarcoma", "DISEASE", 90, 102], ["pLV", "GENE_OR_GENE_PRODUCT", 53, 56], ["retrovirus", "ORGANISM", 78, 88], ["Rous sarcoma virus", "ORGANISM", 90, 108], ["pLV", "PROTEIN", 53, 56], ["Rous sarcoma virus", "SPECIES", 90, 108], ["Rous sarcoma virus", "SPECIES", 90, 108], ["This molecular weight", "TEST", 0, 21], ["another enveloped retrovirus (Rous sarcoma virus", "PROBLEM", 60, 108], ["an estimated mass", "TEST", 146, 163], ["retrovirus", "ANATOMY", 78, 88], ["diameter", "OBSERVATION_MODIFIER", 119, 127], ["mass", "OBSERVATION", 159, 163]]], ["An on-rate (ka) of 2.9 \u00d7 10 6 M -1 s -1 (\u00b1 1.1 \u00d7 10 5 ), an offrate (kd) of 2.4 \u00d7 10 -3 s -1 (\u00b1 1.9 \u00d7 10 -5 ), and a dissociation constant (KD) of 8.5 \u00d7 10 -10 M were determined in these direct binding measurements, which is comparable to the IC50 of heparin determined in Table 1 .DiscussionHere, we report the development of a lentiviral pseudotyping system for SARS-CoV-2 and its use in screening potential viral entry inhibitors.", [["heparin", "CHEMICAL", 251, 258], ["heparin", "SIMPLE_CHEMICAL", 251, 258], ["lentiviral", "ORGANISM", 329, 339], ["SARS-CoV", "SPECIES", 364, 372], ["ka", "TEST", 12, 14], ["\u00b1", "TEST", 41, 42], ["an offrate", "TEST", 57, 67], ["kd", "TEST", 69, 71], ["s", "TEST", 88, 89], ["\u00b1", "TEST", 94, 95], ["\u00d7", "TEST", 100, 101], ["a dissociation constant", "TEST", 115, 138], ["KD", "TEST", 140, 142], ["heparin", "TREATMENT", 251, 258], ["a lentiviral pseudotyping system", "TREATMENT", 327, 359], ["SARS", "PROBLEM", 364, 368], ["CoV", "TEST", 369, 372], ["viral entry inhibitors", "TREATMENT", 410, 432]]], ["While a few pseudotyping systems for SARS-CoV-2 are in development, this report provides evidence that lentiviral pseudotyped SARS-CoV-2 can be used to identify potential inhibitors for follow up studies in mouse models and clinical trials.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "ORGANISM", 37, 47], ["lentiviral pseudotyped SARS-CoV-2", "ORGANISM", 103, 136], ["mouse", "ORGANISM", 207, 212], ["mouse", "SPECIES", 207, 212], ["SARS-CoV", "SPECIES", 37, 45], ["mouse", "SPECIES", 207, 212], ["SARS", "PROBLEM", 37, 41], ["lentiviral pseudotyped SARS", "PROBLEM", 103, 130], ["follow up studies", "TEST", 186, 203]]], ["These pseudoparticles can also be utilized for screening of inhibitors of SPG-hACE2 binding and resultant virus entry through biophysical methods such as SPR, with results that are arguably more biologically relevant than isolated SGP.", [["SPG", "GENE_OR_GENE_PRODUCT", 74, 77], ["hACE2", "GENE_OR_GENE_PRODUCT", 78, 83], ["SGP", "GENE_OR_GENE_PRODUCT", 231, 234], ["SPG", "PROTEIN", 74, 77], ["hACE2", "PROTEIN", 78, 83], ["SGP", "PROTEIN", 231, 234], ["screening of inhibitors", "TREATMENT", 47, 70], ["SPG-hACE2 binding", "PROBLEM", 74, 91], ["resultant virus entry", "PROBLEM", 96, 117], ["biophysical methods", "TEST", 126, 145], ["SGP", "OBSERVATION", 231, 234]]], ["Their ability to both infect cells and respond to heparin in a manner consistent with previously published results from active SARS-CoV-2 7 suggest that this lentiviral pseudotyping system may be useful for screening potential viral entry inhibitors as they represent SPG on their surface in its native confirmation.", [["cells", "ANATOMY", 29, 34], ["surface", "ANATOMY", 281, 288], ["heparin", "CHEMICAL", 50, 57], ["cells", "CELL", 29, 34], ["heparin", "SIMPLE_CHEMICAL", 50, 57], ["SARS-CoV-2 7", "ORGANISM", 127, 139], ["lentiviral", "ORGANISM", 158, 168], ["SPG", "SIMPLE_CHEMICAL", 268, 271], ["surface", "CELLULAR_COMPONENT", 281, 288], ["both infect cells", "PROBLEM", 17, 34], ["heparin", "TREATMENT", 50, 57], ["active SARS", "PROBLEM", 120, 131], ["CoV", "TEST", 132, 135], ["this lentiviral pseudotyping system", "PROBLEM", 153, 188], ["screening potential viral entry inhibitors", "TREATMENT", 207, 249], ["SPG", "PROBLEM", 268, 271], ["infect cells", "OBSERVATION", 22, 34], ["active", "OBSERVATION_MODIFIER", 120, 126], ["SARS", "OBSERVATION", 127, 131]]], ["The use of the pseudotyped systems to conveniently test potential inhibitors of viral attachment and entry has allowed us to perform structure-function analysis to begin to understand the important characteristics of inhibitory sulfated polysaccharides.", [["sulfated polysaccharides", "SIMPLE_CHEMICAL", 228, 252], ["the pseudotyped systems", "TREATMENT", 11, 34], ["viral attachment", "PROBLEM", 80, 96], ["structure-function analysis", "TEST", 133, 160], ["inhibitory sulfated polysaccharides", "TREATMENT", 217, 252]]], ["Our finding that enoxaparin, a partially depolymerized heparin with an average molecular weight of ~4.5 kDa, has lower potency than UFH (average molecular weight ~15 kDa) even in terms of mg/L is consistent with previous SPR results 6 , as well as SPR results presented here (Figure S5 , Supplementary Information) .", [["enoxaparin", "CHEMICAL", 17, 27], ["heparin", "CHEMICAL", 55, 62], ["UFH", "CHEMICAL", 132, 135], ["enoxaparin", "CHEMICAL", 17, 27], ["enoxaparin", "SIMPLE_CHEMICAL", 17, 27], ["heparin", "SIMPLE_CHEMICAL", 55, 62], ["UFH", "SIMPLE_CHEMICAL", 132, 135], ["enoxaparin", "TREATMENT", 17, 27], ["a partially depolymerized heparin", "TREATMENT", 29, 62], ["UFH", "TEST", 132, 135], ["weight", "TEST", 155, 161], ["lower potency", "OBSERVATION_MODIFIER", 113, 126]]], ["The lower potency and higher KD of the partially depolymerized heparin is consistent with a binding interaction that involves multiple binding sites on each UFH polysaccharide molecule, which we have also found in some of our previous studies of protein-GAG interactions 15, 16 .DiscussionAs shown in Figure 2 , the inhibitory abilities of UFH, sulfated fucan and sulfated galactan from marine sources suggest that there is considerable flexibility in the SGP GAG binding site(s).", [["heparin", "CHEMICAL", 63, 70], ["UFH", "CHEMICAL", 157, 160], ["UFH", "CHEMICAL", 340, 343], ["fucan", "CHEMICAL", 354, 359], ["galactan", "CHEMICAL", 373, 381], ["sulfated fucan", "CHEMICAL", 345, 359], ["sulfated galactan", "CHEMICAL", 364, 381], ["heparin", "SIMPLE_CHEMICAL", 63, 70], ["GAG", "SIMPLE_CHEMICAL", 254, 257], ["UFH", "SIMPLE_CHEMICAL", 340, 343], ["sulfated fucan", "SIMPLE_CHEMICAL", 345, 359], ["sulfated galactan", "SIMPLE_CHEMICAL", 364, 381], ["SGP", "GENE_OR_GENE_PRODUCT", 456, 459], ["GAG", "SIMPLE_CHEMICAL", 460, 463], ["UFH polysaccharide molecule", "PROTEIN", 157, 184], ["SGP GAG binding site", "DNA", 456, 476], ["the partially depolymerized heparin", "TREATMENT", 35, 70], ["a binding interaction", "PROBLEM", 90, 111], ["multiple binding sites", "PROBLEM", 126, 148], ["protein", "TEST", 246, 253], ["UFH", "TREATMENT", 340, 343], ["sulfated fucan", "TREATMENT", 345, 359], ["sulfated galactan", "TREATMENT", 364, 381], ["considerable flexibility in the SGP GAG binding site", "PROBLEM", 424, 476], ["lower potency", "OBSERVATION_MODIFIER", 4, 17], ["higher KD", "OBSERVATION_MODIFIER", 22, 31], ["heparin", "OBSERVATION", 63, 70], ["consistent with", "UNCERTAINTY", 74, 89], ["binding interaction", "OBSERVATION", 92, 111], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["binding sites", "OBSERVATION", 135, 148], ["considerable", "OBSERVATION_MODIFIER", 424, 436], ["flexibility", "OBSERVATION_MODIFIER", 437, 448], ["SGP GAG", "ANATOMY", 456, 463]]], ["UFH, sulfated fucan from L. variegatus and sulfated galactan from B. occidentalis all demonstrate substantial inhibitory potency, even though they do not share monosaccharide composition, glycosidic linkage sites or stereochemistry, or sites of sulfation (Figure 3) .", [["UFH", "CHEMICAL", 0, 3], ["fucan", "CHEMICAL", 14, 19], ["galactan", "CHEMICAL", 52, 60], ["sulfated fucan", "CHEMICAL", 5, 19], ["monosaccharide", "CHEMICAL", 160, 174], ["UFH", "SIMPLE_CHEMICAL", 0, 3], ["sulfated fucan", "SIMPLE_CHEMICAL", 5, 19], ["L. variegatus", "ORGANISM", 25, 38], ["sulfated galactan", "SIMPLE_CHEMICAL", 43, 60], ["B. occidentalis", "ORGANISM", 66, 81], ["monosaccharide", "SIMPLE_CHEMICAL", 160, 174], ["L. variegatus", "SPECIES", 25, 38], ["B. occidentalis", "SPECIES", 66, 81], ["L. variegatus", "SPECIES", 25, 38], ["B. occidentalis", "SPECIES", 66, 81], ["UFH", "TREATMENT", 0, 3], ["sulfated fucan", "TREATMENT", 5, 19], ["L. variegatus", "TREATMENT", 25, 38], ["sulfated galactan", "TREATMENT", 43, 60], ["substantial inhibitory potency", "PROBLEM", 98, 128], ["glycosidic linkage sites", "PROBLEM", 188, 212], ["substantial", "OBSERVATION_MODIFIER", 98, 109], ["inhibitory potency", "OBSERVATION", 110, 128]]], ["However, the poor inhibitory activity of chondroitin sulfate indicates that inhibition is not merely a question of presenting negative charge on a linear polymer.DiscussionThe role of structural specificity rather than negative charge density is also supported by some of the SPR competition results presented here; dermatan sulfate, which largely has one sulfo group per disaccharide, competed for SGP binding similarly to CS-D and CS-E, which have two sulfo groups per disaccharide ( Figure S4 , Supplementary Information).DiscussionAlso supporting some degree of structural specificity of the SGP GAG binding site(s) are the results from specifically chemically desulfated UFH and enoxaparin.", [["chondroitin sulfate", "CHEMICAL", 41, 60], ["dermatan sulfate", "CHEMICAL", 316, 332], ["UFH", "CHEMICAL", 676, 679], ["enoxaparin", "CHEMICAL", 684, 694], ["chondroitin sulfate", "CHEMICAL", 41, 60], ["dermatan sulfate", "CHEMICAL", 316, 332], ["sulfo", "CHEMICAL", 356, 361], ["disaccharide", "CHEMICAL", 372, 384], ["CS-D", "CHEMICAL", 424, 428], ["CS-E", "CHEMICAL", 433, 437], ["sulfo", "CHEMICAL", 454, 459], ["disaccharide", "CHEMICAL", 471, 483], ["enoxaparin", "CHEMICAL", 684, 694], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 41, 60], ["dermatan sulfate", "SIMPLE_CHEMICAL", 316, 332], ["SGP", "SIMPLE_CHEMICAL", 399, 402], ["CS-D", "SIMPLE_CHEMICAL", 424, 428], ["CS-E", "SIMPLE_CHEMICAL", 433, 437], ["SGP GAG", "GENE_OR_GENE_PRODUCT", 596, 603], ["UFH", "SIMPLE_CHEMICAL", 676, 679], ["enoxaparin", "SIMPLE_CHEMICAL", 684, 694], ["SGP", "PROTEIN", 399, 402], ["SGP GAG binding site", "DNA", 596, 616], ["chondroitin sulfate", "TREATMENT", 41, 60], ["a linear polymer", "TREATMENT", 145, 161], ["dermatan sulfate", "TREATMENT", 316, 332], ["SGP binding", "PROBLEM", 399, 410], ["the SGP GAG binding site", "PROBLEM", 592, 616], ["chemically desulfated UFH", "TREATMENT", 654, 679], ["enoxaparin", "TREATMENT", 684, 694]]], ["While complete desulfation and specific N-desulfation greatly decreases the potency of both UFH and enoxaparin to inhibit SARS-CoV-2 attachment and entry, 6O-desulfation has little effect on potency and no effect on efficacy in this assay (Figure 4 and Table 1 ).", [["N-desulfation", "CHEMICAL", 40, 53], ["UFH", "CHEMICAL", 92, 95], ["enoxaparin", "CHEMICAL", 100, 110], ["6O-desulfation", "CHEMICAL", 155, 169], ["enoxaparin", "CHEMICAL", 100, 110], ["6O", "CHEMICAL", 155, 157], ["N-desulfation", "SIMPLE_CHEMICAL", 40, 53], ["UFH", "SIMPLE_CHEMICAL", 92, 95], ["enoxaparin", "SIMPLE_CHEMICAL", 100, 110], ["CoV-2", "GENE_OR_GENE_PRODUCT", 127, 132], ["6O-desulfation", "SIMPLE_CHEMICAL", 155, 169], ["both UFH", "TREATMENT", 87, 95], ["enoxaparin", "TREATMENT", 100, 110], ["SARS", "TEST", 122, 126], ["CoV", "TEST", 127, 130], ["desulfation", "TREATMENT", 158, 169], ["this assay", "TEST", 228, 238]]], ["These results are similar but not identical to previously described SPR results performed on GAG binding to SGP monomer and trimer 6, 7 .", [["GAG", "SIMPLE_CHEMICAL", 93, 96], ["SGP monomer", "PROTEIN", 108, 119], ["trimer 6, 7", "PROTEIN", 124, 135]]], ["In this study we undertook SPR studies on pLV-S to better understand the interaction of a pseudovirus particle containing multiple surfaceDiscussionSPGs.", [["surface", "ANATOMY", 131, 138], ["pseudovirus", "ORGANISM", 90, 101], ["this study", "TEST", 3, 13], ["SPR studies", "TEST", 27, 38], ["pLV", "TREATMENT", 42, 45], ["a pseudovirus particle", "TREATMENT", 88, 110], ["multiple", "OBSERVATION_MODIFIER", 122, 130], ["surface", "OBSERVATION_MODIFIER", 131, 138]]], ["The pLV-S showed very tight (~ 1nM) binding to immobilized heparin that could be effectively competed with using soluble heparin and non-anticoagulant heparin.DiscussionFurther studies to characterize both pLV-S and SGP-sulfated polysaccharide interactions are required to understand the optimal binding structure(s).Heparin and enoxaparin sodium desulfation for pseudotyped virus inhibition:Prior to desulfation, heparin and enoxaparin sodium were first converted to their pyridinium salts by passing through a self-packed cation-exchange column with Dowex 50 W resin, followed by lyophilization.", [["pLV-S", "CHEMICAL", 4, 9], ["heparin", "CHEMICAL", 59, 66], ["heparin", "CHEMICAL", 121, 128], ["heparin", "CHEMICAL", 151, 158], ["Heparin", "CHEMICAL", 317, 324], ["enoxaparin sodium", "CHEMICAL", 329, 346], ["heparin", "CHEMICAL", 414, 421], ["enoxaparin sodium", "CHEMICAL", 426, 443], ["pyridinium salts", "CHEMICAL", 474, 490], ["enoxaparin sodium", "CHEMICAL", 329, 346], ["enoxaparin sodium", "CHEMICAL", 426, 443], ["pyridinium", "CHEMICAL", 474, 484], ["heparin", "SIMPLE_CHEMICAL", 59, 66], ["heparin", "SIMPLE_CHEMICAL", 121, 128], ["non-anticoagulant heparin", "SIMPLE_CHEMICAL", 133, 158], ["pLV-S", "GENE_OR_GENE_PRODUCT", 206, 211], ["SGP-sulfated polysaccharide", "SIMPLE_CHEMICAL", 216, 243], ["Heparin", "SIMPLE_CHEMICAL", 317, 324], ["enoxaparin", "SIMPLE_CHEMICAL", 329, 339], ["sodium", "SIMPLE_CHEMICAL", 340, 346], ["pseudotyped", "ORGANISM", 363, 374], ["heparin", "SIMPLE_CHEMICAL", 414, 421], ["enoxaparin sodium", "SIMPLE_CHEMICAL", 426, 443], ["pyridinium salts", "SIMPLE_CHEMICAL", 474, 490], ["cation", "SIMPLE_CHEMICAL", 524, 530], ["pLV-S", "CELL_LINE", 4, 9], ["pLV", "PROTEIN", 206, 209], ["The pLV-S", "TEST", 0, 9], ["very tight (~ 1nM) binding", "PROBLEM", 17, 43], ["immobilized heparin", "TREATMENT", 47, 66], ["soluble heparin", "TREATMENT", 113, 128], ["non-anticoagulant heparin", "TREATMENT", 133, 158], ["DiscussionFurther studies", "TEST", 159, 184], ["pLV", "TEST", 206, 209], ["SGP-sulfated polysaccharide interactions", "TREATMENT", 216, 256], ["Heparin", "TREATMENT", 317, 324], ["enoxaparin sodium desulfation", "TREATMENT", 329, 358], ["pseudotyped virus inhibition", "TREATMENT", 363, 391], ["desulfation", "TREATMENT", 401, 412], ["heparin", "TREATMENT", 414, 421], ["enoxaparin sodium", "TREATMENT", 426, 443], ["their pyridinium salts", "TREATMENT", 468, 490], ["a self-packed cation-exchange column", "TREATMENT", 510, 546], ["Dowex 50 W resin", "TREATMENT", 552, 568], ["pLV", "OBSERVATION", 4, 7], ["pLV", "OBSERVATION", 206, 209]]], ["27 For N-desulfation, the 1 mg pyridinium salts were resuspended in 1 mL 5% methanol in DMSO and heated at 50\u00b0C for 1.5 hour.", [["N-desulfation", "CHEMICAL", 7, 20], ["pyridinium salts", "CHEMICAL", 31, 47], ["methanol", "CHEMICAL", 76, 84], ["DMSO", "CHEMICAL", 88, 92], ["pyridinium", "CHEMICAL", 31, 41], ["methanol", "CHEMICAL", 76, 84], ["DMSO", "CHEMICAL", 88, 92], ["pyridinium salts", "SIMPLE_CHEMICAL", 31, 47], ["methanol", "SIMPLE_CHEMICAL", 76, 84], ["DMSO", "SIMPLE_CHEMICAL", 88, 92], ["N-desulfation", "TREATMENT", 7, 20], ["the 1 mg pyridinium salts", "TREATMENT", 22, 47], ["DMSO", "TREATMENT", 88, 92]]], ["The sample was diluted and purified with a 3 kDa Amicon Ultra centrifugal filter (Millipore, Temecula, CA, USA) to remove low molecular weight impurities.", [["sample", "ANATOMY", 4, 10], ["a 3 kDa Amicon Ultra centrifugal filter (Millipore", "TREATMENT", 41, 91]]], ["28 For 6-O-desulfation, the 1 mg pyridinium salts were added to 10 volumes (w/w) of MSTFA and 100 volumes (v/w) of pyridine.", [["6-O-desulfation", "CHEMICAL", 7, 22], ["pyridinium salts", "CHEMICAL", 33, 49], ["pyridine", "CHEMICAL", 115, 123], ["6-O-desulfation", "CHEMICAL", 7, 22], ["pyridinium", "CHEMICAL", 33, 43], ["pyridine", "CHEMICAL", 115, 123], ["6-O-desulfation", "SIMPLE_CHEMICAL", 7, 22], ["pyridinium salts", "SIMPLE_CHEMICAL", 33, 49], ["MSTFA", "SIMPLE_CHEMICAL", 84, 89], ["pyridine", "SIMPLE_CHEMICAL", 115, 123], ["desulfation", "TREATMENT", 11, 22], ["the 1 mg pyridinium salts", "TREATMENT", 24, 49], ["MSTFA", "TREATMENT", 84, 89], ["pyridine", "TREATMENT", 115, 123]]], ["The mixture was incubated at 100\u00b0C for 30 min and then quickly cooled in an ice-bath.", [["an ice-bath", "TREATMENT", 73, 84]]], ["29 The sample was dried under nitrogen gas flow and purified with a 3 kDa Amicon Ultra centrifugal filter (Millipore, Temecula, CA, USA) to remove low molecular weight impurities.", [["sample", "ANATOMY", 7, 13], ["nitrogen", "CHEMICAL", 30, 38], ["nitrogen gas flow", "TREATMENT", 30, 47], ["a 3 kDa Amicon Ultra centrifugal filter (Millipore", "TREATMENT", 66, 116]]], ["Selectively desulfated products were analyzed by proton NMR to determine the extent and specificity of desulfation.", [["Selectively desulfated products", "TREATMENT", 0, 31], ["proton NMR", "TEST", 49, 59], ["desulfation", "PROBLEM", 103, 114]]], ["Details of the NMR analyses are shown in the Supplementary Information.", [["the NMR analyses", "TEST", 11, 27]]], ["For full desulfation, the 1 mg pyridinium salts were resuspended in 1 mL 10% methanol in DMSO and heated at 100\u00b0C for 6 hours.", [["pyridinium salts", "CHEMICAL", 31, 47], ["methanol", "CHEMICAL", 77, 85], ["DMSO", "CHEMICAL", 89, 93], ["pyridinium", "CHEMICAL", 31, 41], ["methanol", "CHEMICAL", 77, 85], ["DMSO", "CHEMICAL", 89, 93], ["pyridinium salts", "SIMPLE_CHEMICAL", 31, 47], ["methanol", "SIMPLE_CHEMICAL", 77, 85], ["DMSO", "SIMPLE_CHEMICAL", 89, 93], ["full desulfation", "TREATMENT", 4, 20], ["the 1 mg pyridinium salts", "TREATMENT", 22, 47], ["DMSO", "TREATMENT", 89, 93]]], ["30 The fully-desulfated products were dried, and administered as pyridinium salts for further studies.Heparin and enoxaparin sodium desulfation for pseudotyped virus inhibition:Surface Plasmon Resonance: Biotinylated heparin was prepared by conjugating its reducing end to amine-PEG3-Biotin (Pierce, Rockford, IL).", [["pyridinium salts", "CHEMICAL", 65, 81], ["Heparin", "CHEMICAL", 102, 109], ["enoxaparin sodium", "CHEMICAL", 114, 131], ["heparin", "CHEMICAL", 217, 224], ["amine-PEG3-Biotin", "CHEMICAL", 273, 290], ["pyridinium", "CHEMICAL", 65, 75], ["enoxaparin sodium", "CHEMICAL", 114, 131], ["amine", "CHEMICAL", 273, 278], ["PEG3", "CHEMICAL", 279, 283], ["Biotin", "CHEMICAL", 284, 290], ["pyridinium salts", "SIMPLE_CHEMICAL", 65, 81], ["Heparin", "SIMPLE_CHEMICAL", 102, 109], ["enoxaparin", "SIMPLE_CHEMICAL", 114, 124], ["sodium", "SIMPLE_CHEMICAL", 125, 131], ["pseudotyped", "ORGANISM", 148, 159], ["Biotinylated heparin", "SIMPLE_CHEMICAL", 204, 224], ["amine-PEG3-Biotin", "SIMPLE_CHEMICAL", 273, 290], ["Pierce", "SIMPLE_CHEMICAL", 292, 298], ["IL", "GENE_OR_GENE_PRODUCT", 310, 312], ["The fully-desulfated products", "TREATMENT", 3, 32], ["pyridinium salts", "TREATMENT", 65, 81], ["further studies", "TEST", 86, 101], ["Heparin", "TREATMENT", 102, 109], ["enoxaparin sodium desulfation", "TREATMENT", 114, 143], ["pseudotyped virus inhibition", "TREATMENT", 148, 176], ["Surface Plasmon Resonance", "TREATMENT", 177, 202], ["Biotinylated heparin", "TREATMENT", 204, 224], ["PEG3-Biotin (Pierce, Rockford, IL", "TREATMENT", 279, 312]]], ["In brief, heparin (2 mg) andHeparin and enoxaparin sodium desulfation for pseudotyped virus inhibition:amine-PEG3-Biotin (2 mg, Pierce, Rockford, IL) were dissolved in 200 \u00b5l H2O, 10 mg NaCNBH3 was added.", [["heparin", "CHEMICAL", 10, 17], ["Heparin", "CHEMICAL", 28, 35], ["enoxaparin sodium", "CHEMICAL", 40, 57], ["amine-PEG3-Biotin", "CHEMICAL", 103, 120], ["H2O", "CHEMICAL", 175, 178], ["NaCNBH3", "CHEMICAL", 186, 193], ["enoxaparin sodium", "CHEMICAL", 40, 57], ["amine", "CHEMICAL", 103, 108], ["Biotin", "CHEMICAL", 114, 120], ["H2O", "CHEMICAL", 175, 178], ["NaCNBH3", "CHEMICAL", 186, 193], ["heparin", "SIMPLE_CHEMICAL", 10, 17], ["Heparin", "SIMPLE_CHEMICAL", 28, 35], ["enoxaparin sodium desulfation", "SIMPLE_CHEMICAL", 40, 69], ["pseudotyped virus", "ORGANISM", 74, 91], ["amine-PEG3-Biotin", "SIMPLE_CHEMICAL", 103, 120], ["NaCNBH3", "SIMPLE_CHEMICAL", 186, 193], ["heparin", "TREATMENT", 10, 17], ["Heparin", "TREATMENT", 28, 35], ["enoxaparin sodium desulfation", "TREATMENT", 40, 69], ["pseudotyped virus inhibition", "TREATMENT", 74, 102], ["amine-PEG3-Biotin", "TREATMENT", 103, 120], ["Pierce, Rockford, IL)", "TREATMENT", 128, 149], ["NaCNBH3", "TREATMENT", 186, 193]]], ["The reaction mixture was heated at 70 \u00b0C for 24 h, after that a further 10 mg NaCNBH3 was added and the reaction was heated at 70 \u00b0C for another 24 h.", [["NaCNBH3", "CHEMICAL", 78, 85], ["NaCNBH3", "CHEMICAL", 78, 85], ["NaCNBH3", "SIMPLE_CHEMICAL", 78, 85], ["The reaction mixture", "TREATMENT", 0, 20], ["a further 10 mg NaCNBH3", "TREATMENT", 62, 85], ["the reaction", "PROBLEM", 100, 112]]], ["After cooling to room temperature, the mixture was desalted with the spin column were injected over heparin chip at a flow rate of 30 \uf06dL/min, respectively.", [["heparin", "CHEMICAL", 100, 107], ["heparin", "SIMPLE_CHEMICAL", 100, 107], ["the spin column", "TREATMENT", 65, 80], ["heparin chip", "TREATMENT", 100, 112], ["a flow rate", "TEST", 116, 127]]], ["After each run, the dissociation and the regeneration were performed as described above and where binding was observed at 1 \uf06dM, the IC50 was determined.", [["the dissociation", "PROBLEM", 16, 32], ["the IC50", "TEST", 128, 136]]]], "PMC5338018": [["Network density, measured as the ratio of the number of connections and the number of possible connections between all cities in the network, was lower than 1% in the three studied networks (Supplementary Table S1).", [["density", "OBSERVATION", 8, 15]]], ["The degree distribution of the network was better fitted to an exponential (R2 = 0.991) than to a power-law (R2 = 0.88) function (Supplementary Fig. S1).Description of the medieval network ::: ResultsNetwork transitivity was around 10% for the overall and the trade networks and only 5% for the pilgrimage network.", [["S1", "GENE_OR_GENE_PRODUCT", 149, 151], ["S1", "PROTEIN", 149, 151], ["the pilgrimage network", "TREATMENT", 291, 313], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23]]], ["In all cases, network transitivity was significantly higher than expected in a random network (Supplementary Table S1).", [["network", "MULTI-TISSUE_STRUCTURE", 14, 21]]], ["The values of local transitivity were very similar to the global values (Overall network = 0.098 \u00b1 0.006; Trade network = 0.063 \u00b1 0.020; Pilgrimage network = 0.018 \u00b1 0.017).", [["The values", "TEST", 0, 10], ["local transitivity", "TEST", 14, 32], ["Trade network", "TEST", 106, 119], ["Pilgrimage network", "TEST", 137, 155], ["local transitivity", "OBSERVATION", 14, 32]]], ["However, most cities had transitivity values equal to zero (Supplementary Fig. S2), indicating that they did not form closed triples.Description of the medieval network ::: ResultsAs for centrality, the mean city degree was 3.18 \u00b1 0.06 for the overall network, indicating that as an average a city was connected to other three cities.", [["transitivity values", "PROBLEM", 25, 44], ["centrality", "TEST", 187, 197]]], ["Nevertheless, degree ranged between 1 and 19, with most cities having a degree between 1 and 5 (Supplementary Fig. S3).", [["degree", "TEST", 14, 20]]], ["Mean degree was 2.49 \u00b1 0.06 for the trade network and 0.69 \u00b1 0.03 for the pilgrimage network.", [["Mean degree", "TEST", 0, 11], ["the pilgrimage network", "TREATMENT", 70, 92]]], ["Closeness centrality shared the same pattern; most cities had very low values whereas some cities had high values (Supplementary Figs S3\u2013S5).Description of the medieval network ::: ResultsThere were significant correlations between both centrality metrics in the three types of networks (p < 0.0001 in all cases, N = 1311 cities; Pearson product-moment correlation; Supplementary Table S2), and these correlations were higher than the correlation expected in a network with the same degree distribution but randomly reshuffling the links among the cities (Table S2).", [["very low values", "PROBLEM", 62, 77], ["high values", "PROBLEM", 102, 113], ["significant", "OBSERVATION_MODIFIER", 199, 210]]], ["Local transitivity was positively correlated with closeness in the overall network (Supplementary Table S3) and negatively correlated with degree (Supplementary Fig. S6).Relationship between city mortality and network attributes ::: ResultsWe found information about mortality on 58 cities (Supplementary Table S4).", [["S6", "GENE_OR_GENE_PRODUCT", 166, 168], ["S6", "PROTEIN", 166, 168], ["transitivity", "OBSERVATION", 6, 18]]], ["The centrality of these cities expanded through the whole range of centralities observed in the whole set of cities (Supplementary Table S4).", [["centrality", "OBSERVATION_MODIFIER", 4, 14], ["cities", "OBSERVATION_MODIFIER", 24, 30], ["expanded", "OBSERVATION_MODIFIER", 31, 39]]], ["The average mortality rate of this pool of cities was 51 \u00b1 2% (mean \u00b1 1 SE), ranging between 0% in Turku and over 70% in Ajaccio, Montpellier, Avignon and other southern France cities.", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["There was positive spatial (r = 0.32, P = 0.005, Mantel test) and temporal (r = 0.20, P = 0.019, Mantel test) autocorrelation in mortality rates, indicating that nearby cities or those cities infected at the same time had similar rates of mortality.Relationship between city mortality and network attributes ::: ResultsThere was a significant positive relationship between local transitivity and mortality rate of the cities both in the overall network as well as in the trade network (Table 1, Fig. 2).", [["P", "TEST", 38, 39], ["Mantel test", "TEST", 49, 60], ["temporal", "TEST", 66, 74], ["P", "TEST", 86, 87], ["Mantel test", "TEST", 97, 108], ["mortality rates", "TEST", 129, 144], ["a significant positive relationship between local transitivity", "PROBLEM", 329, 391], ["positive", "OBSERVATION_MODIFIER", 10, 18], ["spatial", "OBSERVATION_MODIFIER", 19, 26], ["significant", "OBSERVATION_MODIFIER", 331, 342], ["positive", "OBSERVATION", 343, 351], ["local transitivity", "OBSERVATION", 373, 391]]], ["This means that cities located in dense regions of the network were more affected by the plague than cities located in sparse regions.", [["dense", "OBSERVATION_MODIFIER", 34, 39], ["regions", "OBSERVATION_MODIFIER", 40, 47], ["plague", "OBSERVATION_MODIFIER", 89, 95], ["sparse", "OBSERVATION_MODIFIER", 119, 125]]], ["However, it could not be computed for the pilgrimage network because all cities but two had open triples.", [["the pilgrimage network", "TREATMENT", 38, 60], ["open triples", "TREATMENT", 92, 104]]], ["Similarly, we found a significant positive relationship between mortality rate and the centrality metrics for the overall network (Table 1, Fig. 2).", [["a significant positive relationship between mortality rate", "PROBLEM", 20, 78], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["positive", "OBSERVATION", 34, 42]]], ["Central cities underwent higher mortality rate.", [["higher", "OBSERVATION_MODIFIER", 25, 31]]], ["These relationships maintained significant for degree in the trade network (Table 1).Simulating the effect of centrality and transitivity on the probability of multiple infections ::: ResultsThe relationship between number of infections per city and its centrality and transitivity was significantly positive in all cases except in the scenario with lowest infectivity for closeness (Fig. 3).", [["infections", "DISEASE", 169, 179], ["infections", "DISEASE", 226, 236], ["infections", "PROBLEM", 226, 236], ["significantly positive", "PROBLEM", 286, 308], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["multiple", "OBSERVATION_MODIFIER", 160, 168], ["infections", "OBSERVATION", 169, 179], ["number", "OBSERVATION_MODIFIER", 216, 222], ["infections", "OBSERVATION", 226, 236], ["lowest infectivity", "OBSERVATION", 350, 368]]], ["This means that, irrespective of the transmission rate, central and transitive cities tend to be reached by the diseases multiple times, whereas peripheral cities with low transitivity are reached by the disease few times.", [["the transmission rate", "TEST", 33, 54], ["central and transitive cities", "PROBLEM", 56, 85], ["the diseases", "PROBLEM", 108, 120], ["low transitivity", "PROBLEM", 168, 184], ["central", "OBSERVATION_MODIFIER", 56, 63], ["diseases", "OBSERVATION", 112, 120], ["low transitivity", "OBSERVATION", 168, 184], ["disease", "OBSERVATION", 204, 211]]], ["We found that, although significant, the relationship between multiple infections and centrality and transitivity steadily decreased when the diseases became more infective (Fig. 3).", [["infections", "DISEASE", 71, 81], ["multiple infections", "PROBLEM", 62, 81], ["transitivity", "PROBLEM", 101, 113], ["the diseases", "PROBLEM", 138, 150], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["multiple", "OBSERVATION_MODIFIER", 62, 70], ["infections", "OBSERVATION", 71, 81], ["transitivity", "OBSERVATION_MODIFIER", 101, 113], ["steadily", "OBSERVATION_MODIFIER", 114, 122], ["decreased", "OBSERVATION_MODIFIER", 123, 132]]], ["That is, the advantage of being isolated decreased when the disease is severe and transmit very fast.Structure of the medieval network ::: DiscussionThe topology of the medieval network had a transitivity significantly higher than that expected in random networks, a property shared with small-world networks28.", [["medieval network", "MULTI-TISSUE_STRUCTURE", 169, 185], ["the disease", "PROBLEM", 56, 67], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["disease", "OBSERVATION", 60, 67], ["severe", "OBSERVATION_MODIFIER", 71, 77]]], ["In particular, the exponential degree distribution of the medieval networks suggests that they were single scale small-world networks.", [["exponential", "OBSERVATION_MODIFIER", 19, 30], ["degree", "OBSERVATION_MODIFIER", 31, 37], ["distribution", "OBSERVATION_MODIFIER", 38, 50]]], ["In fact, the highest degree observed was just 19 even although there were 1311 cities.", [["highest degree", "OBSERVATION_MODIFIER", 13, 27]]], ["Degree provides a description of network connectivity based on the individual components and assesses the importance of a node based on its reachability.", [["node", "ANATOMY", 122, 126], ["network", "MULTI-TISSUE_STRUCTURE", 33, 40], ["node", "MULTI-TISSUE_STRUCTURE", 122, 126], ["a node", "TREATMENT", 120, 126], ["node", "OBSERVATION", 122, 126]]], ["Cities with high values of closeness act as bridges, connecting one part of the network to another that would otherwise be sparsely or not connected at all.", [["high values", "OBSERVATION_MODIFIER", 12, 23]]], ["Consequently, this correlation indicates that the importance of a given city for the disease transmission in the medieval network appears both at local and global scales.Structure of the medieval network ::: DiscussionThe observed high transitivity in the medieval networks suggests that the dynamics of the infection was predominantly a local process9.", [["infection", "DISEASE", 308, 317], ["medieval network", "MULTI-TISSUE_STRUCTURE", 113, 129], ["the disease transmission", "PROBLEM", 81, 105], ["The observed high transitivity", "PROBLEM", 218, 248], ["the infection", "PROBLEM", 304, 317], ["high transitivity", "OBSERVATION", 231, 248], ["infection", "OBSERVATION", 308, 317]]], ["Under these circumstances, the probability of infection of a given city probably depended more on the transmission from the surrounding cities than from distant cities9.", [["infection", "DISEASE", 46, 55], ["infection", "PROBLEM", 46, 55], ["infection", "OBSERVATION", 46, 55], ["distant cities9", "OBSERVATION", 153, 168]]], ["Despite of this, infection spreading tends to be fast in networks bearing high transitivity28.", [["infection", "DISEASE", 17, 26], ["infection spreading", "PROBLEM", 17, 36], ["infection", "OBSERVATION", 17, 26], ["high transitivity", "OBSERVATION", 74, 91]]], ["The correlations between both centrality metrics and between clustering coefficient and closeness insinuate that the infection probably arrived sooner to those cities located in dense and highly interconnected subsets of cities.", [["infection", "DISEASE", 117, 126], ["the infection", "PROBLEM", 113, 126], ["infection", "OBSERVATION", 117, 126], ["dense", "OBSERVATION_MODIFIER", 178, 183], ["highly", "OBSERVATION_MODIFIER", 188, 194], ["interconnected", "OBSERVATION_MODIFIER", 195, 209], ["subsets", "OBSERVATION_MODIFIER", 210, 217]]], ["All these features may explain why the Black Death invaded so easily and fast most places from China to Iberian Peninsula and British Islands in less than a decade2.Relationship between city centrality, transitivity and mortality rate ::: DiscussionWe found that nearby cities had similar mortality rates.", [["Death", "DISEASE", 45, 50], ["the Black Death", "PROBLEM", 35, 50], ["may explain", "UNCERTAINTY", 19, 30], ["Iberian Peninsula", "ANATOMY", 104, 121], ["British", "OBSERVATION_MODIFIER", 126, 133], ["Islands", "OBSERVATION_MODIFIER", 134, 141]]], ["In the same way, we also found that those cities being infected at the same time had similar mortality rates.", [["infected", "OBSERVATION", 55, 63]]], ["Spatio-temporal autocorrelation in mortality rate was found even despite we connected cities through linear routes rather than through the real routes across sea and land.", [["Spatio", "TEST", 0, 6], ["mortality rate", "TEST", 35, 49], ["temporal", "OBSERVATION_MODIFIER", 7, 15]]], ["Theoretical studies have shown that the spatial structure of the networks strongly influences the transmission dynamics of infectious disease9.", [["infectious disease9", "DISEASE", 123, 142], ["Theoretical studies", "TEST", 0, 19], ["infectious disease9", "PROBLEM", 123, 142], ["infectious", "OBSERVATION", 123, 133]]], ["In fact, spatio-temporal travelling waves are frequent in epidemics2930.", [["temporal", "OBSERVATION_MODIFIER", 16, 24]]], ["The observed autocorrelation in our study system agrees with these theoretical expectations and indicates the occurrence of a spatio-temporal dynamics in the spread of Black Death across Eurasia.", [["Death", "DISEASE", 174, 179], ["our study system", "TEST", 32, 48], ["a spatio-temporal dynamics", "PROBLEM", 124, 150], ["Black Death", "PROBLEM", 168, 179]]], ["Future research should consider more sophisticated modelling to correctly determine the influence of space and time in the dynamics of the Black Death.Relationship between city centrality, transitivity and mortality rate ::: DiscussionCities exhibiting higher centrality and local transitivity underwent higher rates of mortality than peripheral ones.", [["Death", "DISEASE", 145, 150], ["higher centrality", "PROBLEM", 253, 270], ["local transitivity", "PROBLEM", 275, 293], ["higher", "OBSERVATION_MODIFIER", 253, 259], ["centrality", "OBSERVATION_MODIFIER", 260, 270], ["local transitivity", "OBSERVATION", 275, 293]]], ["This pattern has been detected despite we only considered processes related with the transmission of the disease between cities, and omitted the processes occurring within cities and related to the transmission among individuals.", [["the disease between cities", "PROBLEM", 101, 127], ["disease", "OBSERVATION", 105, 112]]], ["In addition, this significant relationship was found after controlling for the spatio-temporal dynamics observed in the spread of the plague in Europe during the fourteenth century, and even despite the uncertainty of data on mortality during the fourteenth century2, suggesting thereby that the association was robust.", [["the spatio-temporal dynamics", "PROBLEM", 75, 103], ["plague", "OBSERVATION", 134, 140]]], ["Furthermore, this relationship occurred irrespective of the metric used to calculate centrality, indicating that those cities reached sooner and easier by the diseases are those supporting higher rates of mortality.", [["the diseases", "PROBLEM", 155, 167]]], ["Nevertheless, the mortality intensity may be reduced in central cities by means of drastic practices.", [["the mortality intensity", "PROBLEM", 14, 37], ["drastic practices", "TREATMENT", 83, 100], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["central cities", "OBSERVATION", 56, 70]]], ["Consequently, despite its high centrality, the city remained functionally isolated and the impact of the disease was very mild.Relationship between city centrality, transitivity and mortality rate ::: DiscussionThe relationship between transitivity and mortality was stronger in the overall network than in any of the other two partial networks, an outcome suggesting the occurrence of a synergic effect of the trading and pilgrimage networks.", [["its high centrality", "PROBLEM", 22, 41], ["the disease", "PROBLEM", 101, 112], ["transitivity and mortality", "PROBLEM", 236, 262], ["pilgrimage networks", "TREATMENT", 423, 442], ["high centrality", "OBSERVATION", 26, 41], ["disease", "OBSERVATION", 105, 112], ["very", "OBSERVATION_MODIFIER", 117, 121], ["mild", "OBSERVATION_MODIFIER", 122, 126]]], ["This outcome agrees with some recent studies showing that epidemics spread easier in multiple networks22.A potential mechanism explained the observed pattern ::: DiscussionThe pattern we have found in this study may be explained by the occurrence of multiple infections.", [["infections", "DISEASE", 259, 269], ["some recent studies", "TEST", 25, 44], ["epidemics", "PROBLEM", 58, 67], ["this study", "TEST", 201, 211], ["multiple infections", "PROBLEM", 250, 269], ["multiple", "OBSERVATION_MODIFIER", 250, 258], ["infections", "OBSERVATION", 259, 269]]], ["Recent molecular evidence suggests that multiple infections were frequent during the Black Death pandemic.", [["infections", "DISEASE", 49, 59], ["Death", "DISEASE", 91, 96], ["multiple infections", "PROBLEM", 40, 59], ["evidence suggests", "UNCERTAINTY", 17, 34], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["infections", "OBSERVATION", 49, 59]]], ["It has been recently shown that different clones of Yersinia pestis were involved in the Black Death pandemic27.", [["Yersinia pestis", "DISEASE", 52, 67], ["Death", "DISEASE", 95, 100], ["Yersinia pestis", "ORGANISM", 52, 67], ["Yersinia pestis", "SPECIES", 52, 67], ["Yersinia pestis", "SPECIES", 52, 67], ["Yersinia pestis", "PROBLEM", 52, 67], ["different", "OBSERVATION_MODIFIER", 32, 41], ["clones", "OBSERVATION_MODIFIER", 42, 48], ["Yersinia pestis", "OBSERVATION", 52, 67]]], ["Similarly, according to molecular analyses in human skeletons, it seems that Y. pestis entered Europe several times2627.", [["Y. pestis", "DISEASE", 77, 86], ["human", "ORGANISM", 46, 51], ["Y. pestis", "ORGANISM", 77, 86], ["human", "SPECIES", 46, 51], ["Y. pestis", "SPECIES", 77, 86], ["human", "SPECIES", 46, 51], ["Y. pestis", "SPECIES", 77, 86], ["human skeletons", "ANATOMY", 46, 61]]], ["Under this scenario of multiple infections, we presume that central, well-connected cities with high local transitivity had higher likelihood of being invaded multiple times by pathogens.", [["infections", "DISEASE", 32, 42], ["multiple infections", "PROBLEM", 23, 42], ["high local transitivity", "PROBLEM", 96, 119], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["infections", "OBSERVATION", 32, 42], ["central", "OBSERVATION_MODIFIER", 60, 67], ["high", "OBSERVATION_MODIFIER", 96, 100], ["local transitivity", "OBSERVATION", 101, 119]]], ["Central cities are those cities that, by having a peculiar history, structure, size, etc., are highly connected with the rest of the cities in the medieval network.", [["medieval network", "MULTI-TISSUE_STRUCTURE", 147, 163], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["This means that those cities were receiving pilgrims, goods and people from many other different cities.", [["people", "SPECIES", 64, 70]]], ["This density of commercial and spiritual connections would have entailed a high probability of receiving recurrent waves of pathogens2.", [["recurrent waves of pathogens2", "PROBLEM", 105, 134]]], ["Our simulation study fully supports this idea.", [["Our simulation study", "TEST", 0, 20]]], ["We found that those cities having higher centrality and transitivity in the medieval network were infected more times by the plague than peripheral cities with low transitivity, irrespective of the plague infectivity level and the centrality metric used (Fig. 3).", [["medieval network", "MULTI-TISSUE_STRUCTURE", 76, 92], ["low transitivity", "PROBLEM", 160, 176], ["the plague infectivity level", "PROBLEM", 194, 222], ["higher", "OBSERVATION_MODIFIER", 34, 40], ["centrality", "OBSERVATION_MODIFIER", 41, 51], ["infected", "OBSERVATION", 98, 106], ["low transitivity", "OBSERVATION", 160, 176], ["plague infectivity", "OBSERVATION", 198, 216]]], ["These theoretical findings agree with some empirical evidence also showing that re-infection was common in central cities.", [["re-infection", "PROBLEM", 80, 92], ["re-infection", "OBSERVATION", 80, 92], ["central", "ANATOMY_MODIFIER", 107, 114]]], ["For example, multiple bacterial strains invaded London, a central city in our network, during the Black Death pandemic31.A potential mechanism explained the observed pattern ::: DiscussionWhen a city is recurrently invaded, the overall mortality will be higher due to several, non-exclusive reasons.", [["Death", "DISEASE", 104, 109], ["multiple bacterial strains", "PROBLEM", 13, 39], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["bacterial", "OBSERVATION_MODIFIER", 22, 31], ["strains", "OBSERVATION_MODIFIER", 32, 39], ["invaded", "OBSERVATION_MODIFIER", 40, 47], ["central", "OBSERVATION_MODIFIER", 58, 65]]], ["A first factor increasing the mortality rate in a given city could be due to different infection waves affecting different parts of the city.", [["infection", "DISEASE", 87, 96], ["A first factor", "PROBLEM", 0, 14], ["the mortality rate", "PROBLEM", 26, 44], ["different infection waves", "PROBLEM", 77, 102], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["different", "OBSERVATION_MODIFIER", 77, 86], ["infection", "OBSERVATION", 87, 96]]], ["In this case, the overall mortality rate will be the cumulative outcome of partial mortalities caused by each infection wave.", [["infection", "DISEASE", 110, 119], ["partial mortalities", "PROBLEM", 75, 94], ["each infection wave", "PROBLEM", 105, 124], ["infection", "OBSERVATION", 110, 119]]], ["In addition, a city invaded multiple times could receive different pathogen strains.", [["different pathogen strains", "PROBLEM", 57, 83]]], ["Theoretical models suggest that multiple infections with different strains generally lead to the evolution of population-wide increased virulence45, magnifying even more the devastating effects of the epidemic in that city.ConclusionsOur findings may have important consequences for identifying epidemic hotspots.", [["infections", "DISEASE", 41, 51], ["multiple infections", "PROBLEM", 32, 51], ["different strains", "PROBLEM", 57, 74], ["wide increased virulence45", "PROBLEM", 121, 147], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["infections", "OBSERVATION", 41, 51], ["wide", "OBSERVATION_MODIFIER", 121, 125], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["epidemic", "OBSERVATION_MODIFIER", 201, 209]]], ["Our study suggests that the spread of the plague in Europe was related to the medieval trading and pilgrimage network.", [["pilgrimage network", "MULTI-TISSUE_STRUCTURE", 99, 117], ["Our study", "TEST", 0, 9], ["spread", "OBSERVATION_MODIFIER", 28, 34], ["plague", "OBSERVATION", 42, 48]]], ["More importantly, our study provides quantitative support based on different network structural measures about a functional connection between the position of nodes (cities, villages, airports, harbors, etc.) in a network and their vulnerability to pandemics.", [["nodes", "ANATOMY", 159, 164], ["our study", "TEST", 18, 27], ["quantitative support", "TREATMENT", 37, 57], ["nodes", "OBSERVATION", 159, 164]]], ["We suggest that the mechanism behind this relationship is the higher recurrence of reinfection events in central nodes because the disease can reach them sooner and more often.", [["central nodes", "ANATOMY", 105, 118], ["central nodes", "MULTI-TISSUE_STRUCTURE", 105, 118], ["reinfection events", "PROBLEM", 83, 101], ["central nodes", "PROBLEM", 105, 118], ["the disease", "PROBLEM", 127, 138], ["reinfection", "OBSERVATION", 83, 94], ["central nodes", "OBSERVATION", 105, 118]]], ["It is indispensable to test how prevalent is this pattern nowadays3233, where both the transportation network and the vulnerability of each node can be more accurately determined and where the topology of the entire network has probably changed as a consequence of many longer paths connecting more efficiently distant parts of the transportation networks.", [["node", "ANATOMY", 140, 144], ["node", "MULTI-TISSUE_STRUCTURE", 140, 144], ["node", "OBSERVATION", 140, 144]]], ["Knowing whether central nodes, besides fuelling the propagation of epidemics, are also more severely affected by diseases even in modern transportation networks is crucial to identify vulnerable human populations.", [["central nodes", "ANATOMY", 16, 29], ["central nodes", "MULTI-TISSUE_STRUCTURE", 16, 29], ["human", "ORGANISM", 195, 200], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["central nodes", "PROBLEM", 16, 29], ["epidemics", "PROBLEM", 67, 76], ["diseases", "PROBLEM", 113, 121], ["central nodes", "OBSERVATION", 16, 29], ["propagation", "OBSERVATION_MODIFIER", 52, 63], ["epidemics", "OBSERVATION", 67, 76], ["more severely", "OBSERVATION_MODIFIER", 87, 100], ["diseases", "OBSERVATION", 113, 121]]], ["This is specially relevant for those places in the world that are still isolated from the global transportation networks and where the spreading patterns may be pretty close to the patterns observed in medieval networks.", [["medieval networks", "MULTI-TISSUE_STRUCTURE", 202, 219]]], ["If the history provides clues to understand the future, focusing our effort in vulnerable nodes may save time and resources by improving our ability of controlling deadly epidemics.Materials and MethodsTo build the medieval trading and pilgrimage networks, we obtained the medieval routes from the Old World Trade Routes Project, OWTRAD34 (Supplementary Methods and Table S5).", [["nodes", "ANATOMY", 90, 95], ["nodes", "MULTI-TISSUE_STRUCTURE", 90, 95], ["Methods", "TREATMENT", 195, 202], ["nodes", "OBSERVATION", 90, 95]]], ["We checked whether the network followed a single-scale or a scale-free distribution by fitting the degree distribution to exponential and power-law functions using semi-log and log-log regressions, respectively.", [["free distribution", "OBSERVATION", 66, 83]]], ["Afterwards, we calculated the global transitivity of each network and the local transitivity and centrality of each city.", [["local transitivity", "OBSERVATION", 74, 92]]], ["Local transitivity was calculated by local clustering coefficient3, whereas centrality was calculated by degree and closeness (Supplementary Methods).", [["Local transitivity", "PROBLEM", 0, 18], ["transitivity", "OBSERVATION", 6, 18]]], ["Degree is the number of nodes connected to a given node3.", [["nodes", "ANATOMY", 24, 29], ["nodes", "MULTI-TISSUE_STRUCTURE", 24, 29], ["number", "OBSERVATION_MODIFIER", 14, 20], ["nodes", "OBSERVATION", 24, 29]]], ["Closeness is the sum of the graph-distances from one node to all other nodes in the network3.", [["node", "ANATOMY", 53, 57], ["network3", "DNA", 84, 92], ["node", "OBSERVATION", 53, 57], ["nodes", "OBSERVATION", 71, 76]]], ["The number of people dying to the plague was recorded using Benedictow2, Horrox35 and Sistach36 books and systematically searching in Google Scholar and SCOPUS including the words \u201cBlack Death\u201d, \u201cplague\u201d, \u201cmortality\u201d, \u201csurvival\u201d, and \u201cdeath\u201d (Supplementary Methods).", [["Death", "DISEASE", 187, 192], ["death", "DISEASE", 235, 240], ["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["Spatio-temporal autocorrelation was checked by performing Mantel tests between the across-cities distances in mortality rate and the spatial and temporal distances (Supplementary Methods).", [["Spatio", "TEST", 0, 6], ["Mantel tests", "TEST", 58, 70], ["mortality rate", "TEST", 110, 124]]], ["The relationship between centrality and mortality rate during the Black Death pandemic was explored by fitting spatially-explicit generalised linear models.", [["Death", "DISEASE", 72, 77], ["mortality rate", "TEST", 40, 54], ["the Black Death pandemic", "PROBLEM", 62, 86]]], ["The dependent variable was mortality rate estimated as the proportion of the population dying due to the plague in each city.", [["plague", "DISEASE", 105, 111], ["mortality rate", "TEST", 27, 41], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22], ["plague", "OBSERVATION", 105, 111]]], ["Finally, we simulated the diffusion of plague throughout our medieval network by using a susceptible-infectious-susceptible (SIS) epidemic model.", [["medieval network", "MULTI-TISSUE_STRUCTURE", 61, 77], ["a susceptible-infectious-susceptible (SIS) epidemic model", "PROBLEM", 87, 144], ["infectious", "OBSERVATION", 101, 111]]], ["In these models we allowed cities to be repeatedly infected without recovering from the diseases.", [["the diseases", "PROBLEM", 84, 96], ["infected", "OBSERVATION", 51, 59], ["diseases", "OBSERVATION", 88, 96]]], ["Because our goal was to model how the plague moved among medieval cities following the trading and pilgrimage network, the transmission of the diseases was given by the contact network among cities (Supplementary Methods).", [["pilgrimage network", "TREATMENT", 99, 117], ["the diseases", "PROBLEM", 139, 151], ["diseases", "OBSERVATION", 143, 151]]], ["The probability of a city of becoming infected depends thus on the number of infected cities contacting with the focal city multiplied by the transmission rate of the disease.", [["infected", "PROBLEM", 38, 46], ["the disease", "PROBLEM", 163, 174], ["infected", "OBSERVATION", 38, 46], ["infected", "OBSERVATION", 77, 85], ["focal", "OBSERVATION_MODIFIER", 113, 118], ["disease", "OBSERVATION", 167, 174]]], ["Using a susceptible-infectious-susceptible (SIS) epidemic model, we simulated the spreading of the Black Death along the medieval network (Supplementary Methods, Appendix 3).", [["Death", "DISEASE", 105, 110], ["a susceptible-infectious-susceptible (SIS) epidemic model", "PROBLEM", 6, 63], ["the Black Death", "PROBLEM", 95, 110], ["infectious", "OBSERVATION_MODIFIER", 20, 30]]], ["We repeated the diffusion of the disease in several infectivity scenarios ranging between transmission rate of 0.05 (very low infectivity rate) to 0.95 (very high infectivity rate).", [["the disease", "PROBLEM", 29, 40], ["several infectivity scenarios", "PROBLEM", 44, 73], ["transmission rate", "TEST", 90, 107], ["disease", "OBSERVATION", 33, 40], ["several", "OBSERVATION_MODIFIER", 44, 51], ["infectivity", "OBSERVATION_MODIFIER", 52, 63]]], ["We did 1000 simulations for each infectivity scenario.", [["each infectivity scenario", "PROBLEM", 28, 53]]], ["The epidemic was started in all simulations from central Asian cities.", [["The epidemic", "PROBLEM", 0, 12], ["epidemic", "OBSERVATION_MODIFIER", 4, 12], ["central", "ANATOMY_MODIFIER", 49, 56]]], ["We obtained the number of times a given city was infected during each simulation (Appendix 3).", [["infected", "OBSERVATION", 49, 57]]], ["Afterward, using the same statistical models explained in the previous section, we tested whether the number of infections was related to the centrality and transitivity of the cities.Additional InformationHow to cite this article: G\u00f3mez, J. M. and Verd\u00fa, M. Network theory may explain the vulnerability of medieval human settlements to the Black Death pandemic.", [["infections", "DISEASE", 112, 122], ["Death", "DISEASE", 347, 352], ["human", "ORGANISM", 316, 321], ["human", "SPECIES", 316, 321], ["human", "SPECIES", 316, 321], ["infections", "PROBLEM", 112, 122], ["infections", "OBSERVATION", 112, 122]]], ["Rep.7, 43467; doi: 10.1038/srep43467 (2017).Additional InformationPublisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["Rep.7, 43467", "CHEMICAL", 0, 12]]]], "PMC7382324": []}